QuickLinks -- Click here to rapidly navigate through this document

As filed with the Securities and Exchange Commission on June 30, 2015.

Registration No. 333-204622


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



Amendment No. 5
to
Form S-1
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933



NATERA, INC.
(Exact Name of Registrant as Specified in its Charter)



Delaware
(State or Other Jurisdiction of
Incorporation or Organization)
  8071
(Primary Standard Industrial
Classification Code Number)
  01-0894487
(I.R.S. Employer
Identification Number)



Natera, Inc.
201 Industrial Road, Suite 410
San Carlos, California 94070
(650) 249-9090
(Address, including zip code and telephone number, including area code, of registrant's principal executive offices)



Herm Rosenman
Chief Financial Officer
Natera, Inc.
201 Industrial Road, Suite 410
San Carlos, California 94070
(650) 249-9090
(Name, address, including zip code and telephone number, including area code, of agent for service)



Copies to:

Robert V. Gunderson, Jr., Esq.
John F. Dietz, Esq.
Richard C. Blake, Esq.
Gunderson Dettmer Stough
Villeneuve Franklin & Hachigian, LLP
1200 Seaport Blvd.
Redwood City, California 94063
(650) 321-2400

 

Daniel Rabinowitz, Esq.
Secretary and General Counsel
Natera, Inc.
201 Industrial Road, Suite 410
San Carlos, California 94070
(650) 249-9090

 

Alan F. Denenberg, Esq.
Davis Polk & Wardwell LLP
1600 El Camino Real
Menlo Park, California 94025
(650) 752-2004



           Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.

          If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  o

          If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

          If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

          If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

          Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o   Accelerated filer o   Non-accelerated filer ý
(Do not check if a
smaller reporting company)
  Smaller reporting company o



           The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to such Section 8(a), may determine.

   



Explanatory Note

        This amendment to the Registration Statement on Form S-1, or Registration Statement, is being submitted solely for the purposes of submitting Exhibits 10.8, 10.8.2, 10.8.3 and 10.13 herewith. No changes or additions are being made hereby to the Prospectus constituting Part I of the Registration Statement (not included herein) or to Items 13, 14, 15 or 17 of Part II of the Registration Statement.



PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13.    Other Expenses of Issuance and Distribution

        The following table sets forth the various expenses expected to be incurred and payable by us in connection with the sale and distribution of our common stock, other than underwriting discounts and commissions. All amounts are estimates except for the Securities and Exchange Commission (SEC) registration fee, the Financial Industry Regulatory Authority (FINRA) filing fee and the Nasdaq Global Select Market listing fee.

 
  Payable
by us
 

SEC registration fee

  $ 14,198  

FINRA filing fee

    18,828  

Nasdaq Global Select Market listing fee

    200,000  

Accounting fees and expenses

    1,100,000  

Legal fees and expenses

    1,980,000  

Printing and engraving expenses

    250,000  

Registrar and transfer agent fees and expenses

    16,000  

Miscellaneous fees and expenses

    120,974  
       

Total

  $ 3,700,000  
       
       

Item 14.    Indemnification of Directors and Officers

        Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended, or the Securities Act.

        As permitted by the Delaware General Corporation Law, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions relating to the limitation of liability and indemnification of directors and officers. The amended and restated certificate of incorporation provides that our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability:

    for any breach of the director's duty of loyalty to us or our stockholders;

    for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

    in respect of unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

    for any transaction from which the director derives any improper personal benefit.

        Our amended and restated certificate of incorporation also provides that if Delaware law is amended after the approval by our stockholders of the certificate of incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law.

        Our amended and restated bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by Delaware law, as it now exists or may in the future be amended, against all expenses and liabilities reasonably incurred in connection with their service for or on our behalf. Our

II-1


amended and restated bylaws provide that we shall advance the expenses incurred by a director or officer in advance of the final disposition of an action or proceeding, and permit us to secure insurance on behalf of any director, officer, employee, or other enterprise agent for any liability arising out of his action in that capacity, whether or not Delaware law would otherwise permit indemnification.

        We intend to enter into indemnification agreements with each of our directors and executive officers and certain other key employees, a form of which is attached as Exhibit 10.4. The form of agreement provides that we will indemnify each of our directors, executive officers and such other key employees against any and all expenses incurred by that director, executive officer, or other key employee because of his status as one of our directors, executive officers or other key employees, to the fullest extent permitted by Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws. In addition, the form agreement provides that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our directors, executive officers and other key employees in connection with a legal proceeding.

        Reference is made to the underwriting agreement contained in Exhibit 1.1 to this registration statement, indemnifying our directors and officers against limited liabilities. In addition, Section 2.9 of our amended and restated investors' rights agreement, or IRA, contained in Exhibit 4.2 to this registration statement provides for indemnification of certain of our stockholders against liabilities described in our IRA.

        We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Exchange Act of 1934, as amended, that might be incurred by any director or officer in his capacity as such.

Item 15.    Recent Sales of Unregistered Securities

        The following sets forth information regarding all unregistered securities sold from January 1, 2012 through May 31, 2015 giving effect to a 1-for-1.63 reverse stock split of our capital stock that was effected on June 19, 2015:

        Prior to January 1, 2012, we issued and sold an aggregate of $19,999,998.66 in principal of convertible promissory notes to seven accredited investors, accruing interest at a rate of 0.20% per annum. On February 20, 2013, all outstanding principal and unpaid accrued interest in connection with such convertible promissory notes were converted into shares of our Series D preferred stock at $4.8819 per share. (1)

        On January 28, 2013, we issued and sold an aggregate of $2,000,000.00 in principal of convertible promissory notes to six accredited investors, accruing interest at a rate of 2.0% per annum, compounded annually. On February, 20, 2013, all outstanding principal and unpaid accrued interest in connection with such convertible promissory notes were converted into shares of our Series E preferred stock at $6.0199 per share. (1)

        On February 20, 2013, we issued an aggregate of 5,485,123 shares of our Series C preferred stock at $2.2168 per share to nine accredited investors in exchange for the cancellation of certain outstanding convertible promissory notes, the aggregate outstanding principal and unpaid accrued interest equal to approximately $12,159,430. (1)

        On February 20, 2013, we issued an aggregate of 4,106,523 shares of our Series D preferred stock at $4.8819 per share to seven accredited investors in exchange for the cancellation of certain outstanding convertible promissory notes, the aggregate outstanding principal and unpaid accrued interest equal to approximately $20,047,440. (1)

        From February 20, 2013 to July 26, 2013, we issued and sold an aggregate of 5,884,594 shares of our Series E preferred stock at $6.0199 per share to 20 accredited investors for an aggregate consideration of approximately $35,424,812. (1)

II-2


        On April 18, 2013, we issued to Royalty Opportunities S.á r.l., a warrant to purchase up to 376,691 shares of our common stock at $2.3229 per share. The warrant has a net exercise provision and contains provisions for the adjustment of the exercise price and the number of shares issuable upon the exercise of the warrant in the event of certain patent registrations, stock dividends, stock splits, recapitalizations, reclassifications, consolidations and other fundamental transactions. (1)

        From November 20, 2014 to December 11, 2014, we issued and sold an aggregate of 4,348,535 shares of our Series F preferred stock at $12.7629 per share to eight accredited investors for an aggregate consideration of approximately $55,499,987. On November 20, 2014, we issued warrants to purchase an aggregate of 429,440 shares of common stock at $0.0163 per share to 20 accredited investors. The warrant has a net exercise provision and contains provisions for the adjustment of the exercise price and the number of shares issuable upon the exercise of the warrant in the event of stock dividends, stock splits, recapitalizations, reclassifications, consolidations and other fundamental transactions. (1)

        We have granted to our directors, officers and employees options to purchase 9,704,311 shares of common stock under our 2007 Amended and Restated Stock Plan, as it may have been further amended, with per share exercise prices ranging from $1.141 to $7.4491, and issued 4,348,602 shares of common stock upon exercise of such options for aggregate consideration of $477,105.32, at exercise prices ranging from $0.0652 to $3.7816. (2)

        Except with respect to the sale and issuance of our Series E preferred stock in February 20, 2013, in which Leerink Swann LLC received a commission in connection with such sale, none of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. The Registrant believes that each transaction was exempt from the registration requirements of the Securities Act in reliance on the following exemptions:

    (1)
    These transactions were deemed to be exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder as transactions by an issuer not involving any public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients made representations to us that such recipient was an "accredited investor," as defined under Rule 501 of the Securities Act, and that such recipient had adequate information about us or had adequate access, through their relationships with us, to information about us.

    (2)
    These transactions were deemed to be exempt from registration under the Securities Act in reliance upon Rule 701 promulgated under Section 3(b) of the Securities Act pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate information about us or had adequate access, through their relationships with us, to information about us.

Item 16.    Exhibits and Financial Statement Schedules

    (a) Exhibits.     We have filed the exhibits listed on the accompanying Exhibit Index, which is incorporated herein by reference.

    (b) Financial Statement Schedules.     All schedules have been omitted because the information required to be presented in them is not applicable or is shown in the financial statements or related notes, which is incorporated herein by reference.

II-3


Item 17.    Undertakings

        The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

        Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

        The undersigned registrant hereby undertakes that:

    (1)
    For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

    (2)
    For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II-4



SIGNATURES

        Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Amendment No. 5 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Carlos, State of California, on the 30 th day of June, 2015.

    NATERA, INC.

 

 

By:

 

/s/ HERM ROSENMAN

Herm Rosenman
Chief Financial Officer

        Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 5 to Registration Statement has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Name
 
Title
 
Date
/s/ MATTHEW RABINOWITZ

Matthew Rabinowitz
  Chief Executive Officer (Principal Executive Officer), President and Chairman   June 30, 2015

/s/ HERM ROSENMAN

Herm Rosenman

 

Chief Financial Officer (Principal Financial and Accounting Officer)

 

June 30, 2015

*

Jonathan Sheena

 

Chief Technology Officer and Director

 

June 30, 2015

*

Roelof F. Botha

 

Director

 

June 30, 2015

*

Todd Cozzens

 

Director

 

June 30, 2015

*

Edward C. Driscoll, Jr.

 

Director

 

June 30, 2015

*

James I. Healy

 

Director

 

June 30, 2015

*

John Steuart

 

Director

 

June 30, 2015

*By:

 

/s/ MATTHEW RABINOWITZ

Attorney-in-Fact

 

 

 

 

II-5



EXHIBIT INDEX

Exhibit
Number
 
Description
  1.1 Form of Underwriting Agreement.

 

3.1


Restated Certificate of Incorporation of the Registrant, as amended.

 

3.1.1


Certificate of Amendment of Restated Certificate of Incorporation of Registrant, dated June 19, 2015.

 

3.2


Form of Amended and Restated Certificate of Incorporation of the Registrant, to be in effect upon the completion of this offering.

 

3.3


Amended and Restated Bylaws of the Registrant.

 

3.4


Form of Amended and Restated Bylaws of the Registrant, to be in effect upon the completion of this offering.

 

4.1


Form of Common Stock Certificate.

 

4.2


Amended and Restated Investors' Rights Agreement, dated November 20, 2014.

 

5.1


Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.

 

10.1


2007 Stock Plan and form of agreements thereunder.

 

10.2


2015 Equity Incentive Plan and forms of agreements thereunder.

 

10.3


2015 Employee Stock Purchase Plan.

 

10.4


Form of Indemnification Agreement, by and between Registrant and each of its directors and executive officers.

 

10.5


Sublease Agreement, dated December 13, 2011, by and between Registrant and Nektar Therapeutics, as amended January 31, 2012 and January 3, 2013.

 

10.6


Sublease Agreement, dated March 21, 2014, by and between Registrant and Intrexon Corporation.

 

10.7

†**

Loan and Security Agreement, dated November 21, 2011, by and between Registrant and Comerica Bank, as amended on January 27, 2012, May 31, 2012, January 28, 2013, April 18, 2013 and December 18, 2014.

 

10.8

**

Credit Agreement, dated April 18, 2013, by and between Registrant and ROS Acquisition Offshore LP, as amended on June 6, 2014 and April 9, 2015.

 

10.8.1


Guarantee, dated April 18, 2013, by and between Natera International, Inc. and ROS Acquisition Offshore LP.

 

10.8.2

**

Pledge and Security Agreement, dated April 18, 2013, by and between the Registrant, Natera International, Inc., and ROS Acquisition Offshore LP.

 

10.8.3

**

Royalty Agreement, dated April 18, 2013, by and between Registrant and Royalty Opportunities S.à r.l., as amended on June 6, 2014.

 

10.9


Warrant, dated April 18, 2013, by and between Registrant and Royalty Opportunities S.á r.l.

 

10.10


Warrant, dated November 2, 2009, by and between Registrant and Silicon Valley Bank.

 

10.11


Form of Warrant to Purchase Common Stock.

 

10.12


Form of Warrant to Purchase Common Stock.

 

10.13

**

Supply Agreement, dated September 18, 2014, by and between Registrant and Illumina, Inc., as amended (conformed copy).

 

10.14


Compensation Program for Non-Employee Directors.

 

10.15


Amended Employment Agreement, by and between Registrant and Matthew Rabinowitz, dated June 7, 2007.

 

10.16


Amended Employment Agreement, by and between Registrant and Jonathan Sheena, dated June 7, 2007.

 

10.17


Offer Letter, by and between Registrant and Herm Rosenman, dated January 17, 2014.

 

21.1


List of Subsidiaries of the Registrant.

 

23.1


Consent of Independent Registered Public Accounting Firm.

 

23.2


Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1).

 

24.1


Power of Attorney.

Previously filed.

**
Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been submitted separately to the Securities and Exchange Commission.



QuickLinks

Explanatory Note
PART II INFORMATION NOT REQUIRED IN PROSPECTUS
SIGNATURES
EXHIBIT INDEX

Exhibit 10.8

 

Execution Version

 

CONFIDENTIAL TREATMENT REQUESTED

 

 

CREDIT AGREEMENT

 

dated as of April 18, 2013

 

by and between

 

NATERA, INC.,

 

as the Borrower,

 

and

 

ROS ACQUISITION OFFSHORE LP

 

as the Lender

 

 



 

TABLE OF CONTENTS

 

 

 

 

Page

 

 

 

 

ARTICLE I DEFINITIONS AND ACCOUNTING TERMS

1

 

 

 

 

 

SECTION 1.1

Defined Terms

1

 

SECTION 1.2

Use of Defined Terms

20

 

SECTION 1.3

Cross-References

20

 

SECTION 1.4

Accounting and Financial Determinations

20

 

SECTION 1.5

Other Loan Documents

20

 

 

 

 

ARTICLE II COMMITMENT AND BORROWING PROCEDURES

20

 

 

 

 

 

SECTION 2.1

Commitment

20

 

SECTION 2.2

Borrowing Procedure

20

 

SECTION 2.3

Funding

21

 

SECTION 2.4

Reduction of the Commitment Amounts

21

 

 

 

 

ARTICLE III REPAYMENTS, PREPAYMENTS, INTEREST AND FEES

21

 

 

 

 

 

SECTION 3.1

Repayments and Prepayments; Application

21

 

SECTION 3.2

Repayments and Prepayments

21

 

SECTION 3.3

Application

21

 

SECTION 3.4

Interest Rate

22

 

SECTION 3.5

Default Rate

22

 

SECTION 3.6

Payment Dates

22

 

SECTION 3.7

Repayment Premium

22

 

 

 

 

ARTICLE IV LIBO RATE AND OTHER PROVISIONS

23

 

 

 

 

 

SECTION 4.1

Increased Costs, Etc.

23

 

SECTION 4.2

Increased Capital Costs

23

 

SECTION 4.3

Taxes

23

 

SECTION 4.4

Payments, Computations; Proceeds of Collateral, Etc.

24

 

SECTION 4.5

Setoff

25

 

SECTION 4.6

LIBO Rate Not Determinable

25

 

 

 

 

ARTICLE V CONDITIONS TO MAKING THE LOANS

26

 

 

 

 

 

SECTION 5.1

Credit Extensions

26

 

SECTION 5.2

Secretary’s Certificate, Etc.

26

 

SECTION 5.3

Closing Date Certificate

26

 

SECTION 5.4

Payment of Outstanding Indebtedness, Etc.

27

 

SECTION 5.5

Delivery of Note

27

 

SECTION 5.6

Financial Information, Etc.

27

 

SECTION 5.7

[Intentionally Omitted]

27

 

SECTION 5.8

Solvency, Etc.

27

 

SECTION 5.9

Guarantee

27

 

i



 

 

SECTION 5.10

Security Agreements

27

 

SECTION 5.11

Intellectual Property Security Agreements

28

 

SECTION 5.12

Royalty Agreement

28

 

SECTION 5.13

Warrant Agreement

28

 

SECTION 5.14

Opinions of Counsel

28

 

SECTION 5.15

Insurance

29

 

SECTION 5.16

Closing Fees, Expenses, Etc.

29

 

SECTION 5.17

Anti-Terrorism Laws

29

 

SECTION 5.18

Satisfactory Legal Form

29

 

SECTION 5.19

U.S. Panorama Net Sales

29

 

SECTION 5.20

Disclosure Schedules

29

 

 

 

 

ARTICLE VI REPRESENTATIONS AND WARRANTIES

29

 

 

 

 

 

SECTION 6.1

Organization, Etc.

30

 

SECTION 6.2

Due Authorization, Non-Contravention, Etc.

30

 

SECTION 6.3

Government Approval, Regulation, Etc.

30

 

SECTION 6.4

Validity, Etc.

30

 

SECTION 6.5

Financial Information

30

 

SECTION 6.6

No Material Adverse Change

31

 

SECTION 6.7

Litigation, Labor Matters and Environmental Matters

31

 

SECTION 6.8

Subsidiaries

31

 

SECTION 6.9

Ownership of Properties

31

 

SECTION 6.10

Taxes

31

 

SECTION 6.11

Benefit Plans, Etc.

32

 

SECTION 6.12

Accuracy of Information

32

 

SECTION 6.13

Regulations U and X

32

 

SECTION 6.14

Solvency

32

 

SECTION 6.15

Intellectual Property

32

 

SECTION 6.16

Material Agreements

34

 

SECTION 6.17

Permits

34

 

SECTION 6.18

Regulatory Matters

35

 

SECTION 6.19

Transactions with Affiliates

37

 

SECTION 6.20

Investment Company Act

37

 

SECTION 6.21

OFAC

37

 

SECTION 6.22

Deposit and Disbursement Accounts

37

 

 

 

 

ARTICLE VII AFFIRMATIVE COVENANTS

38

 

 

 

 

 

SECTION 7.1

Financial Information, Reports, Notices, Etc.

38

 

SECTION 7.2

Maintenance of Existence; Compliance with Contracts, Laws, Etc.

40

 

SECTION 7.3

Maintenance of Properties

40

 

SECTION 7.4

Insurance

41

 

SECTION 7.5

Books and Records

41

 

SECTION 7.6

Environmental Law Covenant

42

 

SECTION 7.7

Use of Proceeds

42

 

SECTION 7.8

Future Guarantors, Security, Etc.

42

 

ii



 

 

SECTION 7.9

Obtaining of Permits, Etc.

43

 

SECTION 7.10

Product Licenses

43

 

SECTION 7.11

Maintenance of Regulatory Authorizations, Contracts, Intellectual Property, Etc.

43

 

SECTION 7.12

Inbound Licenses

43

 

SECTION 7.13

Cash Management

44

 

SECTION 7.14

Board Observation Rights

44

 

SECTION 7.15

Product Agreements

45

 

SECTION 7.16

Supply of Reagents

45

 

 

 

 

ARTICLE VIII NEGATIVE COVENANTS

46

 

 

 

 

 

SECTION 8.1

Business Activities

46

 

SECTION 8.2

Indebtedness

46

 

SECTION 8.3

Liens

47

 

SECTION 8.4

Minimum Liquidity

48

 

SECTION 8.5

Investments

49

 

SECTION 8.6

Restricted Payments, Etc.

50

 

SECTION 8.7

Consolidation, Merger; Permitted Acquisitions, Etc.

50

 

SECTION 8.8

Permitted Dispositions

50

 

SECTION 8.9

Modification of Certain Agreements

51

 

SECTION 8.10

Transactions with Affiliates

51

 

SECTION 8.11

Restrictive Agreements, Etc.

51

 

SECTION 8.12

Sale and Leaseback

52

 

SECTION 8.14

Change in Name, Location or Executive Office or Executive Management; Change in Fiscal Year

52

 

SECTION 8.15

Benefit Plans and Agreements

52

 

 

 

 

ARTICLE IX EVENTS OF DEFAULT

53

 

 

 

 

 

SECTION 9.1

Listing of Events of Default

53

 

SECTION 9.2

Action if Bankruptcy

55

 

SECTION 9.3

Action if Other Event of Default

55

 

 

 

 

ARTICLE X MISCELLANEOUS PROVISIONS

56

 

 

 

 

 

SECTION 10.1

Waivers, Amendments, Etc.

56

 

SECTION 10.2

Notices; Time

56

 

SECTION 10.3

Payment of Costs and Expenses

56

 

SECTION 10.4

Indemnification

57

 

SECTION 10.5

Survival

58

 

SECTION 10.6

Severability

58

 

SECTION 10.7

Headings

58

 

SECTION 10.8

Execution in Counterparts, Effectiveness, Etc.

58

 

SECTION 10.9

Governing Law; Entire Agreement

58

 

SECTION 10.10

Successors and Assigns

58

 

SECTION 10.11

Other Transactions

59

 

SECTION 10.12

Forum Selection and Consent to Jurisdiction

59

 

SECTION 10.13

Waiver of Jury Trial

59

 

iii



 

 

SECTION 10.14

Confidentiality

60

 

SECTION 10.15

Exceptions to Confidentiality

61

 

SCHEDULES:

 

Schedule 1.1

 

Competitors

 

 

 

Schedule 1.2

 

Tangible Fixed Assets

 

 

 

Schedule 6.6

 

Material Adverse Change

 

 

 

Schedule 6.7(a)

 

Litigation

 

 

 

Schedule 6.8

 

Existing Subsidiaries

 

 

 

Schedule 6.10

 

Taxes

 

 

 

Schedule 6.15(a)

 

Intellectual Property

 

 

 

Schedule 6.15(b)

 

Intellectual Property Exceptions

 

 

 

Schedule 6.15(b)(v)

 

Intellectual Property Sole Ownership Exceptions

 

 

 

Schedule 6.15(c)

 

Intellectual Property Infringement

 

 

 

Schedule 6.15(e)

 

Infringement Notices

 

 

 

Schedule 6.16

 

Material Agreements

 

 

 

Schedule 6.17

 

Permits

 

 

 

Schedule 6.18(b)

 

Regulatory Actions

 

 

 

Schedule 6.18(c)

 

Regulatory Compliance

 

 

 

Schedule 6.18(d)

 

Key Permit Matters

 

 

 

Schedule 6.18(e)

 

Certain Regulatory Enforcement Matters

 

 

 

Schedule 6.18(g)

 

Certain Regulatory Disclosure Matters

 

 

 

Schedule 6.18(h)

 

Studies, Tests and Clinical and Preclinical Trials

 

 

 

Schedule 6.19

 

Transactions with Affiliates

 

 

 

Schedule 6.22

 

Deposit and Disbursement Accounts

 

 

 

Schedule 7.7

 

Use of Proceeds

 

iv



 

Schedule 8.2(b)

 

Indebtedness to be Paid

 

 

 

Schedule 8.2(c)

 

Existing Indebtedness

 

 

 

Schedule 8.3(c)

 

Existing Liens

 

 

 

Schedule 8.5(a)

 

Investments

 

 

 

Schedule 10.2

 

Notice Information

 

EXHIBITS:

 

Exhibit A

-

 

Form of Promissory Note

Exhibit B

-

 

Form of Loan Request

Exhibit C

-

 

Form of Compliance Certificate

Exhibit D

-

 

Form of Guarantee

Exhibit E

-

 

Form of Security Agreement

 

v


 

CREDIT AGREEMENT

 

THIS CREDIT AGREEMENT dated as of April 18, 2013 (as amended, supplemented or otherwise modified from time to time, this “ Agreement ”), is by and between NATERA, INC., a Delaware corporation (the “ Borrower ”) and ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors, transferees and assignees, the “ Lender ”). The Borrower and the Lender are sometimes referred to herein individually as a “ Party ” and collectively as the “ Parties ”.

 

W I T N E S S E T H :

 

WHEREAS, the Borrower has requested that the Lender provide a senior term loan facility to the Borrower in an aggregate principal amount of $30,000,000 (with $20,000,000 available at the Closing and $10,000,000 available prior to December 31, 2014, subject to the terms and conditions set forth herein); and

 

WHEREAS, the Lender is willing, on the terms and subject to the conditions hereinafter set forth, to extend the Commitment and make the Loans to the Borrower;

 

NOW, THEREFORE, the parties hereto agree as follows.

 

ARTICLE I

DEFINITIONS AND ACCOUNTING TERMS

 

SECTION 1.1 Defined Terms . The following terms (whether or not underscored) when used in this Agreement, including its preamble and recitals, shall, except where the context otherwise requires, have the following meanings (such meanings to be equally applicable to the singular and plural forms thereof):

 

Affiliate ” of any Person means any other Person which, directly or indirectly, Controls, is Controlled by or is under common Control with such Person. “ Control ” (and its correlatives) by any Person means the power of such Person, directly or indirectly, (i) to vote 10% or more of the Voting Securities (determined on a fully diluted basis) of another Person, or (ii) to direct or cause the direction of the management and policies of such other Person (whether by contract or otherwise).

 

Agreement ” is defined in the preamble.

 

Applicable Margin ” means 8.00%.

 

Authorized Officer ” means, relative to the Borrower or any of the Subsidiaries, those of its officers, general partners or managing members (as applicable) whose signatures and incumbency shall have been certified to the Lender pursuant to Section 5.2 .

 

Benefit Plan ” means any employee benefit plan, as defined in section 3(3) of ERISA, that either: (i) is a “multiemployer plan,” as defined in section 3(37) of ERISA, (ii) is subject to section 412 of the Code, section 302 of ERISA or Title IV of ERISA, or (iii) provides welfare

 



 

benefits to terminated employees, other than to the extent required by section 4980B(f) of the Code and the corresponding provisions of ERISA.

 

Borrower ” is defined in the preamble .

 

Borrower LDTs ” means the laboratory-developed tests and associated services or products developed, designed, validated, marketed, and performed by the Borrower and its Subsidiaries, including the Panorama test.

 

Borrower Medical Devices ” means any products researched, developed, marketed, manufactured, stored, distributed by or for the Borrower, including in vitro diagnostic medical devices, reagents, software, sample collection kits and any other device or accessory.

 

Business Day ” means any day which is neither a Saturday or Sunday nor a legal holiday on which banks are authorized or required to be closed in New York, New York, Luxembourg or the Cayman Islands.

 

Capital Securities ” means, with respect to any Person, all shares of, interests or participations in, or other equivalents in respect of (in each case however designated, whether voting or non-voting), of such Person’s capital stock, whether now outstanding or issued after the Closing Date.

 

Capitalized Lease Liabilities ” means, with respect to any Person, all monetary obligations of such Person and its Subsidiaries under any leasing or similar arrangement which have been (or, in accordance with GAAP, should be) classified as capitalized leases, and for purposes of each Loan Document the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP, and the stated maturity thereof shall be the date of the last payment of rent or any other amount due under such lease prior to the first date upon which such lease may be terminated by the lessee without payment of a premium or a penalty.

 

Cash Equivalent Investment ” means, at any time:

 

(a)                                  any direct obligation of (or unconditionally guaranteed by) the United States (or any agency or political subdivision thereof, to the extent such obligations are supported by the full faith and credit of the United States) maturing not more than one year after such time;

 

(b)                                  commercial paper maturing not more than one year from the date of issue, which is issued by a corporation (other than an Affiliate of the Borrower or any of its Subsidiaries) organized under the laws of any state of the United States or of the District of Columbia and rated A-1 or higher by S&P or P-1 or higher by Moody’s;

 

(c)                                   any domestic or Eurodollar certificate of deposit, demand or time deposit or bankers acceptance, maturing not more than 180 days after its date of issuance, issued or placed with any bank or trust company organized under the laws of the United States (or any state thereof) and which has (or is a subsidiary of a bank holding company which has) (x) a credit rating of A2 or higher from Moody’s or A or higher from S&P and (y) a combined capital and surplus greater than $500,000,000; or

 

2



 

(d)                                  investments in money market mutual funds at least 95% of the assets of which are comprised of securities of the types described in clauses (a) through (c) of this definition.

 

Casualty Event ” means the material damage to, or destruction or condemnation of, as the case may be, property of any Person.

 

Change in Control ” means and shall be deemed to have occurred if (except if occurring in connection with an issuance by the Borrower of Capital Securities or other equity interests in connection with a public equity offering or a private equity offering primarily to venture investors for capital raising purposes) (i) any “person” or “group” (within the meaning of Rule 13d-5 of the Securities Exchange Act of 1934 as in effect on the date hereof) shall own, directly or indirectly, beneficially or of record, determined on a fully diluted basis, more than 40% of the Voting Securities of the Borrower; (ii) a majority of the seats (other than vacant seats) on the board of directors (or equivalent) of the Borrower shall at any time be occupied by persons who were neither (x) nominated by the board of directors of the Borrower nor (y) appointed by directors so nominated, or (iii) the Borrower shall cease to directly own, beneficially and of record (other than director’s qualifying shares or investments by foreign nationals to the extent mandated by applicable laws), 100% of the issued and outstanding Capital Securities of the Subsidiaries.

 

Change in Law ” means the occurrence, after the date of this Agreement, of any of the following: (i) the adoption or taking effect of any law, rule, regulation or treaty, (ii) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (iii) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority; provided that, notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law”, regardless of the date enacted, adopted or issued.

 

CLIA ” means the Clinical Laboratory Improvement Amendments of 1988, as amended together with any rule, regulation, interpretation, guidance document, policy, judgment lawfully issued or promulgated thereunder by CMS (or any predecessor entity).

 

CLIA Accreditation ” means a certificate of compliance or certificate of accreditation from an accreditation program approved by CMS permitting a clinical laboratory to perform tests of high complexity.

 

Closing Date ” means the date of the making of the Initial Loan hereunder, which in no event shall be later than April 18, 2013.

 

Closing Date Certificate ” means a closing date certificate executed and delivered by an Authorized Officer of the Borrower in form and substance satisfactory to the Lender.

 

3



 

CMS ” means the U.S. Center for Medicare and Medicaid Services.

 

Code ” means the Internal Revenue Code of 1986, and the regulations thereunder, in each case as amended from time to time.

 

Comerica ” means Comerica Bank, a Texas banking association (together with its successors and assigns).

 

Commitment ” means the Lender’s obligation (if any) to make Loans hereunder.

 

Commitment Amount ” means the Initial Commitment Amount plus the Delayed Draw Commitment Amount.

 

Competitor ” means any Person who competes with the Company in the general field of genetic testing for reproductive indications, including those Persons identified on Schedule 1.1 as updated from time to time.

 

Compliance Certificate ” means a certificate duly completed and executed by an Authorized Officer of the Borrower, substantially in the form of Exhibit C hereto, together with such changes thereto as the Lender may from time to time request for the purpose of monitoring the Borrower’s compliance with the financial covenants contained herein.

 

Confidential Information ” means any and all information or material (whether written or oral, or in electronic or other form) that, at any time before, on or after the Closing Date, has been or is provided or communicated to the Receiving Party by or on behalf of the Disclosing Party pursuant to this Agreement or in connection with the transactions contemplated hereby, and shall include the existence and terms of this Agreement, and shall include all information received from the Disclosing Party or any of its Affiliates relating to the Disclosing Party or its Affiliates, to their respective businesses, or to any Product, other than any such information that is available to the Receiving Party on a non-confidential basis prior to disclosure by the Disclosing Party.

 

Contingent Liability ” means any agreement, undertaking or arrangement by which any Person guarantees, endorses or otherwise becomes or is contingently liable upon (by direct or indirect agreement, contingent or otherwise, to provide funds for payment, to supply funds to, or otherwise to invest in, a debtor, or otherwise to assure a creditor against loss) the Indebtedness of any other Person (other than by endorsements of instruments in the course of collection), or guarantees the payment of dividends or other distributions upon the Capital Securities of any other Person. The amount of any Person’s obligation under any Contingent Liability shall (subject to any limitation set forth therein) be deemed to be the outstanding principal amount of the debt, obligation or other liability guaranteed thereby.

 

Control ” is defined within the definition of “ Affiliate ”.

 

Controlled Account ” is defined in Section 7.13 .

 

Copyrights ” means all copyrights, whether statutory or common law, and all exclusive and nonexclusive licenses from third parties or rights to use copyrights owned by such third

 

4



 

parties, along with any and all (i) renewals, revisions, extensions, derivative works, enhancements, modifications, updates and new releases thereof, (ii) income, royalties, damages, claims and payments now and hereafter due and/or payable with respect thereto, including, without limitation, damages and payments for past, present or future infringements thereof, (iii) rights to sue for past, present and future infringements thereof, and (iv) foreign copyrights and any other rights corresponding thereto throughout the world.

 

Copyright Security Agreement ” means any Copyright Security Agreement executed and delivered by the Borrower or any of the Subsidiaries in substantially the form of Exhibit C to the Security Agreement, as amended, supplemented, amended and restated or otherwise modified from time to time.

 

Default ” means any Event of Default or any condition, occurrence or event which, after notice or lapse of time or both, would constitute an Event of Default.

 

Delayed Draw Closing Date ” means the date of the making of the Delayed Draw Loan hereunder, which in no event shall be later than December 31, 2014.

 

Delayed Draw Commitment Amount ” means $10,000,000.

 

Delayed Draw Commitment Termination Date ” means the earliest to occur of (i) the Delayed Draw Closing Date (immediately after the making of the Delayed Draw Loan on such date), (ii) December 31, 2014, if the Delayed Draw Loan shall not have been made hereunder prior to such date and (iii) the Initial Commitment Termination Date, if the Initial Loan shall not have been made hereunder prior to or on such date.

 

Delayed Draw Loan ” is defined in Section 2.1 .

 

Designated Jurisdiction ” means any country or territory to the extent that such country or territory is the subject of any Sanction.

 

Device ” means any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is (a) recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them, (b) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or (c) intended to affect the structure or any function of the body of man or other animals; and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes.

 

Device Approval Application ” means a premarket approval application (PMA) submitted under Section 515 of the FD&C Act (21 U.S.C. § 360e), a de novo request submitted under Section 513(f) of the FD&C Act (21 U.S.C. § 360c(f)), or premarket notification submitted under Section 510(k) of the FD&C Act (21 U.S.C. § 360(k)) (“510(k)”), as defined in the FD&C Act, or any corresponding foreign application in the Territory (as defined in the Royalty Agreement), including, with respect to the European Union, a submission to a Notified Body for a Certificate of Conformity with an applicable Council Directive.

 

5



 

Disclosing Party ” means the Party disclosing Confidential Information.

 

Disposition ” (or similar words such as “ Dispose ”) means any sale, transfer, lease, license, contribution or other conveyance (including by way of merger) of, or the granting of options, warrants or other rights to, any of the Borrower’s or the Subsidiaries’ assets (including accounts receivable and Capital Securities of Subsidiaries) to any other Person (other than to the Borrower or any of its Subsidiaries) in a single transaction or series of transactions.

 

Disqualified Capital Securities ” shall mean any Capital Securities that, by their terms (or by the terms of any security or other Capital Securities into which they are convertible or for which they are exchangeable) or upon the happening of any event or condition, (a) mature or are mandatorily redeemable (other than solely for Qualified Capital Securities), pursuant to a sinking fund obligation or otherwise (except as a result of a Change in Control or asset sale so long as any rights of the holders thereof upon the occurrence of a Change in Control or asset sale event shall be subject to the prior repayment in full of the Loans and all other Obligations that are accrued and payable and the termination of the Commitment), (b) are redeemable at the option of the holder thereof (other than solely for Qualified Capital Securities) (except as a result of a Change in Control or asset sale so long as any rights of the holders thereof upon the occurrence of a Change in Control or asset sale event shall be subject to the prior repayment in full of the Loans and all other Obligations that are accrued and payable and the termination of the Commitment), in whole or in part, (c) provide for the scheduled payment of dividends in cash or (d) are or become convertible into or exchangeable for Indebtedness or any other Capital Securities that would constitute Disqualified Capital Securities, in each case, prior to the date that is one hundred and eighty-one (181) days after the Maturity Date; provided that if such Capital Securities are issued pursuant to a plan for the benefit of employees of the Borrower or any of its Subsidiaries, or by any such plan to such employees, such Capital Securities shall not constitute Disqualified Capital Securities solely because they may be required to be repurchased by the Borrower or its Subsidiaries in order to satisfy applicable statutory or regulatory obligations.

 

EMA ” means the European Medicines Agency or any successor entity.

 

Environmental Laws ” means all federal, state, local or international laws, statutes, rules, regulations, codes, directives, treaties, requirements, ordinances, orders, decrees, judgments, injunctions, notices or binding agreements issued, promulgated or entered into by any Governmental Authority, relating in any way to the environment, natural resources, Hazardous Material or health and safety matters.

 

Environmental Liability ” means any liability, loss, claim, suit, action, investigation, proceeding, damage or commitment, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of or affecting the Borrower or any Subsidiary directly or indirectly arising from, in connection with or based upon (i) any Environmental Law or Environmental Permit, (ii) the generation, use, handling, transportation, storage, treatment, recycling, presence, disposal, Release or threatened Release of, or exposure to, any Hazardous Materials, or (iii) any contract, agreement, penalty, order, decree, settlement, injunction or other arrangement (including operation of law) pursuant to

 

6



 

which liability is assumed, entered into, inherited or imposed with respect to any of the foregoing.

 

Environmental Permit ” is defined in Section 6.7 .

 

ERISA ” means the Employee Retirement Income Security Act of 1974, as amended from time to time.

 

ERISA Affiliate ” means, as applied to any Person, (i) any corporation that is a member of a controlled group of corporations within the meaning of section 414(b) of the Code of which that Person is a member, (ii) any trade or business (whether or not incorporated) that is a member of a group of trades or businesses under common control within the meaning of section 414(c) of the Code of which that Person is a member, and (iii) any member of an affiliated service group within the meaning of section 414(m) or 414(o) of the Code of which that Person, any corporation described in clause (i) above or any trade or business described in clause (ii) above is a member.

 

Event of Default ” is defined in Section 9.1 .

 

Exchange Act ” means the Securities Exchange Act of 1934, as amended.

 

Excluded Account ” is defined in Section 7.13 .

 

FATCA ” means Sections 1471 through 1474 of the Code, as of the Closing Date (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreements entered into pursuant to Section 1471(b)(1) of the Code.

 

FDA ” means the U.S. Food and Drug Administration and any successor entity.

 

FD&C Act ” means the U.S. Food, Drug and Cosmetic Act (or any successor thereto), as amended from time to time, and the rules, regulations, guidelines, guidance documents and compliance policy guides issued or promulgated thereunder.

 

Fiscal Month ” means a calendar month ending on the last Business Day of that calendar month.

 

Fiscal Quarter ” means a quarter ending on the last day of March, June, September or December.

 

Fiscal Year ” means any period of twelve consecutive calendar months ending on December 31; references to a Fiscal Year with a number corresponding to any calendar year ( e.g. , the “2012 Fiscal Year”) refer to the Fiscal Year ending on December 31 of such calendar year.

 

Foreign Lender ” means a Lender that is organized under the laws of a jurisdiction outside of the United States.

 

7



 

F.R.S. Board ” means the Board of Governors of the Federal Reserve System or any successor thereto.

 

FTC Act ” means the Federal Trade Commission Act.

 

GAAP ” means generally accepted accounting principles in the United States.

 

Governmental Authority ” means any national, supranational, federal, state, county, provincial, local, municipal or other government or political subdivision thereof (including any Regulatory Agency), whether domestic or foreign, and any agency, authority, commission, ministry, instrumentality, regulatory body, court, tribunal, arbitrator, central bank or other Person exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to any such government.

 

Guarantee ” means the guarantee executed and delivered by each Guarantor, substantially in the form of Exhibit D hereto, as amended, supplemented, amended and restated or otherwise modified from time to time.

 

Guarantors ” means, collectively, the Subsidiaries existing on the Closing Date and each future Subsidiary required to execute a Guarantee pursuant to Section 7.8 .

 

Hazardous Material ” means any material, substance, chemical, mixture or waste which is capable of damaging or causing harm to any living organism, the environment or natural resources, including all explosive, special, hazardous, polluting, toxic, industrial, dangerous, biohazardous, medical, infectious or radioactive substances, materials or wastes, noise, odor, electricity or heat, and including petroleum or petroleum products, byproducts or distillates, asbestos or asbestos-containing materials, urea formaldehyde, polychlorinated biphenyls, radon gas, ozone-depleting substances, greenhouse gases, and all other substances or wastes of any nature regulated pursuant to any Environmental Law or as to which any Governmental Authority requires investigation, reporting or remedial action.

 

Hedging Obligations ” means, with respect to any Person, all liabilities of such Person under currency exchange agreements, interest rate swap agreements, interest rate cap agreements and interest rate collar agreements, and all other agreements or arrangements designed to protect such Person against fluctuations in interest rates or currency exchange rates.

 

herein ”, “ hereof ”, “ hereto ”, “ hereunder ” and similar terms contained in any Loan Document refer to such Loan Document as a whole and not to any particular Section, paragraph or provision of such Loan Document.

 

IDE ” means an application, including an application filed with a Regulatory Authority, for authorization to commence human clinical studies, including (a) an Investigational Device Exemption as defined in the FD&C Act or any successor application or procedure filed with the FDA, (b) an abbreviated IDE as specified in FDA regulations in 21 C.F.R. § 812.2(b), (c) any equivalent of a United States IDE in other countries or regulatory jurisdictions, (d) all amendments, variations, extensions and renewals thereof that may be filed with respect to the foregoing and (e) all related documents and correspondence thereto, including documents and correspondence with Institutional Review Boards (IRBs).

 

8



 

Illumina ” is defined in Section 7.16 .

 

Impermissible Qualification ” means any qualification or exception to the opinion or certification of any independent public accountant as to any financial statement of the Borrower (i) which is of a “going concern” or similar nature other than any such qualification in any opinion given in the Fiscal Year of the Maturity Date that is based solely on a determination that the Borrower may not have sufficient cash or other available resources to run the business for the Fiscal Year of the Maturity Date as a result of the Loans maturing during such Fiscal Year, (ii) which relates to the limited scope of examination of matters relevant to such financial statement, or (iii) which relates to the treatment or classification of any item in such financial statement and which, as a condition to its removal, would require an adjustment to such item the effect of which would be to cause the Borrower to be in Default.

 

including ” and “ include ” means including without limiting the generality of any description preceding such term, and, for purposes of each Loan Document, the parties hereto agree that the rule of ejusdem generis shall not be applicable to limit a general statement, which is followed by or referable to an enumeration of specific matters, to matters similar to the matters specifically mentioned.

 

Indebtedness ” of any Person means:

 

(a)                                  all obligations of such Person for borrowed money or advances and all obligations of such Person evidenced by bonds, debentures, notes or similar instruments;

 

(b)                                  all obligations, contingent or otherwise, relative to the face amount of all letters of credit, whether or not drawn, and banker’s acceptances issued for the account of such Person;

 

(c)                                   all Capitalized Lease Liabilities of such Person and all obligations of such Person arising under Synthetic Leases;

 

(d)                                  net Hedging Obligations of such Person;

 

(e)                                   all obligations of such Person in respect of Disqualified Capital Securities;

 

(f)                                    whether or not so included as liabilities in accordance with GAAP, all obligations of such Person to pay the deferred purchase price of property or services (excluding trade accounts payable in the ordinary course of business which are not overdue for a period of more than 90 days or, if overdue for more than 90 days, as to which a dispute exists and adequate reserves in conformity with GAAP have been established on the books of such Person), and indebtedness secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) a Lien on property owned or being acquired by such Person (including indebtedness arising under conditional sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse; and

 

(g)                                   all Contingent Liabilities of such Person in respect of any of the foregoing.

 

9



 

The Indebtedness of any Person shall include the Indebtedness of any other Person (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person’s ownership interest in or other relationship with such Person, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor.

 

Indemnified Liabilities ” is defined in Section 10.4 .

 

Indemnified Parties ” is defined in Section 10.4 .

 

Infringement ” and “ Infringes ” mean the misappropriation or other violation of know-how, trade secrets, confidential information, and/or Intellectual Property.

 

Initial Commitment Amount ” means $20,000,000.

 

Initial Commitment Termination Date ” means the earliest to occur of (i) the Closing Date (immediately after the making of the Initial Loan on such date), and (ii) April 18, 2013, if the Initial Loan shall not have been made hereunder prior to such date.

 

Initial Loan ” is defined in Section 2.1.

 

Intellectual Property ” means all (i) Patents and all patent applications of any type, registrations and renewals, reissues, reexaminations and patent rights in any lawful form thereof; (ii) Trademarks and all applications, registrations and renewals thereof; (iii) Copyrights and other works of authorship (registered or unregistered), and all applications, registrations and renewals therefor; (iv) computer software, databases, data and documentation; (v) trade secrets and confidential business information, whether patentable or unpatentable and whether or not reduced to practice, know-how, inventions, manufacturing processes and techniques, research and development information, data and other information included in or supporting Regulatory Authorizations, including financial, marketing and business data, pricing and cost information, business, finance and marketing plans, customer and prospective customer lists and information, and supplier and prospective supplier lists and information; (vi) other intellectual property or similar proprietary rights; (vii) copies and tangible embodiments of any of the foregoing (in whatever form or medium); and (viii) any and all improvements to any of the foregoing.

 

Intercreditor Agreement ” means the Intercreditor Agreement, dated as of the date hereof, by and among Comerica, the Lender and ROS.

 

Interest Period ” means, (a) initially, the period beginning on (and including) the date on which the Initial Loan is made hereunder pursuant to Section 2.3 and ending on (and including) the last day of the Fiscal Quarter in which the Loan was made, and (b) thereafter, the period beginning on (and including) the first day of each succeeding Fiscal Quarter and ending on the earlier of (and including) (x) the last day of such Fiscal Quarter and (y) the Maturity Date.

 

Investment ” means, relative to any Person, (i) any loan, advance or extension of credit made by such Person to any other Person, including the purchase by such Person of any bonds, notes, debentures or other debt securities of any other Person, (ii) Contingent Liabilities in favor of any other Person, and (iii) any Capital Securities held by such Person in any other Person.

 

10


 

The amount of any Investment shall be the original principal or capital amount thereof less all returns of principal or equity thereon and shall, if made by the transfer or exchange of property other than cash, be deemed to have been made in an original principal or capital amount equal to the fair market value of such property at the time of such Investment.

 

Joint Venture ” means a joint venture, partnership or other similar arrangement, in corporate, partnership or similar legal form.

 

Key Permits ” means all material Permits relating to the Products, including all Regulatory Authorizations.

 

knowledge ” of the Borrower means the actual knowledge of any officer of the Borrower after due inquiry.

 

Lender ” is defined in the preamble.

 

LIBO Rate ” means the three-month London Interbank Offered Rate for deposits in U.S. Dollars at approximately 11:00 a.m. (London, England time), quoted by the Lender from the appropriate Bloomberg or Telerate page selected by the Lender (or any successor thereto or similar source determined by the Lender from time to time), which shall be that three-month London Interbank Offered Rate for deposits in U.S. Dollars in effect two Business Days prior to the last Business Day of the relevant Fiscal Quarter, adjusted for any reserve requirement and any subsequent costs arising from a change in governmental regulation, such rate to be rounded up to the nearest 1/16 of 1% and such rate to be reset quarterly as of the first Business Day of each Fiscal Quarter. If the Initial Loan is advanced other than on the first Business Day of a Fiscal Quarter, the initial LIBO Rate shall be that three-month London Interbank Offered Rate for deposits in U.S. Dollars in effect two Business Days prior to the date of the Initial Loan, which rate shall be in effect until (and including) the last Business Day of the Fiscal Quarter next ending. The Lender’s internal records of applicable interest rates shall be determinative in the absence of manifest error.

 

Lien ” means any security interest, mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or otherwise), charge against or interest in property, or other priority or preferential arrangement of any kind or nature whatsoever, to secure payment of a debt or performance of an obligation.

 

Liquidity ” means, at any time, an amount determined for the Borrower equal to the sum of unrestricted cash-on-hand and Cash Equivalent Investments of the Borrower, to the extent held in a Controlled Account located in the United States.

 

Loan Documents ” means, collectively, this Agreement, the Notes, the Security Agreement, the Royalty Agreement, the Warrant Agreement, each other agreement pursuant to which the Lender is granted a Lien to secure the Obligations (including any mortgages entered into pursuant to Section 7.9 ), the Guarantee, and each other agreement, certificate, document or instrument delivered in connection with any Loan Document, whether or not specifically mentioned herein or therein.

 

11



 

Loan Request ” means a Loan request and certificate duly executed by an Authorized Officer of the Borrower substantially in the form of Exhibit B hereto.

 

Loans ” means the Initial Loan and the Delayed Draw Loan.

 

MAA ” means a marketing authorization application filed with any regulatory authority in the European Union.

 

Material Adverse Effect ” means a material adverse effect on (i) the business, condition (financial or otherwise), operations, or properties of the Borrower or of the Borrower and the Subsidiaries taken as a whole, (ii) the rights and remedies of the Lender under any Loan Document or (iii) the ability of the Borrower or of the Borrower and its Subsidiaries taken as a whole, to perform Obligations under any Loan Document.

 

Material Agreements ” means (i) each contract or agreement to which the Borrower or any Subsidiary is a party involving aggregate payments of more than $[*] in any Fiscal Year, whether such payments are being made by the Borrower or any Subsidiary to a non-Affiliated Person, or by a non-Affiliated Person to the Borrower or any Subsidiary; and (ii) all other contracts or agreements, individually or in the aggregate, material to the business, operations, properties or condition (financial or otherwise) of the Borrower or of the Borrower and its Subsidiaries taken as a whole.

 

Maturity Date ” means April 18, 2019.

 

Moody’s ” means Moody’s Investors Service, Inc.

 

Net Asset Sales Proceeds ” means, with respect to the Disposition (other than Dispositions permitted by Sections 8.8(i), (ii), (iii)  and (iv) ) after the Closing Date by the Borrower or any Subsidiary to any Person of any assets of the Borrower or its Subsidiaries, the excess of gross cash proceeds received by the Borrower from such Disposition over all reasonable and customary costs and expenses, and including Taxes payable by the recipient of such proceeds, incurred in connection with such Disposition which have not been paid to Affiliates of the Borrower in connection therewith.

 

Net Casualty Proceeds ” means, with respect to any Casualty Event, the amount of any insurance proceeds or condemnation awards received by the Borrower or any of the Subsidiaries in connection with such Casualty Event, other than proceeds that are used to repair or replace the assets subject to such Casualty Event within 180 days of receipt of such proceeds with respect to such Casualty Event with like or similar assets of substantially equal or better value and utility, in excess of $1,000,000 per occurrence, or $2,000,000 in the aggregate cumulatively through the Termination Date (in each case net of all reasonable and customary collection expenses thereof), but excluding any proceeds or awards required to be paid to a creditor (other than the Lender) which holds a first priority Lien permitted by clause (f) of Section 8.3 on the property which is the subject of such Casualty Event.

 

956 Impact ” will be deemed to exist to the extent the issuance of a guaranty by, grant of a Lien by, or pledge of greater than two-thirds of the voting Capital Securities or similar equity interests of, a Subsidiary that is a “controlled foreign corporation” within the meaning of Section

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

12



 

957 of the Code, would result in incremental income tax liability as a result of the application of Section 956 of the Code, taking into account actual anticipated repatriation of funds, foreign tax credits and other relevant factors.

 

Net Revenue ” means net sales, distribution income, service payments, license income, and other forms of consideration made to Natera and its Subsidiaries related to all products and services (including all Products) and shall be determined in accordance with GAAP. Net Revenue shall be determined in a manner consistent with the methodologies, practices and procedures used in developing Natera’s audited financial statements.

 

Non-Excluded Taxes ” means any Taxes other than (a) Taxes imposed on or measured by a Person’s net income, and franchise Taxes with respect to the Lender imposed by any Governmental Authority under the laws of which the Lender is organized or in which it maintains its applicable lending office, (b) branch profits taxes imposed by the United States or any similar tax imposed by any other jurisdiction described in paragraph (a) above and (c) (i) any withholding tax that is imposed by the United States on amounts payable to a Foreign Lender at the time such Foreign Lender first becomes a party to this Agreement (or designates a new lending office), except to the extent that such Foreign Lender (or its assignor, if any) was entitled, at the time of designation of a new lending office (or assignment), to receive additional amounts from the Borrower with respect to such withholding tax pursuant to Section 4.3(a) or (ii) any U.S. federal withholding Taxes or other amounts imposed or payable under FATCA.

 

Note ” means a promissory note of the Borrower payable to the Lender, in the form of Exhibit A hereto (as such promissory note may be amended, endorsed or otherwise modified from time to time), evidencing the aggregate Indebtedness of the Borrower to the Lender resulting from the outstanding amount of the Loans, and also means all other promissory notes accepted from time to time in substitution therefor or renewal thereof.

 

Obligations ” means all obligations (monetary or otherwise, whether absolute or contingent, matured or unmatured) of the Borrower and each Subsidiary arising under or in connection with a Loan Document other than the Warrant Agreement and the principal of and premium, if any, and interest (including interest accruing during the pendency of any proceeding of the type described in Section 9.1(h) , whether or not allowed in such proceeding) on the Loans.

 

OFAC ” means the Office of Foreign Assets Control of the United States Department of the Treasury.

 

Organic Document ” means, relative to the Borrower or any Subsidiary, its certificate of incorporation, by-laws, certificate of partnership, partnership agreement, certificate of formation, limited liability agreement, operating agreement and all shareholder agreements, voting trusts and similar arrangements applicable to the Borrower’s or any Subsidiary’s Capital Securities.

 

Other Taxes ” means any and all stamp, documentary or similar Taxes, or any other excise or property Taxes or similar levies that arise on account of any payment made or required to be made under any Loan Document or from the execution, delivery, registration, recording or enforcement of any Loan Document (excluding, for the avoidance of doubt Taxes described in clauses (a), (b) or (c) of the definition of Non-Excluded Taxes).

 

13



 

Other Administrative Proceeding ” means any administrative proceeding relating to a dispute involving a patent office or other relevant intellectual property registry which relates to validity, opposition, revocation, ownership or enforceability of the relevant Intellectual Property.

 

Panorama Net Revenue ” means Net Revenue from the sale of the Borrower’s non-invasive prenatal screening test for the determination of the sex of the fetus and the detection of denovo and inherited genetic abnormalities including, but not limited to, trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), sex chromosome abnormalities, triploidy, micro deletions, microduplications, and disease-linked genetic mutations seen in parent blood samples that may be present in the child.

 

Parallel Entity ” means a Person for which the right to vote at least 30% or more of its Voting Securities is held, directly or indirectly, by (i) stockholders holding at least 50% of the Voting Securities of the Borrower or (ii) Dr. Matthew Rabinowitz and either or both of (a) Sequoia Capital XII and its Affiliates and (b) Claremont Creek Ventures, L.P. and its Affiliates.

 

Party ” and “ Parties ” have the meanings set forth in the preamble hereto.

 

Patent ” means any patent, any type of patent application or invention disclosure, including all divisions, continuations, continuations in-part, provisionals, continued prosecution applications, substitutions, reissues, reexaminations, renewals, extensions, restorations, supplemental protection certificates and patent rights in any form and other additions in connection therewith, whether in or related to the United States or any foreign country or other jurisdiction.

 

Patent Security Agreement ” means any Patent Security Agreement executed and delivered by the Borrower or any of the Subsidiaries in substantially the form of Exhibit A to the Security Agreement, as amended, supplemented, amended and restated or otherwise modified from time to time.

 

Permits ” means all permits, licenses, registrations, certificates, orders, approvals, authorizations, consents, waivers, franchises, variances and similar rights issued by or obtained from any Governmental Authority or any other Person, including, without limitation, those relating to Environmental Laws.

 

Permitted Acquisition ” means the purchase or other acquisition of all of the Capital Securities (other than qualifying directors shares) in, or all or substantially all of the property of, or all or substantially all of any business or division of, any Person (other than any joint venture owned by another Person that is purchased or acquired) that, upon the consummation thereof, will be wholly-owned directly by the Borrower or one or more of its Wholly-Owned Subsidiaries (including as a result of a merger or consolidation); provided that, with respect to each Permitted Acquisition:

 

(a)                                  any such newly-created or acquired Subsidiary shall comply with the requirements of Section 7.8 and the Lender shall have received (or shall receive in connection with the closing of such acquisition) a first priority perfected security interest, subject only to Liens permitted under Section 8.3, in the property (including, without limitation, equity interests) acquired with respect to the entity acquired;

 

14



 

(b)                                  the lines of business of the Person to be (or the property of which is to be) so purchased or otherwise acquired shall be permitted pursuant to Section 8.1;

 

(c)                                   in the case of a purchase or other acquisition of the Capital Securities of another Person, the board of directors (or other comparable governing body) of such other Person shall have duly approved such purchase or other acquisition;

 

(d)                                  the total cash and noncash consideration paid by or on behalf of the Borrower and its Subsidiaries for any such purchase or other acquisition, when aggregated with the consideration paid by or on behalf of the Borrower and its Subsidiaries for all other Permitted Acquisitions after the Closing Date shall not exceed the aggregate amount of $[*] in any Fiscal Year and an aggregate cumulative amount of $[*];

 

(e)                                   immediately before and after giving effect to any such purchase or other acquisition, no Default or Event of Default, shall exist or result therefrom; and

 

(f)                                    the Borrower shall have delivered to the Lender, at least 10 Business Days prior to the date on which any such purchase or other acquisition is to be consummated, a written notice describing such transaction, and thereafter, if requested by the Lender for any such transaction involving consideration in excess of $[*], (i) historical financial statements of or related to the Person or assets to be acquired, (ii) twelve month projections for such Person or assets to be acquired and for Borrower after giving effect to such transaction, and (iii) material documentation and other information relating to such transaction and reasonably requested by the Lender.

 

Permitted Joint Venture ” means any Investment in Joint Ventures customary in the Borrower’s industry; provided that, with respect to each Permitted Joint Venture:

 

(a)                                  the lines of business of the Joint Venture shall be permitted pursuant to Section 8.1;

 

(b)                                  other than as expressly permitted under clause (c) below, there shall be no recourse to the Borrower or any Subsidiary for any Indebtedness or obligations of the Joint Venture;

 

(c)                                   the sum of the aggregate cash amount (including any recourse or assumed Indebtedness referenced in clause (b)) plus the fair market value of tangible assets Invested in Permitted Joint Ventures, together with all Investments pursuant to Section 8.5(k), shall not exceed $[*]; provided that such sum shall not include any loan, advance or extension of credit that has been repaid; and

 

(d)                                  there shall be no transfer or license by the Borrower or any Subsidiary of assets to the Joint Venture other than tangible assets and Intellectual Property for use solely outside of the United States.

 

Permitted Subordinated Indebtedness ” means Indebtedness incurred after the Closing Date by the Borrower or the Subsidiaries that is (i) subordinated to the Obligations and all other

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

15



 

Indebtedness owing from the Borrower or the Subsidiaries to the Lender pursuant to a written subordination agreement satisfactory to the Lender in its sole discretion and (ii) in an amount and on terms approved by the Lender in its sole discretion.

 

Person ” means any natural person, corporation, limited liability company, partnership, joint venture, association, trust or unincorporated organization, Governmental Authority or any other legal entity, whether acting in an individual, fiduciary or other capacity.

 

Privacy Laws ” means all applicable security and privacy standards regarding protected health information under (i) the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, including the regulations promulgated thereunder (collectively “ HIPAA ”) and (ii) any applicable state privacy Laws.

 

Product ” means any service or product (including software products and services) designed, developed, manufactured, licensed, marketed, sold, performed, or otherwise commercialized by the Borrower or any of its Subsidiaries, including Borrower LDTs and Borrower Medical Devices and any such product in development.

 

Product Agreement ” means each agreement, license, document, instrument, interest (equity or otherwise) or the like under which one or more parties grants or receives any right, title or interest with respect to any Product Development and Commercialization Activities in respect of one or more Products specified therein or to exclude third parties from engaging in, or otherwise restricting any right, title or interest as to any Product Development and Commercialization Activities with respect thereto, including each contract or agreement with suppliers (including human tissue supply agreements), manufacturers, distributors, clinical research organizations, hospitals, group purchasing organizations, wholesalers, pharmacies or any other Person related to any such entity.

 

Product Development and Commercialization Activities ” means, with respect to any Product, any combination of research, development, manufacture, import, use, sale, importation, storage, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other commercialization activities, receipt of payment in respect of any of the foregoing, or like activities the purpose of which is to commercially exploit such Product.

 

Purchase Money Indebtedness ” means Indebtedness (1) consisting of the deferred purchase price for equipment incurred in connection with the acquisition of such equipment, where the amount of such Indebtedness does not exceed the greater of (a) the cost of the equipment being financed and (b) the fair market value of such equipment; and (2) incurred to finance such acquisition by the Borrower or a Subsidiary of such equipment.

 

Purchase Orders ” is defined in Section 7.16 .

 

Qualified Capital Securities ” shall mean any Capital Securities that are not Disqualified Capital Securities.

 

Receiving Party ” means the Party receiving Confidential Information.

 

16



 

Recipient ” is defined in Section  10.14 .

 

Refinance ” means, in respect of any Indebtedness, to refinance, extend, renew, repay, prepay, redeem, defease or retire, or to issue other Indebtedness in exchange or replacement for, such Indebtedness.

 

Regulatory Agencies ” means any Governmental Authority that is concerned with the use, control, safety, efficacy, reliability, manufacturing, marketing, distribution, sale or other Product Development and Commercialization Activities relating to any Product of the Borrower or any of the Subsidiaries, including CMS, FDA, and all similar agencies in other jurisdictions, and includes Standard Bodies.

 

Regulatory Authorizations ” means all approvals, clearances, notifications, authorizations, orders, exemptions, registrations, certifications, licenses and permits granted by, submitted to or filed with any Regulatory Agencies necessary for the manufacture, development, distribution, use, storage, import, export, transport, promotion, marketing, sale or other commercialization of any Product in any country or jurisdiction, including any Device Approval Application and CLIA Accreditation.

 

Related Parties ” means the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of the Borrower and the Subsidiaries.

 

Release ” means any releasing, disposing, discharging, injecting, spilling, leaking, leaching, pumping, pouring, dumping, depositing, emitting, escaping, emptying, seeping, dispersal, migrating or placing, including movement through, into or upon the environment or any natural or man-made structure.

 

Repayment Premium ” means a premium of ten percent (10%) of the principal amount of any prepayment or repayment of the Borrower on the Initial Loan or the Delayed Draw Loan, as applicable.

 

Restricted Payment ” means (i) the declaration or payment of any dividend on, or the making of any payment or distribution on account of, or setting apart assets for a sinking or other analogous fund for the purchase, redemption, defeasance, retirement or other acquisition of, any class of Capital Securities of the Borrower or any Subsidiary or any warrants, options or other right or obligation to purchase or acquire any such Capital Securities, whether now or hereafter outstanding, or (ii) the making of any other distribution in respect of such Capital Securities, in each case either directly or indirectly, whether in cash, property or obligations of the Borrower or any Subsidiary or otherwise.

 

Revenue Base ” means, with respect to any period, the Net Revenue of all Products for such period.

 

ROS ” means Royalty Opportunities S.à r.l, a Luxembourg société à responsabilité limitée.

 

17



 

Royalty Agreement ” means the Royalty Agreement, dated as of the date hereof, among the Borrower and ROS.

 

S&P ” means Standard & Poor’s Rating Services, a division of The McGraw-Hill Companies, Inc.

 

Sanctions ” means any international economic sanction administered or enforced by the United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union, Her Majesty’s Treasury or other relevant sanctions authority.

 

SEC ” means the Securities and Exchange Commission.

 

Security Agreement ” means the Pledge and Security Agreement executed and delivered by each of the parties thereto, substantially in the form of Exhibit E hereto, as amended, supplemented, amended and restated or otherwise modified from time to time.

 

Solvent ” means, with respect to any Person on a particular date, that on such date (i) the fair value of the property of such Person is greater than the total amount of liabilities, including contingent liabilities, of such Person, (ii) the present fair saleable value of the assets of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured, (iii) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond its ability to pay as such debts and liabilities mature, (iv) such Person is not engaged in a business or a transaction, and is not about to engage in a business or a transaction, for which the property of such Person would constitute an unreasonably small capital and (v) such Person has not executed this Agreement or any other Loan Document, or made any transfer or incurred any obligations hereunder or thereunder, with actual intent to hinder, delay or defraud either present or future creditors. The amount of Contingent Liabilities at any time shall be computed as the amount that, in light of all the facts and circumstances existing at such time, can reasonably be expected to become an actual or matured liability.

 

Standard Bodies ” means any of the organizations that create, sponsor or maintain safety, quality or other standards, including ISO, ANSI, CEN and SCC and the like.

 

Subsidiary ” means, with respect to any Person, any other Person of which more than 50% of the outstanding Voting Securities of such other Person (irrespective of whether at the time Capital Securities of any other class or classes of such other Person shall or might have voting power upon the occurrence of any contingency) is at the time directly or indirectly owned or controlled by such Person, by such Person and one or more other Subsidiaries of such Person, or by one or more other Subsidiaries of such Person. Unless the context otherwise specifically requires, the term “Subsidiary” shall be a reference to a Subsidiary of Borrower.

 

Synthetic Lease ” means, as applied to any Person, any lease (including leases that may be terminated by the lessee at any time) of any property (whether real, personal or mixed) (i) that is not a capital lease in accordance with GAAP and (ii) in respect of which the lessee retains or obtains ownership of the property so leased for federal income tax purposes, other than any such lease under which that Person is the lessor.

 

18



 

Tangible Fixed Assets “ means the equipment set forth on Schedule 1.2 hereto and other tangible fixed assets acquired with the proceeds of Indebtedness permitted pursuant to Section 8.2(e).

 

Taxes ” means all income, stamp or other taxes, duties, levies, imposts, charges, assessments, fees, deductions or withholdings, now or hereafter imposed, levied, collected, withheld or assessed by any Governmental Authority, and all interest, penalties or similar liabilities with respect thereto.

 

Third Party ” means any Person other than the Borrower or any of its Subsidiaries.

 

Termination Date ” means the date on which all Obligations in respect of the Loans have been paid in full in cash and the Commitment shall have terminated.

 

Trademark ” means any trademark, service mark, trade name, logo, symbol, trade dress, domain name, corporate name or other indicator of source or origin, and all applications and registrations therefor, together with all of the goodwill associated therewith.

 

Trademark Security Agreement ” means any Trademark Security Agreement executed and delivered by the Borrower or any of the Subsidiaries substantially in the form of Exhibit B to any Security Agreement, as amended, supplemented, amended and restated or otherwise modified from time to time.

 

UCC ” means the Uniform Commercial Code as in effect from time to time in the State of New York; provided that, if, with respect to any financing statement or by reason of any provisions of law, the perfection or the effect of perfection or non-perfection of the security interests granted to the Lender pursuant to the applicable Loan Document is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than New York, then “UCC” means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of each Loan Document and any financing statement relating to such perfection or effect of perfection or non-perfection.

 

United States ” or “ U.S. ” means the United States of America, its fifty states and the District of Columbia.

 

Voting Securities ” means, with respect to any Person, Capital Securities of any class or kind ordinarily having the power to vote for the election of directors, managers or other voting members of the governing body of such Person.

 

Warrant Agreement ” means the Warrant Agreement, dated as of the date hereof, among the Borrower and Royalty Opportunities S.à r.l.

 

Wholly-Owned Subsidiary ” means any direct or indirect Subsidiaries of Borrower, all of the outstanding Capital Securities of which (other than any director’s qualifying shares or investments by foreign nationals mandated by applicable laws) is owned directly or indirectly by Borrower.

 

19


 

SECTION 1.2 Use of Defined Terms . Unless otherwise defined or the context otherwise requires, terms for which meanings are provided in this Agreement shall have such meanings when used in each other Loan Document and the schedules attached hereto.

 

SECTION 1.3 Cross-References . Unless otherwise specified, references in a Loan Document to any Article or Section are references to such Article or Section of such Loan Document, and references in any Article, Section or definition to any clause are references to such clause of such Article, Section or definition.

 

SECTION 1.4 Accounting and Financial Determinations . Unless otherwise specified, all accounting terms used in each Loan Document shall be interpreted, and all accounting determinations and computations thereunder (including under Section 8.4 and the definitions used in such calculations) shall be made, in accordance with GAAP, as in effect from time to time; provided that, if either the Borrower or the Lender requests an amendment to any provision hereof to eliminate the effect of any change occurring after the date hereof in GAAP or the application thereof on the operation of such provision, regardless of whether any such notice is given before or after such change in GAAP or the application thereof, then such provision shall be interpreted on the basis of GAAP in effect and applied immediately before such change shall have become effective until such request shall have been withdrawn or such provision amended in accordance herewith. Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed on a consolidated basis for the Borrower and the Subsidiaries, in each case without duplication.

 

SECTION 1.5 Other Loan Documents . Notwithstanding anything in the Intercreditor Agreement or any other Loan Document to the contrary, nothing in the Intercreditor Agreement or any other Loan Document shall permit the Borrower to take any actions or omit to take any actions in violation of this Agreement.

 

ARTICLE II

COMMITMENT AND BORROWING PROCEDURES

 

SECTION 2.1 Commitment . On the terms and subject to the conditions of this Agreement, the Lender agrees to make a term loan (the “ Initial Loan ”) to the Borrower on the Closing Date in an amount equal to (but not less than) the Initial Commitment Amount. On the terms and subject to the conditions of this Agreement, the Lender agrees to make a term loan (the “ Delayed Draw Loan ”) to the Borrower on the Delayed Draw Closing Date in an amount equal to (but not less than) the Delayed Draw Commitment Amount. No amounts paid or prepaid with respect to the Loans may be reborrowed.

 

SECTION 2.2 Borrowing Procedure . The Borrower may irrevocably request that the Initial Loan be made by delivering to the Lender a Loan Request on or before 10:00 a.m. on a Business Day at least three Business Days prior to the proposed Closing Date. The Borrower may irrevocably request that the Delayed Draw Loan be

 

20



 

made by delivering to the Lender a Loan Request on or before 10:00 a.m. on a Business Day at least three Business Days prior to the proposed Delayed Draw Closing Date.

 

SECTION 2.3 Funding . After receipt of the Loan Request for the Initial Loan, the Lender shall, on the Closing Date and subject to the terms and conditions hereof, make the requested proceeds of the Initial Loan available to the Borrower by wire transfer to the account the Borrower shall have specified in its Loan Request. After receipt of the Loan Request for the Delayed Draw Loan, the Lender shall, on the Delayed Draw Closing Date and subject to the terms and conditions hereof, make the requested proceeds of the Delayed Draw Loan available to the Borrower by wire transfer to the account the Borrower shall have specified in its Loan Request.

 

SECTION 2.4 Reduction of the Commitment Amounts . The Initial Commitment Amount shall automatically and permanently be reduced to zero on the Initial Commitment Termination Date. The Delayed Draw Commitment Amount shall automatically and permanently be reduced to zero on the Delayed Draw Commitment Termination Date.

 

ARTICLE III

REPAYMENTS, PREPAYMENTS, INTEREST AND FEES

 

SECTION 3.1 Repayments and Prepayments; Application . The Borrower agrees that the Loans, and any fees or interest accrued or accruing thereon, shall be repaid and prepaid solely in U.S. dollars pursuant to the terms of this Article III .

 

SECTION 3.2 Repayments and Prepayments . The Borrower shall repay in full the unpaid principal amount of the Loans on the Maturity Date. Prior thereto, payments and prepayments of the Loans shall be made as set forth below.

 

(a)                                  The Borrower shall have the right, with at least three Business Days’ notice to the Lender, at any time and from time to time to prepay any unpaid principal amount of the Loans, in whole or in part.

 

(b)                                  Within three Business Days of receipt by the Borrower of any (i) Net Casualty Proceeds or (ii) Net Asset Sales Proceeds, the Borrower shall notify the Lender thereof. If requested by the Lender, the Borrower shall within three Business Days of such request make a mandatory prepayment of the Loans, in an amount equal to 100% of such proceeds (or such lesser amount as the Lender may specify on the date of such request), to be applied as set forth in Section 3.3 and in Section 3.7.

 

(c)                                   The Borrower shall repay the Loans in full immediately upon any acceleration of the Maturity Date thereof pursuant to Section 9.2 or Section 9.3 , unless, pursuant to Section 9.3 , only a portion of the Loans is so accelerated (in which case the portion so accelerated shall be so repaid).

 

SECTION 3.3 Application . Except as provided in Section 4.4(b) , amounts repaid or prepaid in respect of the outstanding principal amount of the Loans pursuant

 

21



 

to clauses (b) or (c) of Section 3.2 shall be applied pro rata to the Initial Loan and Delayed Draw Term Loan.

 

SECTION 3.4 Interest Rate . During any applicable Interest Period, the Loans shall accrue interest during such Interest Period at a rate per annum equal to the sum of (i) the Applicable Margin plus (ii) the higher of (x) the LIBO Rate for such Interest Period and (y) 1.00%. The interest rate shall be recalculated and, if necessary, adjusted for each Interest Period, in each case pursuant to the terms hereof.

 

SECTION 3.5 Default Rate . At all times commencing upon the date any Event of Default occurs, and continuing until such Event of Default is no longer continuing, the Applicable Margin shall be increased by 5% per annum.

 

SECTION 3.6 Payment Dates . Interest accrued on the Loans shall be payable in cash, without duplication:

 

(a)                                  on the Maturity Date therefor;

 

(b)                                  on the date of any payment or prepayment, in whole or in part, of principal outstanding on such Loan on the principal amount so paid or prepaid;

 

(c)                                   on the last day of each Fiscal Quarter; provided that if such day is not a Business Day, then such payment shall be made on the next succeeding Business Day; and

 

(d)                                  on that portion of the Loans that is accelerated pursuant to Section 9.2 or Section 9.3 , immediately upon such acceleration.

 

Interest accrued on the Loans or other monetary Obligations after the date such amount is due and payable (whether on the Maturity Date, upon acceleration or otherwise) shall be payable upon demand.

 

SECTION 3.7 Repayment Premium . Any repayment of principal pursuant to this Article III (other than any repayments of principal due on the Maturity Date) shall be accompanied by the Repayment Premium; provided that, if the Maturity Date is accelerated pursuant to a breach of Section 8.4 (which breach constitutes an Event of Default under Section 9.1(c ), the Borrower shall not have to pay the Repayment Premium; and provided , further , that if any prepayment is required pursuant to Section 3.2(b) , the amount of the required principal prepayment shall be reduced such that the sum of such required principal prepayment plus the applicable Repayment Premium shall equal 100% of the Net Asset Sale Proceeds or the Net Casualty Sale Proceeds, as applicable (or such lesser amount as required to be prepaid by the Lender pursuant to Section 3.2(b) ).

 

22



 

ARTICLE IV

LIBO RATE AND OTHER PROVISIONS

 

SECTION 4.1 Increased Costs, Etc . The Borrower agrees to reimburse the Lender for any increase in the cost to the Lender of, or any reduction in the amount of any sum receivable by the Lender in respect of, the Lender’s Commitment and the making, continuation or maintaining of the Loans hereunder that may arise in connection with any Change in Law, except for such changes with respect to increased capital costs and Taxes which are governed by Section 4.2 and Section 4.3 , respectively. The Lender shall notify the Borrower in writing of the occurrence of any such event, stating the reasons therefor and the additional amount required fully to compensate the Lender for such increased cost or reduced amount. Such additional amounts shall be payable by the Borrower directly to the Lender within ten Business Days of its receipt of such notice, and such notice shall, in the absence of manifest error, be conclusive and binding on the Borrower. Failure or delay on the part of the Lender to demand compensation pursuant to this Section 4.1 shall not constitute a waiver of such Lender’s right to demand such compensation; provided that the Borrower shall not be required to compensate the Lender pursuant to this Section for any increased costs or reductions incurred more than 180 days prior to the date that such Lender notifies the Borrower of the Change in Law giving rise to such increased costs or reductions and of such Lender’s intention to claim compensation therefor; provided further that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the 180-day period referred to above shall be extended to include the period of retroactive effect thereof.

 

SECTION 4.2 Increased Capital Costs . If any Change in Law affects or would affect the amount of capital required or expected to be maintained by the Lender or any Person controlling the Lender, and the Lender determines (in good faith and in its reasonable discretion) that the rate of return on its or such controlling Person’s capital as a consequence of the Commitment or the Loans made by it hereunder is reduced to a level below that which the Lender or such controlling Person could have achieved but for the occurrence of any such circumstance, then upon notice from time to time by the Lender to the Borrower, the Borrower shall within ten Business Days following receipt of such notice pay directly to the Lender additional amounts sufficient to compensate the Lender or such controlling Person for such reduction in rate of return. A statement of the Lender as to any such additional amount or amounts shall, in the absence of manifest error, be prima facie evidence of the accuracy thereof. In determining such amount, the Lender may use any method of averaging and attribution that it (in its reasonable discretion) shall deem applicable.

 

SECTION 4.3 Taxes . The Borrower covenants and agrees as follows with respect to Taxes.

 

(a)                                  Any and all payments by the Borrower under each Loan Document shall be made without setoff, counterclaim or other defense, and free and clear of, and without deduction or withholding for or on account of, any Taxes. In the event that any Taxes are imposed and required to be deducted or withheld from any payment required to be made by the Borrower or any of the Subsidiaries to or on behalf of the Lender under any Loan Document, then:

 

23



 

(i)                                       if such Taxes are Non-Excluded Taxes, the amount of such payment shall be increased as may be necessary so that such payment is made, after withholding or deduction for or on account of such Taxes, in an amount that is not less than the amount provided for in such Loan Document; and

 

(ii)                                    the Borrower shall withhold the full amount of such Taxes from such payment (as increased pursuant to clause (a)(i) and shall pay such amount to the Governmental Authority imposing such Taxes in accordance with applicable law.

 

(b)                                  In addition, the Borrower shall pay all Other Taxes imposed to the relevant Governmental Authority imposing such Other Taxes in accordance with applicable law.

 

(c)                                   As promptly as practicable after the payment of any Taxes or Other Taxes required to be paid by the Borrower under Section 4.3(a) , or (b) , and in any event within 45 days of any such payment being due (as may be extended by if contested in good faith by appropriate proceedings), the Borrower shall furnish to the Lender a copy of an official receipt (or a certified copy thereof) evidencing the payment of such Taxes or Other Taxes.

 

(d)                                  The Borrower shall indemnify the Lender for any Non-Excluded Taxes and Other Taxes levied, imposed or assessed on (and whether or not paid directly by) the Lender whether or not such Non-Excluded Taxes or Other Taxes are correctly or legally asserted by the relevant Governmental Authority. Promptly upon having knowledge that any such Non-Excluded Taxes or Other Taxes have been levied, imposed or assessed, and promptly upon notice thereof by the Lender, the Borrower shall pay such Non-Excluded Taxes or Other Taxes directly to the relevant Governmental Authority. In addition, the Borrower shall indemnify the Lender for any incremental Taxes that may become payable by the Lender as a result of any failure of the Borrower to pay any Taxes when due and for which it has received timely notice to the appropriate Governmental Authority or to deliver to the Lender, pursuant to clause (c) , documentation evidencing the payment of Taxes or Other Taxes. With respect to indemnification for Non-Excluded Taxes and Other Taxes actually paid by the Lender or the indemnification provided in the immediately preceding sentence, such indemnification shall be made within 30 days after the date the Lender makes written demand therefor. The Borrower acknowledges that any payment made to the Lender or to any Governmental Authority in respect of the indemnification obligations of the Borrower provided in this clause shall constitute a payment in respect of which the provisions of clause (a) and this clause shall apply.

 

SECTION 4.4 Payments, Computations; Proceeds of Collateral, Etc .

 

(a)                                  Unless otherwise expressly provided in a Loan Document, all payments by the Borrower pursuant to each Loan Document shall be made without setoff, deduction or counterclaim not later than 2:00 p.m. on the date due in same day or immediately available funds to such account as the Lender shall specify from time to time by notice to the Borrower. Funds received after 2:00 p.m. on any day shall be deemed to have been

 

24



 

received by the Lender on the next succeeding Business Day. All interest and fees shall be computed on the basis of the actual number of days (including the first day but excluding the last day) occurring during the period for which such interest or fee is payable over a year comprised of 360 days. Payments due on other than a Business Day shall be made on the next succeeding Business Day and such extension of time shall be included in computing interest and fees in connection with that payment.

 

(b)                                  All amounts received as a result of the exercise of remedies under the Loan Documents (including from the proceeds of collateral securing the Obligations) or under applicable law shall be applied upon receipt to the Obligations as follows: (i) first, to the payment in full in cash of all interest (including interest accruing after the commencement of a proceeding in bankruptcy, insolvency or similar law, whether or not permitted as a claim under such law) and fees owing under the Loan Documents, and all costs and expenses owing to the Lender pursuant to the terms of the Loan Documents, until paid in full in cash, (ii) second, after payment in full in cash of the amounts specified in clause (b)(i) , to the payment of the principal amount of the Loans then outstanding, (iii) third, after payment in full in cash of the amounts specified in clauses (b)(i) and (b)(ii) , to the payment of all other Obligations owing to the Lender, and (iv) fourth, after payment in full in cash of the amounts specified in clauses (b)(i) through (b)(iii) , and following the Termination Date, to the Borrower or any other Person lawfully entitled to receive such surplus.

 

SECTION 4.5 Setoff . The Lender shall, upon the occurrence and during the continuance of any Default described in clauses (i) through (iv) of Section 9.1(h) or, upon the occurrence and during the continuance of any other Event of Default, have the right to appropriate and apply to the payment of the Obligations owing to it (whether or not then due), and (as security for such Obligations) the Borrower hereby grants to the Lender a continuing security interest in, any and all balances, credits, deposits, accounts or moneys of the Borrower then or thereafter maintained with or on behalf of the Lender. The Lender agrees promptly to notify the Borrower after any such appropriation and application made by the Lender; provided that, the failure to give such notice shall not affect the validity of such setoff and application. The rights of the Lender under this Section are in addition to other rights and remedies (including other rights of setoff under applicable law or otherwise) which the Lender may have.

 

SECTION 4.6 LIBO Rate Not Determinable . If prior to the commencement of any Interest Period, adequate and reasonable means do not exist for ascertaining the LIBO Rate for such Interest Period, then the Lender shall give notice thereof to the Borrower as promptly as practicable. In the event of any such determination, the Loans shall, until the Lender has advised the Borrower that the circumstances giving rise to such notice no longer exist, bear interest at the interest rate in effect for the immediately preceding Interest Period.

 

25



 

ARTICLE V

CONDITIONS TO MAKING THE LOANS

 

SECTION 5.1 Credit Extensions . The obligation of the Lender to make the Initial Loan shall be subject to the execution and delivery of this Agreement by the parties hereto, the delivery of a Loan Request as requested pursuant to Section 2.3 , and the satisfaction of each of the conditions precedent set forth below in this Article (other than Sections 5.19 and 5.20 ). The obligation of the Lender to make the Delayed Draw Loan shall be subject to the prior making of the Initial Loan, the delivery of a Loan Request as requested pursuant to Section 2.3 , and the satisfaction of each of the conditions precedent set forth below in Sections 5.3 , 5.8 , 5.19 and 5.20 .

 

SECTION 5.2 Secretary’s Certificate, Etc . The Lender shall have received from the Borrower and each Subsidiary party to a Loan Document, (i) a copy of a good standing certificate, dated a date reasonably close to the Closing Date, for each such Person and (ii) a certificate, dated as of the Closing Date, duly executed and delivered by such Person’s Secretary or Assistant Secretary, managing member or general partner, as applicable, as to

 

(a)                                  resolutions of each such Person’s Board of Directors (or other managing body, in the case of other than a corporation) then in full force and effect authorizing the execution, delivery and performance of each Loan Document to be executed by such Person and the transactions contemplated hereby and thereby;

 

(b)                                  the incumbency and signatures of those of its officers, managing member or general partner, as applicable, authorized to act with respect to each Loan Document to be executed by such Person; and

 

(c)                                   the full force and validity of each Organic Document of such Person and copies thereof;

 

upon which certificates the Lender may conclusively rely until it shall have received a further certificate of the Secretary, Assistant Secretary, managing member or general partner, as applicable, of any such Person canceling or amending the prior certificate of such Person.

 

SECTION 5.3 Closing Date Certificate . The Lender shall have received a Closing Date Certificate, dated as of the Closing Date or Delayed Draw Closing Date, as the case may be, and duly executed and delivered by an Authorized Officer of the Borrower, in which certificate the Borrower shall agree and acknowledge that the statements made therein shall be deemed to be true and correct representations and warranties of the Borrower as of such date, and, at the time such certificate is delivered, such statements shall in fact be true and correct, and such statements shall include that (i) the representations and warranties set forth in each Loan Document shall, in each case, be true and correct, (ii) no Default shall have then occurred and be continuing, or would result from the Loan to be advanced on the Closing Date or Delayed Draw Closing Date, as the case may be, and (c) all of the conditions set forth in this Article V have been satisfied. All documents and agreements required to be appended to the Closing Date Certificate, if any, shall be in form and substance satisfactory to the Lender, shall have been executed and delivered by the requisite parties, and shall be in full force and effect.

 

26



 

SECTION 5.4 Payment of Outstanding Indebtedness, Etc . All Indebtedness identified in Schedule 8.2(b) , together with all interest, all prepayment premiums and all other amounts due and payable with respect thereto, shall have been paid in full from the proceeds of the Loan and the commitments in respect of such Indebtedness shall have been terminated, and all Liens securing payment of any such Indebtedness shall have been released and the Lender shall have received all Uniform Commercial Code Form UCC-3 termination statements or other instruments (including customary payoff letters) as may be suitable or appropriate in connection therewith.

 

SECTION 5.5 Delivery of Note . The Lender shall have received a Note duly executed and delivered by an Authorized Officer of the Borrower.

 

SECTION 5.6 Financial Information, Etc . The Lender shall have received

 

(a)                                  audited consolidated financial statements of the Borrower and the Subsidiaries for each of the fiscal years ended December 31, 2010 and December 31, 2011.

 

(b)                                  unaudited consolidated balance sheets of the Borrower and the Subsidiaries for each fiscal quarter ended after January 1, 2012 and prior to January 1, 2013, together with the related consolidated statement of operations, shareholder’s equity and cash flows for the twelve months then ended; and

 

(c)                                   such other financial information as to the Borrower and the Subsidiaries and their respective businesses, assets and liabilities as the Lender may reasonably request.

 

SECTION 5.7 Intentionally Omitted .

 

SECTION 5.8 Solvency, Etc . The Lender shall have received a solvency certificate duly executed and delivered by the chief financial or accounting Authorized Officer of the Borrower, dated as of the Closing Date or Delayed Draw Closing Date, as the case may be, in form and substance satisfactory to the Lender.

 

SECTION 5.9 Guarantee . The Lender shall have received executed counterparts of the Guarantee, dated as of the date hereof, duly executed and delivered by each Subsidiary.

 

SECTION 5.10 Security Agreements . The Lender shall have received executed counterparts of the Security Agreement, dated as of the date hereof, duly executed and delivered by the Borrower and each Subsidiary, together with

 

(a)                                  certificates (in the case of Capital Securities that are securities (as defined in the UCC)) evidencing all of the issued and outstanding Capital Securities owned by the Borrower or any Subsidiary in the Borrower and the Subsidiaries, which certificates in each case shall be accompanied by undated instruments of transfer duly executed in blank, or, in the case of Capital Securities that are uncertificated securities (as defined in the UCC), confirmation and evidence satisfactory to the Lender that the security interest

 

27



 

therein has been transferred to and perfected by the Lender in accordance with Articles 8 and 9 of the UCC.

 

(b)                                  financing statements suitable in form for naming the Borrower and each Subsidiary as a debtor and the Lender as the secured party, or other similar instruments or documents to be filed under the UCC of all jurisdictions as may be necessary or, in the opinion of the Lender, desirable to perfect the security interests of the Lender pursuant to the Security Agreement;

 

(c)                                   UCC Form UCC-3 termination statements, if any, necessary to release all Liens and other rights of any Person (i) in any assets of the Borrower or any Subsidiary, and (ii) securing any of the Indebtedness identified in Schedule 8.2(b) , together with such other UCC Form UCC-3 termination statements as the Lender may reasonably request from the Borrower or any Subsidiary;

 

(d)                                  landlord access agreements and bailee letters in form and substance satisfactory to the Lender from each landlord to the Borrower or any Subsidiary and each other Person that has possession of any Collateral (as defined in the Security Agreement); and

 

(e)                                   evidence that all deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar accounts of the Borrower and each Subsidiary are Controlled Accounts.

 

SECTION 5.11 Intellectual Property Security Agreements . The Lender shall have received a Patent Security Agreement, a Copyright Security Agreement and a Trademark Security Agreement, as applicable, each dated as of the Closing Date, duly executed and delivered by the Borrower or any Subsidiary that, pursuant to the Security Agreement, is required to provide such intellectual property security agreements to the Lender.

 

SECTION 5.12 Royalty Agreement . The Lender shall have received an executed counterpart of the Royalty Agreement, dated as of the date hereof, executed and delivered by an Authorized Officer of the Borrower.

 

SECTION 5.13 Warrant Agreement . The Lender shall have received an executed counterpart of the Warrant Agreement, dated as of the date hereof, executed and delivered by an Authorized Officer of the Borrower.

 

SECTION 5.14 Opinions of Counsel . The Lender shall have received opinions, dated the Closing Date and addressed to the Lender, from

 

(a)                                  Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Borrower and the Subsidiaries, in form and substance satisfactory to the Lender; and

 

(b)                                  Chapman and Cutler LLP counsel to the Borrower and the Subsidiaries, in form and substance satisfactory to the Lender.

 

28



 

SECTION 5.15 Insurance . The Lender shall have received certified copies of the insurance policies (or binders in respect thereof), from one or more insurance companies satisfactory to the Lender, evidencing coverage required to be maintained pursuant to each Loan Document, with the Lender named as loss payee or additional insured, as applicable.

 

SECTION 5.16 Closing Fees, Expenses, Etc . The Lender shall have received for its own account all fees, costs and expenses due and payable pursuant to Section 10.3 .

 

SECTION 5.17 Anti-Terrorism Laws . The Lender shall have received, as applicable, all documentation and other information required by bank regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including the U.S.A. Patriot Act.

 

SECTION 5.18 Satisfactory Legal Form . All documents executed or submitted pursuant hereto by or on behalf of the Borrower or any Subsidiary shall be satisfactory in form and substance to the Lender and its counsel, and the Lender and its counsel shall have received all information, approvals, resolutions, opinions, documents or instruments as the Lender or its counsel may reasonably request.

 

SECTION 5.19 U.S. Panorama Net Revenue . The Lender shall be satisfied that the Panorama Net Revenue for sales in the United States for the twelve full calendar months prior to the Delayed Draw Closing Date was at least $[*]; provided that such Panorama Net Revenue will exclude any advancement of revenues due to changing any specific previously deferred revenue amounts to comply with GAAP and related deferral/cash accounting basis. For the avoidance of doubt, the measurement period will not include more than twelve months as the measurement period of Net Revenue.

 

SECTION 5.20 Disclosure Schedules . Immediately prior to the Delayed Draw Closing Date, the Borrower shall deliver to the Lender updates to Schedules 6.15(a) , 6.16 , 6.19 and 6.22 , each such updated Schedule to be complete and accurate as of the Delayed Draw Closing Date. The Borrower may update Schedule 1.1 from time to time with the consent of the Lender (such consent not to be unreasonably withheld or delayed).

 

ARTICLE VI

REPRESENTATIONS AND WARRANTIES

 

In order to induce the Lender to enter into this Agreement and to make the Loans hereunder, the Borrower represents and warrants, in each case (unless otherwise stated) on the Closing Date and on the Delayed Drawing Closing Date, to the Lender as set forth in this Article. For the avoidance of doubt, no representation or warranty in this Article VI is made on the Delayed Drawing Closing Date until immediately prior to the making of the Delayed Draw Loan.

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

29


 

SECTION 6.1 Organization, Etc The Borrower and each Subsidiary (a) is validly organized and existing and in good standing under the laws of the jurisdiction of its incorporation or organization, is duly qualified to do business and is in good standing as a foreign entity in each jurisdiction where the nature of its business requires such qualification (unless the failure to so qualify as a foreign entity could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect), and (b) has full power and authority and holds all requisite governmental licenses, permits and other approvals required (i) to enter into and perform its Obligations under each Loan Document to which it is a party, and (ii) to own and hold under lease its property and to conduct its business in all material respects substantially as currently conducted by it.

 

SECTION 6.2 Due Authorization, Non-Contravention, Etc . The execution, delivery and performance by the Borrower and each Subsidiary of each Loan Document executed or to be executed by it are in each case within such Person’s powers, have been duly authorized by all necessary action, and do not

 

(a)                                  contravene (i) the Borrower’s or any Subsidiary’s Organic Documents, (ii) any court decree or order binding on or affecting the Borrower or any Subsidiary or (iii) any law or governmental regulation binding on or affecting the Borrower or any Subsidiary; or

 

(b)                                  result in (i) or require the creation or imposition of any Lien on the Borrower’s or any Subsidiary’s properties (except as permitted by this Agreement) or (ii) a default under any material contract, agreement, or instrument binding on or affecting the Borrower or any Subsidiary.

 

SECTION 6.3 Government Approval, Regulation, Etc . No authorization or approval or other action by, and no notice to or filing with, any Governmental Authority or other Person (other than those that have been, or on the Closing Date will be, duly obtained or made and which are, or on the Closing Date will be, in full force and effect) is required for the due execution, delivery or performance by the Borrower or any Subsidiary of any Loan Document to which it is a party.

 

SECTION 6.4 Validity, Etc . Each Loan Document to which the Borrower or any Subsidiary is a party constitutes the legal, valid and binding obligations of such Person enforceable against such Person in accordance with its respective terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and by principles of equity).

 

SECTION 6.5 Financial Information . The financial statements of the Borrower and the Subsidiaries furnished to the Lender pursuant to Sections 5.6 and 7.1 have been prepared in accordance with GAAP, consistently applied, and in all material respects present fairly the consolidated financial condition of the Persons covered thereby as at the dates thereof and the results of their operations for the periods then ended.

 

30



 

SECTION 6.6 No Material Adverse Change . Except as set forth on Schedule 6.6 , there has been no material adverse change in the business, financial performance or condition, operations (including the results thereof), assets, or properties of the Borrower or any Subsidiary since December 31, 2012.

 

SECTION 6.7 Litigation, Labor Matters and Environmental Matters .

 

(a)                                  Except as described on Schedule 6.7(a) , there are no actions, suits or proceedings by or before any arbitrator or Governmental Authority pending against or, to the knowledge of the Borrower, threatened against or affecting the Borrower or any Subsidiary (i) as to which there is a reasonable likelihood of an adverse determination and that, if adversely determined, would reasonably be expected, individually or in the aggregate, to result in liabilities in excess of $[*] or (ii) that would reasonably be likely to adversely affect this Agreement or the transactions contemplated hereby.

 

(b)                                  There are no labor controversies pending against or, to the knowledge of the Borrower, threatened against or affecting the Borrower or any Subsidiary (i) that would reasonably be expected, individually or in the aggregate, to result in liabilities in excess of $[*] or (ii) that would reasonably be likely to adversely affect this Agreement or the transaction contemplated hereby.

 

(c)                                   Neither the Borrower nor any Subsidiary (i) has failed to comply with any Environmental Law or to obtain, maintain or comply with any Permit under or in connection with any Environmental Law (“ Environmental Permit ”), except to the extent that any such failure could not reasonably be expected to have or result in a Material Adverse Effect; or (ii) is or has been subject to any Environmental Liability, has received notice of any Environmental Liability, or knows of any basis for any Environmental Liability, except to the extent that the foregoing could not reasonably be expected to have or result in a Material Adverse Effect.

 

SECTION 6.8 Subsidiaries . The Borrower has no Subsidiaries except those Subsidiaries which are identified in Schedule 6.8 (which Schedule also identifies the direct and indirect owners of the Capital Securities of such Subsidiaries) or which are permitted to have been organized or acquired after the Closing Date in accordance with Section 8.5 or Section 8.7 .

 

SECTION 6.9 Ownership of Properties . The Borrower and each Subsidiary owns (i) in the case of owned real property, good and marketable fee title to, and (ii) in the case of owned personal property, good and valid title to, or, in the case of leased real or personal property, valid and enforceable leasehold interests (as the case may be) in, all of its material properties and assets, tangible and intangible, of any nature whatsoever, free and clear in each case of all Liens or claims, except for Liens permitted pursuant to Section 8.3 .

 

SECTION 6.10 Taxes . Except as set forth on Schedule 6.10 , the Borrower and each Subsidiary has filed all tax returns and reports required by law to have been filed by it and has paid all material Taxes due and owing, except any such Taxes

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

31



 

which are being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books.

 

SECTION 6.11 Benefit Plans, Etc . None of the Borrower or any of the Subsidiaries or any of their respective ERISA Affiliates sponsors, maintains, contributes to, is required to contribute to, or has any actual or potential liability with respect to, any Benefit Plan. None of the Borrower or any of the Subsidiaries is a party to any collective bargaining agreement, and none of the employees of the Borrower or any of the Subsidiaries (each in his or her capacity as an employee of the Borrower or a Subsidiary) are subject to any collective bargaining agreement. Each “employee benefit plan” as defined in section 3(3) of ERISA that provides retirement benefits and that is sponsored by the Borrower or any of their ERISA Affiliates intended to be tax qualified under section 401 or 501 of the Code has a determination letter or opinion letter from the Internal Revenue Service on which it is entitled to rely, and no assets of any such plan are invested in Capital Securities of the Borrower. Each employee benefit plan, program or arrangement sponsored, maintained, contributed to or required to be contributed to by the Borrower or any Subsidiary has complied in all material respects with its terms and applicable law.

 

SECTION 6.12 Accuracy of Information . None of the information heretofore or contemporaneously furnished in writing to the Lender by or on behalf of the Borrower or any Subsidiary in connection with any Loan Document or any transaction contemplated hereby contains any untrue statement of a material fact, or omits to state any material fact necessary to make any information, in light of the circumstances under which it is made, not misleading in any material respect as of the time when made or delivered.

 

SECTION 6.13 Regulations U and X . None of the Borrower or any Subsidiary is engaged in the business of extending credit for the purpose of buying or carrying margin stock, and no proceeds of the Loans will be used to purchase or carry margin stock or otherwise for a purpose which violates, or would be inconsistent with, F.R.S. Board Regulation U or Regulation X. Terms for which meanings are provided in F.R.S. Board Regulation U or Regulation X or any regulations substituted therefor, as from time to time in effect, are used in this Section with such meanings.

 

SECTION 6.14 Solvency . The Borrower, individually, and the Borrower and its Subsidiaries taken as a whole, on a consolidated basis, both before and after giving effect to the Loans, are Solvent.

 

SECTION 6.15 Intellectual Property .

 

(a)                                  Schedule 6.15(a) sets forth a complete and accurate list as of the Closing Date or Delayed Draw Closing Date, as the case may be, of all (i) Patents including any Patent applications and other material so defined as Patents, (ii) registered and material unregistered Trademarks (including domain names) and any pending registrations for Trademarks, and (iii) any other registered Intellectual Property, in each case owned or

 

32



 

licensed by the Borrower or any of the Subsidiaries and material to the business of the Borrower or such Subsidiary. For each item of Intellectual Property listed on Schedule 6.15(a) , the Borrower has, where relevant, indicated (A) the countries in each case in which such item is registered, (B) the application numbers, (C) the registration or patent numbers, (D) with respect to the Patents, the expected expiration date of the issued Patents, (E) the owner of such item of Intellectual Property and (F) with respect to material Intellectual Property owned by any Third Party, the agreement pursuant to which that Intellectual Property is licensed to the Borrower or any Subsidiary.

 

(b)                                  With respect to all Intellectual Property listed on Schedule 6.15(a) , except as set forth on Schedule 6.15(b) :

 

(i)                                       the Borrower or a Subsidiary owns, has a valid license or rights in any other form to all, rights associated with such Intellectual Property free and clear of any and all Liens other than Liens permitted pursuant to Section 8.3 , and all such Intellectual Property are in full force and effect, and have not expired, lapsed or been forfeited, cancelled or abandoned unless permitted hereunder, except, on the Delayed Draw Closing Date, where such event or circumstance is not reasonably expected to be material to the Borrower and its Subsidiaries;

 

(ii)                                    each of the Borrower and the Subsidiaries, as applicable, has taken commercially reasonable actions to maintain and protect such Intellectual Property and there are no unpaid maintenance or material renewal fees payable by the Borrower or any of the Subsidiaries that are currently overdue for any of such registered Intellectual Property;

 

(iii)                                 there is no proceeding challenging the validity or enforceability of any such Intellectual Property and none of the Intellectual Property is the subject of any Other Administrative Proceeding, except, on the Delayed Draw Closing Date, where such challenge is not reasonably expected to be material to the Borrower and its Subsidiaries;

 

(iv)                                to the knowledge of the Borrower, (A) such Intellectual Property is valid, enforceable and subsisting and (B) no event has occurred, and nothing has been done or omitted to have been done, that would affect the validity or enforceability of such Intellectual Property, except, on the Delayed Draw Closing Date, where such event is not reasonably expected to be material to the Borrower and its Subsidiaries; and

 

(v)                                   each of the Borrower and each Subsidiary is the sole and exclusive owner of all right, title and interest in and to all such Intellectual Property that is owned by it, except that Intellectual Property listed on Schedule 6.15(b)(v) and except, on the Delayed Draw Closing Date, for Dispositions permitted pursuant to Section 8.8 .

 

(c)                                   To the knowledge of the Borrower, except as set forth on Schedule 6.15(c) , no Third Party is committing any act of Infringement of any Intellectual Property

 

33



 

listed on Schedule 6.15(a) , except, on the Delayed Draw Closing Date, where such Infringement is not reasonably expected to be material to the Borrower and its Subsidiaries.

 

(d)                                  With respect to each license agreement listed on Schedule 6.15(a) , (x) such license agreement (i) is in full force and effect and is binding upon and enforceable against the Borrower and the Subsidiaries party thereto and, to Borrower’s knowledge, all other parties thereto in accordance with its terms, (ii) has not been amended or otherwise modified, and (iii) no material default or breach by Borrower or its Subsidiaries, and to Borrower’s knowledge, any other party thereto, has occurred and is continuing thereunder, and (y) none of the Borrower or any of the Subsidiaries has to the knowledge of the Borrower taken any action that would permit any other Person party to any such license agreement to have, and to the knowledge of the Borrower no such Person otherwise has, any defenses, counterclaims or rights of setoff thereunder.

 

(e)                                   Except as set forth on Schedule 6.15(e) , none of the Borrower or any of the Subsidiaries has received written notice from any Third Party alleging that the conduct of its business (including the development, manufacture, use, sale or other commercialization of any Product) Infringes any Intellectual Property of that Third Party and, to the knowledge of the Borrower, the conduct of its business and the business of the Subsidiaries (including the development, manufacture, use, sale or other commercialization of any Product) does not Infringe any Intellectual Property of any Third Party.

 

(f)                                    The Borrower and the Subsidiaries have used commercially reasonable efforts and precautions to protect their respective commercially significant unregistered Intellectual Property.

 

SECTION 6.16 Material Agreements . Set forth on Schedule 6.16 is a complete and accurate list as of the Closing Date or Delayed Draw Closing Date, as the case may be, of all Material Agreements of the Borrower or any of the Subsidiaries, with an adequate description of the parties thereto, subject matter thereof and amendments and modifications thereto, and as of such dates, respectively, (a) each such Material Agreement (i) is in full force and effect and is binding upon and enforceable against the Borrower and the Subsidiaries party thereto and to Borrower’s knowledge all other parties thereto in accordance with its terms, (ii) has not been amended or otherwise modified and (iii) no material default or breach by Borrower or its Subsidiaries, and to Borrower’s knowledge, any other party thereto, has occurred and is continuing thereunder, and (b) none of the Borrower or any of the Subsidiaries has taken any action that to Borrower’s knowledge would permit any other Person party to any Material Agreement to have any defenses, counterclaims or rights of setoff thereunder.

 

SECTION 6.17 Permits . Except as set forth on Schedule 6.17 , the Borrower and the Subsidiaries have all material Permits, including material Environmental Permits, necessary or required for the ownership, operation and conduct of their

 

34



 

business and the distribution of the Products. All such Permits are validly held and there are no material defaults thereunder.

 

SECTION 6.18 Regulatory Matters .

 

(a)                                  The Borrower and its Subsidiaries have conducted and conduct their business in material compliance with all applicable U.S. federal, state, local or foreign laws, statutes, ordinances, rules, regulations, judgments, orders, injunctions, decrees, arbitration awards and Key Permits issued by any Governmental Authority (collectively, “Laws”).

 

(i)                                      Borrower LDTs were researched, developed, designed, and validated solely by Borrower in material compliance with all applicable Laws, including the FDCA, CLIA, Privacy Laws and state laws, and have been and continue to be performed, marketed, and conducted in material compliance with all applicable Laws, including the FDCA, FTC Act, CLIA, Privacy Laws and state laws, including the laws of New York.

 

(ii)                                   Borrower Medical Devices have been and are being researched, developed, designed, investigated, manufactured, marketed, and distributed in material compliance with all applicable Laws, including the FDCA, the FTC Act, Privacy Laws and state laws.

 

(b)                                  Except as set forth on Schedule 6.18(b) , to the Borrower’s knowledge, (i) no investigation by any Governmental Authority with respect to the Borrower is pending or threatened, and (ii) the Borrower has not received any written communication from any Person (including any Governmental Authority) of any noncompliance with any Laws or any written communication from any Governmental Authority of any material issues, problems, or concerns regarding the quality or performance of the Products.

 

(c)                                   Except as set forth on Schedule 6.18(c) , the Borrower holds free and clear of all Liens, except those permitted pursuant to Section 8.3 , all Key Permits, including all authorizations under the FDCA, CLIA, and state laws, necessary for the research and development and commercialization of the Products and to carry on Borrower’s business with respect to the Products. All such Key Permits are valid, and in full force and effect and Borrower is in compliance with all material terms and conditions of such Key Permits. The Borrower has not received any written notice that any Key Permits have been or are being revoked, withdrawn, suspended or challenged.

 

(d)                                  Except as set forth on Schedule 6.18(d) , (i) the Borrower has made available to Lender all Key Permits and material written correspondence submitted to or received from FDA, CMS, or other Governmental Authority (including minutes and official contact reports relating to any material written communications with any Governmental Authority) in the Borrower’s possession or control, and (ii) there has been no material untrue statement of fact and no fraudulent statement made by the Borrower, any of the Subsidiaries, or any of their respective agents or representatives to the FDA,

 

35



 

CMS, or any other Governmental Authority, and there has been no failure to disclose any material fact required to be disclosed to the FDA or any other Governmental Authority.

 

(e)                                   Except as set forth on Schedule 6.18(e) , no right of the Borrower to receive reimbursements pursuant to any government program or private program has ever been terminated or otherwise materially adversely affected as a result of any investigation or enforcement action, whether by any Governmental Authority or other Third Party, and the Borrower has not been the subject of any inspection, investigation, or audit, by any Governmental Authority for the purpose of any alleged improper activity.

 

(f)                                    To Borrower’s knowledge, there is no arrangement relating to the Borrower providing for any rebates, kickbacks or other forms of compensation that are unlawful to be paid to any Person in return for the referral of business or for the arrangement for recommendation of such referrals. All billings by the Borrower for its services have been true and correct in all material respects (other than any inadvertent errors corrected in the ordinary course of business) and, to the Borrower’s knowledge, are in compliance with all applicable Laws, including the Federal False Claim Act or any applicable state false claim or fraud Law.

 

(g)                                   Except as set forth on Schedule 6.18(g) , the Borrower has not, and to the knowledge of the Borrower, no officer, director, employee or agent of the Borrower has (i) been convicted of, charged with, or to the Borrower’s knowledge, investigated for any federal or state health program-related offense or any other offense related to healthcare or been excluded or suspended from participation in any such program; or within the past five (5) years, been convicted of, charged with or, to the Borrower’s knowledge, investigated for a violation of Laws related to fraud, theft, embezzlement, breach of fiduciary responsibility, financial misconduct, obstruction of an investigation or controlled substances, or been subject to any judgment, stipulation, order or decree of, or criminal or civil fine or penalty imposed by, any Governmental Authority related to fraud, theft, embezzlement, breach of fiduciary responsibility, financial misconduct, obstruction of an investigation or controlled substances; (ii) been convicted of any crime or engaged in any conduct for which debarment is mandated or permitted by 21 U.S.C. § 335a, and, to the Borrower’s knowledge, no such debarment proceedings or investigations are pending or threatened; or (iii) been convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in the federal health care programs under Section 1128 of the Social Security Act or any similar applicable Law.

 

(h)                                  Except as set forth on Schedule 6.18(h) , all studies, tests and preclinical and clinical trials conducted relating to the Products, by or on behalf of the Borrower and the Subsidiaries and, to the knowledge of the Borrower, their respective licensees, licensors and Third Party services providers and consultants, have been conducted, and are currently being conducted, in all material respects, in accordance with all applicable Laws, procedures and controls pursuant to, where applicable, current good clinical practices and current good laboratory practices and other applicable laws, rules regulations. All results of such studies, tests and trials, and all other material information related to such studies, tests and trials, have been made available to the Lender as

 

36



 

requested by it. To the extent necessary by applicable Law, the Borrower has obtained all necessary Regulatory Authorizations material to the conduct of its business required to be obtained by it, including an IDE for the conduct of any clinical investigations conducted by or on behalf of the Borrower.

 

(i)                                      To the Borrower’s knowledge, none of the clinical investigators in any clinical trial conducted by or on behalf of the Borrower has been or is disqualified or otherwise sanctioned by the FDA, the Department of Health and Human Services, or any Governmental Authority and, to the Borrower’s knowledge, no such disqualification, or other sanction of any such clinical investigator is pending or threatened. The Borrower has not received any written communication from the FDA or any other Governmental Authority requiring or threatening the termination or suspension of any clinical trials conducted by, or on behalf of, the Borrower.

 

(j)                                     The transactions contemplated by the Loan Documents (or contemplated by the conditions to effectiveness of any Loan Document) will not cause the Borrower or any of its Subsidiaries to require any Regulatory Authorizations relating to the Products not already required of the Borrower or its Subsidiaries.

 

SECTION 6.19 Transactions with Affiliates . Except as set forth on Schedule 6.19 , none of the Borrower or any Subsidiary has entered into, renewed, extended or been a part to, any transaction (including the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any of its Affiliates during the three-year period immediately prior to the Closing Date.

 

SECTION 6.20 Investment Company Act . None of the Borrower or any Subsidiary is an “investment company” or is “controlled” by an “investment company,” as such terms are defined in, or subject to regulation under, the Investment Company Act of 1940, as amended.

 

SECTION 6.21 OFAC . None of the Borrower, any Subsidiary or, to the knowledge of the Borrower, any Related Party (a) is currently the subject of any Sanctions, (b) is located, organized or residing in any Designated Jurisdiction, or (c) is or has been (within the previous five (5) years) engaged in any transaction with any Person who is now or was then the subject of Sanctions or who is located, organized or residing in any Designated Jurisdiction. No Loan, nor the proceeds from any Loan, has been or will be used, directly or indirectly, to lend, contribute or provide to, or has been or will be otherwise made available to fund, any activity or business in any Designated Jurisdiction or to fund any activity or business of any Person located, organized or residing in any Designated Jurisdiction or who is the subject of any Sanctions, or in any other manner that will result in any violation by any Person (including the Lender and its Affiliates) of Sanctions.

 

SECTION 6.22 Deposit and Disbursement Accounts . Set forth on Schedule 6.22 is a complete and accurate list as of the Closing Date or Delayed Draw Closing Date, as the case may be, of all banks and other financial institutions at which the Borrower or any Subsidiary maintains deposit accounts, lockboxes, disbursement

 

37



 

accounts, investment accounts or other similar accounts, such Schedule correctly identifies the name, address and telephone number of each bank or financial institution, the name in which each such account is held, the type of each such account, and the complete account number for each such account, and each such account is a Controlled Account as required pursuant to Section 7.13 .

 

ARTICLE VII

AFFIRMATIVE COVENANTS

 

The Borrower covenants and agrees with the Lender that until the Termination Date has occurred, the Borrower will, and will cause the Subsidiaries to, perform or cause to be performed the obligations set forth below.

 

SECTION 7.1 Financial Information, Reports, Notices, Etc . The Borrower will furnish the Lender copies of the following financial statements, reports, notices and information:

 

(a)                                  as soon as available and in any event within 30 days after the end of each Fiscal Month, in each case with supporting detail and certified as complete and correct by the chief financial or accounting Authorized Officer of the Borrower (subject to normal year-end audit adjustments), (i) unaudited reports of the Panorama Net Revenue and the Revenue Base for such Fiscal Month and the Liquidity of the Borrower at the end of such Fiscal Month and (ii) beginning with the Fiscal Month of April 2013, unaudited reports of (x) the Panorama Net Revenue and the Revenue Base for the period commencing at the end of the previous Fiscal Year and ending with the end of such Fiscal Month, and including in comparative form the figures for the corresponding Fiscal Month in, and the year to date portion of, the immediately preceding Fiscal Year, with supporting detail and certified as complete and correct by the chief financial or accounting Authorized Officer of the Borrower (subject to normal year-end audit adjustments) and (y) the Liquidity of the Borrower for the corresponding Fiscal Month in the preceding Fiscal Year, in comparative form;

 

(b)                                  as soon as available and in any event within 45 days after the end of each of the first three Fiscal Quarters of each Fiscal Year, an unaudited consolidated balance sheet of the Borrower and the Subsidiaries as of the end of such Fiscal Quarter and consolidated statements of income and cash flow of the Borrower and the Subsidiaries for such Fiscal Quarter and for the period commencing at the end of the previous Fiscal Year and ending with the end of such Fiscal Quarter, and including (in each case) in comparative form the figures for the corresponding Fiscal Quarter in, and the year to date portion of, the immediately preceding Fiscal Year, certified as complete and correct by the chief financial or accounting Authorized Officer of the Borrower (subject to normal year-end audit adjustments);

 

(c)                                   as soon as available and in any event not later than August 31, 2013, with respect to the Fiscal Year ended December 31, 2012, and as soon as available and in any event within 120 days after the end of each Fiscal Year beginning with the Fiscal Year ended December 31, 2013, a copy of the consolidated balance sheet of the Borrower and

 

38



 

the Subsidiaries, and the related consolidated statements of income and cash flow of the Borrower and the Subsidiaries for such Fiscal Year, setting forth in comparative form the figures for the immediately preceding Fiscal Year, audited (without any Impermissible Qualification) by an independent accounting firm which is (i) registered with the Public Company Accounting Oversight Board (PCAOB) to audit public companies and (ii) reasonably acceptable to the Lender, which shall include a calculation of the financial covenant set forth in Section 8.4 and stating that, in performing the examination necessary to deliver the audited financial statements of the Borrower, no knowledge was obtained of any Event of Default;

 

(d)                                  concurrently with the delivery of the financial information pursuant to clauses (b) and (c) , a Compliance Certificate, executed by the chief financial or accounting Authorized Officer of the Borrower, (i) showing compliance with the financial covenants set forth in Section 8.4 and stating that no Default has occurred and is continuing (or, if a Default has occurred, specifying the details of such Default and the action that the Borrower or any of the Subsidiaries has taken or proposes to take with respect thereto), (ii) stating that no Subsidiary has been formed or acquired since the delivery of the last Compliance Certificate (or, if a Subsidiary has been formed or acquired since the delivery of the last Compliance Certificate, a statement that such Subsidiary has complied with Section 7.8 ) and (iii) stating that no real property has been acquired by the Borrower or any of the Subsidiaries since the delivery of the last Compliance Certificate (or, if any real property has been acquired since the delivery of the last Compliance Certificate, a statement that the Borrower has complied with Section 7.8 with respect to such real property);

 

(e)                                   as soon as possible and in any event within five Business Days after the Borrower obtains knowledge of the occurrence of a Default, a statement of an Authorized Officer of the Borrower setting forth details of such Default and the action which the Borrower or any of the Subsidiaries has taken or proposes to take with respect thereto;

 

(f)                                    as soon as possible and in any event within five Business Days after the Borrower obtains knowledge of (i) the occurrence of any material adverse development with respect to any litigation, action, proceeding or labor controversy described in Schedule 6.7 , (ii) the commencement of any litigation, action, proceeding or labor controversy of the type and materiality described in Section 6.7 , notice thereof and, to the extent the Lender requests, copies of all documentation relating thereto, and (iii) any return, recovery, dispute or claim related to Product or finished goods inventory that involves more than $250,000.

 

(g)                                   as soon as possible and in any event within five Business Days after the Borrower obtains knowledge of (i) any written claim that the Borrower, any of the Subsidiaries or one of their ERISA Affiliates has any liability under a Benefit Plan, (ii) any effort to unionize the employee of the Borrower or any Subsidiary, or (iii) written correspondence received from the Internal Revenue Service regarding the qualification of a retirement plan under Section 401(a) of the Code that could reasonably be expected to result in material liability to the Borrower.

 

39


 

(h)                                  promptly after the sending or filing thereof, copies of all material reports, notices, prospectuses and registration statements which the Borrower or any of the Subsidiaries files with the SEC or any national securities exchange;

 

(i)                                      promptly upon receipt thereof, copies of all “management letters” (or equivalent) submitted to the Borrower or any of the Subsidiaries by the independent public accountants referred to in clause (b) in connection with each audit made by such accountants;

 

(j)                                     on the date that the Borrower furnishes unaudited reports to the Lender pursuant to Section 7.1(a)(i) , during the pendency of the following patent applications, a report providing an update on the status of the following patent applications, in form satisfactory to Lender: (i) U.S. Serial No. 11/603,406, filed 11-22-2006, titled “System and Method for Cleaning Noisy Genetic Data From Target Individuals Using Genetic Data from Genetically Related Individuals” and (ii) U.S. Serial No. 12/076,348, filed 03-17-2008, titled “System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number”;

 

(k)                                  within 45 days after the end of each Fiscal Quarter for the Fiscal Quarter most recently ended, a report listing (i) all Material Agreements entered into during such Fiscal Quarter and (ii) all existing Material Agreements amended or terminated during such Fiscal Quarter, and (iii) revenue recognition audit notes as approved by the Borrower’s chief financial officer with respect to items listed in clause (i);

 

(l)                                      as soon as available, but in any event not later than January 31 of each calendar year, the Borrower’s financial and business projections and budget for such year, with evidence of approval thereof by Borrower’s board of directors; and

 

(m)                              such other financial and other information as the Lender may from time to time reasonably request (including information and reports in such detail as the Lender may request with respect to the terms of and information provided pursuant to the Compliance Certificate).

 

SECTION 7.2 Maintenance of Existence; Compliance with Contracts, Laws, Etc . Each of the Borrower, and each Subsidiary will preserve and maintain its legal existence (except as otherwise permitted by Section 8.7 ), perform in all material respects its obligations under Material Agreements to which the Borrower or any of the Subsidiaries is a party, and comply in all material respects with all applicable laws, rules, regulations and orders, including the payment (before the same become delinquent), of all Taxes, imposed upon the Borrower or any of the Subsidiaries or upon their property except to the extent being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP have been set aside on the books of the Borrower or any of the Subsidiaries, as applicable.

 

SECTION 7.3 Maintenance of Properties . Each of the Borrower and the Subsidiaries will maintain, preserve, protect and keep its and their respective

 

40



 

properties in good repair, working order and condition (ordinary wear and tear excepted), and make necessary repairs, renewals and replacements so that the business carried on by the Borrower or any of the Subsidiaries may be properly conducted at all times, unless the Borrower or any of the Subsidiaries determines in good faith that the continued maintenance of such property is no longer economically desirable, necessary or useful to the business of the Borrower or any of the Subsidiaries or the Disposition of such property is otherwise permitted by Section 8.7 or Section 8.8 .

 

SECTION 7.4 Insurance . Each of the Borrower and each of the Subsidiaries will maintain:

 

(a)                                  insurance on its property with financially sound and reputable insurance companies against business interruption, loss and damage in at least the amounts (and with only those deductibles) customarily maintained, and against such risks as are typically insured against in the same general area, by Persons of comparable size engaged in the same or similar business as the Borrower and the Subsidiaries; and

 

(b)                                  all worker’s compensation, employer’s liability insurance or similar insurance as may be required under the laws of any state or jurisdiction in which it may be engaged in business.

 

Without limiting the foregoing, all insurance policies required pursuant to this Section shall (i) name the Lender as mortgagee and loss payee (in the case of property insurance) and additional insured (in the case of liability insurance), as applicable, and provide that no cancellation or material modification as to the amount or scope of coverage of the policies will be made without the prior written notice to the Lender, and (ii) be in addition to any requirements to maintain specific types of insurance contained in the other Loan Documents.

 

SECTION 7.5 Books and Records . Each of the Borrower and each of the Subsidiaries will keep books and records in accordance with GAAP which accurately reflect all of its business affairs and transactions and permit the Lender or any of its representatives, at reasonable times and intervals (not to include the first 10 calendar days of any Fiscal Month unless explicitly permitted by the Borrower, except in the event that a Default or Event of Default has occurred or is continuing) upon reasonable notice to the Borrower, to visit the Borrower’s or any of the Subsidiaries’ offices, to discuss the Borrower’s or any of the Subsidiaries’ financial or other matters with its officers and employees, and its independent public accountants (and the Borrower hereby authorizes such independent public accountant to discuss the Borrower’s and any of the Subsidiaries’ financial and other matters with the Lender or its representatives whether or not any representative of the Borrower or any of the Subsidiaries is present) and to examine (and photocopy extracts from) any of its books and records. The Borrower shall pay any fees of such independent public accountant incurred in connection with the Lender’s exercise of its rights pursuant to this Section but unless a Default or Event of Default has occurred and is continuing at the time of such examination not more than once in any calendar year.

 

41



 

SECTION 7.6 Environmental Law Covenant . Each of the Borrower and each of the Subsidiaries will (i) use and operate all of its and their businesses, facilities and properties in material compliance with all Environmental Laws, and keep and maintain all Environmental Permits and remain in compliance therewith, except to the extent that the failure to do so could not reasonably be expected to have or result in a Material Adverse Effect, and (ii) promptly notify the Lender of, and provide the Lender with copies of all written material claims, complaints, notices or inquiries relating to, any actual or alleged non-compliance with any Environmental Laws or Environmental Permits or any actual or alleged Environmental Liabilities that the Borrower reasonably determines has or could result in a Material Adverse Effect. The Borrower and each of the Subsidiaries will promptly resolve, remedy and mitigate any such non-compliance or Environmental Liabilities in accordance with reasonable business practices, and shall keep the Lender informed as to the progress of same.

 

SECTION 7.7 Use of Proceeds . The Borrower will apply the proceeds of the Loan according to the sources and uses table in Schedule 7.7 .

 

SECTION 7.8 Future Guarantors, Security, Etc . The Borrower and each Subsidiary will execute any documents, financing statements, agreements and instruments, and take all further action that may be required under applicable law, or that the Lender may reasonably request, in order to effectuate the transactions contemplated by the Loan Documents and in order to grant, preserve, protect and perfect the validity and first priority (subject to Liens permitted by Section 8.3 ) of the Liens created or intended to be created by the Loan Documents. The Borrower will promptly cause any subsequently acquired or organized Subsidiary to execute a supplement (in form and substance satisfactory to the Lender) to the Guarantee and each other applicable Loan Document in favor of the Lender; provided that (other than with respect to any Subsidiary formed or acquired in a Permitted Acquisition) the Borrower shall not, and no Subsidiary shall, be required to execute or cause the execution of any Guaranty or the pledge of any Collateral Securities if a 956 Impact would result therefrom. The Borrower will promptly notify the Lender of any subsequently acquired ownership interest in real property and will provide the Lender with a description of such real property, the acquisition date thereof and the purchase price therefor. In addition, from time to time, each of the Borrower and each of the Subsidiaries will, at its cost and expense, promptly secure the Obligations by pledging or creating, or causing to be pledged or created, perfected Liens with respect to such of its assets and properties as the Lender shall designate, it being agreed that it is the intent of the parties that the Obligations shall be secured by, among other things, substantially all the assets of the Borrower and the Subsidiaries (including real property and personal property acquired subsequent to the Closing Date). Such Liens will be created under the Loan Documents in form and substance satisfactory to the Lender, and the Borrower and each of the Subsidiaries shall deliver or cause to be delivered to the Lender all such instruments and documents (including mortgages, legal opinions, title insurance policies and lien searches) as the Lender shall reasonably request to evidence compliance with this Section.

 

42



 

SECTION 7.9 Obtaining of Permits, Etc . With respect to Products, each of the Borrower and each of the Subsidiaries will obtain, maintain and preserve, and take all necessary action to timely renew all Permits and accreditations which are necessary and material in the proper conduct of its business.

 

SECTION 7.10 Product Licenses . The Borrower and each of the Subsidiaries shall (i) maintain each Permit, including each Regulatory Authorization, from, or file any notice or registration in, each jurisdiction in which the Borrower or any of the Subsidiaries are required to obtain any Permit or Regulatory Authorization or to file any notice or registration, in order to sell or distribute the Products and (ii) promptly provide evidence of same to the Lender.

 

SECTION 7.11 Maintenance of Regulatory Authorizations, Contracts, Intellectual Property, Etc . With respect to the Products, each of the Borrower and each of the Subsidiaries will (i) maintain in full force and effect all material Regulatory Authorizations, contract rights, authorizations or other rights necessary for the operations of its business; (ii) notify the Lender, promptly after learning thereof, of any material product recalls, safety alerts, corrections, withdrawals, marketing suspensions, removals or the like conducted, to be undertaken or issued, by the Borrower, any of the Subsidiaries or their respective suppliers whether or not at the request, demand or order of any Governmental Authority or otherwise with respect to any Product, or any basis for undertaking or issuing any such action or item; (iii) maintain in full force and effect or pursue the prosecution of, as the case may be, and pay all costs and expenses relating to, all Intellectual Property owned or controlled by the Borrower or any of the Subsidiaries and all Material Agreements, except in the event that the Borrower determines in its reasonable commercial judgment not to do so; (iv) notify the Lender, promptly after learning thereof, of any material Infringement or other violation by any Person of its Intellectual Property and aggressively pursue any such Infringement or other violation except in any specific circumstances where the Borrower or any of the Subsidiaries determines that it is not commercially reasonable to do so; (v) use commercially reasonable efforts to pursue and maintain in full force and effect legal protection for, and protect against Infringement with respect to, all Intellectual Property, including Patents, developed or controlled by the Borrower or any of the Subsidiaries, except in the event that the Borrower determines in its reasonable commercial judgment not to do so; and (vi) notify the Lender, promptly after learning thereof, of any material claim by any Person that the conduct of the Borrower’s or any of the Subsidiaries’ business (including the development, manufacture, use, sale or other commercialization of any Product) Infringes in any material respect any Intellectual Property of that Person and use commercially reasonable efforts to resolve such claim, except when the Borrower determines in its reasonable commercial judgment not to do so.

 

SECTION 7.12 Inbound Licenses; Product Agreements . Each of the Borrower and the Subsidiaries will make commercially reasonable efforts to exclude from (i) any material inbound licenses or similar agreements relating to Intellectual Property (other than over-the-counter or “open-source” software, or similar Intellectual Property, that is commercially available to the public) and (ii) any material Product

 

43



 

Agreements entered into after the Closing Date, any provisions that would prohibit or restrict such license or agreement, or rights thereunder, from becoming subject to a security interest in favor of the Lender.

 

SECTION 7.13 Cash Management . Each of the Borrower and the Subsidiaries will:

 

(a)                                  maintain a current and complete list of all accounts (of the type initially set forth on Schedule 6.22 ) and promptly deliver any updates to such list to the Lender; execute and(other than accounts exclusively used for (i) payroll, payroll taxes and other employee wage and benefit programs to or for the benefit of the Borrower’s or a Subsidiary’s employees, which shall in no event hold in the aggregate more than the amount reasonably expected to meet such payroll expenses for the following calendar month, including bonuses and other payments to be paid within the following calendar month, (ii) the receipt of receivables solely funded by Medicare or Medicaid, which shall in no event hold in the aggregate more than $5,000 and whose total cash balances shall be automatically swept to a Controlled Account (as defined below), on a monthly basis and (iii) assets that are subject to a Permitted Lien pursuant to Section 8.3(m) (collectively, the “ Excluded Accounts ”)) maintain an account control agreement for each such account, in form and substance reasonably acceptable to the Lender (each such account, a “ Controlled Account ”);

 

(b)                                  deposit promptly after the date of receipt thereof in accordance with prudent business practices all cash, checks, drafts or other similar items of payment relating to or constituting payments made in respect of any and all accounts and other rights and interests into Controlled Accounts; and

 

(c)                                   at any time after the occurrence and during the continuance of an Event of Default, at the request of the Lender, promptly cause all payments constituting proceeds of accounts to be directed into lockbox accounts under agreements in form and substance satisfactory to the Lender.

 

SECTION 7.14 Board Observation Rights .

 

(a)                                  The Borrower shall permit one (1) person representing the Lender (the “ Observer ”) to attend and observe (but not vote) at all meetings of the Borrower’s (or its Subsidiaries, as applicable) board of directors and any committee thereof, whether in person, by telephone or otherwise. The Borrower shall notify the Observer in writing at least five (5) Business Days in advance of (i) the date and time for each general or special meeting of its board of directors or any committee thereof and (ii) the adoption of any resolutions or actions by written consent (describing, in reasonable detail, the nature and substance of such action). The general meetings shall take place on no less than a quarterly basis. The Borrower shall concurrently deliver to the Observer all notices and any materials delivered to the board of directors or any committees thereof in connection with a board meeting or action to be taken by written consent, including a draft of any material resolutions or actions proposed to be adopted by written consent. The Observer

 

44



 

shall be free prior to such meeting or adoption by consent to contact the board of directors and discuss the pending actions to be taken.

 

(b)                                  The Borrower (or its Subsidiaries, as applicable) shall pay the Observer’s reasonable out-of-pocket expenses (including the cost of travel, meals and lodging) in connection with the attendance of such meetings.

 

(c)                                   If an issue is to be discussed or otherwise arises at any meeting of the board of directors of the Borrower or committee thereof which, in the reasonable good faith judgment of the board of directors, is not appropriate to be discussed in the presence of the Observer in order to avoid a conflict of interest on the part of such Observer or would result in disclosure of trade secrets or to preserve an attorney-client privilege, then such issue may be discussed without the Observer being present and any materials delivered to the board of directors pertaining to such issue need not be delivered to the Observer, so long as the Observer is given notice of the occurrence of such judgment by the board of directors, that the Observer is being excused, and that certain materials will not be delivered to the Observer.

 

(d)                                  The rights described in this Section 7.14 shall terminate and be of no further force or effect upon the assignment or transfer of the Lender’s rights and obligations hereunder or under any other Loan Document.

 

SECTION 7.15 Product Agreements . The Borrower and any of the Subsidiaries will make commercially reasonable efforts not to enter into any (i) amendment with respect to any existing Product Agreement or (ii) new Product Agreement that contains (a) any provision that permits any counterparty other than the Borrower or any of the Subsidiaries to terminate such Product Agreement for any reasons related to the insolvency or change of control of the Borrower or any of the Subsidiaries or assignment of such Product Agreement by the Borrower or any of the Subsidiaries, (b) any provision which restricts or penalizes a security interest in, or the assignment of, any Product Agreements, upon the sale, merger or other disposition of all or a material portion of a Product to which such Product Agreement relates, or (c) any other provision that has or is likely to adversely effect, in any material respect, any Product to which such agreement relates or to the Lender’s rights hereunder.

 

SECTION 7.16 Supply of Reagents . Borrower shall within three months of the Closing Date, either (i) enter into an agreement with Illumina, Inc. (“ Illumina ”) for a committed supply of reagents for commercial use at prices no more than [*] set forth on the Purchase Orders with Illumina dated March 20, 2013 (the “ Purchase Orders ”), copies of which have been provided to the Lender, or (ii) succeed in causing Illumina to provide the reagents to Borrower for commercial use in the amounts and on the prices set forth in the Purchase Orders, or (iii) whether through Illumina or alternative suppliers, achieve committed costs for at least one year for its NIPT test such that the sequencing component of the test is no more than [*] than the cost initially communicated to Lender (which was [*]).

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

45



 

ARTICLE VIII

NEGATIVE COVENANTS

 

The Borrower covenants and agrees with the Lender that until the Termination Date has occurred, the Borrower and the Subsidiaries will perform or cause to be performed the obligations set forth below.

 

SECTION 8.1 Business Activities . None of the Borrower or any of the Subsidiaries or any Permitted Joint Venture, will engage in any business activity except those business activities engaged in on the date of this Agreement and activities reasonably incidental thereto; provided that the foregoing shall not prohibit the Borrower or any Subsidiary from developing any new Products within or related to its general field of genetic testing for reproductive indications, utilizing newly developed technologies in such field or exploiting any existing Products in new territories or for different purposes.

 

SECTION 8.2 Indebtedness . None of the Borrower or any of the Subsidiaries will create, incur, assume or permit to exist any Indebtedness, other than:

 

(a)                                  Indebtedness in respect of the Obligations and Indebtedness arising under the Royalty Agreement;

 

(b)                                  until the Closing Date, Indebtedness that is to be repaid in full as further identified in Schedule 8.2(b) ;

 

(c)                                   Indebtedness existing as of the Closing Date which is identified in Schedule 8.2(c) , and Refinancing of such Indebtedness in a principal amount not in excess of that which is outstanding on the Closing Date (as such amount has been reduced following the Closing Date);

 

(d)                                  unsecured Indebtedness in respect of performance, surety or appeal bonds provided in the ordinary course of business in an aggregate amount at any time outstanding not to exceed $500,000;

 

(e)                                   Purchase Money Indebtedness and Capitalized Lease Liabilities, and Refinancings thereof, in a principal amount not to exceed $8,000,000 in the aggregate outstanding at any time, and, without duplication, Contingent Liabilities incurred in connection therewith;

 

(f)                                    Permitted Subordinated Indebtedness;

 

(g)                                   Indebtedness of any Subsidiary or the Borrower owing to the Borrower or any Subsidiary;

 

(h)                                  other Indebtedness of the Borrower and the Subsidiaries in an aggregate amount at any time outstanding not to exceed $100,000;

 

46



 

(i)                                      Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of business;

 

(j)                                     Indebtedness permitted to exist, and subject to the limitations, with respect to Permitted Joint Ventures; and

 

(k)                                  Indebtedness in respect of reimbursement obligations under letters of credit posted in the ordinary course of business to secure the Borrower’s or a Subsidiary’s real property lease obligations, not to exceed $1,000,000 in the aggregate.

 

provided that, no Indebtedness otherwise permitted by clauses (c), (e), (f), (g), (h) or ( j) shall be assumed, created or otherwise incurred if a Default has occurred and is then continuing or would result therefrom.

 

SECTION 8.3 Liens . None of the Borrower or any of the Subsidiaries will create, incur, assume or permit to exist any Lien upon any of its property (including Capital Securities of any Person), revenues or assets, whether now owned or hereafter acquired, except:

 

(a)                                  Liens securing payment of the Obligations;

 

(b)                                  until the Closing Date, Liens securing payment of Indebtedness of the type described in clause (b) of Section 8.2 ;

 

(c)                                   Liens existing as of the Closing Date and disclosed in Schedule 8.3(c) securing Indebtedness described in clause (c) of Section 8.2 , and Refinancings of such Indebtedness; provided that, no such Lien shall encumber any additional property and the amount of Indebtedness secured by such Lien is not increased from that existing on the Closing Date (as such Indebtedness may have been permanently reduced subsequent to the Closing Date);

 

(d)                                  Liens securing payment of Permitted Subordinated Indebtedness that are (i) subordinate to the Liens securing payment of the Obligations and all other Indebtedness owing from the Borrower or the Subsidiaries to the Lender and (ii) subject to a written subordination agreement satisfactory to the Lender in its sole discretion;

 

(e)                                   Liens securing Indebtedness of the Borrower or the Subsidiaries permitted pursuant to Section 8.2(e) ( provided that (i) such Liens shall be created within 180 days of the acquisition of the assets financed with such Indebtedness, (ii) such Liens do not at any time encumber any property other than the property so financed and other Tangible Fixed Assets, and (iii) such Liens on assets of the Borrower or the Subsidiaries, other than those referenced in clause (ii), that may come into existence after all of the Obligations and any successive Refinancings thereof have been paid and satisfied in full, and that shall not be evidenced by any UCC financing statements filed prior to their coming into existence;

 

(f)                                    Liens in favor of carriers, warehousemen, mechanics, materialmen and landlords granted in the ordinary course of business for amounts not overdue or being

 

47



 

diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books;

 

(g)                                   Liens incurred or deposits made in the ordinary course of business in connection with worker’s compensation, unemployment insurance or other forms of governmental insurance or benefits, or to secure performance of tenders, statutory obligations, bids, leases or other similar obligations (other than for borrowed money) entered into in the ordinary course of business or to secure obligations on surety and appeal bonds or performance bonds;

 

(h)                                  judgment Liens in existence for less than 45 days after the entry thereof or with respect to which execution has been stayed or the payment of which is covered in full (subject to a customary deductible) by insurance maintained with responsible insurance companies and which do not otherwise result in an Event of Default under Section 9.1(f) ;

 

(i)                                      easements, rights-of-way, zoning restrictions, minor defects or irregularities in title and other similar encumbrances not interfering in any material respect with the value or use of the property to which such Lien is attached; and

 

(j)                                     Liens for Taxes not at the time delinquent or thereafter payable without penalty or being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books;

 

(k)                                  licenses and/or sublicenses of Intellectual Property otherwise permitted under this Agreement or the other Loan Documents, and restrictions under licenses of Intellectual Property entered into in the ordinary course of business pursuant to which a Borrower is a licensee;

 

(l)                                      banker’s liens, rights of setoff and Liens in favor of financial institutions incurred made in the ordinary course of business arising in connection with the Borrower’s or any Subsidiary’s deposit accounts or securities accounts held at such institutions to secure solely payment of fees and similar costs and expenses and provided such accounts are maintained in compliance with Section 7.13(a) hereof; and

 

(m)                              cash collateral pledged to secure Indebtedness in respect of letters of credit permitted pursuant to Section 8.2(k) or held as security deposits in respect of the Borrower’s or a Subsidiary’s real property lease obligations incurred in the ordinary course of business, not to exceed $1,000,000 in the aggregate.

 

The Lender agrees to execute and deliver such collateral subordination agreements and related documents as reasonably requested of it to confirm the priority of the Liens permitted pursuant to clauses (e) and (m) of Section 8.3.

 

SECTION 8.4 Minimum Liquidity . The Liquidity of the Borrower shall not at any time be less than (i) $5,000,000 if the Initial Loan, but not the Delayed Draw Loan, has been funded to the Borrower and (ii) $7,000,000 if both the Initial Loan and the Delayed Draw Loan have been funded to the Borrower. The Borrower shall maintain an

 

48



 

amount equal to the amount required under this Section 8.4 , along with its other cash and Cash Equivalent Investments, in a Controlled Account as required pursuant to Section 7.13(a) hereof.

 

SECTION 8.5 Investments . None of the Borrower or any of the Subsidiaries will purchase, make, incur, assume or permit to exist any Investment in any other Person, except:

 

(a)                                  Investments existing on the Closing Date and identified in Schedule 8.5(a) ;

 

(b)                                  Cash Equivalent Investments;

 

(c)                                   Investments received in connection with the bankruptcy or reorganization of, or settlement of delinquent accounts and disputes with, customers and suppliers, in each case in the ordinary course of business;

 

(d)                                  Investments consisting of any deferred portion of the sales price received by the Borrower or any of the Subsidiaries in connection with any Disposition permitted under Section 8.8 ;

 

(e)                                   Investments constituting (i) accounts receivable arising, (ii) trade debt granted, or (iii) deposits made in connection with the purchase price of goods or services, in each case in the ordinary course of business;

 

(f)                                    Investments consisting of travel advances and employee relocation loans, and other employee loans and advances in the ordinary course of business, not to exceed $100,000 in the aggregate outstanding at any given time;

 

(g)                                   Investments consisting of loans to employees, officers, or directors relating to the purchase of equity securities of the Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by the Borrower’s Board of Directors, not to exceed the aggregate amount of $250,000 in any Fiscal Year;

 

(h)                                  Investments permitted pursuant to the definition of Permitted Joint Ventures;

 

(i)                                      Investments of the Borrower, or of any Wholly-Owned Subsidiary, in any Wholly-Owned Subsidiary (including pursuant to a Permitted Acquisition) that is, at the time of such Investment, a Guarantor;

 

(j)                                     Permitted Acquisitions;

 

(k)                                  Investments in Subsidiaries that are not Guarantors, in an amount not to exceed, together with Investments in Permitted Joint Ventures, $5,000,000;

 

(l)                                      other Investments in an amount not to exceed $100,000 in the aggregate outstanding at any given time; and

 

49


 

(m)          any Investment which when made complies with the requirements of the definition of the term “Cash Equivalent Investment” may continue to be held notwithstanding that such Investment if made thereafter would not comply with such requirements.

 

SECTION 8.6 Restricted Payments, Etc . Without the prior written consent of the Lender, none of the Borrower or any of the Subsidiaries will declare or make a Restricted Payment, or make any deposit for any Restricted Payment, other than Restricted Payments made by the Borrower or Subsidiaries to the Borrower or any Subsidiaries.

 

SECTION 8.7 Consolidation, Merger; Permitted Acquisitions, Etc . None of the Borrower or any of the Subsidiaries will liquidate or dissolve, consolidate with, or merge into or with, any other Person, or purchase or otherwise acquire all or substantially all of the assets of any Person (or any division thereof) other than in connection with a Permitted Acquisition; provided that, so long as no Event of Default has occurred and is continuing (or would occur), any Subsidiary may liquidate or dissolve voluntarily into, and may merge with and into, the Borrower or any Subsidiary that is a Guarantor; and provided further, in connection with any Permitted Acquisition, the Borrower or any Subsidiary of the Borrower may merge into or consolidate with any other Person or permit any other Person to merge into or consolidate with it, so long as (i) the Person surviving such merger with any Subsidiary shall be a direct or indirect Wholly-Owned Subsidiary of the Borrower and a Guarantor, and (ii) in the case of any such merger to which the Borrower is a party, the Borrower is the surviving Person.

 

SECTION 8.8 Permitted Dispositions . None of the Borrower or any of the Subsidiaries will Dispose of any of its assets (including accounts receivable and Capital Securities of Subsidiaries) to any Person in one transaction or series of transactions unless such Disposition (i) is inventory, and non-exclusive licenses of Intellectual Property in connection therewith, or obsolete, damaged, worn out or surplus property (including fixed assets no longer used or useful in the business of the Borrower and its Subsidiaries at the time of such Disposition) Disposed of in the ordinary course of its business, (ii) is a transaction permitted by Section 8.7 , (iii) is a license for the use of the Intellectual Property of the Borrower, or any of the Subsidiaries, in each instance that is approved by Borrower’s (or such Subsidiary’s) Board of Directors and which could not result in a legal transfer of title of the licensed property but that may be exclusive in respects other than territory, including but not limited to field of use, and that may be exclusive as to territory only as to discrete geographical areas outside of the United States, (iv) is pursuant to the definition of Permitted Joint Venture, or (v) (A) is on fair market value terms in an arms-length transaction; provided that in no event shall the aggregate cumulative amount of cash and noncash consideration payable in connection with Dispositions exceed $3,000,000, (B) not less than 75% of the aggregate sales price from any one such Disposition shall be paid in cash at the closing of such Disposition or within 30 days thereafter, (C) immediately prior to and immediately after giving effect to any such Disposition, there does not exist a Default, and (D) in connection with any Disposition permitted by this clause (vi) where the cash and noncash consideration (whether in one or a series of transactions) exceeds $100,000, an Authorized Officer of the Borrower

 

50



 

delivers a certificate to the Lender to the effect that each of clauses (A) through C) of this definition has been satisfied.

 

SECTION 8.9 Modification of Certain Agreements . None of the Borrower or any of the Subsidiaries will consent to any amendment, supplement, waiver or other modification of, or enter into any forbearance from exercising any rights with respect to, the terms or provisions contained in (i) any Organic Documents of the Borrower or any of the Subsidiaries, if the result would have an adverse effect on the rights or remedies of the Lender under this Agreement, the Royalty Agreement or any Loan Document, or (ii) any agreement governing any Permitted Subordinated Indebtedness, if the result would shorten the maturity date thereof or advance the date on which any cash payment is required to be made thereon or would otherwise change any terms thereof in a manner adverse to the Lender.

 

SECTION 8.10 Transactions with Affiliates . Other than transactions that constitute Investments permitted pursuant to Sections 8.5(f)  or (g) , none of the Borrower or any of the Subsidiaries will enter into or cause or permit to exist any arrangement, transaction or contract (including for the purchase, lease or exchange of property or the rendering of services) with any of its Affiliates, unless:

 

(a) such arrangement, transaction or contract is:

 

(x)(i) between or among the Borrower or any of its Subsidiaries, (ii) provides normal and reasonable compensation, benefits, reimbursement of expenses and indemnification to officers and directors, (iii) is a cash Investment in the Borrower, or (iv) is between or among the Borrower or any of its Subsidiaries on the one hand and a Permitted Joint Venture on the other hand and is not otherwise prohibited hereunder, and

 

(y)(i) is on fair and reasonable terms no less favorable to the Borrower or any Subsidiary than it could obtain in an arm’s-length transaction with a Person that is not one of its Affiliates and (ii) is of the kind which would be entered into by a prudent Person in its position with a Person that is not one of its Affiliates; or

 

(b) such arrangement, transaction or contract is not between or among the Borrower and any Parallel Entity and the Borrower has:

 

(x) provided the Lender with not less than 20 days’ prior written notice of such arrangement, transaction or contract and (y) certified in writing to the Lender that such arrangement, transaction or contract (i) satisfies the requirements of clause (a)(y), and (ii) has been approved by the Borrower’s board of directors; or

 

(c) such arrangement, transaction or contract is approved by the Lender.

 

SECTION 8.11 Restrictive Agreements, Etc . None of the Borrower or any of the Subsidiaries will enter into any agreement prohibiting (i) the creation or

 

51



 

assumption of any Lien upon its properties, revenues or assets, whether now owned or hereafter acquired, (ii) the ability of the Borrower or any of the Subsidiaries to amend or otherwise modify any Loan Document, or (iii) the ability of the Borrower or any Subsidiary to make any payments, directly or indirectly, to the Borrower, including by way of dividends, advances, repayments of loans, reimbursements of management and other intercompany charges, expenses and accruals or other returns on investments. The foregoing prohibitions shall not apply to restrictions contained (x) in any Loan Document, or (y) in the case of clause (i) , (A) contained in any agreement governing any Indebtedness permitted by clauses (e)  or (k)  of Section 8.2 as to the assets financed with the proceeds of such Indebtedness and secured by Liens permitted by clauses (e)  or (k)  of Section 8.3 , or (B) contained in any agreement governing an Indebtedness permitted by clause (j) of Section 8.2, or (C) with respect to restrictions on assignment customarily found in leases, licenses and other Contracts, or (z) in the case of clause (iii) , any Indebtedness permitted by clauses (e)  or (f)  of Section 8.2 .

 

SECTION 8.12 Sale and Leaseback . None of the Borrower or any of the Subsidiaries will directly or indirectly enter into any agreement or arrangement providing for the sale or transfer by it of any property (now owned or hereafter acquired) to a Person and the subsequent lease or rental of such property from such Person (other than Tangible Fixed Assets).

 

SECTION 8.13 Change in Name, Location or Executive Office or Executive Management; Change in Fiscal Year . None of the Borrower or any of the Subsidiaries will:

 

(a)           without 30 days’ prior written notice to the Lender, (i) change its legal name or any trade name used to identify it in the conduct of its business or ownership of its properties, (ii) relocate its chief executive office, principal place of business or any office in which it maintains books or records relating to its business (including the establishment of any new office or facility), or (iii) change its federal taxpayer identification number or organizational number (or equivalent);

 

(b)           replace its chief executive officer or chief financial officer without written notification to the Lender within 30 days thereafter;

 

(c)           change its jurisdiction of organization or legal structure; or

 

(d)           change its Fiscal Year or any of its Fiscal Quarters.

 

SECTION 8.14 Benefit Plans and Agreements . None of the Borrower or any Subsidiary will (i) become the sponsor of, incur any responsibility to contribute to or otherwise incur actual or potential liability with respect to, any Benefit Plan, (ii) allow any “employee benefit plan” as defined in section 3(3) of ERISA that provides retirement benefits and that is sponsored by the Borrower, any Subsidiary or any of their ERISA Affiliates intended to be tax qualified under section 401 or 501 of the Code to cease to be tax qualified, (iii) allow the assets of any tax qualified retirement plan to become invested in Capital Securities of the Borrower or any Subsidiary or (iv)

 

52



 

allow any employee benefit plan, program or arrangement sponsored, maintained, contributed to or required to be contributed to by the Borrower or any Subsidiary to fail to comply in all material respects with its terms and applicable law.

 

ARTICLE IX

EVENTS OF DEFAULT

 

SECTION 9.1 Listing of Events of Default . Each of the following events or occurrences described in this Article shall constitute an “ Event of Default ”.

 

(a)           Non-Payment of Obligations . The Borrower shall default in the payment or prepayment when due of (i) any principal of or interest on any Loan, or (ii) any fee described in Article III or any other monetary Obligation, and in the case of clause (ii)  such default shall continue unremedied for a period of two Business Days after such amount was due.

 

(b)           Breach of Warranty . Any representation or warranty made or deemed to be made by the Borrower or any of the Subsidiaries in any Loan Document (including any certificates delivered pursuant to Article V ) is or shall be incorrect when made or deemed to have been made in any material respect.

 

(c)           Non-Performance of Certain Covenants and Obligations . The Borrower or any Subsidiary shall default in the due performance or observance of any of its obligations under (i)  Section 7.1(a), (b), (c), (d), (e), (j), (k)  or (l), Section 7.7 , or Article VIII, or (ii) any clause under Section 7.1 other than those referenced in the foregoing clause (i) and such default shall continue unremedied for a period of 10 days after the earlier to occur of (A) notice thereof given to the Borrower by the Lender or (B) the date on which the Borrower has knowledge of such default.

 

(d)           Non-Performance of Other Covenants and Obligations . The Borrower or any Subsidiary shall default in the due performance and observance of any other covenant, obligation or agreement contained in any Loan Document executed by it, and such default shall continue unremedied for a period of 30 days after the earlier to occur of (i) notice thereof given to the Borrower by the Lender or (ii) the date on which the Borrower has knowledge of such default.

 

(e)           Default on Other Indebtedness . A default shall occur in the payment of any amount when due (subject to any applicable grace period), whether by acceleration or otherwise, of any principal or stated amount of, or interest or fees on, any Indebtedness of the Borrower or any of the Subsidiaries having a principal or stated amount, individually or in the aggregate, in excess of $500,000, or a default shall occur in the performance or observance of any obligation or condition with respect to such Indebtedness if the effect of such default is to accelerate the maturity of any such Indebtedness or such default shall continue unremedied for any applicable period of time sufficient to permit the holder or holders of such Indebtedness, or any trustee or agent for such holders, to cause or declare such Indebtedness to become due and payable or to require such Indebtedness to be prepaid, redeemed, purchased or defeased, or require an

 

53



 

offer to purchase or defease such Indebtedness to be made, prior to its expressed maturity.

 

(f)            Judgments . Any judgment or order for the payment of money individually or in the aggregate in excess of $500,000 (exclusive of any amounts fully covered by insurance (less any applicable deductible) and as to which the insurer has acknowledged its responsibility to cover such judgment or order) shall be rendered against the Borrower or any of the Subsidiaries and such judgment shall not have been vacated or discharged or stayed or bonded pending appeal within 30 days after the entry thereof or enforcement proceedings shall have been commenced by any creditor upon such judgment or order.

 

(g)           Change in Control . Any Change in Control shall occur.

 

(h)           Bankruptcy, Insolvency, Etc. The Borrower or (except as permitted pursuant to Section 8.7) any of the Subsidiaries shall

 

(i)            become insolvent or generally fail to pay, or admit in writing its inability or unwillingness generally to pay, debts as they become due;

 

(ii)           apply for, consent to, or acquiesce in the appointment of a trustee, receiver, sequestrator or other custodian for any substantial part of the property of any thereof, or make a general assignment for the benefit of creditors;

 

(iii)          in the absence of such application, consent or acquiescence in or permit or suffer to exist the appointment of a trustee, receiver, sequestrator or other custodian for a substantial part of the property of any thereof, and such trustee, receiver, sequestrator or other custodian shall not be discharged within 60 days; provided that, the Borrower and each Subsidiary hereby expressly authorizes the Lender to appear in any court conducting any relevant proceeding during such 60-day period to preserve, protect and defend its rights under the Loan Documents;

 

(iv)          permit or suffer to exist the commencement of any bankruptcy, reorganization, debt arrangement or other case or proceeding under any bankruptcy or insolvency law or any dissolution, winding up or liquidation proceeding, in respect thereof, and, if any such case or proceeding is not commenced by the Borrower or any Subsidiary, such case or proceeding shall be consented to or acquiesced in by the Borrower or such Subsidiary, as the case may be, or shall result in the entry of an order for relief or shall remain for 60 days undismissed; provided that, the Borrower and each Subsidiary hereby expressly authorizes the Lender to appear in any court conducting any such case or proceeding during such 60-day period to preserve, protect and defend its rights under the Loan Documents; or

 

(v)           take any action authorizing, or in furtherance of, any of the foregoing.

 

54


 

(i)            Impairment of Security, Etc . Any Loan Document shall (except in accordance with its terms) terminate or the terms thereof shall cease to be the legally valid, binding and enforceable obligation of the Borrower or any Subsidiary thereto; the Borrower or any Subsidiary shall contest in any manner such validity, binding nature or enforceability; or, except as permitted under any Loan Document, any Lien securing any Obligation shall, in whole or in any material part, cease to be a perfected first priority Lien.

 

(j)            Key Permit Events . Any Key Permit or any of the Borrower’s or any Subsidiary’s material rights or interests thereunder is terminated or amended in any manner materially adverse to the Borrower or the Borrower and its Subsidiaries taken as a whole.

 

(k)           Material Adverse Change . Any circumstance occurs that has had or would reasonably be expected to cause a Material Adverse Effect.

 

(l)            Key Person Even t. If either of Dr. Matthew Rabinowitz or Jonathan Sheena ceases to be employed full time by the Borrower and actively working as the Chief Executive Officer and Chief Technology Officer, as applicable, unless within 180 days after such individual ceases to be employed full time and actively working the Borrower hires a replacement for such individual reasonably acceptable to the Lender.

 

(m)          Regulatory Matters . If any of the following occurs and has had or would reasonably be expected to have or result in a Material Adverse Effect: (i) the FDA, CMS, EMA or any other Governmental Authority (A) issues a letter or other communication asserting that any Product lacks a required Regulatory Authorization or (B) initiates enforcement action against, or issues a warning letter with respect to, the Borrower or any of the Subsidiaries, or any of their Products or the manufacturing facilities therefor, that causes the Borrower or such Subsidiary to discontinue marketing or withdraw any of its material Products, or causes a material delay in the manufacture or offering of any of its material Products, which discontinuance, withdrawal or delay could reasonably be expected to last for more than three months; (ii) a recall; or (iii) the Borrower or any of the Subsidiaries enters into a settlement agreement with the FDA, CMS, EMA or any other Governmental Authority.

 

SECTION 9.2 Action if Bankruptcy . If any Event of Default described in clauses (i) through (iv) of Section 9.1(h)  with respect to the Borrower shall occur, the Commitments (if not theretofore terminated) shall automatically terminate and the outstanding principal amount of the Loans and all other Obligations shall automatically be and become immediately due and payable, without notice or demand to any Person.

 

SECTION 9.3 Action if Other Event of Default . If any Event of Default (other than any Event of Default described in clauses (i) through (iv) of Section 9.1(h)) shall occur for any reason, whether voluntary or involuntary, and be continuing, the Lender may, by notice to the Borrower declare all or any portion of the outstanding principal amount of the Loans and other Obligations to be due and payable and/or the

 

55



 

Commitments (if not theretofore terminated) to be terminated, whereupon the full unpaid amount of the Loans and other Obligations which shall be so declared due and payable shall be and become immediately due and payable, without further notice, demand or presentment, and the Commitments shall terminate.

 

ARTICLE X

MISCELLANEOUS PROVISIONS

 

SECTION 10.1 Waivers, Amendments, Etc . The provisions of each Loan Document may from time to time be amended, modified or waived, if such amendment, modification or waiver is in writing and consented to by the Lender and the Borrower.

 

No failure or delay on the part of the Lender in exercising any power or right under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such power or right preclude any other or further exercise thereof or the exercise of any other power or right. No notice to or demand on the Borrower or any of the Subsidiaries in any case shall entitle it or any of them to any notice or demand in similar or other circumstances. No waiver or approval by the Lender under any Loan Document shall, except as may be otherwise stated in such waiver or approval, be applicable to subsequent transactions. No waiver or approval hereunder shall require any similar or dissimilar waiver or approval thereafter to be granted hereunder.

 

SECTION 10.2 Notices; Time . All notices and other communications provided under any Loan Document shall be in writing or by facsimile and addressed, delivered or transmitted, if to the Borrower or the Lender, to the applicable Person at its address or facsimile number set forth on Schedule 10.2 hereto, or at such other address or facsimile number as may be designated by such party in a notice to the other parties. Any notice, if mailed and properly addressed with postage prepaid or if properly addressed and sent by pre-paid courier service, shall be deemed given when received; any notice, if transmitted by facsimile, shall be deemed given when the confirmation of transmission thereof is received by the transmitter. Documents required to be delivered pursuant to Section 7.1 may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which (i) the Borrower posts such documents, or provides a link thereto on the Borrower’s website or the Internet at the following website address: [*], or (ii) such documents are posted on the Borrower’s behalf on an Internet or intranet website, if any, to which the Lender has access (whether a commercial or third-party website), and in each case an email with a link to such posting has been provided to the Lender’s email addresses set forth on Schedule 10.2 heretofore. Unless otherwise indicated, all references to the time of a day in a Loan Document shall refer to New York City time.

 

SECTION 10.3 Payment of Costs and Expenses . [*]

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

56



 

[*]

 

(a)           [*];

 

(b)           [*]; and

 

(c)           [*].

 

The Borrower further agrees to pay, and to hold the Lender harmless from all liability for, any stamp or other taxes which may be payable in connection with the execution or delivery of each Loan Document, the Loans or the issuance of the Note. The Borrower also agrees to reimburse the Lender upon demand for all reasonable out-of-pocket expenses (including reasonable attorneys’ fees and legal expenses of counsel to the Lender) incurred by the Lender in connection with (x) the negotiation of any restructuring or “work-out” with the Borrower, whether or not consummated, of any Obligations and (y) the enforcement of any Obligations.

 

SECTION 10.4 Indemnification . In consideration of the execution and delivery of this Agreement by the Lender, the Borrower hereby indemnifies, agrees to defend, exonerates and holds the Lender and each of its officers, directors, employees and agents (collectively, the “ Indemnified Parties ”) free and harmless from and against any and all actions, causes of action, suits, losses, costs, liabilities, obligations and damages, and expenses incurred in connection therewith (irrespective of whether any such Indemnified Party is a party to the action for which indemnification hereunder is sought), including reasonable attorneys’ and professionals’ fees and disbursements, whether incurred in connection with actions between the parties hereto or the parties hereto and third parties (collectively, the “ Indemnified Liabilities ”), including, without limitation, Indemnified Liabilities arising out of or relating to (i) the entering into and performance of any Loan Document by any of the Indemnified Parties (including any action brought by or on behalf of the Borrower as the result of any determination by the Lender pursuant to Article V not to fund any Loan as a consequence of the Borrower’s failure to satisfy the conditions set forth therein), and (ii) any Environmental Liability; provided that the Borrower shall have no obligation or liability under this Section 10.4 with respect to any Indemnified Liabilities that arise from or are the direct result of an Indemnified Party’s gross negligence or willful misconduct. If and to the extent that the foregoing indemnification may be unenforceable for any reason, the Borrower agrees to make the maximum contribution

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

57



 

to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law.

 

SECTION 10.5 Survival . The obligations of the Borrower under Section 4.1 , Section 4.2 , Section 4.3 , Section 10.3 and Section 10.4 , shall in each case survive any assignment by the Lender and the occurrence of the Termination Date. The representations and warranties made by the Borrower in each Loan Document shall survive the execution and delivery of such Loan Document.

 

SECTION 10.6 Severability . Any provision of any Loan Document which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of such Loan Document or affecting the validity or enforceability of such provision in any other jurisdiction.

 

SECTION 10.7 Headings . The various headings of each Loan Document are inserted for convenience only and shall not affect the meaning or interpretation of such Loan Document or any provisions thereof.

 

SECTION 10.8 Execution in Counterparts, Effectiveness, Etc. . This Agreement may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. This Agreement shall become effective when counterparts hereof executed on behalf of the Borrower and the Lender, shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

SECTION 10.9 Governing Law; Entire Agreement . EACH LOAN DOCUMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). The Loan Documents constitute the entire understanding among the parties hereto with respect to the subject matter thereof and supersede any prior agreements, written or oral, with respect thereto.

 

SECTION 10.10 Successors and Assigns . This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns; provided that, the Borrower may not assign or transfer its rights or obligations hereunder without the consent of the Lender; provided , further, that the Lender may not assign or transfer its rights or obligations hereunder or under the other Loan Documents to a Competitor of the Borrower without the prior written consent of the Borrower, except in the case that (i) an Event of Default has occurred and (ii) such

 

58



 

Event of Default continues for [*] days after the Lender has notified the Borrower of its intent to make such an assignment or transfer to a Competitor.

 

SECTION 10.11 Other Transactions . Nothing contained herein shall preclude the Lender, from engaging in any transaction, in addition to those contemplated by the Loan Documents, with the Borrower or any of its Affiliates in which the Borrower or such Affiliate is not restricted hereby from engaging with any other Person.

 

SECTION 10.12 Forum Selection and Consent to Jurisdiction . ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, ANY LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE LENDER OR THE BORROWER IN CONNECTION HEREWITH OR THEREWITH SHALL BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT, ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE LENDER’S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. EACH OF THE BORROWER AND THE LENDER IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK AT THE ADDRESS FOR NOTICES SPECIFIED IN SECTION 10.2 . EACH OF THE BORROWER AND THE LENDER HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT THAT EITHER THE BORROWER OR THE LENDER HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, THE BORROWER AND THE LENDER, EACH ON ITS OWN BEHALF, HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER THE LOAN DOCUMENTS.

 

SECTION 10.13 Waiver of Jury Trial . THE LENDER AND THE BORROWER HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, EACH LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

59



 

DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE LENDER OR THE BORROWER IN CONNECTION THEREWITH. THE BORROWER ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION (AND EACH OTHER PROVISION OF EACH OTHER LOAN DOCUMENT TO WHICH IT IS A PARTY) AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE LENDER ENTERING INTO THE LOAN DOCUMENTS.

 

SECTION 10.14 Confidential Information . Subject to the provisions of Section 10.15, at all times prior to the fifth anniversary of the Termination Date, the Receiving Party shall keep confidential and shall not publish or otherwise disclose any Confidential Information furnished to it by the Disclosing Party, except to those of the Receiving Party’s employees, advisors or consultants who have a need to know such information to assist such Party in the performance of such Party’s obligations or in the exercise of such Party’s rights hereunder and who are subject to obligations of confidentiality consistent with these provisions (collectively, “ Recipients ”). Notwithstanding anything to the contrary set forth herein, (a) the Lender may disclose this Agreement and the terms and conditions hereof and any information related hereto, other than to any Competitor of Natera or any of its Subsidiaries, to (i) its Affiliates, (ii) potential and actual assignees of any of the Lender’s rights hereunder and (iii) potential and actual investors in, or lenders to, the Lender (including, in each of the foregoing cases, such Person’s employees, advisors or consultants); provided that in each case, each such Recipient shall be subject to reasonable obligations of confidentiality; and (b) upon receiving consent from the Lender, which consent shall not be unreasonably withheld, delayed or conditioned, the Borrower may disclose this Agreement and the terms and conditions hereof and information related hereto, to potential or actual permitted acquirers or assignees, collaborators and other (sub)licensees, permitted subcontractors, investment bankers, investors, lenders (including, in each of the foregoing cases, such Person’s employees, advisors or consultants who have a need to receive and review such information); provided that in each case, each such Recipient shall be subject to reasonable obligations of confidentiality. In addition to the foregoing, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in order to comply with applicable laws (including any securities law or regulation or the rules of a securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance, provided that the Receiving Party (x) will only disclose those portions of the Confidential Information that are necessary or required to be so disclosed, (y) to the extent legally permissible, will notify the Disclosing Party of the Receiving Party’s intent to make any disclosure pursuant thereto, and (z) to the extent reasonably practicable, the Receiving Party shall provide such notice in advance of the disclosure so as to allow the Disclosing Party an opportunity to seek (at the Disclosing Party’s sole expense) a protective order or other appropriate remedy; provided , however, that no such notice will be required in respect of disclosures of Confidential Information to regulatory authorities having or claiming to have jurisdiction over the Receiving Party in connection with routine regulatory examinations. In the event that no such protective order or other remedy is obtained or

 

60



 

that the Disclosing Party waives compliance with the provisions hereof, the Receiving Party and its Representatives may disclose such Confidential Information as may be required or requested.

 

SECTION 10.15 Exceptions to Confidentiality . The Receiving Party’s obligations set forth in this Agreement shall not extend to any Confidential Information of the Disclosing Party:

 

(a)           that is or hereafter becomes part of the public domain (other than as a result of a disclosure by the Receiving Party or its Recipients in violation of this Agreement);

 

(b)           that is received from a Third Party without restriction on disclosure and without, to the knowledge of the Receiving Party, breach of any agreement between such Third Party and the Disclosing Party;

 

(c)           that the Receiving Party can demonstrate by competent evidence was already in its possession without any limitation on disclosure prior to its receipt from the Disclosing Party;

 

(d)           that is generally made available to Third Parties by the Disclosing Party without restriction on disclosure; or

 

(e)           that the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party without use of or reference to the Confidential Information.

 

[ Signature Page Follows ]

 

61



 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the day and year first above written.

 

 

 

NATERA, INC.,

 

as the Borrower

 

 

 

By:

/s/ Matthew Rabinowitz

 

 

Name:

Matthew Rabinowitz

 

 

Title:

Chief Executive Officer

 

 

 

 

 

ROS ACQUISITION OFFSHORE LP,

 

as the Lender

 

 

 

By OrbiMed Advisors LLC,

 

its investment manager

 

 

 

By:

 

 

 

Name:

Samuel D. Isaly

 

 

Title:

Managing Member

 

[ Signature Page to Credit Agreement ]

 



 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the day and year first above written.

 

 

 

NATERA, INC.,

 

as the Borrower

 

 

 

By:

 

 

 

Name:

Matthew Rabinowitz

 

 

Title:

Chief Executive Officer

 

 

 

 

 

ROS ACQUISITION OFFSHORE LP,

 

as the Lender

 

 

 

By OrbiMed Advisors LLC,

 

its investment manager

 

 

 

By:

/s/ Samuel D. Isaly

 

 

Name:

Samuel D. Isaly

 

 

Title:

Managing Member

 

[ Signature Page to Credit Agreement ]

 


 

EXHIBIT A

FORM OF PROMISSORY NOTE

 

$30,000,000

April [ · ], 2013

 

FOR VALUE RECEIVED, NATERA, INC., a Delaware corporation (the “ Borrower ”), hereby promises to pay to the order of [ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership] (together with its Affiliates, successors, transferees and assigns, the “ Lender ”), on the Maturity Date the principal sum of [TWENTY MILLION DOLLARS ($20,000,000) or, if a Delayed Draw Loan is made to the Borrower, THIRTY MILLION DOLLARS ($30,000,000)] or, in either case if less, the aggregate unpaid principal amount of the Loans (and any continuation thereof) made (or continued) by the Lender pursuant to the Credit Agreement, dated as of April [ · ], 2013 (as amended, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and between the Borrower and the Lender. Unless otherwise defined herein or the context otherwise requires, terms used in this Note have the meanings provided in the Credit Agreement.

 

The Borrower also promises to pay interest on the unpaid principal amount hereof from time to time outstanding from the date hereof until maturity (whether by acceleration or otherwise) and, after maturity upon demand, until paid in full, at the rates per annum and on the dates specified in the Credit Agreement, as well as any other amounts that may be due to the Lender upon maturity (whether by acceleration or otherwise) under or in respect of this Note.

 

Payments of both principal and interest are to be made in U.S. Dollars in same day or immediately available funds to the account designated by the Lender pursuant to the Credit Agreement.

 

This Note is referred to in, and evidences Indebtedness incurred under, the Credit Agreement, to which reference is made for a description of the security and guarantee for this Note and for a statement of the terms and conditions on which the Borrower is permitted and required to make prepayments and repayments of the unpaid principal amount of the Indebtedness evidenced by this Note and on which such Indebtedness may be declared to be immediately due and payable. Any prepaid principal of this Note may not be reborrowed.

 

All parties hereto, whether as makers, endorsers or otherwise, severally waive presentment for payment, demand, protest and notice of dishonor.

 

THIS NOTE HAS BEEN DELIVERED IN NEW YORK, NEW YORK AND SHALL BE DEEMED TO BE A CONTRACT MADE UNDER AND GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).

 

[ Signature Page Follows ]

 



 

 

NATERA, INC.

 

 

 

 

 

By:

 

 

 

Name:

[ · ]

 

 

Title:

Chief Executive Officer

 

[ Signature Page to Promissory Note ]

 



 

EXHIBIT B

FORM OF LOAN REQUEST

 

[DATE]

 

[ROS Acquisition Offshore LP

C/O Walkers Corporate Services Limited

Walker House, 87 Mary Street

George Town, Grand Cayman KY 1-9005, Cayman Islands

Attention: Board of Directors]

 

with a copy to:

 

OrbiMed Advisors LLC

601 Lexington Avenue, 54th Floor

New York, NY 10022

Attention: Tadd Wessel and Matthew Rizzo

 

Ladies and Gentlemen:

 

Reference is hereby made to that certain Credit Agreement, dated as of April [ · ], 2013 (as amended, supplemented or otherwise modified from time to time and in effect on the date hereof, the “ Credit Agreement ”), by and between Natera, Inc., a Delaware corporation (the “ Borrower ”), and [ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership] (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

Unless otherwise defined herein or the context otherwise requires, terms used herein have the meanings provided in the Credit Agreement.

 

Pursuant to the provisions of Section 2.2 of the Credit Agreement, the Borrower hereby requests [an Initial ][a Delayed Draw ]Loan of $[ ] to be made on                , 201   (the “ Proposed Disbursement Date ”), which Loan shall be evidenced by [that certain Promissory Note dated as of April      , 2013 in the aggregate original principal amount of $30,000,000.00][                ].

 

The undersigned hereby represent(s) and warrant(s) to the Lender that:

 

(a)           the proceeds of the proposed Loan are to be used for the purposes set forth in Section 7.7 of the Credit Agreement;

 

(b)           bank account details and wire transfer instructions for disbursement of the proceeds of the proposed Loan are set forth on Schedule A hereto;

 

(c)           no Default has occurred and is continuing or would result from the proposed Loan;

 

(d)           all conditions required to be satisfied (or waived by the Lender), as set forth in Article V of the Credit Agreement, as applicable, as of the Proposed Disbursement Date for the

 



 

making of the Loan requested hereby have been, and are, fully satisfied (or duly waived by the Lender); and

 

(e)           the representations and warranties contained in Article VI of the Credit Agreement and in the other Loan Documents are true and correct in all material respects (except with respect to any representation or warranty that contains a materiality qualifier, which representation or warranty shall be true and correct in all respects), before and after giving effect to the making of the proposed Loan and to the application of the proceeds thereof, as though made on and as of the date hereof, except to the extent that they relate specifically to an earlier specified date (in which case they are true and correct in all material respects on and as of such earlier date) or are affected by transactions or events occurring after the date of the Credit Agreement which are not prohibited thereunder.

 

The officer signing below is an Authorized Officer of the undersigned and is authorized to request the Loan contemplated hereby and issue this Loan Request on behalf of the undersigned.

 

[ Signature Page Follows ]

 

2



 

 

Very truly yours,

 

 

 

 

 

NATERA, INC.,

 

 

 

as the Borrower

 

 

 

 

 

By:

 

 

 

Name:

[ · ]

 

 

Title:

Chief Executive Officer

 

[ Signature Page to Loan Request ]

 



 

Schedule A

 

Disbursement / Wire Instructions

 

[ Schedules to Loan Request ]

 



 

EXHIBIT C

FORM OF COMPLIANCE CERTIFICATE

 

NATERA, INC.

 

COMPUTATION DATE:              , 201   

 

This Compliance Certificate (this “ Certificate ”) is delivered pursuant to [Section 5.7][Section 7.1(d)] of the Credit Agreement, dated as of April [ · ], 2013 (as amended, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and between Natera, Inc., a Delaware corporation (the “ Borrower ”), and [ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership] (together with its Affiliates, successors, transferees and assignees, the “ Lender ”). Unless otherwise defined herein or the context otherwise requires, terms used in this Certificate have the meanings provided in the Credit Agreement.

 

This Certificate relates to the [Fiscal Month][Fiscal Quarter][Fiscal Year] commencing on              , 201    and ending on              , 201     (such latter date being the “ Computation Date ”).

 

The undersigned is duly authorized to execute and deliver this Certificate on behalf of the Borrower. By executing this Certificate, the undersigned hereby certifies to the Lender that as of the Computation Date:

 

(a) [Attached hereto as Annex I are (i) an unaudited report of the Panorama Net Revenue and the Revenue Base for the Fiscal Month ending on the Computation Date and for the period commencing at the end of the previous Fiscal Year and ending with the end of such Fiscal Month, and including in comparative form the figures for the corresponding Fiscal Month in, and the year to date portion of, the immediately preceding Fiscal Year, and (ii) an unaudited report of the Liquidity of the Borrower at the end of such Fiscal Month, and including in comparative form the Liquidity of the Borrower for the corresponding Fiscal Month in the preceding Fiscal Year, in each case with supporting detail and certified as complete and correct by the chief financial or accounting Authorized Officer of the Borrower (subject to normal year-end audit adjustments).](1)

 

[Attached hereto as Annex I are the unaudited consolidated balance sheet of Borrower and the Subsidiaries as of the end of such Fiscal Quarter and consolidated statements of income and cash flow of the Borrower and the Subsidiaries for such Fiscal Quarter and for the period commencing at the end of the previous Fiscal Year and ending with the end of such Fiscal Quarter, and including (in each case) in comparative form the figures for the corresponding Fiscal Quarter in, and year to date portion of, the immediately preceding Fiscal Year, certified as complete and correct by the chief

 


(1) INCLUDE FOR MONTHLY FINANCIAL DELIVERABLES.

 



 

financial or accounting Authorized Officer of the Borrower (subject to normal year-end audit adjustments).](2)

 

[Attached hereto as Annex I are the consolidated balance sheet of Borrower and the Subsidiaries, and the related consolidated statements of income and cash flow of the Borrower and the Subsidiaries for such Fiscal Year, setting forth in comparative form the figures for the immediately preceding Fiscal Year, audited (without any Impermissible Qualification) by an independent accounting firm which is (i) registered with the Public Company Accounting Oversight Board (PCAOB) to audit public companies and (ii) reasonably acceptable to the Lender, which shall include a calculation of the financial covenants set forth in Section 8.4 of the Credit Agreement and stating that, in performing the examination necessary to deliver the audited financial statements of the Borrower, no knowledge was obtained of any Event of Default.](3)

 

(b) The financial statements delivered with this Certificate in accordance with Section 7.1(a), (b) and (c) of the Credit Agreement fairly present in all material respects the financial condition of the Borrower and the Subsidiaries (subject to the absence of footnotes and to normal year-end audit adjustments in the case of unaudited financial statements).

 

(c) [As of the Computation Date, the Borrower and the Subsidiaries are in compliance in all respects with the financial covenants set forth in Section 8.4 of the Credit Agreement. [Set forth on Attachment 1 hereto are calculations showing compliance with such financial covenants as of the Computation Date.]

 

(d) No Default has occurred and is continuing[ except as set forth on Attachment [2] hereto, which includes a description of the nature and period of existence of such Default and what action the Borrower or any of the Subsidiaries has taken, is taking, or proposes to take with respect thereto].

 

(e) Subsequent to the date of the most recent Compliance Certificate submitted by the undersigned pursuant to Section 7.1(d) of the Credit Agreement, neither the Borrower nor any Subsidiary has formed or acquired any new Subsidiary[ except as set forth on Attachment [2] hereto, in which case such new Subsidiary has complied with the requirements of Section 7.8 of the Credit Agreement].

 

(f) Subsequent to the date of the most recent Compliance Certificate submitted by the undersigned pursuant to Section 7.1(d) of the Credit Agreement, neither the Borrower nor any Subsidiary has acquired any ownership interest in any real property[ except as set forth on Attachment [2] hereto, in which case the Borrower has complied with the requirements of Section 7.8 of the Credit Agreement with respect to such real property].

 

[ Signature Page Follows ]

 


(2) INCLUDE FOR QUARTERLY FINANCIAL DELIVERABLES.

(3) INCLUDE FOR ANNUAL FINANCIAL DELIVERABLES.

 



 

IN WITNESS WHEREOF, the undersigned has caused this Certificate to be executed and delivered, and the certification and warranties contained herein to be made, by its chief financial or accounting Authorized Officer as of the date first above written.

 

 

 

NATERA, INC.

 

 

 

 

 

By:

 

 

 

Name: [ ]

 

 

Title: Chief Executive Officer

 

[ Signature Page to Compliance Certificate ]

 


 

[ Annex 1 ]

 



 

[ Attachment 1 ]

 



 

[ Attachment 2 ]

 



 

EXHIBIT D

FORM OF GUARANTEE

 

This GUARANTEE, dated as of April [ · ], 2013 (as amended, supplemented or otherwise modified from time to time, this “ Guarantee ”), is made by [Insert names of all subsidiaries][, a Delaware corporation] (together with any additional Persons named pursuant to Section 5.5, each a “ Guarantor ” and collectively the “ Guarantors ”), in favor of [ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership] (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W I T N E S S E T H :

 

WHEREAS, pursuant to the Credit Agreement, dated as of April [ · ], 2013 (as amended, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and between the Borrower and the Lender, the Lender has extended a Commitment to make Loans to the Borrower; and

 

WHEREAS, as a condition precedent to the making of the Initial Loan under the Credit Agreement, the Guarantors are required to execute and deliver this Guarantee;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in order to induce the Lender to make the Loans to the Borrower, each Guarantor hereby agrees, for the benefit of the Lender, as follows.

 

ARTICLE I

DEFINITIONS

 

SECTION 1.1. Certain Terms . The following terms (whether or not underscored) when used in this Guarantee, including its preamble and recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof):

 

Credit Agreement ” is defined in the first recital .

 

Guarantor ” is defined in the preamble .

 

Guarantee ” is defined in the preamble .

 

Lender ” is defined in the preamble .

 

Obligor ” is defined in Section 2.1(a) .

 

SECTION 1.2. Credit Agreement Definitions . Unless otherwise defined herein or the context otherwise requires, terms used in this Guarantee, including its preamble and recitals, have the meanings provided in the Credit Agreement.

 



 

ARTICLE II

GUARANTEE PROVISIONS

 

SECTION 2.1. Guarantee . Each Guarantor jointly and severally, absolutely, unconditionally and irrevocably:

 

(a)  guarantees the full and punctual payment when due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise, of all Obligations of the Borrower and the Subsidiaries (each, an “ Obligor ”) now or hereafter existing, whether for principal, interest (including interest accruing at the then applicable Default Rate as provided in Section 3.5 of the Credit Agreement, whether or not a claim for post-filing or post-petition interest is allowed under applicable law following the institution of a proceeding under bankruptcy, insolvency or similar laws), fees, expenses or otherwise (including all such amounts which would become due but for the operation of the automatic stay under Section 362(a) of the United States Bankruptcy Code, 11 U.S.C. §362(a), and the operation of Sections 502(b) and 506(b) of the United States Bankruptcy Code, 11 U.S.C. §502(b) and §506(b)); and

 

(b)  indemnifies and holds harmless the Lender for any and all costs and expenses (including the reasonable fees and out-of-pocket expenses of counsel to the Lender) incurred by the Lender in enforcing any rights under this Guarantee, except to the extent such amounts arise or are incurred as a consequence of the Lender’s own gross negligence or willful misconduct;

 

provided , that each Guarantor shall only be liable under this Guarantee for the maximum amount of such liability that can be hereby incurred without rendering this Guarantee, as it relates to such Guarantor, voidable under applicable law relating to fraudulent conveyance or fraudulent transfer, and not for any greater amount. This Guarantee constitutes a guarantee of payment when due and not of collection, and each Guarantor specifically agrees that it shall not be necessary or required that the Lender exercise any right, assert any claim or demand or enforce any remedy whatsoever against such Guarantor or any other Person before or as a condition to the obligations of such Guarantor becoming due hereunder.

 

SECTION 2.2. Reinstatement, etc. Each Guarantor agrees that this Guarantee shall continue to be effective or be reinstated (including on or after the Termination Date), as the case may be, if at any time any payment (in whole or in part) of any of the Obligations is invalidated, declared to be fraudulent or preferential, set aside, rescinded or must otherwise be restored by the Lender, including upon the occurrence of any Event of Default set forth in Section 9.1(h) of the Credit Agreement or otherwise, all as though such payment had not been made.

 

SECTION 2.3. Guarantee Absolute, etc. This Guarantee shall in all respects be a continuing, absolute, unconditional and irrevocable guarantee of payment, and shall remain in full force and effect until (unless reinstated pursuant to Section 2.2 above) the Termination Date has occurred. Each Guarantor guarantees that the Obligations shall be paid strictly in accordance with the terms of each Loan Document under which they arise, regardless of any law, regulation or order now or hereafter in effect in any jurisdiction affecting any of such terms or the rights of

 

2



 

the Lender with respect thereto. The liability of each Guarantor under this Guarantee shall be absolute, unconditional and irrevocable irrespective of:

 

(a)  any lack of validity, legality or enforceability of any Loan Document;

 

(b)  the failure of the Lender (i) to assert any claim or demand or to enforce any right or remedy against such Guarantor or any other Person (including any other guarantor) under the provisions of any Loan Document or otherwise, or (ii) to exercise any right or remedy against any other guarantor (including such Guarantor and any other Guarantor) of, or collateral securing, any Obligations;

 

(c)  any change in the time, manner or place of payment of, or in any other term of, all or any part of the Obligations, or any other extension, compromise or renewal of any Obligation, or any amendment to, rescission, waiver, or other modification of, or any consent to or departure from, any of the terms of any Loan Document;

 

(d)  any reduction, limitation, impairment or termination of any Obligations for any reason, including any claim of waiver, release, surrender, alteration or compromise, and shall not be subject to (and each Guarantor hereby waives any right to or claim of) any defense or setoff, counterclaim, recoupment or termination whatsoever by reason of the invalidity, illegality, irregularity, compromise, unenforceability of, or any other event or occurrence affecting, any Obligations or otherwise;

 

(e)  any addition, exchange or release of any collateral or of any Person that is (or will become) a guarantor of the Obligations, or any surrender or non-perfection of any collateral, or any amendment to, or waiver or release of, or addition to, or consent to or departure from, any other guarantee held by the Lender securing any of the Obligations; or

 

(f)  any other circumstance which might otherwise constitute a defense available to, or a legal or equitable discharge of, any Obligor, any surety or any guarantor (including any Guarantor).

 

SECTION 2.4. Setoff . Each Guarantor hereby irrevocably authorizes the Lender, without the requirement that any notice be given to such Guarantor (such notice being expressly waived by such Guarantor), upon the occurrence and during the continuance of any Event of Default, to appropriate and apply to the payment of the Obligations owing to it (whether or not then due), and (as security for such Obligations) each Guarantor hereby grants to the Lender a continuing security interest in, any and all balances, credits, deposits, accounts or moneys of such Guarantor then or thereafter maintained with or on behalf of the Lender. The Lender agrees to notify such Guarantor after any such set-off and application made by the Lender; provided , that the failure to give such notice shall not affect the validity of such setoff and application. The rights of the Lender under this Section are in addition to other rights and remedies (including other rights of setoff under applicable law or otherwise) which the Lender may have.

 

3



 

SECTION 2.5. Waiver, etc. Each Guarantor waives promptness, diligence, notice of acceptance and any other notice with respect to any of the Obligations and this Guarantee and any requirement that the Lender protect, secure, perfect or insure any Lien, or any property subject thereto, or exhaust any right or take any action against any Obligor or any other Person (including any Guarantor) or entity or any collateral securing the Obligations, as the case may be.

 

SECTION 2.6. Postponement of Subrogation, etc. Each Guarantor agrees that it will not exercise any rights which it may acquire by way of rights of subrogation under any Loan Document to which it is a party, nor shall such Guarantor seek or be entitled to seek any contribution or reimbursement from the Borrower or any other Obligor or Guarantor, in respect of any payment made under any Loan Document or otherwise, until following the Termination Date. Any amount paid to such Guarantor on account of any such subrogation rights prior to the Termination Date shall be held in trust for the benefit of the Lender and shall immediately be paid and turned over to the Lender in the exact form received by such Guarantor (duly endorsed in favor of the Lender, if required), to be credited and applied against the Obligations, whether matured or unmatured, in accordance with Section 2.7 ; provided , that if such Guarantor has made payment to the Lender of all or any part of the Obligations and the Termination Date has occurred, then, at such Guarantor’s request, the Lender will, at the expense of such Guarantor, execute and deliver to such Guarantor appropriate documents (without recourse and without representation or warranty) necessary to evidence the transfer by subrogation to such Guarantor of an interest in the Obligations resulting from such payment. In furtherance of the foregoing, at all times prior to the Termination Date, such Guarantor shall refrain from taking any action or commencing any proceeding against the Borrower or any other Obligor or Guarantor (or their successors or assigns, whether in connection with a bankruptcy proceeding or otherwise) to recover any amounts in respect of payments made under this Guarantee to the Lender.

 

SECTION 2.7. Payments; Application . Each Guarantor agrees that all obligations of such Guarantor hereunder shall be paid solely in U.S. Dollars to the Lender in immediately available funds, without set-off, counterclaim or other defense and in accordance with Sections 3.2, 3.3, 4.3 and 4.4 of the Credit Agreement, free and clear of and without deduction for any Non-Excluded Taxes, such Guarantor hereby agreeing to comply with and be bound by the provisions of Sections 3.2, 3.3, 4.3 and 4.4 of the Credit Agreement in respect of all payments and application of such payments made by it hereunder and the provisions of which Sections are hereby incorporated into and made a part of this Guarantee by this reference as if set forth herein; provided , that references to the “Borrower” in such Sections shall be deemed to be references to such Guarantor, and references to “this Agreement” in such Sections shall be deemed to be references to this Guarantee.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES

 

In order to induce the Lender to enter into the Credit Agreement and make the Loans thereunder, each Guarantor represents and warrants to the Lender as set forth below.

 

4



 

SECTION 3.1. Credit Agreement Representations and Warranties . The representations and warranties contained in Article VI of the Credit Agreement, insofar as the representations and warranties contained therein are applicable to such Guarantor and its properties, are true and correct in all material respects as of the Closing Date and the Delayed Draw Closing Date, if applicable, each such representation and warranty set forth in such Article (insofar as applicable as aforesaid) and all other terms of the Credit Agreement to which reference is made therein, together with all related definitions and ancillary provisions, being hereby incorporated into this Guarantee by this reference as though specifically set forth in this Article.

 

SECTION 3.2. Financial Condition, etc . Each Guarantor has knowledge of the Borrower’s and each other Guarantor’s financial condition and affairs and has adequate means to obtain from each such Person on an ongoing basis information relating thereto and to each such Person’s ability to pay and perform the Obligations, and agrees to assume the responsibility for keeping, and to keep, so informed for so long as this Guarantee is in effect. Each Guarantor acknowledges and agrees that the Lender shall have no obligation to investigate the financial condition or affairs of the Borrower or any other Guarantor for the benefit of such Guarantor nor to advise such Guarantor of any fact respecting, or any change in, the financial condition or affairs of each such Person that might become known to the Lender at any time, whether or not the Lender knows or believes or has reason to know or believe that any such fact or change is unknown to such Guarantor, or might (or does) materially increase the risk of such Guarantor as guarantor, or might (or would) affect the willingness of such Guarantor to continue as a guarantor of the Obligations.

 

SECTION 3.3. Best Interests . It is in the best interests of each Guarantor to execute this Guarantee inasmuch as each Guarantor will, as a result of being an Affiliate of the Borrower, derive substantial direct and indirect benefits from the Loans made to the Borrower by the Lender pursuant to the Credit Agreement, and each Guarantor agrees that the Lender is relying on this representation in agreeing to make the Loans to the Borrower.

 

ARTICLE IV

COVENANTS, ETC.

 

SECTION 4.1. Covenants . Each Guarantor covenants and agrees that, at all times prior to the Termination Date, it will perform, comply with and be bound by all of the agreements, covenants and obligations contained in the Credit Agreement (including Articles VII and VIII of the Credit Agreement) which are applicable to such Guarantor or its properties, each such agreement, covenant and obligation contained in the Credit Agreement and all other terms of the Credit Agreement to which reference is made in this Article, together with all related definitions and ancillary provisions, being hereby incorporated into this Guarantee by this reference as though specifically set forth in this Article.

 

ARTICLE V

MISCELLANEOUS PROVISIONS

 

SECTION 5.1. Loan Document . This Guarantee is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed,

 

5


 

administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

 

SECTION 5.2. Binding on Successors, Transferees and Assigns; Assignment . This Guarantee shall remain in full force and effect until the Termination Date has occurred, shall be binding upon each Guarantor and its successors, transferees and assigns and shall inure to the benefit of and be enforceable by the Lender; provided , that such Guarantor may not (unless otherwise permitted under the terms of the Credit Agreement) assign any of its obligations hereunder without the prior written consent of the Lender. Without limiting the generality of the foregoing, the Lender may assign or otherwise transfer (in whole or in part) its Commitment, Note or Loans held by it to any other Person, and such other Person shall thereupon become vested with all rights and benefits in respect thereof granted to the Lender under each Loan Document (including this Guarantee) or otherwise.

 

SECTION 5.3. Amendments, etc. No amendment to or waiver of any provision of this Guarantee, nor consent to any departure by any Guarantor from its obligations under this Guarantee, shall in any event be effective unless the same shall be in writing and signed by the Lender and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

SECTION 5.4. Notices . All notices and other communications provided for hereunder shall be given or made as set forth in Section 10.2 of the Credit Agreement.

 

SECTION 5.5. Additional Guarantors . Upon the execution and delivery by any other Person of a supplement in the form of Annex I hereto, such Person shall become a “Guarantor” hereunder with the same force and effect as if it were originally a party to this Guarantee and named as a “Guarantor” hereunder. The execution and delivery of such supplement shall not require the consent of any other Guarantor hereunder, and the rights and obligations of each Guarantor hereunder shall remain in full force and effect notwithstanding the addition of any new Guarantor as a party to this Guarantee.

 

SECTION 5.6. No Waiver; Remedies . In addition to, and not in limitation of, Section 2.3 and Section 2.5 , no failure on the part of the Lender to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by law.

 

SECTION 5.7. Further Assurances . Each Guarantor agrees, upon the written request of the Lender, to execute and deliver to the Lender, from time to time, any additional instruments or documents deemed to be reasonably necessary by the Lender to cause this Guarantee to be, become or remain valid and effective in accordance with its terms.

 

SECTION 5.8. Section Captions . Section captions used in this Guarantee are for convenience of reference only and shall not affect the construction of this Guarantee.

 

6



 

SECTION 5.9. Severability . Any provision of this Guarantee which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Guarantee or affecting the validity or enforceability of such provision in any other jurisdiction.

 

SECTION 5.10. Governing Law, Entire Agreement, etc. THIS GUARANTEE AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS GUARANTEE OR ANY OTHER LOAN DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Guarantee, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter hereof and supersedes any prior agreements, written or oral, with respect hereto.

 

SECTION 5.11. Forum Selection and Consent to Jurisdiction . ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS GUARANTEE, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE LENDER OR ANY GUARANTOR IN CONNECTION HEREWITH SHALL BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE LENDER’S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. THE LENDER BY ACCEPTANCE OF THIS GUARANTEE AND EACH GUARANTOR IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK AT THE ADDRESS FOR NOTICES SPECIFIED IN SECTION 10.2 OF THE CREDIT AGREEMENT. THE LENDER BY ACCEPTANCE OF THIS GUARANTEE AND EACH GUARANTOR HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT THAT THE LENDER BY ACCEPTANCE OF THIS GUARANTEE OR ANY GUARANTOR HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, THE LENDER BY ACCEPTANCE OF THIS GUARANTEE AND SUCH GUARANTOR, EACH ON ITS OWN BEHALF, HEREBY IRREVOCABLY WAIVES

 

7



 

TO THE FULLEST EXTENT PERMITTED BY LAW SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER THIS GUARANTEE.

 

SECTION 5.12. Counterparts . This Guarantee may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. This Guarantee shall become effective when counterparts hereof executed on behalf of each Guarantor shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Guarantee by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Guarantee.

 

SECTION 5.13. Waiver of Jury Trial . THE LENDER BY ACCEPTANCE OF THIS GUARANTEE AND EACH GUARANTOR HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS GUARANTEE, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE LENDER OR ANY GUARANTOR IN CONNECTION HEREWITH. EACH GUARANTOR ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION (AND EACH OTHER PROVISION OF EACH OTHER LOAN DOCUMENT TO WHICH IT IS A PARTY) AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE LENDER TO ENTER INTO THE LOAN DOCUMENTS.

 

[ Signature Page Follows ]

 

8



 

IN WITNESS WHEREOF, each Guarantor has caused this Guarantee to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

Name:

[       ]

 

 

Title:

[       ]

 

[ Signature Page to Guarantee ]

 



 

ANNEX I

to Guarantee

 

SUPPLEMENT TO

GUARANTEE

 

This SUPPLEMENT, dated as of                       ,            (this “ Supplement ”), is to the Guarantee, dated as of March [ · ], 2013 (as amended, supplemented, amended and restated or otherwise modified from time to time, the “ Guarantee ”), by the Guarantors (such term, and other terms used in this Supplement, to have the meanings set forth in Article I of the Guarantee) from time to time party thereto, in favor of [ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership] (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W I T N E S S E T H :

 

WHEREAS, pursuant to a Credit Agreement, dated as of [ ], 2013 (as amended, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”), by and between Natera, Inc., a Delaware corporation (the “ Borrower ”) and the Lender, the Lender has extended a Commitment to make the Loans to the Borrower;

 

WHEREAS, pursuant to the provisions of Section 5.5 of the Guarantee, each of the undersigned is becoming a Guarantor under the Guarantee; and

 

WHEREAS, each of the undersigned desires to become a “Guarantor” under the Guarantee in order to induce the Lender to continue to extend Loans under the Credit Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each of the undersigned agrees, for the benefit of the Lender, as follows.

 

SECTION 1.   Party to Guarantee, etc . In accordance with the terms of the Guarantee, by its signature below, each of the undersigned hereby irrevocably agrees to become a Guarantor under the Guarantee with the same force and effect as if it were an original signatory thereto and each of the undersigned hereby (a) agrees to be bound by and comply with all of the terms and provisions of the Guarantee applicable to it as a Guarantor and (b) represents and warrants that the representations and warranties made by it as a Guarantor thereunder are true and correct as of the date hereof, unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct as of such earlier date. In furtherance of the foregoing, each reference to a “Guarantor” and/or “Guarantors” in the Guarantee shall be deemed to include each of the undersigned.

 

SECTION 2.   Representations . Each of the undersigned Guarantors hereby represents and warrants that this Supplement has been duly authorized, executed and delivered by it and

 



 

that this Supplement and the Guarantee constitute its legal, valid and binding obligation, enforceable against it in accordance with its terms.

 

SECTION 3.   Full Force of Guarantee . Except as expressly supplemented hereby, the Guarantee shall remain in full force and effect in accordance with its terms.

 

SECTION 4.   Severability . Wherever possible each provision of this Supplement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Supplement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Supplement or the Guarantee.

 

SECTION 5.   Governing Law, Entire Agreement, etc . THIS SUPPLEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SECURITY AGREEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Supplement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto.

 

SECTION 6.   Effective . This Supplement shall become effective when a counterpart hereof executed by the Guarantor shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

[ Signature Page Follows ]

 

2



 

IN WITNESS WHEREOF, each of the parties hereto has caused this Supplement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

 

[NAME OF ADDITIONAL SUBSIDIARY]

 

 

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

 

 

 

 

 

 

[NAME OF ADDITIONAL SUBSIDIARY]

 

 

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

[ Signature Page to Guarantee Supplement ]

 



 

EXHIBIT E

PLEDGE AND SECURITY AGREEMENT

 

This PLEDGE AND SECURITY AGREEMENT, dated as of April [ · ], 2013 (as amended, supplemented or otherwise modified from time to time, this “ Security Agreement ”), is made by NATERA, INC., a Delaware corporation (the “ Borrower ”) and NATERA INTERNATIONAL, INC. (together with the Borrower and with any other entity that may become a party hereto as provided herein, each a “ Grantor ” and, collectively, the “ Grantors ”) in favor of [ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership], for itself and as agent for the other parties to which the Grantors may owe any Obligations (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W I T N E S S E T H :

 

WHEREAS, pursuant to the Credit Agreement, dated as of April [ · ], 2013 (as amended, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and between the Borrower and the Lender, the Lender has extended a Commitment to make Loans to the Borrower; and

 

WHEREAS, as a condition precedent to the making of the Initial Loan under the Credit Agreement, each Grantor is required to execute and deliver this Security Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees, for the benefit of the Lender, as follows:

 

ARTICLE I

DEFINITIONS

 

SECTION 1.1. Certain Terms . The following terms (whether or not underscored) when used in this Security Agreement, including its preamble and recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof):

 

Borrower ” is defined in the preamble.

 

Collateral ” is defined in Section 2.1 .

 

Collateral Accounts ” is defined in clause (b)  of Section 4.3 .

 

Computer Hardware and Software Collateral ” means (a) all of the Grantors’ computer and other electronic data processing hardware, integrated computer systems, central processing units, memory units, display terminals, printers, features, computer elements, card readers, tape drives, hard and soft disk drives, cables, electrical supply hardware, generators, power equalizers, accessories and all peripheral devices and other related computer hardware, including all operating system software, utilities and application programs in whatsoever form; (b) all software programs (including both source code, object code and all related applications and data files) designed for use on the computers and electronic data processing hardware described in

 



 

clause (a)  above; (c) all firmware associated therewith; (d) all documentation (including flow charts, logic diagrams, manuals, guides, specifications, training materials, charts and pseudo codes) with respect to such hardware, software and firmware described in the preceding clauses (a)  through (c) ; and (e) all rights with respect to all of the foregoing, including copyrights, licenses, options, warranties, service contracts, program services, test rights, maintenance rights, support rights, improvement rights, renewal rights and indemnifications and any substitutions, replacements, improvements, error corrections, updates, additions or model conversions of any of the foregoing.

 

Control Agreement ” means an authenticated record in form and substance reasonably satisfactory to the Lender, that provides for the Lender to have “control” (as defined in the UCC) over certain Collateral.

 

Copyright Collateral ” means all copyrights of the Grantors, whether statutory or common law, whether registered or unregistered and whether published or unpublished, now or hereafter in force throughout the world including all of the Grantors’ rights, titles and interests in and to all copyrights registered in the United States Copyright Office or anywhere else in the world, including the copyrights referred to in Item A of Schedule V , and registrations and recordings thereof and all applications for registration thereof, whether pending or in preparation, all copyright licenses, including each copyright license referred to in Item B of Schedule V , the right to sue for past, present and future infringements of any of the foregoing, all rights corresponding thereto, all extensions and renewals of any thereof and all Proceeds of the foregoing, including licenses, royalties, income, payments, claims, damages and Proceeds of suit, which are owned or licensed by the Grantors.

 

Credit Agreement ” is defined in the first recital .

 

Distributions ” means all dividends paid on Capital Securities, liquidating dividends paid on Capital Securities, shares (or other designations) of Capital Securities resulting from (or in connection with the exercise of) stock splits, reclassifications, warrants, options, non-cash dividends, mergers, consolidations, and all other distributions (whether similar or dissimilar to the foregoing) on or with respect to any Capital Securities constituting Collateral.

 

Filing Statements ” is defined in clause (b)  of Section 3.7 .

 

General Intangibles ” means all “general intangibles” and all “payment intangibles”, each as defined in the UCC, and shall include all interest rate or currency protection or hedging arrangements, all tax refunds, all licenses, permits, concessions and authorizations and all Intellectual Property Collateral (in each case, regardless of whether characterized as general intangibles under the UCC).

 

Grantor ” and “ Grantors ” are defined in the preamble .

 

Intellectual Property Collateral ” means, collectively, the Computer Hardware and Software Collateral, the Copyright Collateral, the Patent Collateral, the Trademark Collateral, the Trade Secrets Collateral, Product Agreements and Regulatory Authorizations.

 

2



 

Intercompany Note ” means any promissory note evidencing loans made by any Grantor to any other Grantor.

 

Investment Property ” means, collectively, (a) all “investment property” as such term is defined in Section 9-102(a)(49) of the UCC and (b) whether or not constituting “investment property” as so defined, all Pledged Notes.

 

Lender ” is defined in the preamble .

 

Patent Collateral ” means:

 

(a)                                 all of the Grantors’ (i) inventions and discoveries, whether patentable or not, and (ii) letters patent and applications for letters patent throughout the world, including all patent applications in preparation for filing and each patent and patent application referred to in Item A of Schedule III ;

 

(b)                                 all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the items described in clause (a) ;

 

(c)                                  all patent licenses, and other agreements providing any Grantor with the right to use any items of the type referred to in clauses (a)  and (b)  above, including each patent license referred to in Item B of Schedule III ; and

 

(d)                                 all Proceeds of, and rights associated with, the foregoing (including licenses, royalties income, payments, claims, damages and Proceeds of infringement suits) and the right to sue third parties for past, present or future infringements of any patent or patent application and for breach or enforcement of any patent license.

 

Permitted Liens ” means all Liens permitted by Section 8.3 of the Credit Agreement.

 

Pledged Notes ” means all promissory notes listed on Item J of Schedule II (as such schedule may be amended or supplemented from time to time), all Intercompany Notes at any time issued to any Grantor and all other promissory notes issued to or held by any Grantor.

 

Securities Act ” is defined in clause (a)  of Section 6.2 .

 

Security Agreement ” is defined in the preamble .

 

Trade Secrets Collateral ” means all of the Grantors’ common law and statutory trade secrets and all other confidential, proprietary or useful information, and all know-how obtained by or used in or contemplated at any time for use in the business of any Grantor (all of the foregoing being collectively called a “ Trade Secret ”), whether or not such Trade Secret has been reduced to a writing or other tangible form, including all documents and things embodying, incorporating or referring in any way to such Trade Secret, all Trade Secret licenses, and including the right to sue for and to enjoin and to collect damages for the actual or threatened misappropriation of any Trade Secret and for the breach or enforcement of any such Trade Secret license.

 

3


 

Trademark Collateral ” means :

 

(a)           (i) all of the Grantors’ trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, certification marks, collective marks, logos and other source or business identifiers, and all goodwill of the business associated therewith, now existing or hereafter adopted or acquired including those referred to in Item A of Schedule IV , whether currently in use or not, all registrations and recordings thereof and all applications in connection therewith, whether pending or filed, including registrations, recordings and applications in the United States Patent and Trademark Office or in any office or agency of the United States of America, or any State thereof or any other country or political subdivision thereof or otherwise, and all common-law rights relating to the foregoing, and (ii) the right to obtain all reissues, extensions or renewals of the foregoing (collectively referred to as the “ Trademarks ”);

 

(b)           all Trademark licenses for the grant by or to any Grantors of any right to use any Trademark, including each Trademark license referred to in Item B of Schedule IV ; and

 

(c)           all of the goodwill of the business connected with the use of, and symbolized by the items described in, clause (a) , and to the extent applicable clause (b) ;

 

(d)           the right to sue third parties for past, present and future infringements of any Trademark Collateral described in clause (a)  and, to the extent applicable, clause (b) ; and

 

(e)           all Proceeds of, and rights associated with, the foregoing, including any claim by any Grantor against third parties for past, present or future infringement or dilution of any Trademark, Trademark registration or Trademark license, or for any injury to the goodwill associated with the use of any such Trademark or for breach or enforcement of any Trademark license and all rights corresponding thereto throughout the world.

 

SECTION 1.2. Credit Agreement Definitions . Unless otherwise defined herein or the context otherwise requires, terms used in this Security Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement.

 

SECTION 1.3. UCC Definitions . When used herein the terms “Account”, “Certificate of Title”, “Certificated Securities”, “Chattel Paper”, “Commercial Tort Claim”, “Commodity Account”, “Commodity Contract”, “Deposit Account”, “Document”, “Electronic Chattel Paper”, “Equipment”, “Goods”, “Instrument”, “Inventory”, “Letter-of-Credit Rights”, “Payment Intangibles”, “Proceeds”, “Promissory Notes”, “Securities Account”, “Security Entitlement”, “Supporting Obligations” and “Uncertificated Securities” have the meaning provided in Article 8 or Article 9, as applicable, of the UCC. “Letters of Credit” has the meaning provided in Section 5-102 of the UCC.

 

4



 

ARTICLE II

SECURITY INTEREST

 

SECTION 2.1. Grant of Security Interest . Each Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all of such Grantor’s right, title and interest in and to the following property, whether now or hereafter existing, owned or acquired by such Grantor, and wherever located, (collectively, the “ Collateral ”):

 

(a)           Accounts;

 

(b)           Chattel Paper;

 

(c)           Commercial Tort Claims listed on Item I of Schedule II (as such schedule may be amended or supplemented from time to time);

 

(d)           Deposit Accounts;

 

(e)           Documents;

 

(f)            General Intangibles;

 

(g)           Goods (including Goods held on consignment with third parties);

 

(h)           Instruments;

 

(i)            Investment Property;

 

(j)            Letter-of-Credit Rights and Letters of Credit;

 

(k)           Supporting Obligations;

 

(l)            all books, records, writings, databases, information and other property relating to, used or useful in connection with, evidencing, embodying, incorporating or referring to, any of the foregoing in this Section;

 

(m)          all Proceeds of the foregoing and, to the extent not otherwise included, (A) all payments under insurance (whether or not the Lender is the loss payee thereof) in respect of Collateral and (B) all tort claims; and

 

(n)           all other property and rights of every kind and description and interests therein.

 

Notwithstanding the foregoing, the term “Collateral” shall not include:

 

(i)            any General Intangibles or other rights arising under any contracts, instruments, licenses or other documents as to which the grant of a security interest would (A) constitute a violation of a valid and enforceable restriction in favor of a third party on such grant, unless and until any required consents shall

 

5



 

have been obtained, or (B) give any other party to such contract, instrument, license or other document the right to terminate its obligations thereunder;

 

(ii)           trademark applications filed in the United States Patent and Trademark Office on the basis of such Grantor’s “intent to use” such trademark, unless and until acceptable evidence of use of the Trademark has been filed with the United States Patent and Trademark Office pursuant to Section 1(c) or Section 1(d) of the Lanham Act (15 U.S.C. 1051, et seq.), to the extent that granting a Lien in such Trademark application prior to such filing would adversely affect the enforceability or validity of such Trademark application;

 

(iii)          any asset, the granting of a security interest in which would be void or illegal under any applicable governmental law, rule or regulation, or pursuant thereto would result in, or permit the termination of, such asset; or

 

(iv)          any asset subject to a Permitted Lien (other than Liens in favor of the Lender) securing obligations permitted under the Credit Agreement to the extent that the grant of other Liens on such asset (A) would result in a breach or violation of, or constitute a default under, the agreement or instrument governing such Permitted Lien, (B) would result in the loss of use of such asset or (C) would permit the holder of such Permitted Lien to terminate the Grantor’s use of such asset;

 

provided , that the property described in paragraphs (i), (iii) and (iv) above shall only be excluded from the term “Collateral” to the extent the conditions stated in such paragraphs are not rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC or any other applicable law.

 

SECTION 2.2. Security for Obligations . This Security Agreement and the Collateral in which the Lender is granted a security interest hereunder by the Grantors secure, on an equal and ratable basis, the payment and performance of all of the Obligations.

 

SECTION 2.3. Grantors Remain Liable . Anything herein to the contrary notwithstanding:

 

(a)           the Grantors will remain liable under the contracts and agreements included in the Collateral to the extent set forth therein, and will perform all of their duties and obligations under such contracts and agreements to the same extent as if this Security Agreement had not been executed;

 

(b)           the exercise by the Lender of any of its rights hereunder will not release any Grantor from any of its duties or obligations under any such contracts or agreements included in the Collateral; and

 

(c)           the Lender will not have any obligation or liability under any contracts or agreements included in the Collateral by reason of this Security Agreement, nor will the Lender be obligated to perform any of the obligations or duties of any Grantor thereunder or to take any action to collect or enforce any claim for payment assigned hereunder.

 

6



 

SECTION 2.4. Distributions on Capital Securities In the event that any Distribution with respect to any Capital Securities pledged hereunder is permitted to be paid pursuant to Section 8.6 of the Credit Agreement, such Distribution or may be paid directly to the applicable Grantor. If any Distribution is made in contravention of Section 8.6 of the Credit Agreement, such Grantor shall hold the same segregated and in trust for the Lender until paid to the Lender in accordance with Section 4.1.5 .

 

SECTION 2.5. Security Interest Absolute, etc. This Security Agreement shall in all respects be a continuing, absolute, unconditional and irrevocable grant of security interest, and shall remain in full force and effect until the Termination Date. All rights of the Lender and the security interests granted to the Lender hereunder, and all obligations of the Grantors hereunder, shall, to the fullest extent permitted by applicable law, in each case, be absolute, unconditional and irrevocable irrespective of:

 

(a)           any lack of validity, legality or enforceability of any Loan Document (other than this Security Agreement);

 

(b)           the failure of the Lender (i) to assert any claim or demand or to enforce any right or remedy against the Borrower or any of the Subsidiaries or any other Person (including any other Grantor) under the provisions of any Loan Document or otherwise, or (ii) to exercise any right or remedy against any other guarantor (including any other Grantor) of, or Collateral securing, any Obligations;

 

(c)           any change in the time, manner or place of payment of, or in any other term of, all or any part of the Obligations, or any other extension, compromise or renewal of any Obligations;

 

(d)           any reduction, limitation, impairment or termination of any Obligations for any reason, including any claim of waiver, release, surrender, alteration or compromise, and shall not be subject to (and each Grantor hereby waives, until payment of all Obligations, any right to or claim of) any defense or setoff, counterclaim, recoupment or termination whatsoever by reason of the invalidity, illegality, nongenuineness, irregularity, compromise, unenforceability of, or any other event or occurrence affecting, any Obligations or otherwise;

 

(e)           any amendment to, rescission, waiver, or other modification of, or any consent to or departure from, any of the terms of any Loan Document;

 

(f)            any addition, exchange or release of any Collateral or of any Person that is (or will become) a Grantor (including the Grantors hereunder), or any surrender or non-perfection of any Collateral, or any amendment to or waiver or release or addition to, or consent to or departure from, any other guaranty held by the Lender securing any of the Obligations; or

 

(g)           any other circumstance which might otherwise constitute a defense available to, or a legal or equitable discharge of the Borrower or any of the Subsidiaries, any surety or any guarantor.

 

7



 

SECTION 2.6. Postponement of Subrogation . Each Grantor agrees that it will not exercise any rights against another Grantor which it may acquire by way of rights of subrogation under any Loan Document to which it is a party until following the Termination Date. No Grantor shall seek or be entitled to seek any contribution or reimbursement from the Borrower or any of the Subsidiaries, in respect of any payment made under any Loan Document or otherwise, until following the Termination Date. Any amount paid to any Grantor on account of any such subrogation rights prior to the Termination Date shall be held in trust for the benefit of the Lender and shall immediately be paid and turned over to the Lender in the exact form received by such Grantor (duly endorsed in favor of the Lender, if required), to be credited and applied against the Obligations, whether matured or unmatured, in accordance with Section 6.1(b) ; provided that if such Grantor has made payment to the Lender of all or any part of the Obligations and the Termination Date has occurred, then at such Grantor’s request, the Lender will, at the expense of such Grantor, execute and deliver to such Grantor appropriate documents (without recourse and without representation or warranty) necessary to evidence the transfer by subrogation to such Grantor of an interest in the Obligations resulting from such payment. In furtherance of the foregoing, at all times prior to the Termination Date, such Grantor shall refrain from taking any action or commencing any proceeding against the Borrower or any of the Subsidiaries (or their successors or assigns, whether in connection with a bankruptcy proceeding or otherwise) to recover any amounts in respect of payments made under this Security Agreement to the Lender.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES

 

In order to induce the Lender to enter into the Credit Agreement and make the Loans thereunder, the Grantors represent and warrant to the Lender as set forth below.

 

SECTION 3.1. As to Capital Securities of the Subsidiaries, Investment Property .

 

(a)           With respect to any Subsidiary of any Grantor that is

 

(i)            a corporation, business trust, joint stock company or similar Person, all Capital Securities issued by such Subsidiary are duly authorized and validly issued, fully paid and non-assessable, and represented by a certificate or certificates; and

 

(ii)           a partnership or limited liability company, no Capital Securities issued by such Subsidiary (A) is dealt in or traded on securities exchanges or in securities markets, (B) expressly provides that such Capital Securities is a security governed by Article 8 of the UCC or (C) is held in a Securities Account, except, with respect to this clause (a)(ii) , Capital Securities (x) for which the Lender is the registered owner or (y) with respect to which the issuer has agreed in an authenticated record with such Grantor and the Lender to comply with any instructions of the Lender without the consent of such Grantor.

 

8



 

(b)           Each Grantor has delivered all Certificated Securities constituting Collateral held by such Grantor in a Subsidiary on the later of the Closing Date or the date such Grantor becomes a party to this Security Agreement to the Lender, together with duly executed undated blank stock powers, or other equivalent instruments of transfer acceptable to the Lender.

 

(c)           With respect to Uncertificated Securities constituting Collateral owned by any Grantor in a Subsidiary on the later of the Closing Date or the date such Grantor becomes a party to this Security Agreement, such Grantor has caused the issuer thereof to agree in an authenticated record with such Grantor and the Lender that such issuer will comply with instructions with respect to such security originated by the Lender without further consent of such Grantor (which instructions the Lender hereby agrees not to give unless an Event of Default has occurred and is continuing). Each party hereto that is such an issuer of any Uncertificated Securities hereby agrees that such party will comply with instructions with respect to such security originated by the Lender (which instructions the Lender hereby agrees not to give unless an Event of Default has occurred and is continuing).

 

(d)           The percentage of the issued and outstanding Capital Securities of each Subsidiary pledged on the Closing Date by each Grantor hereunder is as set forth on Schedule I . All shares of such Capital Securities have been duly and validly issued and are fully paid and nonassessable.

 

(e)           Each of the Intercompany Notes constitutes the legal, valid and binding obligation of the obligor with respect thereto, enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.

 

SECTION 3.2. Grantor Name, Location , etc. In each case as of the date hereof:

 

(a)           (i) The jurisdiction in which each Grantor is located for purposes of Sections 9-301 and 9-307 of the UCC and (ii) the address of each Grantor’s executive office and principal place of business is set forth in Item A of Schedule II .

 

(b)           The Grantors do not have any trade names other than those set forth in Item C of Schedule II hereto.

 

(c)           During the twelve months preceding the later of (i) the date hereof or (ii) the date such Grantor becomes a party to this Security Agreement, no Grantor has been known by any legal name different from the one set forth on the signature page hereto, nor has such Grantor been the subject of any merger or other corporate reorganization, except as set forth in Item D of Schedule II hereto.

 

(d)           Each Grantor’s federal taxpayer identification number (or foreign equivalent) is (and, during the twelve months preceding the date hereof, such Grantor has

 

9



 

not had a federal taxpayer identification number (or equivalent) different from that) set forth in Item E of Schedule II hereto.

 

(e)           No Grantor is a party to any federal, state or local government contract except as set forth in Item F of Schedule II hereto.

 

(f)            No Grantor maintains any Deposit Accounts, Securities Accounts or Commodity Accounts with any Person, in each case, except as set forth on Item G of Schedule II .

 

(g)           No Grantor is the beneficiary of any Letters of Credit, except as set forth on Item H of Schedule II .

 

(h)           No Grantor has Commercial Tort Claims except as set forth on Item I of Schedule II .

 

(i)            The name set forth on the signature page attached hereto is the true and correct legal name (as defined in the UCC) of each Grantor.

 

SECTION 3.3. Ownership, No Liens, etc. Each Grantor owns its Collateral purported to be owned by it free and clear of any Lien, except for any security interest (a) created by this Security Agreement and (b) Permitted Liens. No effective UCC financing statement or other filing similar in effect covering all or any part of the Collateral is on file in any recording office, except those filed in favor of the Lender relating to this Security Agreement, Permitted Liens or as to which a duly authorized termination statement relating to such UCC financing statement or other instrument has been delivered to the Lender on the Closing Date.

 

SECTION 3.4. Possession of Inventory, Control; etc.

 

(a)           Each Grantor has, and agrees that it will maintain, exclusive possession of its Documents, Instruments, Promissory Notes, Equipment and Inventory, other than (i) Equipment and Inventory that is in transit in the ordinary course of business, (ii) Equipment and Inventory that in the ordinary course of business is in the possession or control of a warehouseman, bailee agent or other Person (other than a Person controlled by or under common control with such Grantor) that has been notified of the security interest created in favor of the Lender pursuant to this Security Agreement and has authenticated a record acknowledging that it holds possession of such Collateral for the Lender’s benefit and waives any Lien held by it against such Collateral, (iii) Inventory that is in the possession of a consignee in the ordinary course of business and (iv) Instruments or Promissory Notes that have been delivered to the Lender pursuant to Section 3.5 . In the case of Equipment or Inventory described in clause (ii) above, no lessor or warehouseman of any premises or warehouse upon or in which such Equipment or Inventory is located has (x) issued any warehouse receipt or other receipt in the nature of a warehouse receipt in respect of any such Equipment or Inventory, (y) issued any Document for any such Equipment or Inventory or (z) any Lien (other than Permitted Liens) on any such Equipment or Inventory.

 

10



 

(b)           Each Grantor is the sole entitlement holder of its Deposit Accounts and no other Person (other than the Lender pursuant to this Security Agreement or any other Person with respect to Permitted Liens) has control or possession of, or any other interest in, any of its Deposit Accounts or any other securities or property credited thereto.

 

SECTION 3.5. Negotiable Documents, Instruments and Chattel Paper . Each Grantor has delivered to the Lender possession of all originals of all Documents, Instruments, Promissory Notes, and tangible Chattel Paper (other than any Document, Instrument, Promissory Note or tangible Chattel Paper not exceeding $10,000 in principal amount) owned or held by such Grantor on the Closing Date.

 

SECTION 3.6. Intellectual Property Collateral . Except as disclosed on Schedules III through VI , with respect to any Intellectual Property Collateral:

 

(a)           such Grantor has not made a previous assignment, sale, transfer or agreement constituting a present or future assignment, sale or transfer of any Intellectual Property for purposes of granting a security interest or as Collateral that has not been terminated or releasedt; and

 

(b)           such Grantor has executed and delivered to the Lender Intellectual Property Collateral security agreements for all Copyrights, Patents and Trademarks owned by such Grantor, including all Copyrights, Patents and Trademarks on Schedule III through VI (as such schedules may be amended or supplemented from time to time by notice by such Grantor to the Lender).

 

SECTION 3.7. Validity, etc.

 

(a)           This Security Agreement creates a valid security interest in the Collateral securing the payment of the Obligations to the extent such security interest may be created pursuant to Article 9 of the UCC.

 

(b)           As of the Closing Date, each Grantor has filed or caused to be filed all UCC-1 financing statements in the filing office for each Grantor’s jurisdiction of organization listed in Item A of Schedule II (collectively, the “ Filing Statements ”) (delivered to the Lender the Filing Statements suitable for timely and proper filing in such offices) and has taken all other actions requested by the Lender necessary for the Lender to obtain control of the Collateral as provided in Sections 9-104, 9-105, 9-106 and 9-107 of the UCC.

 

(c)           Upon the filing of the Filing Statements with the appropriate agencies therefor the security interests created under this Security Agreement shall constitute a perfected security interest in the Collateral described on such Filing Statements in favor of the Lender to the extent that a security interest therein may be perfected by filing a financing statement pursuant to the relevant UCC, prior to all other Liens, except for Permitted Liens (in which case such security interest shall be second in priority of right only to the Permitted Liens entitled to priority).

 

11



 

SECTION 3.8. Authorization, Approval, etc. Except as have been obtained or made and are in full force and effect, no authorization, approval or other action by, and no notice to or filing with, any Governmental Authority or any other third party is required either

 

(a)           for the grant by the Grantors of the security interest granted hereby or for the execution, delivery and performance of this Security Agreement by the Grantors;

 

(b)           for the perfection or maintenance of the security interests hereunder (except with respect to the Filing Statements or, with respect to Intellectual Property Collateral, the recordation of any agreements with the United States Patent and Trademark Office or the United States Copyright Office or, with respect to foreign Intellectual Property Collateral, the taking of appropriate action under applicable foreign law and, with respect to after-acquired Intellectual Property Collateral, any subsequent filings in United States intellectual property offices); or

 

(c)           for the exercise by the Lender of the voting or other rights provided for in this Security Agreement, except (i) with respect to any securities issued by a Subsidiary of the Grantors, as may be required in connection with a disposition of such securities by laws affecting the offering and sale of securities generally, the remedies in respect of the Collateral pursuant to this Security Agreement and (ii) any “change of control” or similar filings required by state licensing agencies.

 

SECTION 3.9. Best Interests . It is in the best interests of each Grantor (other than the Borrower) to execute this Security Agreement inasmuch as such Grantor will, as a result of being an Affiliate of the Borrower, derive substantial direct and indirect benefits from the Loans made to the Borrower by the Lender pursuant to the Credit Agreement, and each Grantor agrees that the Lender is relying on this representation in agreeing to make such Loans pursuant to the Credit Agreement to the Borrower.

 

ARTICLE IV

COVENANTS

 

Each Grantor covenants and agrees that, until the Termination Date, such Grantor will perform, comply with and be bound by the obligations set forth below.

 

SECTION 4.1. As to Investment Property, etc.

 

SECTION 4.1.1. Capital Securities of Subsidiaries . No Grantor will allow any of its Subsidiaries:

 

(a)           [Omitted];

 

(b)           that is a partnership or limited liability company, to (i) issue Capital Securities that are to be dealt in or traded on securities exchanges or in securities markets, (ii) expressly provide in its Organic Documents that its Capital Securities are securities

 

12



 

governed by Article 8 of the UCC, or (iii) place such Subsidiary’s Capital Securities in a Securities Account; and

 

(c)           to issue Capital Securities in addition to or in substitution for the Capital Securities pledged hereunder, except to such Grantor (and such Capital Securities are immediately pledged and delivered to the Lender pursuant to the terms of this Security Agreement).

 

SECTION 4.1.2. Investment Property (other than Certificated Securities) .

 

(a)           With respect to any Deposit Accounts, Securities Accounts, Commodity Accounts, Commodity Contracts or Security Entitlements constituting Investment Property owned or held by any Grantor, such Grantor will cause (except for Excluded Accounts) the intermediary maintaining such Investment Property to execute a Control Agreement relating to such Investment Property pursuant to which such intermediary agrees to comply with the Lender’s instructions with respect to such Investment Property without further consent by such Grantor (which instructions the Lender hereby agrees not to give unless an Event of Default has occurred and is continuing).

 

(b)           With respect to any Uncertificated Securities (other than Uncertificated Securities credited to a Securities Account) constituting Investment Property owned or held by any Grantor, such Grantor will cause the issuer of such securities that is not a party hereto to execute a Control Agreement relating to such Investment Property pursuant to which the issuer agrees to comply with the Lender’s instructions with respect to such Uncertificated Securities without further consent by such Grantor (which instructions the Lender hereby agrees not to give unless an Event of Default has occurred and is continuing). Each party hereto that is such an issuer of any Uncertificated Securities hereby agrees that such party will comply with instructions with respect to such security originated by the Lender (which instructions the Lender hereby agrees not to give unless an Event of Default has occurred and is continuing).

 

SECTION 4.1.3. Certificated Securities (Stock Powers). Each Grantor agrees that all Certificated Securities constituting Collateral, including the Capital Securities delivered by such Grantor pursuant to this Security Agreement, will be accompanied by duly executed undated blank stock powers, or other equivalent instruments of transfer reasonably acceptable to the Lender.

 

SECTION 4.1.4. Continuous Pledge . Each Grantor will (subject to the terms of the Credit Agreement) (a) deliver to the Lender all Investment Property and all Payment Intangibles to the extent that such Investment Property or Payment Intangibles are evidenced by a Document, Instrument, Promissory Note or Chattel Paper (other than any Document, Instrument, Promissory Note or Chattel Paper not exceeding $10,000 in the principal amount), and (b) at all times keep pledged to the Lender pursuant hereto, on a first-priority, perfected basis, security interest therein and in all interest and principal with respect to such Payment Intangibles, and all Proceeds and rights from time to time received by or distributable to such Grantor in respect of any of the foregoing Collateral. Each Grantor agrees that it will, promptly following receipt thereof, deliver to the Lender possession of all originals of negotiable Documents, Instruments,

 

13



 

Promissory Notes and Chattel Paper that it acquires following the Closing Date (other than any Document, Instrument, Promissory Note or Chattel Paper not exceeding $10,000 in the principal amount).

 

SECTION 4.1.5. Voting Rights; Dividends, etc. Each Grantor agrees:

 

(a)           upon receipt of notice of the occurrence and continuance of an Event of Default from the Lender and without any request therefor by the Lender, so long as such Event of Default shall continue, to deliver (properly endorsed where required hereby or requested by the Lender) to the Lender all dividends and Distributions with respect to Investment Property, all interest, principal, other cash payments on Payment Intangibles, and all Proceeds of the Collateral, in each case thereafter received by such Grantor, all of which shall be held by the Lender as additional Collateral, except for payments made in accordance with Section 8.6 of the Credit Agreement; and

 

(b)           immediately upon the occurrence and during the continuance of an Event of Default and so long as the Lender has notified such Grantor of the Lender’s intention to exercise its voting power under this clause,

 

(i)            with respect to Collateral consisting of general partner interests or limited liability company interests, to promptly modify its Organic Documents to admit the Lender as a general partner or member, as applicable;

 

(ii)           that the Lender may exercise (to the exclusion of such Grantor) the voting power and all other incidental rights of ownership with respect to any Investment Property constituting Collateral and such Grantor hereby grants the Lender an irrevocable proxy, exercisable under such circumstances, to vote such Investment Property; and

 

(iii)          to promptly deliver to the Lender such additional proxies and other documents as may be necessary to allow the Lender to exercise such voting power.

 

All dividends, Distributions, interest, principal, cash payments, Payment Intangibles and Proceeds that may at any time and from time to time be held by such Grantor, but which such Grantor is then obligated to deliver to the Lender, shall, until delivery to the Lender, be held by such Grantor separate and apart from its other property in trust for the Lender. The Lender agrees that unless an Event of Default shall have occurred and be continuing and the Lender shall have given the notice referred to in clause (b) , such Grantor will have the exclusive voting power with respect to any Investment Property constituting Collateral and the Lender will, upon the written request of such Grantor, promptly deliver such proxies and other documents, if any, as shall be reasonably requested by such Grantor which are necessary to allow such Grantor to exercise that voting power; provided that no vote shall be cast, or consent, waiver, or ratification given, or action taken by such Grantor that would impair any such Collateral or be inconsistent with or violate any provision of any Loan Document.

 

14


 

SECTION 4.2. Change of Name, etc . No Grantor will change its name or place of incorporation or organization or federal taxpayer identification number except as otherwise permitted by the Credit Agreement.

 

SECTION 4.3. As to Accounts .

 

(a)           Each Grantor shall have the right to collect all Accounts so long as no Event of Default shall have occurred and be continuing.

 

(b)           Upon (i) the occurrence and continuance of an Event of Default and (ii) the delivery of notice by the Lender to each Grantor, all Proceeds of Collateral received by such Grantor shall be delivered in kind to the Lender for deposit in a Deposit Account of such Grantor maintained with the Lender (together with any other Deposit Accounts or Security Accounts pursuant to which any portion of the Collateral is deposited with the Lender, the “ Collateral Accounts ”), and such Grantor shall not commingle any such Proceeds, and shall hold separate and apart from all other property, all such Proceeds in express trust for the benefit of the Lender until delivery thereof is made to the Lender.

 

(c)           Following the delivery of notice pursuant to clause (b)(ii) , and so long as an Event of Default shall continue, the Lender shall have the right to apply any amount in the Collateral Account to the payment of any Obligations which are then due and payable in accordance with Section 4.4(b) of the Credit Agreement.

 

(d)           With respect to each of the Collateral Accounts, it is hereby confirmed and agreed that (i) deposits in such Collateral Accounts are subject to a security interest as contemplated hereby, (ii) such Collateral Accounts shall be under the control of the Lender and (iii) the Lender shall have the sole right of withdrawal over such Collateral Account.

 

SECTION 4.4. As to Grantors Use of Collateral .

 

(a)           At any time following the occurrence and during the continuance of an Event of Default, whether before or after the maturity of any of the Obligations, the Lender may exercise any and all rights and remedies to which it is lawfully entitled with respect to the Collateral.

 

(b)           Upon the request of the Lender following the occurrence and during the continuance of an Event of Default, each Grantor will, at its own expense, notify any parties obligated on any of the Collateral to make payment to the Lender of any amounts due or to become due thereunder.

 

(c)           At any time following the occurrence and during the continuation of an Event of Default, the Lender may endorse, in the name of such Grantor, any item, howsoever received by the Lender, representing any payment on or other Proceeds of any of the Collateral.

 

SECTION 4.5. As to Intellectual Property Collateral . Each Grantor covenants and agrees to comply with the following provision:

 

15



 

(a)           such Grantor will not (i) do or fail to perform any act whereby any of the Patent Collateral may lapse or become abandoned or dedicated to the public or unenforceable, (ii) permit any of its licensees to (A) fail to continue to use any of the Trademark Collateral in order to maintain all of the Trademark Collateral in full force free from any claim of abandonment for non-use, (B) fail to maintain the quality of products and services offered under all of the Trademark Collateral at a level substantially consistent with the quality of products and services offered under such Trademark as of the date hereof, (C) fail to employ all of the Trademark Collateral registered with any federal or state or foreign authority with an appropriate notice of such registration, (D) adopt or use any other Trademark which is confusingly similar or a colorable imitation of any of the Trademark Collateral, (E) use any of the Trademark Collateral registered with any federal, state or foreign authority except for the uses for which registration or application for registration of all of the Trademark Collateral has been made or (F) do or permit any act or knowingly omit to do any act whereby any of the Trademark Collateral may become invalid or unenforceable, or (iii) do or permit any act or knowingly omit to do any act whereby any of the Copyright Collateral or any of the Trade Secrets Collateral may lapse or become invalid or unenforceable or placed in the public domain except upon expiration of the end of an unrenewable term of a registration thereof, unless, in the case of any of the foregoing requirements in clauses (i) , (ii)  and (iii) , such Grantor reasonably and in good faith determines that either (x) such Intellectual Property Collateral is of negligible economic value to such Grantor or (y) the loss of such Intellectual Property Collateral would not be material to such Grantor;

 

(b)           such Grantor shall promptly notify the Lender if it knows, or has reason to know, that any application or registration relating to any material item of the Intellectual Property Collateral may, in the Grantor’s reasonable commercial judgment, become abandoned or dedicated to the public or placed in the public domain or invalid or unenforceable, or of any adverse determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States Copyright Office or any foreign counterpart thereof or any court) regarding such Grantor’s ownership of any of the Intellectual Property Collateral, its right to register the same or to keep and maintain and enforce the same;

 

(c)           in no event will such Grantor or any of its agents, employees, designees or licensees file an application for the registration of any Intellectual Property Collateral with the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof, unless such Grantor promptly informs the Lender and, upon request of the Lender (subject to the terms of the Credit Agreement), executes and delivers all agreements, instruments and documents as the Lender may reasonably request to evidence the Lender’s security interest in such Intellectual Property Collateral; and

 

(d)           such Grantor will promptly (but no less than quarterly) execute and deliver to the Lender (as applicable) a Patent Security Agreement, Trademark Security Agreement and/or Copyright Security Agreement, as the case may be, in the forms of Exhibit A , Exhibit B and Exhibit C hereto following its obtaining an interest in any such

 

16



 

Intellectual Property, and shall execute and deliver to the Lender any other document reasonably required to evidence the Lender’s interest in any part of such item of Intellectual Property Collateral.

 

SECTION 4.6. As to Letter-of-Credit Rights .

 

(a)           Each Grantor, by granting a security interest in its Letter-of-Credit Rights to the Lender, intends to (and hereby does) collaterally assign to the Lender its rights (including its contingent rights ) to the Proceeds of all Letter-of-Credit Rights of which it is or hereafter becomes a beneficiary or assignee.

 

(b)           Upon the occurrence of an Event of Default, such Grantor will, promptly upon request by the Lender, (i) notify (and such Grantor hereby authorizes the Lender to notify) the issuer and each nominated person with respect to each of the Letters of Credit that the Proceeds thereof have been assigned to the Lender hereunder and any payments due or to become due in respect thereof are to be made directly to the Lender and (ii) arrange for the Lender to become the transferee beneficiary of such Letter of Credit.

 

SECTION 4.7. As to Commercial Tort Claims . Each Grantor covenants and agrees that, until the payment in full of the Obligations and termination of all Commitments, with respect to any Commercial Tort Claim hereafter arising, it shall deliver to the Lender a supplement in form and substance reasonably satisfactory to the Lender, together with all supplements to schedules thereto, identifying such new Commercial Tort Claim.

 

SECTION 4.8. Electronic Chattel Paper and Transferable Records . If any Grantor at any time holds or acquires an interest in any electronic chattel paper or any “transferable record,” as that term is defined in Section 201 of the U.S. Federal Electronic Signatures in Global and National Commerce Act, or in Section 16 of the U.S. Uniform Electronic Transactions Act as in effect in any relevant jurisdiction, with a value in excess of $100,000, such Grantor shall promptly notify the Lender thereof and, at the request of the Lender, shall take such action as the Lender may reasonably request to vest in the Lender control under Section 9-105 of the UCC of such electronic chattel paper or control under Section 201 of the Federal Electronic Signatures in Global and National Commerce Act or, as the case may be, Section 16 of the Uniform Electronic Transactions Act, as so in effect in such jurisdiction, of such transferable record. The Lender agrees with such Grantor that the Lender will arrange, pursuant to procedures satisfactory to the Lender and so long as such procedures will not result in the Lender’s loss of control, for the Grantor to make alterations to the electronic chattel paper or transferable record permitted under Section 9-105 of the UCC or, as the case may be, Section 201 of the U.S. Federal Electronic Signatures in Global and National Commerce Act or Section 16 of the U.S. Uniform Electronic Transactions Act for a party in control to allow without loss of control, unless an Event of Default has occurred and is continuing or would occur after taking into account any action by such Grantor with respect to such electronic chattel paper or transferable record.

 

SECTION 4.9. Further Assurances, etc. Each Grantor agrees that, from time to time at its own expense, it will, subject to the terms of this Agreement, promptly execute and deliver all further instruments and documents, and take all further action, that may be necessary or that the Lender may reasonably request, in order to perfect, preserve and protect any security interest

 

17



 

granted or purported to be granted hereby or to enable the Lender to exercise and enforce its rights and remedies hereunder with respect to any Collateral. Without limiting the generality of the foregoing, such Grantor will

 

(a)           from time to time upon the request of the Lender, promptly deliver to the Lender such stock powers, instruments and similar documents, reasonably satisfactory in form and substance to the Lender, with respect to such Collateral as the Lender may request and will, from time to time upon the request of the Lender, after the occurrence and during the continuance of any Event of Default, promptly transfer any securities constituting Collateral into the name of any nominee designated by the Lender; if any Collateral shall be evidenced by an Instrument, negotiable Document, Promissory Note or tangible Chattel Paper, deliver and pledge to the Lender hereunder such Instrument, negotiable Document, Promissory Note or tangible Chattel Paper (other than any Instrument, negotiable Document, Promissory Note or tangible Chattel Paper in principal amount less than $10,000) duly endorsed and accompanied by duly executed instruments of transfer or assignment, all in form and substance reasonably satisfactory to the Lender;

 

(b)           file (and hereby authorize the Lender to file) such Filing Statements or continuation statements, or amendments thereto, and such other instruments or notices (including any assignment of claim form under or pursuant to the federal assignment of claims statute, 31 U.S.C. § 3726, any successor or amended version thereof or any regulation promulgated under or pursuant to any version thereof), as may be necessary or that the Lender may reasonably request in order to perfect and preserve the security interests and other rights granted or purported to be granted to the Lender hereby;

 

(c)           at all times keep pledged to the Lender pursuant hereto, on a first-priority, perfected basis, at the request of the Lender, all Investment Property constituting Collateral, all dividends and Distributions with respect thereto, and all interest and principal with respect to Promissory Notes, and all Proceeds and rights from time to time received by or distributable to such Grantor in respect of any of the foregoing Collateral;

 

(d)           not create any tangible Chattel Paper without placing a legend on such tangible Chattel Paper reasonably acceptable to the Lender indicating that the Lender has a security interest in such Chattel Paper;

 

(e)           furnish to the Lender, from time to time at the Lender’s request, statements and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral as the Lender may reasonably request, all in reasonable detail; and

 

(f)            do all things reasonably requested by the Lender in accordance with this Security Agreement in order to enable the Lender to have and maintain control over the Collateral consisting of Investment Property, Deposit Accounts, Letter-of-Credit-Rights and Electronic Chattel Paper.

 

Each Grantor agrees that a carbon, photographic or other reproduction of this Security Agreement or any UCC financing statement covering the Collateral or any part thereof shall be

 

18



 

sufficient as a UCC financing statement where permitted by law. Each Grantor hereby authorizes the Lender to file financing statements describing as the collateral covered thereby “all of the debtor’s personal property or assets” or words to that effect, notwithstanding that such wording may be broader in scope than the Collateral described in this Security Agreement.

 

ARTICLE V

THE LENDER

 

SECTION 5.1. Lender Appointed Attorney-in-Fact . Each Grantor hereby irrevocably appoints the Lender as its attorney-in-fact, with full authority in the place and stead of such Grantor and in the name of such Grantor or otherwise, from time to time in the Lender’s discretion, following the occurrence and during the continuance of an Event of Default, to take any action and to execute any instrument which the Lender may deem necessary or advisable to accomplish the purposes of this Security Agreement, including:

 

(a)           to ask, demand, collect, sue for, recover, compromise, receive and give acquittance and receipts for moneys due and to become due under or in respect of any of the Collateral;

 

(b)           to receive, endorse, and collect any drafts or other Instruments, Documents and Chattel Paper, in connection with clause (a)  above;

 

(c)           to file any claims or take any action or institute any proceedings which the Lender may deem necessary or desirable for the collection of any of the Collateral or otherwise to enforce the rights of the Lender with respect to any of the Collateral; and

 

(d)           to perform the affirmative obligations of such Grantor hereunder.

 

Each Grantor hereby acknowledges, consents and agrees that the power of attorney granted pursuant to this Section is irrevocable and coupled with an interest.

 

SECTION 5.2. Lender May Perform . If any Grantor fails to perform any agreement contained herein, upon 5 days after the earlier to occur of (i) notice thereof given to any such Grantor by the Lender or (ii) the date on which such Grantor has knowledge of such failure, the Lender may itself perform, or cause performance of, such agreement, that the Lender deems necessary for the maintenance, preservation or protection of any of the Collateral or of its security interest therein to the extent provided for herein, and the expenses of the Lender incurred in connection therewith shall be payable by such Grantor pursuant to Section 10.3 of the Credit Agreement.

 

SECTION 5.3. Lender Has No Duty . The powers conferred on the Lender hereunder are solely to protect its interest in the Collateral and shall not impose any duty on it to exercise any such powers. Except for reasonable care of any Collateral in its possession and the accounting for moneys actually received by it hereunder, the Lender shall have no duty as to any Collateral or responsibility for

 

19



 

(a)           ascertaining or taking action with respect to calls, conversions, exchanges, maturities, tenders or other matters relative to any Investment Property, whether or not the Lender has or is deemed to have knowledge of such matters, or

 

(b)           taking any necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral.

 

SECTION 5.4. Reasonable Care . The Lender is required to exercise reasonable care in the custody and preservation of any of the Collateral in its possession; provided that the Lender shall be deemed to have exercised reasonable care in the custody and preservation of any of the Collateral, if it takes such action for that purpose as each Grantor reasonably requests in writing at times other than upon the occurrence and during the continuance of any Event of Default, but failure of the Lender to comply with any such request at any time shall not in itself be deemed a failure to exercise reasonable care.

 

SECTION 5.5. Lender as Agent for Other Secured Parties . The Lender hereby agrees to act as agent of the other parties to which any Grantor may owe any Obligations for all purposes hereunder and under the other Loan Documents pursuant to which any Grantor grants a Lien or other right in any Collateral to secure the Obligations, for purposes of acquiring, holding and enforcing any and all Liens on any Collateral granted by any Grantor to secure any of the Obligations. The Lender may appoint any co-agents, sub-agents or attorneys-in-fact in connection with the foregoing.

 

ARTICLE VI

REMEDIES

 

SECTION 6.1. Certain Remedies . If any Event of Default shall have occurred and be continuing:

 

(a)           The Lender may exercise in respect of the Collateral, in addition to other rights and remedies provided for herein or otherwise available to it, all the rights and remedies of the Lender on default under the UCC (whether or not the UCC applies to the affected Collateral) and also may

 

(i)            take possession of any Collateral not already in its possession without demand and without legal process;

 

(ii)           require each Grantor to, and each Grantor hereby agrees that it will, at its expense and upon request of the Lender forthwith, assemble all or part of the Collateral as directed by the Lender and make it available to the Lender at a place to be designated by the Lender that is reasonably convenient to both parties,

 

(iii)          enter onto the property where any Collateral is located and take possession thereof without demand and without legal process; and

 

20



 

(iv)          without notice except as specified below, lease, license, sell or otherwise dispose of the Collateral or any part thereof in one or more parcels at any public or private sale, at any of the Lender’s offices or elsewhere, for cash, on credit or for future delivery, and upon such other terms as the Lender may deem commercially reasonable. Each Grantor agrees that, to the extent notice of sale shall be required by law, at least ten (10) days’ prior notice to such Grantor of the time and place of any public sale or the time after which any private sale is to be made shall constitute reasonable notification. The Lender shall not be obligated to make any sale of Collateral regardless of notice of sale having been given. The Lender may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned.

 

(b)           All cash Proceeds received by the Lender in respect of any sale of, collection from, or other realization upon, all or any part of the Collateral shall be applied by the Lender against all or any part of the Obligations as set forth in Section 4.4(b) of the Credit Agreement.

 

(c)           The Lender may

 

(i)            transfer all or any part of the Collateral into the name of the Lender or its nominee, with or without disclosing that such Collateral is subject to the Lien hereunder,

 

(ii)           notify the parties obligated on any of the Collateral to make payment to the Lender of any amount due or to become due thereunder,

 

(iii)          withdraw, or cause or direct the withdrawal, of all funds with respect to the Collateral Account;

 

(iv)          enforce collection of any of the Collateral by suit or otherwise, and surrender, release or exchange all or any part thereof, or compromise or extend or renew for any period (whether or not longer than the original period) any obligations of any nature of any party with respect thereto,

 

(v)           endorse any checks, drafts, or other writings in any Grantor’s name to allow collection of the Collateral,

 

(vi)          take control of any Proceeds of the Collateral, and

 

(vii)         execute (in the name, place and stead of any Grantor) endorsements, assignments, stock powers and other instruments of conveyance or transfer with respect to all or any of the Collateral.

 

SECTION 6.2. Securities Laws . If the Lender shall determine to exercise its right to sell all or any of the Collateral that are Capital Securities pursuant to Section 6.1(a)(iv) , each Grantor acknowledges that the Lender may be unable to effect a public sale or other disposition of the Capital Securities by reason of certain prohibitions contained in the Securities Act of 1933, as

 

21



 

from time to time amended (the “ Securities Act ”), federal banking laws, and other applicable laws, but may be compelled to resort to one or more private sales thereof to a restricted group of purchasers. Each Grantor agrees that any such private sale may be at prices and other terms less favorable to the seller than if sold at public sales and that such private sales shall not solely by reason thereof be deemed not to have been made in a commercially reasonable manner. The Lender shall be under no obligation to delay a sale of any of the Capital Securities for the period of time necessary to permit the issuer of such securities to register such securities for public sale under the Securities Act, or such other federal banking or other applicable laws, even if the issuer would agree to do so. Subject to the foregoing, the Lender agrees that any sale of the Capital Securities shall be made in a commercially reasonable manner, and each Grantor agrees to use its reasonable best efforts to cause the issuer or issuers of the Capital Securities contemplated to be sold, to execute and deliver, all at the Grantors’ expense, all such instruments and documents, and to do or cause to be done all such other acts and things as may be necessary or, in the reasonable opinion of the Lender, advisable to exempt such Capital Securities from registration under the provisions of the Securities Act, and to make all amendments to such instruments and documents which, in the opinion of the Lender, are necessary or advisable, all in conformity with the requirements of the Securities Act and the rules and regulations of the Securities and Exchange Commission applicable thereto. Each Grantor further agrees to use its reasonable best efforts (a) to cause such issuer or issuers to exempt or comply with the provisions of the securities or “Blue Sky” laws of any jurisdiction which the Lender designates and obtain all necessary governmental approvals for the sale of the Capital Securities, as requested by the Lender; (b) if required, to cause such issuer or issuers to make available to its security holders, as soon as practicable, an earnings statement (which need not be audited) which will satisfy the provisions of Section 11(a) of the Securities Act; and (c) to do or cause to be done all such other acts and things as may be necessary to make such sale of the Collateral or any part thereof valid and binding and in compliance with applicable law.

 

SECTION 6.3. Compliance with Restrictions . Each Grantor agrees that in any sale of any of the Collateral whenever an Event of Default shall have occurred and be continuing, the Lender is hereby authorized to comply with any limitation or restriction in connection with such sale as it may be advised by counsel is necessary in order to avoid any violation of applicable law (including compliance with such procedures as may restrict the number of prospective bidders and purchasers, require that such prospective bidders and purchasers have certain qualifications, and restrict such prospective bidders and purchasers to Persons who will represent and agree that they are purchasing for their own account for investment and not with a view to the distribution or resale of such Collateral), or in order to obtain any required approval of the sale or of the purchaser by any Governmental Authority or official, and such Grantor further agrees that such compliance shall not result in such sale being considered or deemed not to have been made in a commercially reasonable manner, nor shall the Lender be liable nor accountable to such Grantor for any discount allowed by the reason of the fact that such Collateral is sold in compliance with any such limitation or restriction.

 

SECTION 6.4. Protection of Collateral . The Lender may from time to time, at its option, perform any act which any Grantor fails to perform after being requested in writing so to perform (it being understood that no such request need be given after the occurrence and during the continuance of an Event of Default) and the Lender may from time to time take any other action

 

22



 

which the Lender deems necessary for the maintenance, preservation or protection of any of the Collateral or of its security interest therein.

 

ARTICLE VII

MISCELLANEOUS PROVISIONS

 

SECTION 7.1. Loan Document . This Security Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof. Notwithstanding anything contained herein to contrary, to the extent any provision in this Security Agreement conflicts with any provision in the Credit Agreement, the terms of the Credit Agreement shall control.

 

SECTION 7.2. Binding on Successors, Transferees and Assigns; Assignment . This Security Agreement shall remain in full force and effect until the Termination Date has occurred, shall be binding upon the Grantors and their successors, transferees and assigns and shall inure to the benefit of and be enforceable by the Lender; provided that no Grantor may assign any of its obligations hereunder without the prior consent of the Lender.

 

SECTION 7.3. Amendments, etc. No amendment or modification to or waiver of any provision of this Security Agreement, nor consent to any departure by any Grantor from its obligations under this Security Agreement, shall in any event be effective unless the same shall be in writing and signed by the Lender and the Grantors and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

SECTION 7.4. Notices . All notices and other communications provided for hereunder shall be delivered or made as provided in Section 10.2 of the Credit Agreement.

 

SECTION 7.5. Release of Liens . Upon (a) the Disposition of Collateral in accordance with the Credit Agreement and this Security Agreement or (b) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (i) such Collateral (in the case of clause (a) ) or (ii) all Collateral (in the case of clause (b) ). Upon any such Disposition or termination, the Lender will, at the Grantors’ sole expense, deliver to the Grantors, without any representations, warranties or recourse of any kind whatsoever, all Collateral held by the Lender hereunder, and execute and deliver to the Grantors such documents as the Grantors shall reasonably request to evidence such termination.

 

SECTION 7.6. Additional Grantors . Upon the execution and delivery by any other Person of a supplement in the form of Annex I hereto, such Person shall become a “Grantor” hereunder as of the date of such supplement with the same force and effect as if it were originally a party to this Security Agreement and named as a “Grantor” hereunder. The execution and delivery of such supplement shall not require the consent of any other Grantor hereunder, and the rights and obligations of each Grantor hereunder shall remain in full force and effect notwithstanding the addition of any new Grantor as a party to this Security Agreement.

 

23



 

SECTION 7.7. No Waiver; Remedies . In addition to, and not in limitation of Section 2.4 , no failure on the part of the Lender to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by law.

 

SECTION 7.8. Severability . Any provision of this Security Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Security Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

 

SECTION 7.9. Governing Law, Entire Agreement, etc. THIS SECURITY AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SECURITY AGREEMENT OR ANY OTHER LOAN DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Security Agreement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto

 

SECTION 7.10. Counterparts . This Security Agreement may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. This Security Agreement shall become effective when counterparts hereof executed on behalf of all of the signatories hereto, shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Security Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

[ Signature Page Follows ]

 

24


 

IN WITNESS WHEREOF, each of the parties hereto has caused this Security Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

 

 

NATERA, INC.

 

 

 

 

 

By:

 

 

 

Name:

[ · ]

 

 

Title:

[ · ]

 

 

 

 

 

NATERA INTERNATIONAL, INC.

 

 

 

 

 

By:

 

 

 

Name:

[ · ]

 

 

Title:

[ · ]

 

 

 

 

 

ROS ACQUISITION OFFSHORE LP ,

 

as the Lender, for itself and as agent

 

By ROS Acquisition Offshore GP Ltd.,

 

its General Partner

 

By OrbiMed Advisors LLC,

 

its investment manager

 

 

 

 

 

By:

 

 

 

Name:

[ · ]

 

 

Title:

[ · ]

 

Signature Page to Security Agreement

 



 

EXHIBIT A

to Security Agreement

 

PATENT SECURITY AGREEMENT

 

This PATENT SECURITY AGREEMENT, dated as of            , 2013 (this “ Agreement ”), is made by [NAME OF GRANTOR], a                   (the “ Grantor ”), in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W   I   T   N   E   S   S   E   T   H :

 

WHEREAS, pursuant to a Credit Agreement, dated as of [         ], 2013 (as amended, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and between Natera, Inc., a Delaware corporation (the “ Borrower ”) and the Lender, the Lender has extended a Commitment to make the Loans to the Borrower;

 

WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of [           ], 2013 (as amended, supplemented or otherwise modified from time to time, the “ Security Agreement ”);

 

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (e) of Section 4.5 of the Security Agreement, the Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Patent Collateral (as defined below) to secure all of the Obligations; and

 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of the Lender, as follows:

 

SECTION 1. Definitions . Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

 

SECTION 2. Grant of Security Interest . The Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all of the Grantor’s right, title and interest in and to the following property, whether now or hereafter existing or acquired by the Grantor (the “ Patent Collateral ”):

 

(a)           all of its letters patent and applications for letters patent throughout the world, including each patent and patent application referred to in Item A of Schedule I attached hereto;

 



 

(b)           all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the items described in clause (a) ;

 

(c)           all patent licenses and other agreements providing the Grantor with the right to use any items of the type referred to in clauses (a) and (b) above, including each patent license referred to in Item B of Schedule I attached hereto; and

 

(d)           all Proceeds of, and rights associated with, the foregoing (including licenses, royalties income, payments, claims, damages and Proceeds of infringement suits) and the right to sue third parties for past, present or future infringements of any patent or patent application and for breach or enforcement of any patent license.

 

SECTION 3. Security Agreement . This Agreement has been executed and delivered by the Grantor for the purpose of registering the security interest of the Lender in the Patent Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Lender for its benefit under the Security Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms.

 

SECTION 4. Release of Liens . Upon (i) the Disposition of Patent Collateral in accordance with the Credit Agreement or (ii) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (A) such Patent Collateral (in the case of clause (i) ) or (B) all Patent Collateral (in the case of clause (ii) ). Upon any such Disposition or termination, the Lender will, at the Grantor’s sole expense, deliver to the Grantor, without any representations, warranties or recourse of any kind whatsoever, all Patent Collateral held by the Lender hereunder, and execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination.

 

SECTION 5. Acknowledgment . The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

 

SECTION 6. Loan Document . This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

 

SECTION 7. Effective . This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

[ Signature Page Follows ]

 

2



 

IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

 

 

[NAME OF GRANTOR]

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

Signature Page to Patent Security Agreement

 



 

SCHEDULE I

to Patent Security Agreement

 

Item A. Patents

 

Issued Patents

 

Country

 

Patent No.

 

Issue Date

 

Inventor(s)

 

Title

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pending Patent Applications

 

Country

 

Serial No.

 

Filing Date

 

Inventor(s)

 

Title

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Patent Applications in Preparation

 

 

 

 

 

Expected

 

 

 

 

 

Country

 

Docket No.

 

Filing Date

 

Inventor(s)

 

Title

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Item B. Patent Licenses

 

Country or

 

 

 

 

 

Effective

 

Expiration

 

Subject

 

Territory

 

Licensor

 

Licensee

 

Date

 

Date

 

Matter

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

EXHIBIT B

to Security Agreement

 

TRADEMARK SECURITY AGREEMENT

 

This TRADEMARK SECURITY AGREEMENT, dated as of              , 2013 (this “ Agreement ”), is made by [NAME OF GRANTOR], a                    (the “ Grantor ”), in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W   I   T   N   E   S   S   E   T   H :

 

WHEREAS, pursuant to a Credit Agreement, dated as of [          ], 2013 (as amended, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”), by and between Natera, Inc., a Delaware corporation (the “ Borrower ”) and the Lender, the Lender has extended a Commitment to make the Loans to the Borrower;

 

WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of [            ], 2013 (as amended, supplemented, or otherwise modified from time to time, the “ Security Agreement ”);

 

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (e) of Section 4.5 of the Security Agreement, the Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Trademark Collateral (as defined below) to secure all of the Obligations; and

 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of each Lender, as follows:

 

SECTION 1. Definitions . Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

 

SECTION 2. Grant of Security Interest . The Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all of Grantor’s right, title and interest in and to the following property, whether now or hereafter existing or acquired by the Grantor (the “ Trademark Collateral ”):

 

(a)           (i) all of its trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, certification marks, collective marks, logos and other source or business identifiers, and all goodwill of the business associated therewith, including those referred to in Item A of Schedule I hereto, whether currently in use or not, all registrations and recordings thereof and all

 



 

applications in connection therewith, whether pending or filed, including registrations, recordings and applications in the United States Patent and Trademark Office or in any office or agency of the United States of America or any State thereof, and all common-law rights relating to the foregoing, and (ii) the right to obtain all reissues, extensions or renewals of the foregoing (collectively referred to as the “ Trademarks ”);

 

(b)           all Trademark licenses for the grant by or to the Grantor of any right to use any Trademark, including each Trademark license referred to in Item B of Schedule I hereto;

 

(c)           all of the goodwill of the business connected with the use of, and symbolized by the items described in, clause (a), and to the extent applicable clause (b);

 

(d)           the right to sue third parties for past, present and future infringements of any Trademark Collateral described in clause (a) and, to the extent applicable, clause (b); and

 

(e)           all Proceeds of, and rights associated with, the foregoing, including any claim by the Grantor against third parties for past, present or future infringement or dilution of any Trademark, Trademark registration or Trademark license, or for any injury to the goodwill associated with the use of any such Trademark or for breach or enforcement of any Trademark license and all rights corresponding thereto throughout the world.

 

SECTION 3. Security Agreement . This Agreement has been executed and delivered by the Grantor for the purpose of registering the security interest of the Lender in the Trademark Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Lender for its benefit under the Security Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms.

 

SECTION 4. Release of Liens . Upon (i) the Disposition of Trademark Collateral in accordance with the Credit Agreement or (ii) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (A) such Trademark Collateral (in the case of clause (i) ) or (B) all Trademark Collateral (in the case of clause (ii) ). Upon any such Disposition or termination, the Lender will, at the Grantor’s sole expense, deliver to the Grantor, without any representations, warranties or recourse of any kind whatsoever, all Trademark Collateral held by the Lender hereunder, and execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination.

 

SECTION 5. Acknowledgment . The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Trademark Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

 

2



 

SECTION 6. Loan Document . This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

 

SECTION 7. Effective . This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

[ Signature Page Follows ]

 

3



 

IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and delivered by Authorized Officer as of the date first above written.

 

 

[NAME OF GRANTOR]

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

Signature Page to Trademark Security Agreement

 



 

SCHEDULE I

to Trademark Security Agreement

 

Item A. Trademarks

 

Registered Trademarks

 

Country

 

Trademark

 

Registration No.

 

Registration Date

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pending Trademark Applications

 

Country

 

Trademark

 

Serial No.

 

Filing Date

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trademark Applications in Preparation

 

 

 

 

 

 

 

Expected

 

Products/

 

Country

 

Trademark

 

Docket No.

 

Filing Date

 

Services

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Item B. Trademark Licenses

 

Country or

 

 

 

 

 

 

 

Effective

 

Expiration

 

Territory

 

Trademark

 

Licensor

 

Licensee

 

Date

 

Date

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

EXHIBIT C

to Security Agreement

 

COPYRIGHT SECURITY AGREEMENT

 

This COPYRIGHT SECURITY AGREEMENT, dated as of                       , 2013 (this “ Agreement ”), is made by [NAME OF GRANTOR], a                                  (the “ Grantor ”), in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W I T N E S S E T H :

 

WHEREAS, pursuant to a Credit Agreement, dated as of [        ], 2013 (as amended, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”), among by and between Natera, Inc., a Delaware corporation (the “ Borrower ”) and the Lender, the Lender has extended a Commitment to make the Loans to the Borrower;

 

WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of [        ], 2013 (as amended, supplemented, or otherwise modified from time to time, the “ Security Agreement ”);

 

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (e) of Section 4.5 of the Security Agreement, the Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Copyright Collateral (as defined below) to secure all of the Obligations; and

 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of the Lender, as follows:

 

SECTION 1. Definitions . Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

 

SECTION 2. Grant of Security Interest . The Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all of the Grantor’s right, title and interest in and to the following (the “ Copyright Collateral ”), whether now or hereafter existing or acquired by the Grantor: all copyrights of the Grantor, whether statutory or common law, whether registered or unregistered and whether published or unpublished, now or hereafter in force throughout the world including all of the Grantor’s right, title and interest in and to all copyrights registered in the United States Copyright Office or anywhere else in the world including the copyrights referred to in Item A of Schedule I hereto, and registrations and recordings thereof and all applications for registration thereof, whether pending or in preparation, all copyright licenses, including each copyright license referred to in Item B of Schedule I hereto, the right to sue for

 



 

past, present and future infringements of any of the foregoing, all rights corresponding thereto, all extensions and renewals of any thereof and all Proceeds of the foregoing, including licenses, royalties, income, payments, claims, damages and Proceeds of suit.

 

SECTION 3. Security Agreement . This Agreement has been executed and delivered by the Grantor for the purpose of registering the security interest of the Lender in the Copyright Collateral with the United States Copyright Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Lender for its benefit under the Security Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms.

 

SECTION 4. Release of Liens . Upon (i) the Disposition of Copyright Collateral in accordance with the Credit Agreement or (ii) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (A) such Copyright Collateral (in the case of clause (i) ) or (B) all Copyright Collateral (in the case of clause (ii) ). Upon any such Disposition or termination, the Lender will, at the Grantor’s sole expense, deliver to the Grantor, without any representations, warranties or recourse of any kind whatsoever, all Copyright Collateral held by the Lender hereunder, and execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination.

 

SECTION 5. Acknowledgment . The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Copyright Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

 

SECTION 6. Loan Document . This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

 

SECTION 7. Effective . This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery or a manually executed counterpart of this Agreement.

 

[ Signature Page Follows ]

 

2



 

IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

 

[NAME OF GRANTOR]

 

 

 

 

 

By:

 

 

Name:

 

Title:

 

Signature Page to Copyright Security Agreement

 



 

SCHEDULE I

to Copyright Security Agreement

 

Item A. Copyrights/Mask Works

 

Registered Copyrights/Mask Works

 

Country

 

Registration No.

 

Registration Date

 

Author(s)

 

Title

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Copyright/Mask Work Pending Registration Applications

 

Country

 

Serial No.

 

Filing Date

 

Author(s)

 

Title

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Copyright/Mask Work Registration Applications in Preparation

 

 

 

 

 

Expected

 

 

 

 

 

Country

 

Docket No.

 

Filing Date

 

Author(s)

 

Title

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Item B. Copyright/Mask Work Licenses

 

Country or

 

 

 

 

 

Effective

 

Expiration

 

Territory

 

Licensor

 

Licensee

 

Date

 

Date

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

ANNEX I

to Security Agreement

 

SUPPLEMENT TO

PLEDGE AND SECURITY AGREEMENT

 

This SUPPLEMENT, dated as of                          ,             (this “ Supplement ”), is to the Pledge and Security Agreement, dated as of [          ], 2013 (as amended, supplemented, amended and restated or otherwise modified from time to time, the “ Security Agreement ”), among the Grantors (such term, and other terms used in this Supplement, to have the meanings set forth in Article I of the Security Agreement) from time to time party thereto, in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W I T N E S S E T H :

 

WHEREAS, pursuant to a Credit Agreement, dated as of [         ], 2013 (as amended, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”), by and between Natera, Inc., a Delaware corporation (the “ Borrower ”) and the Lender, the Lender has extended a Commitment to make the Loans to the Borrower;

 

WHEREAS, pursuant to the provisions of Section 7.6 of the Security Agreement, each of the undersigned is becoming a Grantor under the Security Agreement; and

 

WHEREAS, each of the undersigned desires to become a “Grantor” under the Security Agreement in order to induce the Lender to continue to extend Loans under the Credit Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each of the undersigned agrees, for the benefit of the Lender, as follows.

 

SECTION 1. Party to Security Agreement, etc . In accordance with the terms of the Security Agreement, by its signature below, each of the undersigned hereby irrevocably agrees to become a Grantor under the Security Agreement with the same force and effect as if it were an original signatory thereto and each of the undersigned hereby (a) agrees to be bound by and comply with all of the terms and provisions of the Security Agreement applicable to it as a Grantor and (b) represents and warrants that the representations and warranties made by it as a Grantor thereunder are true and correct as of the date hereof, unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct as of such earlier date. In furtherance of the foregoing, each reference to a “Grantor” and/or “Grantors” in the Security Agreement shall be deemed to include each of the undersigned.

 

SECTION 2. Schedules . Each of the undersigned Grantors hereby authorizes the Lender to add the information set forth on the Schedules to this Supplement to the correlative Schedules attached to the Security Agreement.

 



 

SECTION 3. Representations . Each of the undersigned Grantors hereby represents and warrants that this Supplement has been duly authorized, executed and delivered by it and that this Supplement and the Security Agreement constitute its legal, valid and binding obligation, enforceable against it in accordance with its terms.

 

SECTION 4. Full Force of Security Agreement . Except as expressly supplemented hereby, the Security Agreement shall remain in full force and effect in accordance with its terms.

 

SECTION 5. Severability . Wherever possible each provision of this Supplement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Supplement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Supplement or the Security Agreement.

 

SECTION 6. Governing Law, Entire Agreement, etc . THIS SUPPLEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SECURITY AGREEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Supplement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto.

 

SECTION 7. Effective . This Supplement shall become effective when a counterpart hereof executed by the Grantor shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

[ Signature Page Follows ]

 

2



 

IN WITNESS WHEREOF, each of the parties hereto has caused this Supplement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

 

[NAME OF ADDITIONAL SUBSIDIARY]

 

 

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

 

 

 

 

 

 

[NAME OF ADDITIONAL SUBSIDIARY]

 

 

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

Signature Page to Security Agreement Supplement

 



 

[COPY SCHEDULES FROM SECURITY AGREEMENT]

 



 

Execution Version

 

 

CREDIT AGREEMENT

 

SCHEDULES ONLY

 

[ Schedules to Credit Agreement ]

 



 

Execution Version

 

SCHEDULES TO CREDIT AGREEMENT

 

Schedule 1.1                                                                                          Competitors

 

Ariosa Diagnostics/LabCorp/[*]

 

Sequenom

 

Illumina/Verinata/[*]

 

Good Start Genetics

 

BGI

 

Counsyl

 

[*]

 

[*]

 

[*]

 

[*]

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

[ Schedules to Credit Agreement ]

 


 

Schedule 1.2          Tangible Fixed Assets

 

Vendor

 

Description

 

Purchase Date

 

Original Purchase Cost

 

April 1, 2013 Net Asset Value

 

PO #

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

5,705,066.82

 

4,800,586.87

 

Grand Total

 

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

[ Schedules to Credit Agreement ]

 


 

Schedule 6.6                            Material Adverse Change

 

None.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.7(a)             Litigation

 

On April 22, 2011, former employee Gary Siebert filed an action in the U.S. District Court for the Northern District of California alleging that the Borrower made false statements to the government in connection with tracking of employee time and expenditures on certain NIH grants (“Siebert Matter”). Because the case was brought under the False Claims Act, the Attorney General was required by statute to commence an investigation. After investigating the claims, the U.S. Attorney’s Office for the Northern District of California filed a Notice of Election to Decline Intervention. On March 15, 2013 Natera filed a Motion to Dismiss the Siebert Matter and plaintiff responded with an Amended Complaint on March 21, 2013. On April 8, 2013 Borrower filed a Motion to Dismiss the Amended Complaint. The Department of Health and Human Services, Office of Inspector General, Office of investigations (“OIG”) issued an administrative subpoena to the Borrower requesting records related to its NIH grants which subpoena was received on December 5, 2011 (the “OIG Matter”). The OIG presumably issued this subpoena in response to the Siebert Matter, which is described above. The Borrower produced documents in response to the subpoena and met with representatives of the OIG, the U.S. Attorney’s Office for the Northern District of California (the “USAO”), the National Institutes of Health, and the U.S. Department of Justice, Civil Division, on December 11, 2012. The OIG has not communicated with the Borrower regarding the status of the investigation since the December 11, 2012 meeting, but on February 1, 2013, the USAO filed a Notice of Election to Decline Intervention in the Siebert Matter. The Borrower will continue to cooperate with the OIG investigation, to the extent that it continues. 

 

While the Borrower does not believe that there is a reasonable likelihood that the items listed in this Schedule 6.7(a) will be adversely determined against the Borrower and if so determined, would reasonably be expected, individually or in the aggregate, to result in liabilities in excess of $[*], the Borrower nonetheless wishes to bring these matters to your attention.

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.8                            Existing Subsidiaries

 

Natera International, Inc. 100% owned by Natera, Inc.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.10                     Taxes

 

None.

 

[ Schedules to Credit Agreement ]

 


 

Schedule 6.15(a) Intellectual Property

 

 

 

 

 

Application

 

 

 

 

 

 

 

 

 

Issue

 

Expiration

 

 

Title

 

Publication No.

 

No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Date

 

Date

 

Assignee

System and Method for Improving Clinical Decisions by Aggregating, Validating and Analysing Genetic and Phenotypic Data

 

US2006/0052945

 

11/004,274

 

12/3/2004

 

US

 

Issued

 

8,024,128

 

9/20/2011

 

 

 

GSN / Natera

System and Method for Using Genetic, Phenotypic and Clinical Data to Make Predictions for Clinical or Lifestyle Decisions

 

US2007/0027636

 

11/496,982

 

7/31/2006

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data from Target Individuals Using Genetic Data from Genetically Related Individuals

 

US2007/0184467

 

11/603,406

 

11/22/2006

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data from Target Individuals Using Genetic Data from Genetically Related Individuals

 

 

 

13/793,133

 

3/11/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data from Target Individuals Using Genetic Data from Genetically Related Individuals

 

 

 

13/793,186

 

3/11/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

WO2007/062164

 

PCT/US06/045281

 

11/22/2006

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

EP1960929

 

06838311.6

 

11/22/2006

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

EP2437191

 

11175867.8

 

11/22/2006

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

AU2006318425

 

2006318425

 

11/22/2006

 

AU

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

CA2632230

 

2632230

 

11/22/2006

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

Application

 

 

 

 

 

 

 

 

 

Issue

 

Expiration

 

 

Title

 

Publication No.

 

No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Date

 

Date

 

Assignee

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

CN101309703

 

200680049316.3

 

11/22/2006

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

HK1125195

 

9102141.5

 

3/5/2009

 

HK

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

JP2009517050

 

2008-542450

 

11/22/2006

 

JP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Integrating and Validating Genotypic, Phenotypic and Medical Information into a Database According to a Standardized Ontology

 

US2007/0178501

 

11/634,550

 

12/6/2006

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

US2008/0243398

 

12/076,348

 

3/17/2008

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

WO2008/115497

 

PCT/US08/03547

 

3/17/2008

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

EP2140386

 

08742125.1

 

3/17/2008

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

CN101790731

 

200880016123.7

 

3/17/2008

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Cell Genotyping

 

US2011/0033862

 

12/918,445

 

10/7/2010

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Cell Genotyping

 

WO2009/105531

 

PCT/US09/34506

 

2/19/2009

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

Methods for Embryo Characterization and Comparison

 

US2011/0092763

 

12/994,260

 

12/20/2010

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

Application

 

 

 

 

 

 

 

 

 

Issue

 

Expiration

 

 

Title

 

Publication No.

 

No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Date

 

Date

 

Assignee

Methods for Embryo Characterization and Comparison

 

WO2009/146335

 

PCT/US09/45335

 

5/27/2009

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

US2011/0178719

 

13/057,350

 

3/29/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

 

 

13/846,111

 

3/18/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

WO2010/017214

 

PCT/US09/52730

 

8/4/2009

 

PCT

 

Nationa1 Stage Entered

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

EP2321642

 

9805452.1

 

8/4/2009

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

AU2009279734

 

2009279734

 

8/4/2009

 

AU

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

CA2731991

 

2731991

 

8/4/2009

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

CN102171565

 

200980139431.1

 

8/4/2009

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

HK1159248

 

11113782.2

 

12/21/2011

 

HK

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

US2012/0185176

 

13/499,086

 

3/29/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

WO2011/041485

 

PCT/US2010/050824

 

9/30/2010

 

PCT

 

Nationa1 Stage Entered

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

EP2473638

 

10821214.3

 

9/30/2010

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

CA2774252

 

2774252

 

9/30/2010

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

CN10257266

 

201080048121.3

 

9/30/2010

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

 

 

13100216.3

 

1/7/2013

 

HK

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

US2011/0288780

 

13/110,685

 

5/18/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

WO2011/146632

 

PCT/US2011/037018

 

5/18/2011

 

PCT

 

Nationa1 Stage Entered

 

 

 

 

 

 

 

GSN / Natera

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

Application

 

 

 

 

 

 

 

 

 

Issue

 

Expiration

 

 

Title

 

Publication No.

 

No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Date

 

Date

 

Assignee

Methods for Non-invasive Prenatal Ploidy Calling

 

EP2572003

 

11784180.9

 

5/18/2011

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

AU2011255641

 

2011255641

 

5/18/2011

 

AU

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

CA2798758

 

2798758

 

5/18/2011

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

US2012/0270212

 

13/300,235

 

11/18/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

 

 

13/791,397

 

3/8/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

WO2012/108920

 

PCT/US11/615 06

 

11/18/2011

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Paternity Testing

 

US2012/0122701

 

13/335,043

 

12/22/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Paternity Testing

 

 

 

13/846,160

 

3/18/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Paternity Testing

 

WO2012/088456

 

PCT/US11/669 38

 

12/22/2011

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Preimplantation Genetic Diagnosis by Sequencing

 

 

 

PCT/US12/058 578

 

10/3/2012

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Highly Multiplex PCR Methods and Compositions

 

 

 

13/683,604

 

11/21/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Highly Multiplex PCR Methods and Compositions

 

 

 

PCT/US12/663 39

 

11/21/2012

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Highly Multiplex PCR Methods and Compositions

 

 

 

61/767,865

 

2/22/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Informatics Enhanced Analysis of Fetal Samples Subject to Maternal Contamination

 

 

 

13/780,022

 

2/28/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Informatics Enhanced Analysis of Fetal Samples Subject to Maternal Contamination

 

 

 

PCT/US2013/2 8378

 

2/28/2013

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Increasing Fetal Fraction in Maternal Blood

 

 

 

13/793,316

 

3/11/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Increasing Fetal Fraction in Maternal Blood

 

 

 

61/743,423

 

9/4/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 

[ Schedules to Credit Agreement ]

 

 


 

 

 

 

 

Application

 

 

 

 

 

 

 

 

 

Issue

 

Expiration

 

 

Title

 

Publication No.

 

No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Date

 

Date

 

Assignee

Improved Methods and Reagents for Quantification of Amplification Products

 

 

 

61/675,020

 

7/24/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-Invasive Prenatal Testing Using Parental Mosaicism Data

 

 

 

61/684,243

 

8/17/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-Invasive Prenatal Testing Using Parental Mosaicism Data

 

 

 

61/790,108

 

3/15/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods and Compositions for Reducing Genetic Library Contamination

 

 

 

61/683,331

 

8/15/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods and Compositions for Reducing Genetic Library Contamination

 

 

 

61/790,222

 

3/15/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

 

 

 

Country

 

 

 

 

 

 

 

 

 

Security Interest

Trademark

 

Appl. #

 

Reg. #

 

Status

 

of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Information

PRENATUS

 

85/467718

 

 

 

Allowed

 

US

 

11/8/2011

 

 

 

42 Int. medical laboratory services; genetic testing for scientific research purposes in the field of human reproduction

 

44 Int. genetic testing for medical purposes and genetic counseling in the field of human reproduction

 

GSN / Natera

 

 

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

 

 

 

Country

 

 

 

 

 

 

 

 

 

Security Interest

Trademark

 

Appl. #

 

Reg. #

 

Status

 

of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Information

NATERA

 

85/487673

 

4203883

 

Registered

 

US

 

12/5/2011

 

09/04/12

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for scientific purposes

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

 

 

 

Country

 

 

 

 

 

 

 

 

 

Security Interest

Trademark

 

Appl. #

 

Reg. #

 

Status

 

of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Information

NATERA

 

10930469

 

10930469

 

Registered

 

EP

 

6/1/2012

 

10/30/12

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical and scientific research and analysis in the field of genetic testing; medical laboratory services; genetic testing or scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing medical purposes; medical laboratory services

 

44 Int. genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling; genetic testing for medical purposes; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counselingcounseling

 

GSN / Natera

 

 

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

 

 

 

Country

 

 

 

 

 

 

 

 

 

Security Interest

Trademark

 

Appl. #

 

Reg. #

 

Status

 

of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Information

NATERA

 

1580172

 

 

 

Filed

 

CA

 

6/1/2012

 

 

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing

 

44 Int. medical laboratory services; genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling

 

GSN / Natera

 

 

NATERA

 

11022636

 

 

 

Filed

 

CN

 

6/5/2012

 

 

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing

 

GSN / Natera

 

 

NATERA

 

11022635

 

 

 

Filed

 

CN

 

6/5/2012

 

 

 

44 Int. medical laboratory services; genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling

 

GSN / Natera

 

 

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

 

 

 

Country

 

 

 

 

 

 

 

 

 

Security Interest

Trademark

 

Appl. #

 

Reg. #

 

Status

 

of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Information

NATERA

 

2012-44502

 

5521348

 

Registered

 

JP

 

6/4/2012

 

09/14/12

 

42 Int. medical and scientific research and analysis in the field of genetic testing, providing medical and scientific research information in the field of genetic testing, testing; inspection or research on therapeutic approaches and techniques related to medical treatment and providing information thereof, genetic testing for scientific research and analysis purposes, genetic testing for scientific research and analysis purposes in the field of human reproduction, hosting computer sites (web sites) featuring information in the field of genetic testing for medical purposes, research and development for others, providing information in the field of medical research, testing; inspection or research for medical care, computer software design, testing; inspection or research for medical care, computer software design; computer programming or maintenance of computer of computer software with respect to medical data, design of surgical instruments, analysis; research in the field of medical care and consultation thereof, testing or research on

 

GSN / Natera

 

 

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

 

 

 

Country

 

 

 

 

 

 

 

 

 

Security Interest

Trademark

 

Appl. #

 

Reg. #

 

Status

 

of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Information

NATERA

 

1494690

 

 

 

Published

 

AU

 

6/5/2012

 

 

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing

 

44 Int. medical laboratory services; genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling, namely providing information about genetic testing and genetic counseling via a website

 

GSN / Natera

 

 

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

 

 

 

Country

 

 

 

 

 

 

 

 

 

Security Interest

Trademark

 

Appl. #

 

Reg. #

 

Status

 

of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Information

NATERA

 

2012718511

 

 

 

Filed

 

RU (Russian Federation)

 

6/5/2012

 

 

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for medical purposes

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

 

 

 

Country

 

 

 

 

 

 

 

 

 

Security Interest

Trademark

 

Appl. #

 

Reg. #

 

Status

 

of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Information

NATERA

 

840152647

 

 

 

Filed

 

BR (Brazil)

 

6/5/2012

 

 

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for medical purposes

 

GSN / Natera

 

 

NATERA

 

840152671

 

 

 

Filed

 

BR

 

6/5/2012

 

 

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

 

 

 

Country

 

 

 

 

 

 

 

 

 

Security Interest

Trademark

 

Appl. #

 

Reg. #

 

Status

 

of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Information

NATERA

 

2343007

 

 

 

Filed

 

IN (India)

 

6/5/2012

 

 

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for medical purposes

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 

[ Schedules to Credit Agreement ]

 


 

 

 

 

 

 

 

 

 

Country

 

 

 

 

 

 

 

 

 

Security Interest

Trademark

 

Appl. #

 

Reg. #

 

Status

 

of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Information

PANORAMA

 

85/776044

 

 

 

Filed

 

US (foreign filing options are open)

 

11/9/2012

 

 

 

01 Int. kits and reagents for genetic testing for medical and scientific research purposes; kits and reagents for genetic testing for medical and scientific research purposes in the field of human reproduction; kits and reagents for prenatal testing for medical and scientific research purposes; nucleic acid based kits and reagents for testing for fetal chromosomal abnormalities for medical and scientific research purposes

 

42 Int. genetic testing for scientific research purposes; genetic testing for scientific research purposes in the field of human reproduction; prenatal testing for scientific research purposes; testing for fetal chromosomal abnormalities for research purposes; scientific, laboratory, clinical, medical, and technological research and analysis services in the fields of nucleic acid analysis, prenatal testing, and genetics; medical laboratory services; providing a website featuring information about genetic testing for scientific research purposes; providing a

 

GSN / Natera

 

 

 

[ Schedules to Credit Agreement ]

 


 

Schedule 6.15(b)   Intellectual Property Exceptions

 

6.15(b)(iii)

 

On August 17, 2011, DNA Diagnostics Center, Inc. (“DDC”) a distribution partner of the Borrower’s that distributes the Borrower’s non-invasive prenatal paternity test (the “Test”) received an email from Sequenom, Inc. (“Sequenom”) claiming that Sequenom holds the rights to detecting circulating fetal nucleic acids in maternal blood and, as such, DDC needs a license from Sequenom to engage in distribution of the Test. The Borrower contacted Sequenom and informed Sequenom that the Borrower does not believe that the Borrower’s Test violates Sequenom’s rights. Subsequently, on December 6, 2011, counsel to Sequenom sent letters to DDC as well as to the Borrower asking the recipients to comment on the question of violation of Sequenom’s patent rights (the “Sequenom Letters”). On January 6, 2012, the Borrower filed a Declaratory Judgment action against Sequenom in the Northern District of California, alleging that U.S. Patent No. 6,258,540 (“the ‘540 patent”) is invalid, unenforceable, and not infringed. On January 24, 2012, Sequenom asserted the ‘540 patent against the Borrower and DNA Diagnostic Center in the Southern District of California. The Southern District case was dismissed and Sequenom’s claims were added to the Borrower’s case in the Northern District. Ariosa and Verinata (now Illumina) also filed declaratory judgment actions regarding the ‘540 Patent against Sequenom in the Northern District. Sequenom has also asserted counterclaims of infringement of the ‘540 patent against Ariosa and Verinata in both of those cases. All of these cases have been designated related cases in the Northern District of California and assigned to District Judge Susan Illston. Sequenom attempted and failed to obtain a preliminary injunction against Ariosa. In particular, the district court found that Ariosa had raised a “substantial question” regarding validity as well as infringement of the ‘540 patent. Sequenom appealed the denial of the motion for preliminary injunction. The appeals court heard argument in the matter of January 9, 2013. The district court postponed claim construction on several occasions to allow time for the Federal Circuit to issue its decision on the appeal. On March 19, 2013, the USPTO ordered the commencement of an inter partes review of the ‘540 patent that was requested by Ariosa.

 

On December 20, 2012, Genetic Technologies Limited (an Australian company) filed suit against the Borrower in the Delaware District Court alleging infringement of U.S. Patent No. 5,612,179 (the “‘179 patent”). The ‘179 patent expired on March 9, 2010. The ‘179 patent is currently undergoing ex parte re-examination at the United States Patent and Trademark Office. The Borrower has not yet filed an answer to the compliant. We believe that the litigation is without merit. In addition to the Borrower conducting negligible relevant commercial activities prior to the expiration of the patent, we believe the ‘179 patent to be invalid and/or not infringed.

 



 

Schedule 6.15(b)(v)                                       Intellectual Property Sole Ownership Exceptions

 

None.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.15(c)       Intellectual Property Infringement

 

Separately disclosed to the Lender.

 

[*]

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.15(e)       Infringement Notices

 

See Schedule 6.15(b).

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.16                                                                     Material Agreements

 

1.               Sublease between Nektar Therapeutics and Gene Security Network, Inc. as of December 13, 2011, as amended by First Amendment to Sublease dated January 31, 2012 and by Second Amendment to Sublease dated January 3, 2013; Consent to Sublease between BMR-201 Industrial Road LP, Nektar Theraputics, and Gene Security Network, Inc. dated January 24, 2011.

2.               Licensing and Joint Development Agreement between Bio-Reference Laboratories, Inc. and Natera, Inc. dated February 7, 2013

3.               Logistics, Referral Testing and License Agreement between Quest Diagnostics Incorporated and Natera, Inc. dated as of February 6, 2013

4.               Development and Marketing Agreement between DNA Diagnostic Center, Inc. and Gene Security Network dated March 8, 2011 as amended by First Amendment to Development and Marketing Agreement dated July 24, 2012

5.               Memorandum of Understanding between Ascendant MDx and Natera, Inc. dated October 18, 2012

6.               Clinical Laboratory Services Pricing Agreement between ARUP Laboratories, Inc. and Natera, Inc. dated September 19, 2012

7.               Research and Development Agreement between Women & Infants Hospital of Rhode Island and Natera, Inc. dated December 1, 2012

8.               Services Agreement between XIFIN, Inc. and Natera, Inc. dated November 30, 2011

9.               Purchase Order No. 100531 of Natera, Inc. to Illumina, Inc. dated March 20, 2013

10.        Purchase Order No. 100532 of Natera, Inc. to Illumina, Inc. dated March 20, 2013

11.        Purchase Order No. 100695 of Natera, Inc. to The Core Group dated April 10, 2013

12.        Employment Agreement including option acceleration clause between Natera and Steven Chapman dated November 6, 2010.

13.        Employment Agreement including option acceleration clause between Natera and Daniel Rabinowitz dated June 7, 2007

14.        Employment Agreement including option acceleration clause between Natera and Matthew Rabinowitz dated June 7, 2007

15.        Employment Agreement including option acceleration clause between Natera and Brad Roberts dated November 7, 2011

16.        Employment Agreement including option acceleration clause between Natera and Jonathan Sheena dated June 7, 2007

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.17                     Permits.

 

The Borrower has a license application to perform testing in New York pursuant to a waiver.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.18(b)      Regulatory Actions

 

See discussion of Siebert Matter and OIG Matter in Section 6.7(a).

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.18(c)       Regulatory Compliance

 

See Schedule 6.17.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.18(d)      Key Permit Matters.

 

See discussion of Siebert Matter and OIG Matter in Section 6.7(a).

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.18(e)       Certain Regulatory Enforcement Matters

 

None.

 

[ Schedules to Credit Agreement ]

 


 

Schedule 6.18(g)       Certain Regulatory Disclosure Matters

 

See discussion of Siebert Matter and OIG Matter in Section 6.7(a).

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.18(h)      Certain Regulatory Actions

 

See discussion of Siebert Matter and OIG Matter in Section 6.7(a).

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.19                                                                     Transactions with Affiliates

 

On April 30, 2012, the Borrower made a $154,000 full recourse seven-year loan to Matthew Rabinowitz for purchase of shares.

 

On April 30, 2012, the Borrower made a $32,280 full recourse seven-year loan to Jonathan Sheena for purchase of shares.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 6.22                                                                     Deposit and Disbursement Accounts

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 7.7                                                                            Use of Proceeds

 

Proceeds will be used for general corporate expenses, product costs, working capital funding, inventory investment, and other operating expenses.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 8.2(b)                                                             Indebtedness to be Paid

 

None.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 8.2(c)                                                              Existing Indebtedness

 

Revolving credit card facility extended by Comerica Bank in the maximum principal amount of $150,000.00 (the “Credit Card Facility”).

 

[ Schedules to Credit Agreement ]

 



 

Schedule 8.3(c)                                                              Existing Liens

 

Liens in favor of Comerica Bank on funds held in account number [*] (the “Credit Card Collateral Account”), which funds shall not exceed $150,000.00, and which secure obligations of the Borrower to Comerica Bank under the Credit Card Facility. As of the Closing Date, $150,000.00 were on deposit in the Credit Card Collateral Account.

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 8.5(a)                                                             Investments

 

None.

 

[ Schedules to Credit Agreement ]

 



 

Schedule 10.2                                                                     Notice Information

 

If to the Borrower:

 

Natera, Inc.

Attention: Chief Executive Officer

201 Industrial Road #410

San Carlos, CA 94070

(650) 249-9090 (phone)

(650) 649 2385 (fax)

 

If to the Lender:

ROS Acquisition Offshore LP

C/O Walkers Corporate Services Limited

Walker House, 87 Mary Street

George Town, Grand Cayman KY 1-9005, Cayman Islands

Attention: Neil Gray

 

with a copy to:

 

OrbiMed Advisors LLC

601 Lexington Avenue, 54th Floor

New York, NY 10022

Attention: Tadd Wessel and Matthew Rizzo

Email: wesselt@orbimed.com and rizzom@orbimed.com

 

If to ROS:

 

Royalty Opportunities S.àr.l

65 Boulevard Grande-Duchesse

Charlotte

L-1331 Luxembourg

Grand Duché de Luxembourg

Attention: Board of Directors

 

with a copy to:

 

OrbiMed Advisors, LLC

601 Lexington Avenue, 54th Floor

New York, NY 10022

Attention: Tadd Wessel and Matthew Rizzo

Email: wesselt@orbimed.com and rizzom@orbimed.com

Facsimile: (212) 320-0674

 

[ Schedules to Credit Agreement ]

 


 

Execution Version

 

FIRST AMENDMENT TO CREDIT AGREEMENT

 

This FIRST AMENDMENT TO CREDIT AGREEMENT (this “ Amendment ”) is made and entered into as of June 6, 2014 by and among NATERA, INC., a Delaware corporation (the “ Borrower ”), and ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (the “ Lender ”).

 

WHEREAS, the Borrower and the Lender are party to that certain Credit Agreement, dated as of April 18, 2013 (the “ Credit Agreement ”), pursuant to which the Lender has extended credit to the Borrower on the terms set forth therein;

 

WHEREAS, pursuant to Section 10.1 of the Credit Agreement, the Credit Agreement may be amended by an instrument in writing signed by each of the Borrower and the Lender; and

 

WHEREAS, the Borrower and the Lender desire to amend certain provisions of the Credit Agreement as provided in this Amendment.

 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.           Definitions; Loan Document . Capitalized terms used herein without definition shall have the meanings assigned to such terms in the Credit Agreement. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement and the other Loan Documents.

 

2.           Amendment to Definition of Delayed Draw Commitment Amount . The definition of “Delayed Draw Commitment Amount” in Section 1.1 of the Credit Agreement is hereby amended so that the definition reads in its entirety as follows:

 

Delayed Draw Commitment Amount means an amount equal to (a) $10,000,000 or (b) $20,000,000, as determined by the Borrower in its sole discretion.

 

3.           Amendment to Definition of Notes . The definition of “Note” in Section 1.1 of the Credit Agreement is hereby amended so that the definition reads in its entirety as follows:

 

Note ” means a promissory note of the Borrower payable to the Lender, in the form of Exhibit A or F hereto, as applicable (as such promissory note may be amended, endorsed or otherwise modified from time to time), evidencing the aggregate Indebtedness of the Borrower to the Lender resulting from the outstanding amount of the Loans, and also means all other promissory notes accepted from time to time in substitution therefor or renewal thereof.

 



 

4.             Amendment to Definition of Loan Request . The definition of “Loan Request” in Section 1.1 of the Credit Agreement is hereby amended so that the definition reads in its entirety as follows:

 

Loan Request ” means (a) in the event that the Borrower elects a Delayed Draw Commitment Amount equal to $10,000,000, a Loan request and certificate duly executed by an Authorized Officer of the Borrower substantially in the form of Exhibit B hereto or (b) in the event that the Borrower elects a Delayed Draw Commitment Amount equal to $20,000,000, a Loan request and certificate duly executed by an Authorized Officer of the Borrower substantially in the form of Exhibit G hereto.

 

5.             Amendment to Definition of Material Agreement . The definition of “Material Agreement in Section 1.1 of the Credit Agreement is hereby amended such that “[*]” shall be replaced by “[*]”

 

6.             Amendment to Section 5.1 . Section 5.1 of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

SECTION 5.1. Credit Extensions . The obligation of the Lender to make the Initial Loan shall be subject to the execution and delivery of this Agreement by the parties hereto, the delivery of a Loan Request as requested pursuant to Section 2.3 , and the satisfaction of each of the conditions precedent set forth below in this Article (other than Sections 5.19 , 5.20 and 5.21 ). The obligation of the Lender to make the Delayed Draw Loan shall be subject to the prior making of the Initial Loan, the delivery of a Loan Request as requested pursuant to Section 2.3 , and the satisfaction of each of the conditions precedent set forth below in Sections 5.3 , 5.8 , 5.19 , 5.20 and 5.21 .

 

7.             Amendment to Article  V . Article V of the Credit Agreement is hereby amended by inserting the following as a new Section 5.21:

 

SECTION 5.21. Delayed Draw Loan Note . In the event that the Borrower elects a Delayed Draw Commitment Amount equal to $20,000,000, the Lender shall have received a Note in the form of Exhibit F hereto duly executed and delivered by an Authorized Officer of the Borrower, in exchange for the original Note delivered to the Lender on the Closing Date which shall be cancelled, without further action, upon delivery of the new Note to the Lender. The Lender shall promptly deliver to the Borrower the cancelled original Note.

 

8.             Addition to Exhibits of Credit Agreement Exhibits F and G attached hereto are hereby added to the exhibits to the Credit Agreement.

 

9.             Conditions to Effectiveness of Amendment . This Amendment shall become effective upon receipt by the Lender of (i) a Secretary’s Certificate, in a form reasonably acceptable to Lender, duly executed and delivered by the signatories thereto, and (ii) a counterpart signature to this Amendment duly executed and delivered by the Borrower.

 

10.          Expenses . [*]

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

2



 

11.          No Implied Amendment or Waiver . Except as expressly set forth in this Amendment, this Amendment shall not, by implication or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of the Lender under the Credit Agreement or the other Loan Documents, or alter, modify, amend or in any way affect any of the terms, obligations or covenants contained in the Credit Agreement or the other Loan Documents, all of which shall continue in full force and effect. Nothing in this Amendment shall be construed to imply any willingness on the part of the Lender to agree to or grant any similar or future amendment, consent or waiver of any of the terms and conditions of the Credit Agreement or the other Loan Documents.

 

12.          Counterparts; Governing Law . This Amendment may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of such when so executed and delivered shall be an original, but all of such counterparts shall together constitute but one and the same agreement. Delivery of an executed counterpart of a signature page of this Amendment by fax transmission or other electronic mail transmission (e.g., “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Amendment. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).

 

[Remainder of Page Intentionally Left Blank]

 

3



 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized as of the day and year first above written.

 

 

 

NATERA, INC.,

 

as the Borrower

 

 

 

 

 

By:

/s/ Matthew Rabinowitz

 

Name:

Matthew Rabinowitz

 

Title:

Chief Executive Officer

 

 

 

 

 

ROS ACQUISITION OFFSHORE LP,

 

as the Lender

 

 

 

 

 

By OrbiMed Advisors LLC,

 

its investment manager

 

 

 

 

 

By:

/s/ Samuel D. Isaly

 

Name:

Samuel D. Isaly

 

Title:

Managing Member

 

Signature Page to First Amendment to Credit Agreement

 



 

EXHIBIT F

 



 

PROMISSORY NOTE

 

$40,000,000

[Date]

 

FOR VALUE RECEIVED, NATERA, INC., a Delaware corporation (the “ Borrower ”), hereby promises to pay to the order of ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors, transferees and assigns, the “ Lender ”), on the Maturity Date the principal sum of FORTY MILLION DOLLARS ($40,000,000) or, if less, the aggregate unpaid principal amount of the Loans (and any continuation thereof) made (or continued) by the Lender pursuant to the Credit Agreement, dated as of April 18, 2013 (as amended by that certain First Amendment to Credit Agreement, dated as of May     , 2014, and as further supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and between the Borrower and the Lender. Unless otherwise defined herein or the context otherwise requires, terms used in this Note have the meanings provided in the Credit Agreement.

 

The Borrower also promises to pay interest on the unpaid principal amount hereof from time to time outstanding from the date hereof until maturity (whether by acceleration or otherwise) and, after maturity upon demand, until paid in full, at the rates per annum and on the dates specified in the Credit Agreement, as well as any other amounts that may be due to the Lender upon maturity (whether by acceleration or otherwise) under or in respect of this Note.

 

Payments of both principal and interest are to be made in U.S. Dollars in same day or immediately available funds to the account designated by the Lender pursuant to the Credit Agreement.

 

This Note is referred to in, and evidences Indebtedness incurred under, the Credit Agreement, to which reference is made for a description of the security and guarantee for this Note and for a statement of the terms and conditions on which the Borrower is permitted and required to make prepayments and repayments of the unpaid principal amount of the Indebtedness evidenced by this Note and on which such Indebtedness may be declared to be immediately due and payable. Any prepaid principal of this Note may not be reborrowed.

 

All parties hereto, whether as makers, endorsers or otherwise, severally waive presentment for payment, demand, protest and notice of dishonor.

 

THIS NOTE HAS BEEN DELIVERED IN NEW YORK, NEW YORK AND SHALL BE DEEMED TO BE A CONTRACT MADE UNDER AND GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).

 

[ Signature Page Follows ]

 



 

 

NATERA, INC.

 

 

 

 

 

By:

 

 

 

Name:

Matthew Rabinowitz

 

 

Title:

Chief Executive Officer

 

[ Signature Page to Promissory Note ]

 



 

EXHIBIT G

 



 

LOAN REQUEST ($20,000,000 Delayed Draw Loan)

 

[Date]

 

ROS Acquisition Offshore LP

C/O Walkers Corporate Services Limited

Walker House, 87 Mary Street

George Town, Grand Cayman KY 1-9005, Cayman Islands

Attention: Board of Directors

 

with a copy to:

 

OrbiMed Advisors LLC

601 Lexington Avenue, 54th Floor

New York, NY 10022

Attention: Tadd Wessel and Matthew Rizzo

 

Ladies and Gentlemen:

 

Reference is hereby made to that certain Credit Agreement, dated as of April 18, 2013 (as amended by that certain First Amendment to Credit Agreement, dated as of May     , 2014, and as supplemented or otherwise modified from time to time and in effect on the date hereof, the “ Credit Agreement ”), by and between Natera, Inc., a Delaware corporation (the “ Borrower ”), and ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

Unless otherwise defined herein or the context otherwise requires, terms used herein have the meanings provided in the Credit Agreement.

 

Pursuant to the provisions of Section 2.2 of the Credit Agreement, the Borrower hereby requests a Delayed Draw Loan of $20,000,000 to be made on     , 201  (the “ Proposed Disbursement Date ”), which Loan shall be evidenced by that certain Promissory Note dated as of   , 2014 in the aggregate original principal amount of [$40,000,000.00].

 

The undersigned hereby represent(s) and warrant(s) to the Lender that:

 

(a)         the proceeds of the proposed Loan are to be used for the purposes set forth in Section 7.7 of the Credit Agreement;

 

(b)         bank account details and wire transfer instructions for disbursement of the proceeds of the proposed Loan are set forth on Schedule A hereto;

 

(c)          no Default has occurred and is continuing or would result from the proposed Loan;

 

(d)         all conditions required to be satisfied (or waived by the Lender), as set forth in Article V of the Credit Agreement, as applicable, as of the Proposed Disbursement Date for the

 



 

making of the Loan requested hereby have been, and are, fully satisfied (or duly waived by the Lender); and

 

(e)          the representations and warranties contained in Article VI of the Credit Agreement and in the other Loan Documents are true and correct in all material respects (except with respect to any representation or warranty that contains a materiality qualifier, which representation or warranty shall be true and correct in all respects), before and after giving effect to the making of the proposed Loan and to the application of the proceeds thereof, as though made on and as of the date hereof, except to the extent that they relate specifically to an earlier specified date (in which case they are true and correct in all material respects on and as of such earlier date) or are affected by transactions or events occurring after the date of the Credit Agreement which are not prohibited thereunder.

 

The officer signing below is an Authorized Officer of the undersigned and is authorized to request the Loan contemplated hereby and issue this Loan Request on behalf of the undersigned.

 

[ Signature Page Follows ]

 

2



 

 

Very truly yours,

 

 

 

 

 

NATERA, INC.,

 

as the Borrower

 

 

 

By:

 

 

 

Name:

Matthew Rabinowitz

 

 

Title:

Chief Executive Officer

 

[ Signature Page to Loan Request ]

 



 

Schedule A

 

Disbursement / Wire Instructions

 

[ Schedules to Loan Request ]

 



 

WAIVER AND SECOND AMENDMENT TO CREDIT AGREEMENT

 

This WAIVER AND SECOND AMENDMENT TO CREDIT AGREEMENT (this “ Waiver and Amendment ”) is made and entered into as of April 9, 2015 by and among NATERA, INC., a Delaware corporation (the “ Borrower ”), and ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (the “ Lender ”).

 

WHEREAS, the Borrower and the Lender are party to that certain Credit Agreement, dated as of April 18, 2013, as amended by that certain First Amendment to Credit Agreement, dated as of June 6, 2014 (as so further amended, the “ Credit Agreement ”), pursuant to which the Lender has extended credit to the Borrower on the terms set forth therein;

 

WHEREAS, as of the date hereof, the Borrower has incurred Indebtedness in respect of reimbursement obligations under letters of credit to secure real property lease obligations in an amount exceeding $1,000,000 in the aggregate (the “ L/C Threshold Amount ”), and therefore an Event of Default has occurred and is continuing under Section 9.1(c) of the Credit Agreement (the “ Existing Default ”);

 

WHEREAS, the Borrower has requested that the Lender waive the Existing Default and increase the L/C Threshold Amount from $1,000,000 to $1,300,000; and

 

WHEREAS, the Lender is willing to waive the Existing Default and increase the L/C Threshold Amount subject to the conditions set forth herein.

 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.                                       Definitions; Loan Document . Capitalized terms used herein without definition shall have the meanings assigned to such terms in the Credit Agreement. This Waiver and Amendment shall constitute a Loan Document for all purposes of the Credit Agreement and the other Loan Documents.

 

2.                                       Amendment to Section 8.2 . Section 8.2 of the Credit Agreement is hereby amended by replacing the dollar amount “1,000,000” with the dollar amount “$1,300,000” in clause (k) thereof.

 

3.                                       Amendment to Section 8.3 . Section 8.3 of the Credit Agreement is hereby amended by replacing the dollar amount “1,000,000” with the dollar amount $1,300,000” in clause (m) thereof.

 

4.                                       Waiver . The Lender hereby waives the Existing Default and agrees not to exercise any rights or remedies that may be available to it as a result of the occurrence thereof.

 

5.                                       Conditions to Effectiveness of Waiver and Amendment . This Waiver and Amendment shall become effective upon receipt by the Lender and the Borrower of a counterpart signature of the other to this Waiver and Amendment duly executed and delivered by each of the Lender and the Borrower.

 



 

6.                                       Expenses . [*]

 

7.                                       No Implied Amendment or Waiver . Except as expressly set forth in this Waiver and Amendment, this Waiver and Amendment shall not, by implication or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of the Lender under the Credit Agreement or the other Loan Documents, or alter, modify, amend or in any way affect any of the terms, obligations or covenants contained in the Credit Agreement or the other Loan Documents, all of which shall continue in full force and effect. Nothing in this Waiver and Amendment shall be construed to imply any willingness on the part of the Lender to agree to or grant any similar or future amendment, consent or waiver of any of the terms and conditions of the Credit Agreement or the other Loan Documents.

 

8.                                       Counterparts; Governing Law . This Waiver and Amendment may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of such when so executed and delivered shall be an original, but all of such counterparts shall together constitute but one and the same agreement. Delivery of an executed counterpart of a signature page of this Waiver and Amendment by fax transmission or other electronic mail transmission (e.g., “pdf’ or “tif’) shall be effective as delivery of a manually executed counterpart of this Waiver and Amendment. THIS WAIVER AND AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).

 

[Remainder of Page Intentionally Left Blank]

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

2



 

IN WITNESS WHEREOF, the parties hereto have caused this Waiver and Amendment to be executed by their respective officers thereunto duly authorized as of the day and year first above written.

 

 

NATERA, INC.,

 

as the Borrower

 

 

 

 

 

 

 

By:

/s/ Matthew Rabinowitz

   04 / 09 / 2015

 

Name:

Matthew Rabinowitz

 

 

Title:

Chief Executive Officer

 

 

 

 

 

 

ROS ACQUISITION OFFSHORE LP,

as the Lender

 

 

 

 

 

By OrbiMed Advisors LLC,

its investment manager

 

 

 

 

 

By:

/s/ Samuel D. Isaly

 

Name:

Samuel D. Isaly

 

Title:

Managing Director

 


 



Exhibit 10.8.2

 

CONFIDENTIAL TREATMENT REQUESTED

 

Execution Version

 

PLEDGE AND SECURITY AGREEMENT

 

This PLEDGE AND SECURITY AGREEMENT, dated as of April 18, 2013 (as amended, supplemented or otherwise modified from time to time, this “ Security Agreement ”), is made by NATERA, INC., a Delaware corporation (the “ Borrower ”) and NATERA INTERNATIONAL, INC. (together with the Borrower and with any other entity that may become a party hereto as provided herein, each a “ Grantor ” and, collectively, the “ Grantors ”) in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership, for itself and as agent for the other parties to which the Grantors may owe any Obligations (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W I T N E S S E T H :

 

WHEREAS, pursuant to the Credit Agreement, dated as of April 18, 2013 (as amended, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and between the Borrower and the Lender, the Lender has extended a Commitment to make Loans to the Borrower; and

 

WHEREAS, as a condition precedent to the making of the Initial Loan under the Credit Agreement, each Grantor is required to execute and deliver this Security Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees, for the benefit of the Lender, as follows:

 

ARTICLE I
DEFINITIONS

 

SECTION 1.1. Certain Terms . The following terms (whether or not underscored) when used in this Security Agreement, including its preamble and recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof):

 

Borrower ” is defined in the preamble.

 

Collateral ” is defined in Section 2.1 .

 

Collateral Accounts ” is defined in clause (b)  of Section 4.3 .

 

Computer Hardware and Software Collateral ” means (a) all of the Grantors’ computer and other electronic data processing hardware, integrated computer systems, central processing units, memory units, display terminals, printers, features, computer elements, card readers, tape drives, hard and soft disk drives, cables, electrical supply hardware, generators, power equalizers, accessories and all peripheral devices and other related computer hardware, including all operating system software, utilities and application programs in whatsoever form; (b) all software programs (including both source code, object code and all related applications and data files) designed for use on the computers and electronic data processing hardware described in clause (a)  above; (c) all firmware associated therewith; (d) all documentation (including flow

 



 

charts, logic diagrams, manuals, guides, specifications, training materials, charts and pseudo codes) with respect to such hardware, software and firmware described in the preceding clauses (a)  through (c) ; and (e) all rights with respect to all of the foregoing, including copyrights, licenses, options, warranties, service contracts, program services, test rights, maintenance rights, support rights, improvement rights, renewal rights and indemnifications and any substitutions, replacements, improvements, error corrections, updates, additions or model conversions of any of the foregoing.

 

Control Agreement ” means an authenticated record in form and substance reasonably satisfactory to the Lender, that provides for the Lender to have “control” (as defined in the UCC) over certain Collateral.

 

Copyright Collateral ” means all copyrights of the Grantors, whether statutory or common law, whether registered or unregistered and whether published or unpublished, now or hereafter in force throughout the world including all of the Grantors’ rights, titles and interests in and to all copyrights registered in the United States Copyright Office or anywhere else in the world, including the copyrights referred to in Item A of Schedule V , and registrations and recordings thereof and all applications for registration thereof, whether pending or in preparation, all copyright licenses, including each copyright license referred to in Item B of Schedule V , the right to sue for past, present and future infringements of any of the foregoing, all rights corresponding thereto, all extensions and renewals of any thereof and all Proceeds of the foregoing, including licenses, royalties, income, payments, claims, damages and Proceeds of suit, which are owned or licensed by the Grantors.

 

Credit Agreement ” is defined in the first recital .

 

Distributions ” means all dividends paid on Capital Securities, liquidating dividends paid on Capital Securities, shares (or other designations) of Capital Securities resulting from (or in connection with the exercise of) stock splits, reclassifications, warrants, options, non-cash dividends, mergers, consolidations, and all other distributions (whether similar or dissimilar to the foregoing) on or with respect to any Capital Securities constituting Collateral.

 

Filing Statements ” is defined in clause (b)  of Section 3.7 .

 

General Intangibles ” means all “general intangibles” and all “payment intangibles”, each as defined in the UCC, and shall include all interest rate or currency protection or hedging arrangements, all tax refunds, all licenses, permits, concessions and authorizations and all Intellectual Property Collateral (in each case, regardless of whether characterized as general intangibles under the UCC).

 

Grantor ” and “ Grantors ” are defined in the preamble .

 

Intellectual Property Collateral ” means, collectively, the Computer Hardware and Software Collateral, the Copyright Collateral, the Patent Collateral, the Trademark Collateral, the Trade Secrets Collateral, Product Agreements and Regulatory Authorizations.

 

Intercompany Note ” means any promissory note evidencing loans made by any Grantor to any other Grantor.

 

2



 

Investment Property ” means, collectively, (a) all “investment property” as such term is defined in Section 9-102(a)(49) of the UCC and (b) whether or not constituting “investment property” as so defined, all Pledged Notes.

 

Lender ” is defined in the preamble .

 

“Patent Collateral” means:

 

(a)            all of the Grantors’ (i) inventions and discoveries, whether patentable or not, and (ii) letters patent and applications for letters patent throughout the world, including all patent applications in preparation for filing and each patent and patent application referred to in Item A of Schedule III ;

 

(b)            all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the items described in clause (a) ;

 

(c)            all patent licenses, and other agreements providing any Grantor with the right to use any items of the type referred to in clauses (a)  and (b)  above, including each patent license referred to in Item B of Schedule III ; and

 

(d)            all Proceeds of, and rights associated with, the foregoing (including licenses, royalties income, payments, claims, damages and Proceeds of infringement suits) and the right to sue third parties for past, present or future infringements of any patent or patent application and for breach or enforcement of any patent license.

 

Permitted Liens ” means all Liens permitted by Section 8.3 of the Credit Agreement.

 

Pledged Notes ” means all promissory notes listed on Item J of Schedule II (as such schedule may be amended or supplemented from time to time), all Intercompany Notes at any time issued to any Grantor and all other promissory notes issued to or held by any Grantor.

 

Securities Act ” is defined in clause (a)  of Section 6.2 .

 

Security Agreement ” is defined in the preamble .

 

Trade Secrets Collateral ” means all of the Grantors’ common law and statutory trade secrets and all other confidential, proprietary or useful information, and all know-how obtained by or used in or contemplated at any time for use in the business of any Grantor (all of the foregoing being collectively called a “ Trade Secret ”), whether or not such Trade Secret has been reduced to a writing or other tangible form, including all documents and things embodying, incorporating or referring in any way to such Trade Secret, all Trade Secret licenses, and including the right to sue for and to enjoin and to collect damages for the actual or threatened misappropriation of any Trade Secret and for the breach or enforcement of any such Trade Secret license.

 

Trademark Collateral ” means :

 

3



 

(a)            (i) all of the Grantors’ trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, certification marks, collective marks, logos and other source or business identifiers, and all goodwill of the business associated therewith, now existing or hereafter adopted or acquired including those referred to in Item A of Schedule IV , whether currently in use or not, all registrations and recordings thereof and all applications in connection therewith, whether pending or filed, including registrations, recordings and applications in the United States Patent and Trademark Office or in any office or agency of the United States of America, or any State thereof or any other country or political subdivision thereof or otherwise, and all common-law rights relating to the foregoing, and (ii) the right to obtain all reissues, extensions or renewals of the foregoing (collectively referred to as the “ Trademarks ”);

 

(b)            all Trademark licenses for the grant by or to any Grantors of any right to use any Trademark, including each Trademark license referred to in Item B of Schedule IV ; and

 

(c)            all of the goodwill of the business connected with the use of, and symbolized by the items described in, clause (a) , and to the extent applicable clause (b) ;

 

(d)            the right to sue third parties for past, present and future infringements of any Trademark Collateral described in clause (a)  and, to the extent applicable, clause (b) ; and

 

(e)            all Proceeds of, and rights associated with, the foregoing, including any claim by any Grantor against third parties for past, present or future infringement or dilution of any Trademark, Trademark registration or Trademark license, or for any injury to the goodwill associated with the use of any such Trademark or for breach or enforcement of any Trademark license and all rights corresponding thereto throughout the world.

 

SECTION 1.2. Credit Agreement Definitions . Unless otherwise defined herein or the context otherwise requires, terms used in this Security Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement.

 

SECTION 1.3. UCC Definitions . When used herein the terms “Account”, “Certificate of Title”, “Certificated Securities”, “Chattel Paper”, “Commercial Tort Claim”, “Commodity Account”, “Commodity Contract”, “Deposit Account”, “Document”, “Electronic Chattel Paper”, “Equipment”, “Goods”, “Instrument”, “Inventory”, “Letter-of-Credit Rights”, “Payment Intangibles”, “Proceeds”, “Promissory Notes”, “Securities Account”, “Security Entitlement”, “Supporting Obligations” and “Uncertificated Securities” have the meaning provided in Article 8 or Article 9, as applicable, of the UCC. “Letters of Credit” has the meaning provided in Section 5-102 of the UCC.

 

4



 

ARTICLE II
SECURITY INTEREST

 

SECTION 2.1. Grant of Security Interest . Each Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all of such Grantor’s right, title and interest in and to the following property, whether now or hereafter existing, owned or acquired by such Grantor, and wherever located, (collectively, the “ Collateral ”):

 

(a)              Accounts;

 

(b)              Chattel Paper;

 

(c)              Commercial Tort Claims listed on Item I of Schedule II (as such schedule may be amended or supplemented from time to time);

 

(d)              Deposit Accounts;

 

(e)              Documents;

 

(f)              General Intangibles;

 

(g)              Goods (including Goods held on consignment with third parties);

 

(h)              Instruments;

 

(i)               Investment Property;

 

(j)               Letter-of-Credit Rights and Letters of Credit;

 

(k)              Supporting Obligations;

 

(l)               all books, records, writings, databases, information and other property relating to, used or useful in connection with, evidencing, embodying, incorporating or referring to, any of the foregoing in this Section;

 

(m)            all Proceeds of the foregoing and, to the extent not otherwise included, (A) all payments under insurance (whether or not the Lender is the loss payee thereof) in respect of Collateral and (B) all tort claims; and

 

(n)              all other property and rights of every kind and description and interests therein.

 

Notwithstanding the foregoing, the term “Collateral” shall not include:

 

(i)         any General Intangibles or other rights arising under any contracts, instruments, licenses or other documents as to which the grant of a security interest would (A) constitute a violation of a valid and enforceable restriction in favor of a third party on such grant, unless and until any required consents shall

 

5



 

have been obtained, or (B) give any other party to such contract, instrument, license or other document the right to terminate its obligations thereunder;

 

(ii)              trademark applications filed in the United States Patent and Trademark Office on the basis of such Grantor’s “intent to use” such trademark, unless and until acceptable evidence of use of the Trademark has been filed with the United States Patent and Trademark Office pursuant to Section 1(c) or Section 1(d) of the Lanham Act (15 U.S.C. 1051, et seq.), to the extent that granting a Lien in such Trademark application prior to such filing would adversely affect the enforceability or validity of such Trademark application;

 

(iii)             any asset, the granting of a security interest in which would be void or illegal under any applicable governmental law, rule or regulation, or pursuant thereto would result in, or permit the termination of, such asset; or

 

(iv)             any asset subject to a Permitted Lien (other than Liens in favor of the Lender) securing obligations permitted under the Credit Agreement to the extent that the grant of other Liens on such asset (A) would result in a breach or violation of, or constitute a default under, the agreement or instrument governing such Permitted Lien, (B) would result in the loss of use of such asset or (C) would permit the holder of such Permitted Lien to terminate the Grantor’s use of such asset;

 

provided , that the property described in paragraphs (i), (iii) and (iv) above shall only be excluded from the term “Collateral” to the extent the conditions stated in such paragraphs are not rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC or any other applicable law.

 

SECTION 2.2. Security for Obligations . This Security Agreement and the Collateral in which the Lender is granted a security interest hereunder by the Grantors secure, on an equal and ratable basis, the payment and performance of all of the Obligations.

 

SECTION 2.3. Grantors Remain Liable . Anything herein to the contrary notwithstanding:

 

(a)              the Grantors will remain liable under the contracts and agreements included in the Collateral to the extent set forth therein, and will perform all of their duties and obligations under such contracts and agreements to the same extent as if this Security Agreement had not been executed;

 

(b)              the exercise by the Lender of any of its rights hereunder will not release any Grantor from any of its duties or obligations under any such contracts or agreements included in the Collateral; and

 

(c)              the Lender will not have any obligation or liability under any contracts or agreements included in the Collateral by reason of this Security Agreement, nor will the Lender be obligated to perform any of the obligations or duties of any Grantor thereunder or to take any action to collect or enforce any claim for payment assigned hereunder.

 

6



 

SECTION 2.4. Distributions on Capital Securities In the event that any Distribution with respect to any Capital Securities pledged hereunder is permitted to be paid pursuant to Section 8.6 of the Credit Agreement, such Distribution or may be paid directly to the applicable Grantor. If any Distribution is made in contravention of Section 8.6 of the Credit Agreement, such Grantor shall hold the same segregated and in trust for the Lender until paid to the Lender in accordance with Section 4.1.5 .

 

SECTION 2.5. Security Interest Absolute, etc. This Security Agreement shall in all respects be a continuing, absolute, unconditional and irrevocable grant of security interest, and shall remain in full force and effect until the Termination Date. All rights of the Lender and the security interests granted to the Lender hereunder, and all obligations of the Grantors hereunder, shall, to the fullest extent permitted by applicable law, in each case, be absolute, unconditional and irrevocable irrespective of:

 

(a)              any lack of validity, legality or enforceability of any Loan Document (other than this Security Agreement);

 

(b)              the failure of the Lender (i) to assert any claim or demand or to enforce any right or remedy against the Borrower or any of the Subsidiaries or any other Person (including any other Grantor) under the provisions of any Loan Document or otherwise, or (ii) to exercise any right or remedy against any other guarantor (including any other Grantor) of, or Collateral securing, any Obligations;

 

(c)              any change in the time, manner or place of payment of, or in any other term of, all or any part of the Obligations, or any other extension, compromise or renewal of any Obligations;

 

(d)              any reduction, limitation, impairment or termination of any Obligations for any reason, including any claim of waiver, release, surrender, alteration or compromise, and shall not be subject to (and each Grantor hereby waives, until payment of all Obligations, any right to or claim of) any defense or setoff, counterclaim, recoupment or termination whatsoever by reason of the invalidity, illegality, nongenuineness, irregularity, compromise, unenforceability of, or any other event or occurrence affecting, any Obligations or otherwise;

 

(e)              any amendment to, rescission, waiver, or other modification of, or any consent to or departure from, any of the terms of any Loan Document;

 

(f)              any addition, exchange or release of any Collateral or of any Person that is (or will become) a Grantor (including the Grantors hereunder), or any surrender or non-perfection of any Collateral, or any amendment to or waiver or release or addition to, or consent to or departure from, any other guaranty held by the Lender securing any of the Obligations; or

 

(g)              any other circumstance which might otherwise constitute a defense available to, or a legal or equitable discharge of the Borrower or any of the Subsidiaries, any surety or any guarantor.

 

7


 

SECTION 2.6. Postponement of Subrogation . Each Grantor agrees that it will not exercise any rights against another Grantor which it may acquire by way of rights of subrogation under any Loan Document to which it is a party until following the Termination Date. No Grantor shall seek or be entitled to seek any contribution or reimbursement from the Borrower or any of the Subsidiaries, in respect of any payment made under any Loan Document or otherwise, until following the Termination Date. Any amount paid to any Grantor on account of any such subrogation rights prior to the Termination Date shall be held in trust for the benefit of the Lender and shall immediately be paid and turned over to the Lender in the exact form received by such Grantor (duly endorsed in favor of the Lender, if required), to be credited and applied against the Obligations, whether matured or unmatured, in accordance with Section 6.1(b); provided that if such Grantor has made payment to the Lender of all or any part of the Obligations and the Termination Date has occurred, then at such Grantor’s request, the Lender will, at the expense of such Grantor, execute and deliver to such Grantor appropriate documents (without recourse and without representation or warranty) necessary to evidence the transfer by subrogation to such Grantor of an interest in the Obligations resulting from such payment. In furtherance of the foregoing, at all times prior to the Termination Date, such Grantor shall refrain from taking any action or commencing any proceeding against the Borrower or any of the Subsidiaries (or their successors or assigns, whether in connection with a bankruptcy proceeding or otherwise) to recover any amounts in respect of payments made under this Security Agreement to the Lender.

 

ARTICLE III
REPRESENTATIONS AND WARRANTIES

 

In order to induce the Lender to enter into the Credit Agreement and make the Loans thereunder, the Grantors represent and warrant to the Lender as set forth below.

 

SECTION 3.1. As to Capital Securities of the Subsidiaries, Investment Property .

 

(a)           With respect to any Subsidiary of any Grantor that is

 

(i)             a corporation, business trust, joint stock company or similar Person, all Capital Securities issued by such Subsidiary are duly authorized and validly issued, fully paid and non-assessable, and represented by a certificate or certificates; and

 

(ii)            a partnership or limited liability company, no Capital Securities issued by such Subsidiary (A) is dealt in or traded on securities exchanges or in securities markets, (B) expressly provides that such Capital Securities is a security governed by Article 8 of the UCC or (C) is held in a Securities Account, except, with respect to this clause (a)(ii) , Capital Securities (x) for which the Lender is the registered owner or (y) with respect to which the issuer has agreed in an authenticated record with such Grantor and the Lender to comply with any instructions of the Lender without the consent of such Grantor.

 

8



 

(b)            Each Grantor has delivered all Certificated Securities constituting Collateral held by such Grantor in a Subsidiary on the later of the Closing Date or the date such Grantor becomes a party to this Security Agreement to the Lender, together with duly executed undated blank stock powers, or other equivalent instruments of transfer acceptable to the Lender.

 

(c)            With respect to Uncertificated Securities constituting Collateral owned by any Grantor in a Subsidiary on the later of the Closing Date or the date such Grantor becomes a party to this Security Agreement, such Grantor has caused the issuer thereof to agree in an authenticated record with such Grantor and the Lender that such issuer will comply with instructions with respect to such security originated by the Lender without further consent of such Grantor (which instructions the Lender hereby agrees not to give unless an Event of Default has occurred and is continuing). Each party hereto that is such an issuer of any Uncertificated Securities hereby agrees that such party will comply with instructions with respect to such security originated by the Lender (which instructions the Lender hereby agrees not to give unless an Event of Default has occurred and is continuing).

 

(d)            The percentage of the issued and outstanding Capital Securities of each Subsidiary pledged on the Closing Date by each Grantor hereunder is as set forth on Schedule I . All shares of such Capital Securities have been duly and validly issued and are fully paid and nonassessable.

 

(e)            Each of the Intercompany Notes constitutes the legal, valid and binding obligation of the obligor with respect thereto, enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.

 

SECTION 3.2. Grantor Name, Location , etc. In each case as of the date hereof:

 

(a)            (i) The jurisdiction in which each Grantor is located for purposes of Sections 9-301 and 9-307 of the UCC and (ii) the address of each Grantor’s executive office and principal place of business is set forth in Item A of Schedule II .

 

(b)            The Grantors do not have any trade names other than those set forth in Item C of Schedule II hereto.

 

(c)           During the twelve months preceding the later of (i) the date hereof or (ii) the date such Grantor becomes a party to this Security Agreement, no Grantor has been known by any legal name different from the one set forth on the signature page hereto, nor has such Grantor been the subject of any merger or other corporate reorganization, except as set forth in Item D of Schedule II hereto.

 

(d)            Each Grantor’s federal taxpayer identification number (or foreign equivalent) is (and, during the twelve months preceding the date hereof, such Grantor has

 

9



 

not had a federal taxpayer identification number (or equivalent) different from that) set forth in Item E of Schedule II hereto.

 

(e)                No Grantor is a party to any federal, state or local government contract except as set forth in Item F of Schedule II hereto.

 

(f)                No Grantor maintains any Deposit Accounts, Securities Accounts or Commodity Accounts with any Person, in each case, except as set forth on Item G of Schedule II .

 

(g)                No Grantor is the beneficiary of any Letters of Credit, except as set forth on Item H of Schedule II .

 

(h)                No Grantor has Commercial Tort Claims except as set forth on Item I of Schedule II .

 

(i)                 The name set forth on the signature page attached hereto is the true and correct legal name (as defined in the UCC) of each Grantor.

 

SECTION 3.3. Ownership, No Liens, etc. Each Grantor owns its Collateral purported to be owned by it free and clear of any Lien, except for any security interest (a) created by this Security Agreement and (b) Permitted Liens. No effective UCC financing statement or other filing similar in effect covering all or any part of the Collateral is on file in any recording office, except those filed in favor of the Lender relating to this Security Agreement, Permitted Liens or as to which a duly authorized termination statement relating to such UCC financing statement or other instrument has been delivered to the Lender on the Closing Date.

 

SECTION 3.4. Possession of Inventory, Control; etc.

 

(a)               Each Grantor has, and agrees that it will maintain, exclusive possession of its Documents, Instruments, Promissory Notes, Equipment and Inventory, other than (i) Equipment and Inventory that is in transit in the ordinary course of business, (ii) Equipment and Inventory that in the ordinary course of business is in the possession or control of a warehouseman, bailee agent or other Person (other than a Person controlled by or under common control with such Grantor) that has been notified of the security interest created in favor of the Lender pursuant to this Security Agreement and has authenticated a record acknowledging that it holds possession of such Collateral for the Lender’s benefit and waives any Lien held by it against such Collateral, (iii) Inventory that is in the possession of a consignee in the ordinary course of business and (iv) Instruments or Promissory Notes that have been delivered to the Lender pursuant to Section 3.5 . In the case of Equipment or Inventory described in clause (ii) above, no lessor or warehouseman of any premises or warehouse upon or in which such Equipment or Inventory is located has (x) issued any warehouse receipt or other receipt in the nature of a warehouse receipt in respect of any such Equipment or Inventory, (y) issued any Document for any such Equipment or Inventory or (z) any Lien (other than Permitted Liens) on any such Equipment or Inventory.

 

10



 

(b)               Each Grantor is the sole entitlement holder of its Deposit Accounts and no other Person (other than the Lender pursuant to this Security Agreement or any other Person with respect to Permitted Liens) has control or possession of, or any other interest in, any of its Deposit Accounts or any other securities or property credited thereto.

 

SECTION 3.5. Negotiable Documents, Instruments and Chattel Paper . Each Grantor has delivered to the Lender possession of all originals of all Documents, Instruments, Promissory Notes, and tangible Chattel Paper (other than any Document, Instrument, Promissory Note or tangible Chattel Paper not exceeding $10,000 in principal amount) owned or held by such Grantor on the Closing Date.

 

SECTION 3.6. Intellectual Property Collateral . Except as disclosed on Schedules III through VI , with respect to any Intellectual Property Collateral:

 

(a)           such Grantor has not made a previous assignment, sale, transfer or agreement constituting a present or future assignment, sale or transfer of any Intellectual Property for purposes of granting a security interest or as Collateral that has not been terminated or releasedt; and

 

(b)           such Grantor has executed and delivered to the Lender Intellectual Property Collateral security agreements for all Copyrights, Patents and Trademarks owned by such Grantor, including all Copyrights, Patents and Trademarks on Schedule III through VI (as such schedules may be amended or supplemented from time to time by notice by such Grantor to the Lender).

 

SECTION 3.7. Validity, etc.

 

(a)           This Security Agreement creates a valid security interest in the Collateral securing the payment of the Obligations to the extent such security interest may be created pursuant to Article 9 of the UCC.

 

(b)           As of the Closing Date, each Grantor has filed or caused to be filed all UCC-1 financing statements in the filing office for each Grantor’s jurisdiction of organization listed in Item A of Schedule II (collectively, the “ Filing Statements ”) (delivered to the Lender the Filing Statements suitable for timely and proper filing in such offices) and has taken all other actions requested by the Lender necessary for the Lender to obtain control of the Collateral as provided in Sections 9-104, 9-105, 9-106 and 9-107 of the UCC.

 

(c)           Upon the filing of the Filing Statements with the appropriate agencies therefor the security interests created under this Security Agreement shall constitute a perfected security interest in the Collateral described on such Filing Statements in favor of the Lender to the extent that a security interest therein may be perfected by filing a financing statement pursuant to the relevant UCC, prior to all other Liens, except for Permitted Liens (in which case such security interest shall be second in priority of right only to the Permitted Liens entitled to priority).

 

11



 

SECTION 3.8. Authorization, Approval, etc. Except as have been obtained or made and are in full force and effect, no authorization, approval or other action by, and no notice to or filing with, any Governmental Authority or any other third party is required either

 

(a)           for the grant by the Grantors of the security interest granted hereby or for the execution, delivery and performance of this Security Agreement by the Grantors;

 

(b)           for the perfection or maintenance of the security interests hereunder (except with respect to the Filing Statements or, with respect to Intellectual Property Collateral, the recordation of any agreements with the United States Patent and Trademark Office or the United States Copyright Office or, with respect to foreign Intellectual Property Collateral, the taking of appropriate action under applicable foreign law and, with respect to after-acquired Intellectual Property Collateral, any subsequent filings in United States intellectual property offices); or

 

(c)           for the exercise by the Lender of the voting or other rights provided for in this Security Agreement, except (i) with respect to any securities issued by a Subsidiary of the Grantors, as may be required in connection with a disposition of such securities by laws affecting the offering and sale of securities generally, the remedies in respect of the Collateral pursuant to this Security Agreement and (ii) any “change of control” or similar filings required by state licensing agencies.

 

SECTION 3.9. Best Interests . It is in the best interests of each Grantor (other than the Borrower) to execute this Security Agreement inasmuch as such Grantor will, as a result of being an Affiliate of the Borrower, derive substantial direct and indirect benefits from the Loans made to the Borrower by the Lender pursuant to the Credit Agreement, and each Grantor agrees that the Lender is relying on this representation in agreeing to make such Loans pursuant to the Credit Agreement to the Borrower.

 

ARTICLE IV
COVENANTS

 

Each Grantor covenants and agrees that, until the Termination Date, such Grantor will perform, comply with and be bound by the obligations set forth below.

 

SECTION 4.1. As to Investment Property, etc.

 

SECTION 4.1.1. Capital Securities of Subsidiaries . No Grantor will allow any of its Subsidiaries:

 

(a)           [Omitted];

 

(b)           that is a partnership or limited liability company, to (i) issue Capital Securities that are to be dealt in or traded on securities exchanges or in securities markets, (ii) expressly provide in its Organic Documents that its Capital Securities are securities

 

12



 

governed by Article 8 of the UCC, or (iii) place such Subsidiary’s Capital Securities in a Securities Account; and

 

(c)             to issue Capital Securities in addition to or in substitution for the Capital Securities pledged hereunder, except to such Grantor (and such Capital Securities are immediately pledged and delivered to the Lender pursuant to the terms of this Security Agreement).

 

SECTION 4.1.2. Investment Property (other than Certificated Securities) .

 

(a)             With respect to any Deposit Accounts, Securities Accounts, Commodity Accounts, Commodity Contracts or Security Entitlements constituting Investment Property owned or held by any Grantor, such Grantor will cause (except for Excluded Accounts) the intermediary maintaining such Investment Property to execute a Control Agreement relating to such Investment Property pursuant to which such intermediary agrees to comply with the Lender’s instructions with respect to such Investment Property without further consent by such Grantor (which instructions the Lender hereby agrees not to give unless an Event of Default has occurred and is continuing).

 

(b)             With respect to any Uncertificated Securities (other than Uncertificated Securities credited to a Securities Account) constituting Investment Property owned or held by any Grantor, such Grantor will cause the issuer of such securities that is not a party hereto to execute a Control Agreement relating to such Investment Property pursuant to which the issuer agrees to comply with the Lender’s instructions with respect to such Uncertificated Securities without further consent by such Grantor (which instructions the Lender hereby agrees not to give unless an Event of Default has occurred and is continuing). Each party hereto that is such an issuer of any Uncertificated Securities hereby agrees that such party will comply with instructions with respect to such security originated by the Lender (which instructions the Lender hereby agrees not to give unless an Event of Default has occurred and is continuing).

 

SECTION 4.1.3. Certificated Securities (Stock Powers). Each Grantor agrees that all Certificated Securities constituting Collateral, including the Capital Securities delivered by such Grantor pursuant to this Security Agreement, will be accompanied by duly executed undated blank stock powers, or other equivalent instruments of transfer reasonably acceptable to the Lender.

 

SECTION 4.1.4. Continuous Pledge . Each Grantor will (subject to the terms of the Credit Agreement) (a) deliver to the Lender all Investment Property and all Payment Intangibles to the extent that such Investment Property or Payment Intangibles are evidenced by a Document, Instrument, Promissory Note or Chattel Paper (other than any Document, Instrument, Promissory Note or Chattel Paper not exceeding $10,000 in the principal amount), and (b) at all times keep pledged to the Lender pursuant hereto, on a first-priority, perfected basis, security interest therein and in all interest and principal with respect to such Payment Intangibles, and all Proceeds and rights from time to time received by or distributable to such Grantor in respect of any of the foregoing Collateral. Each Grantor agrees that it will, promptly following receipt thereof, deliver to the Lender possession of all originals of negotiable Documents, Instruments,

 

13



 

Promissory Notes and Chattel Paper that it acquires following the Closing Date (other than any Document, Instrument, Promissory Note or Chattel Paper not exceeding $10,000 in the principal amount).

 

SECTION 4.1.5. Voting Rights; Dividends, etc. Each Grantor agrees:

 

(a)           upon receipt of notice of the occurrence and continuance of an Event of Default from the Lender and without any request therefor by the Lender, so long as such Event of Default shall continue, to deliver (properly endorsed where required hereby or requested by the Lender) to the Lender all dividends and Distributions with respect to Investment Property, all interest, principal, other cash payments on Payment Intangibles, and all Proceeds of the Collateral, in each case thereafter received by such Grantor, all of which shall be held by the Lender as additional Collateral, except for payments made in accordance with Section 8.6 of the Credit Agreement; and

 

(b)           immediately upon the occurrence and during the continuance of an Event of Default and so long as the Lender has notified such Grantor of the Lender’s intention to exercise its voting power under this clause,

 

(i)            with respect to Collateral consisting of general partner interests or limited liability company interests, to promptly modify its Organic Documents to admit the Lender as a general partner or member, as applicable;

 

(ii)           that the Lender may exercise (to the exclusion of such Grantor) the voting power and all other incidental rights of ownership with respect to any Investment Property constituting Collateral and such Grantor hereby grants the Lender an irrevocable proxy, exercisable under such circumstances, to vote such Investment Property; and

 

(iii)          to promptly deliver to the Lender such additional proxies and other documents as may be necessary to allow the Lender to exercise such voting power.

 

All dividends, Distributions, interest, principal, cash payments, Payment Intangibles and Proceeds that may at any time and from time to time be held by such Grantor, but which such Grantor is then obligated to deliver to the Lender, shall, until delivery to the Lender, be held by such Grantor separate and apart from its other property in trust for the Lender. The Lender agrees that unless an Event of Default shall have occurred and be continuing and the Lender shall have given the notice referred to in clause (b) , such Grantor will have the exclusive voting power with respect to any Investment Property constituting Collateral and the Lender will, upon the written request of such Grantor, promptly deliver such proxies and other documents, if any, as shall be reasonably requested by such Grantor which are necessary to allow such Grantor to exercise that voting power; provided that no vote shall be cast, or consent, waiver, or ratification given, or action taken by such Grantor that would impair any such Collateral or be inconsistent with or violate any provision of any Loan Document.

 

14


 

SECTION 4.2. Change of Name, etc . No Grantor will change its name or place of incorporation or organization or federal taxpayer identification number except as otherwise permitted by the Credit Agreement.

 

SECTION 4.3. As to Accounts .

 

(a)                                  Each Grantor shall have the right to collect all Accounts so long as no Event of Default shall have occurred and be continuing.

 

(b)                                  Upon (i) the occurrence and continuance of an Event of Default and (ii) the delivery of notice by the Lender to each Grantor, all Proceeds of Collateral received by such Grantor shall be delivered in kind to the Lender for deposit in a Deposit Account of such Grantor maintained with the Lender (together with any other Deposit Accounts or Security Accounts pursuant to which any portion of the Collateral is deposited with the Lender, the “ Collateral Accounts ”), and such Grantor shall not commingle any such Proceeds, and shall hold separate and apart from all other property, all such Proceeds in express trust for the benefit of the Lender until delivery thereof is made to the Lender.

 

(c)                                   Following the delivery of notice pursuant to clause (b)(ii) , and so long as an Event of Default shall continue, the Lender shall have the right to apply any amount in the Collateral Account to the payment of any Obligations which are then due and payable in accordance with Section 4.4(b) of the Credit Agreement.

 

(d)                                  With respect to each of the Collateral Accounts, it is hereby confirmed and agreed that (i) deposits in such Collateral Accounts are subject to a security interest as contemplated hereby, (ii) such Collateral Accounts shall be under the control of the Lender and (iii) the Lender shall have the sole right of withdrawal over such Collateral Account.

 

SECTION 4.4. As to Grantors Use of Collateral .

 

(a)                                  At any time following the occurrence and during the continuance of an Event of Default, whether before or after the maturity of any of the Obligations, the Lender may exercise any and all rights and remedies to which it is lawfully entitled with respect to the Collateral.

 

(b)                                  Upon the request of the Lender following the occurrence and during the continuance of an Event of Default, each Grantor will, at its own expense, notify any parties obligated on any of the Collateral to make payment to the Lender of any amounts due or to become due thereunder.

 

(c)                                   At any time following the occurrence and during the continuation of an Event of Default, the Lender may endorse, in the name of such Grantor, any item, howsoever received by the Lender, representing any payment on or other Proceeds of any of the Collateral.

 

SECTION 4.5. As to Intellectual Property Collateral . Each Grantor covenants and agrees to comply with the following provision:

 

15



 

(a)                                  such Grantor will not (i) do or fail to perform any act whereby any of the Patent Collateral may lapse or become abandoned or dedicated to the public or unenforceable, (ii) permit any of its licensees to (A) fail to continue to use any of the Trademark Collateral in order to maintain all of the Trademark Collateral in full force free from any claim of abandonment for non-use, (B) fail to maintain the quality of products and services offered under all of the Trademark Collateral at a level substantially consistent with the quality of products and services offered under such Trademark as of the date hereof, (C) fail to employ all of the Trademark Collateral registered with any federal or state or foreign authority with an appropriate notice of such registration, (D) adopt or use any other Trademark which is confusingly similar or a colorable imitation of any of the Trademark Collateral, (E) use any of the Trademark Collateral registered with any federal, state or foreign authority except for the uses for which registration or application for registration of all of the Trademark Collateral has been made or (F) do or permit any act or knowingly omit to do any act whereby any of the Trademark Collateral may become invalid or unenforceable, or (iii) do or permit any act or knowingly omit to do any act whereby any of the Copyright Collateral or any of the Trade Secrets Collateral may lapse or become invalid or unenforceable or placed in the public domain except upon expiration of the end of an unrenewable term of a registration thereof, unless, in the case of any of the foregoing requirements in clauses (i) , (ii)  and (iii) , such Grantor reasonably and in good faith determines that either (x) such Intellectual Property Collateral is of negligible economic value to such Grantor or (y) the loss of such Intellectual Property Collateral would not be material to such Grantor;

 

(b)                                  such Grantor shall promptly notify the Lender if it knows, or has reason to know, that any application or registration relating to any material item of the Intellectual Property Collateral may, in the Grantor’s reasonable commercial judgment, become abandoned or dedicated to the public or placed in the public domain or invalid or unenforceable, or of any adverse determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States Copyright Office or any foreign counterpart thereof or any court) regarding such Grantor’s ownership of any of the Intellectual Property Collateral, its right to register the same or to keep and maintain and enforce the same;

 

(c)                                   in no event will such Grantor or any of its agents, employees, designees or licensees file an application for the registration of any Intellectual Property Collateral with the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof, unless such Grantor promptly informs the Lender and, upon request of the Lender (subject to the terms of the Credit Agreement), executes and delivers all agreements, instruments and documents as the Lender may reasonably request to evidence the Lender’s security interest in such Intellectual Property Collateral; and

 

(d)                                  such Grantor will promptly (but no less than quarterly) execute and deliver to the Lender (as applicable) a Patent Security Agreement, Trademark Security Agreement and/or Copyright Security Agreement, as the case may be, in the forms of Exhibit A , Exhibit B and Exhibit C hereto following its obtaining an interest in any such

 

16



 

Intellectual Property, and shall execute and deliver to the Lender any other document reasonably required to evidence the Lender’s interest in any part of such item of Intellectual Property Collateral.

 

SECTION 4.6. As to Letter-of-Credit Rights .

 

(a)                                  Each Grantor, by granting a security interest in its Letter-of-Credit Rights to the Lender, intends to (and hereby does) collaterally assign to the Lender its rights (including its contingent rights) to the Proceeds of all Letter-of-Credit Rights of which it is or hereafter becomes a beneficiary or assignee.

 

(b)                                  Upon the occurrence of an Event of Default, such Grantor will, promptly upon request by the Lender, (i) notify (and such Grantor hereby authorizes the Lender to notify) the issuer and each nominated person with respect to each of the Letters of Credit that the Proceeds thereof have been assigned to the Lender hereunder and any payments due or to become due in respect thereof are to be made directly to the Lender and (ii) arrange for the Lender to become the transferee beneficiary of such Letter of Credit.

 

SECTION 4.7. As to Commercial Tort Claims . Each Grantor covenants and agrees that, until the payment in full of the Obligations and termination of all Commitments, with respect to any Commercial Tort Claim hereafter arising, it shall deliver to the Lender a supplement in form and substance reasonably satisfactory to the Lender, together with all supplements to schedules thereto, identifying such new Commercial Tort Claim.

 

SECTION 4.8. Electronic Chattel Paper and Transferable Records . If any Grantor at any time holds or acquires an interest in any electronic chattel paper or any “transferable record,” as that term is defined in Section 201 of the U.S. Federal Electronic Signatures in Global and National Commerce Act, or in Section 16 of the U.S. Uniform Electronic Transactions Act as in effect in any relevant jurisdiction, with a value in excess of $100,000, such Grantor shall promptly notify the Lender thereof and, at the request of the Lender, shall take such action as the Lender may reasonably request to vest in the Lender control under Section 9-105 of the UCC of such electronic chattel paper or control under Section 201 of the Federal Electronic Signatures in Global and National Commerce Act or, as the case may be, Section 16 of the Uniform Electronic Transactions Act, as so in effect in such jurisdiction, of such transferable record. The Lender agrees with such Grantor that the Lender will arrange, pursuant to procedures satisfactory to the Lender and so long as such procedures will not result in the Lender’s loss of control, for the Grantor to make alterations to the electronic chattel paper or transferable record permitted under Section 9-105 of the UCC or, as the case may be, Section 201 of the U.S. Federal Electronic Signatures in Global and National Commerce Act or Section 16 of the U.S. Uniform Electronic Transactions Act for a party in control to allow without loss of control, unless an Event of Default has occurred and is continuing or would occur after taking into account any action by such Grantor with respect to such electronic chattel paper or transferable record.

 

SECTION 4.9. Further Assurances, etc . Each Grantor agrees that, from time to time at its own expense, it will, subject to the terms of this Agreement, promptly execute and deliver all further instruments and documents, and take all further action, that may be necessary or that the Lender may reasonably request, in order to perfect, preserve and protect any security interest

 

17



 

granted or purported to be granted hereby or to enable the Lender to exercise and enforce its rights and remedies hereunder with respect to any Collateral. Without limiting the generality of the foregoing, such Grantor will

 

(a)                                       from time to time upon the request of the Lender, promptly deliver to the Lender such stock powers, instruments and similar documents, reasonably satisfactory in form and substance to the Lender, with respect to such Collateral as the Lender may request and will, from time to time upon the request of the Lender, after the occurrence and during the continuance of any Event of Default, promptly transfer any securities constituting Collateral into the name of any nominee designated by the Lender; if any Collateral shall be evidenced by an Instrument, negotiable Document, Promissory Note or tangible Chattel Paper, deliver and pledge to the Lender hereunder such Instrument, negotiable Document, Promissory Note or tangible Chattel Paper (other than any Instrument, negotiable Document, Promissory Note or tangible Chattel Paper in principal amount less than $10,000) duly endorsed and accompanied by duly executed instruments of transfer or assignment, all in form and substance reasonably satisfactory to the Lender;

 

(b)                                       file (and hereby authorize the Lender to file) such Filing Statements or continuation statements, or amendments thereto, and such other instruments or notices (including any assignment of claim form under or pursuant to the federal assignment of claims statute, 31 U.S.C. § 3726, any successor or amended version thereof or any regulation promulgated under or pursuant to any version thereof), as may be necessary or that the Lender may reasonably request in order to perfect and preserve the security interests and other rights granted or purported to be granted to the Lender hereby;

 

(c)                                        at all times keep pledged to the Lender pursuant hereto, on a first-priority, perfected basis, at the request of the Lender, all Investment Property constituting Collateral, all dividends and Distributions with respect thereto, and all interest and principal with respect to Promissory Notes, and all Proceeds and rights from time to time received by or distributable to such Grantor in respect of any of the foregoing Collateral;

 

(d)                                       not create any tangible Chattel Paper without placing a legend on such tangible Chattel Paper reasonably acceptable to the Lender indicating that the Lender has a security interest in such Chattel Paper;

 

(e)                                        furnish to the Lender, from time to time at the Lender’s request, statements and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral as the Lender may reasonably request, all in reasonable detail; and

 

(f)                                         do all things reasonably requested by the Lender in accordance with this Security Agreement in order to enable the Lender to have and maintain control over the Collateral consisting of Investment Property, Deposit Accounts, Letter-of-Credit-Rights and Electronic Chattel Paper.

 

Each Grantor agrees that a carbon, photographic or other reproduction of this Security Agreement or any UCC financing statement covering the Collateral or any part thereof shall be

 

18



 

sufficient as a UCC financing statement where permitted by law. Each Grantor hereby authorizes the Lender to file financing statements describing as the collateral covered thereby “all of the debtor’s personal property or assets” or words to that effect, notwithstanding that such wording may be broader in scope than the Collateral described in this Security Agreement.

 

ARTICLE V
THE LENDER

 

SECTION 5.1. Lender Appointed Attorney-in-Fact . Each Grantor hereby irrevocably appoints the Lender as its attorney-in-fact, with full authority in the place and stead of such Grantor and in the name of such Grantor or otherwise, from time to time in the Lender’s discretion, following the occurrence and during the continuance of an Event of Default, to take any action and to execute any instrument which the Lender may deem necessary or advisable to accomplish the purposes of this Security Agreement, including:

 

(a)                                  to ask, demand, collect, sue for, recover, compromise, receive and give acquittance and receipts for moneys due and to become due under or in respect of any of the Collateral;

 

(b)                                  to receive, endorse, and collect any drafts or other Instruments, Documents and Chattel Paper, in connection with clause (a)  above;

 

(c)                                   to file any claims or take any action or institute any proceedings which the Lender may deem necessary or desirable for the collection of any of the Collateral or otherwise to enforce the rights of the Lender with respect to any of the Collateral; and

 

(d)                                  to perform the affirmative obligations of such Grantor hereunder.

 

Each Grantor hereby acknowledges, consents and agrees that the power of attorney granted pursuant to this Section is irrevocable and coupled with an interest.

 

SECTION 5.2. Lender May Perform . If any Grantor fails to perform any agreement contained herein, upon 5 days after the earlier to occur of (i) notice thereof given to any such Grantor by the Lender or (ii) the date on which such Grantor has knowledge of such failure, the Lender may itself perform, or cause performance of, such agreement, that the Lender deems necessary for the maintenance, preservation or protection of any of the Collateral or of its security interest therein to the extent provided for herein, and the expenses of the Lender incurred in connection therewith shall be payable by such Grantor pursuant to Section 10.3 of the Credit Agreement.

 

SECTION 5.3. Lender Has No Duty . The powers conferred on the Lender hereunder are solely to protect its interest in the Collateral and shall not impose any duty on it to exercise any such powers. Except for reasonable care of any Collateral in its possession and the accounting for moneys actually received by it hereunder, the Lender shall have no duty as to any Collateral or responsibility for

 

19



 

(a)                                       ascertaining or taking action with respect to calls, conversions, exchanges, maturities, tenders or other matters relative to any Investment Property, whether or not the Lender has or is deemed to have knowledge of such matters, or

 

(b)                                       taking any necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral.

 

SECTION 5.4. Reasonable Care . The Lender is required to exercise reasonable care in the custody and preservation of any of the Collateral in its possession; provided that the Lender shall be deemed to have exercised reasonable care in the custody and preservation of any of the Collateral, if it takes such action for that purpose as each Grantor reasonably requests in writing at times other than upon the occurrence and during the continuance of any Event of Default, but failure of the Lender to comply with any such request at any time shall not in itself be deemed a failure to exercise reasonable care.

 

SECTION 5.5. Lender as Agent for Other Secured Parties . The Lender hereby agrees to act as agent of the other parties to which any Grantor may owe any Obligations for all purposes hereunder and under the other Loan Documents pursuant to which any Grantor grants a Lien or other right in any Collateral to secure the Obligations, for purposes of acquiring, holding and enforcing any and all Liens on any Collateral granted by any Grantor to secure any of the Obligations. The Lender may appoint any co-agents, sub-agents or attorneys-in-fact in connection with the foregoing.

 

ARTICLE VI
REMEDIES

 

SECTION 6.1. Certain Remedies . If any Event of Default shall have occurred and be continuing:

 

(a)                             The Lender may exercise in respect of the Collateral, in addition to other rights and remedies provided for herein or otherwise available to it, all the rights and remedies of the Lender on default under the UCC (whether or not the UCC applies to the affected Collateral) and also may

 

(i)                                           take possession of any Collateral not already in its possession without demand and without legal process;

 

(ii)                                        require each Grantor to, and each Grantor hereby agrees that it will, at its expense and upon request of the Lender forthwith, assemble all or part of the Collateral as directed by the Lender and make it available to the Lender at a place to be designated by the Lender that is reasonably convenient to both parties,

 

(iii)                                     enter onto the property where any Collateral is located and take possession thereof without demand and without legal process; and

 

20


 

(iv)            without notice except as specified below, lease, license, sell or otherwise dispose of the Collateral or any part thereof in one or more parcels at any public or private sale, at any of the Lender’s offices or elsewhere, for cash, on credit or for future delivery, and upon such other terms as the Lender may deem commercially reasonable. Each Grantor agrees that, to the extent notice of sale shall be required by law, at least ten (10) days’ prior notice to such Grantor of the time and place of any public sale or the time after which any private sale is to be made shall constitute reasonable notification. The Lender shall not be obligated to make any sale of Collateral regardless of notice of sale having been given. The Lender may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned.

 

(b)           All cash Proceeds received by the Lender in respect of any sale of, collection from, or other realization upon, all or any part of the Collateral shall be applied by the Lender against all or any part of the Obligations as set forth in Section 4.4(b) of the Credit Agreement.

 

(c)           The Lender may

 

(i)            transfer all or any part of the Collateral into the name of the Lender or its nominee, with or without disclosing that such Collateral is subject to the Lien hereunder,

 

(ii)           notify the parties obligated on any of the Collateral to make payment to the Lender of any amount due or to become due thereunder,

 

(iii)          withdraw, or cause or direct the withdrawal, of all funds with respect to the Collateral Account;

 

(iv)          enforce collection of any of the Collateral by suit or otherwise, and surrender, release or exchange all or any part thereof, or compromise or extend or renew for any period (whether or not longer than the original period) any obligations of any nature of any party with respect thereto,

 

(v)           endorse any checks, drafts, or other writings in any Grantor’s name to allow collection of the Collateral,

 

(vi)          take control of any Proceeds of the Collateral, and

 

(vii)         execute (in the name, place and stead of any Grantor) endorsements, assignments, stock powers and other instruments of conveyance or transfer with respect to all or any of the Collateral.

 

SECTION 6.2. Securities Laws . If the Lender shall determine to exercise its right to sell all or any of the Collateral that are Capital Securities pursuant to Section 6.1(a)(iv) , each Grantor acknowledges that the Lender may be unable to effect a public sale or other disposition of the Capital Securities by reason of certain prohibitions contained in the Securities Act of 1933, as

 

21



 

from time to time amended (the “ Securities Act ”), federal banking laws, and other applicable laws, but may be compelled to resort to one or more private sales thereof to a restricted group of purchasers. Each Grantor agrees that any such private sale may be at prices and other terms less favorable to the seller than if sold at public sales and that such private sales shall not solely by reason thereof be deemed not to have been made in a commercially reasonable manner. The Lender shall be under no obligation to delay a sale of any of the Capital Securities for the period of time necessary to permit the issuer of such securities to register such securities for public sale under the Securities Act, or such other federal banking or other applicable laws, even if the issuer would agree to do so. Subject to the foregoing, the Lender agrees that any sale of the Capital Securities shall be made in a commercially reasonable manner, and each Grantor agrees to use its reasonable best efforts to cause the issuer or issuers of the Capital Securities contemplated to be sold, to execute and deliver, all at the Grantors’ expense, all such instruments and documents, and to do or cause to be done all such other acts and things as may be necessary or, in the reasonable opinion of the Lender, advisable to exempt such Capital Securities from registration under the provisions of the Securities Act, and to make all amendments to such instruments and documents which, in the opinion of the Lender, are necessary or advisable, all in conformity with the requirements of the Securities Act and the rules and regulations of the Securities and Exchange Commission applicable thereto. Each Grantor further agrees to use its reasonable best efforts (a) to cause such issuer or issuers to exempt or comply with the provisions of the securities or “Blue Sky” laws of any jurisdiction which the Lender designates and obtain all necessary governmental approvals for the sale of the Capital Securities, as requested by the Lender; (b) if required, to cause such issuer or issuers to make available to its security holders, as soon as practicable, an earnings statement (which need not be audited) which will satisfy the provisions of Section 11(a) of the Securities Act; and (c) to do or cause to be done all such other acts and things as may be necessary to make such sale of the Collateral or any part thereof valid and binding and in compliance with applicable law.

 

SECTION 6.3. Compliance with Restrictions . Each Grantor agrees that in any sale of any of the Collateral whenever an Event of Default shall have occurred and be continuing, the Lender is hereby authorized to comply with any limitation or restriction in connection with such sale as it may be advised by counsel is necessary in order to avoid any violation of applicable law (including compliance with such procedures as may restrict the number of prospective bidders and purchasers, require that such prospective bidders and purchasers have certain qualifications, and restrict such prospective bidders and purchasers to Persons who will represent and agree that they are purchasing for their own account for investment and not with a view to the distribution or resale of such Collateral), or in order to obtain any required approval of the sale or of the purchaser by any Governmental Authority or official, and such Grantor further agrees that such compliance shall not result in such sale being considered or deemed not to have been made in a commercially reasonable manner, nor shall the Lender be liable nor accountable to such Grantor for any discount allowed by the reason of the fact that such Collateral is sold in compliance with any such limitation or restriction.

 

SECTION 6.4. Protection of Collateral . The Lender may from time to time, at its option, perform any act which any Grantor fails to perform after being requested in writing so to perform (it being understood that no such request need be given after the occurrence and during the continuance of an Event of Default) and the Lender may from time to time take any other action

 

22



 

which the Lender deems necessary for the maintenance, preservation or protection of any of the Collateral or of its security interest therein.

 

ARTICLE VII
MISCELLANEOUS PROVISIONS

 

SECTION 7.1. Loan Document . This Security Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof. Notwithstanding anything contained herein to contrary, to the extent any provision in this Security Agreement conflicts with any provision in the Credit Agreement, the terms of the Credit Agreement shall control.

 

SECTION 7.2. Binding on Successors, Transferees and Assigns; Assignment . This Security Agreement shall remain in full force and effect until the Termination Date has occurred, shall be binding upon the Grantors and their successors, transferees and assigns and shall inure to the benefit of and be enforceable by the Lender; provided that no Grantor may assign any of its obligations hereunder without the prior consent of the Lender.

 

SECTION 7.3. Amendments, etc. No amendment or modification to or waiver of any provision of this Security Agreement, nor consent to any departure by any Grantor from its obligations under this Security Agreement, shall in any event be effective unless the same shall be in writing and signed by the Lender and the Grantors and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

SECTION 7.4. Notices . All notices and other communications provided for hereunder shall be delivered or made as provided in Section 10.2 of the Credit Agreement.

 

SECTION 7.5. Release of Liens . Upon (a) the Disposition of Collateral in accordance with the Credit Agreement and this Security Agreement or (b) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (i) such Collateral (in the case of clause (a)) or (ii) all Collateral (in the case of clause (b)). Upon any such Disposition or termination, the Lender will, at the Grantors’ sole expense, deliver to the Grantors, without any representations, warranties or recourse of any kind whatsoever, all Collateral held by the Lender hereunder, and execute and deliver to the Grantors such documents as the Grantors shall reasonably request to evidence such termination.

 

SECTION 7.6. Additional Grantors . Upon the execution and delivery by any other Person of a supplement in the form of Annex I hereto, such Person shall become a “Grantor” hereunder as of the date of such supplement with the same force and effect as if it were originally a party to this Security Agreement and named as a “Grantor” hereunder. The execution and delivery of such supplement shall not require the consent of any other Grantor hereunder, and the rights and obligations of each Grantor hereunder shall remain in full force and effect notwithstanding the addition of any new Grantor as a party to this Security Agreement.

 

23



 

SECTION 7.7. No Waiver; Remedies . In addition to, and not in limitation of Section 2.4, no failure on the part of the Lender to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by law.

 

SECTION 7.8. Severability . Any provision of this Security Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Security Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

 

SECTION 7.9. Governing Law, Entire Agreement, etc. THIS SECURITY AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SECURITY AGREEMENT OR ANY OTHER LOAN DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Security Agreement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto

 

SECTION 7.10. Counterparts . This Security Agreement may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. This Security Agreement shall become effective when counterparts hereof executed on behalf of all of the signatories hereto, shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Security Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

[ Signature Page Follows ]

 

24



 

IN WITNESS WHEREOF, each of the parties hereto has caused this Security Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

 

 

NATERA, INC.

 

 

 

 

 

By:

/s/ Matthew Rabinowitz

 

 

Name: Matthew Rabinowitz

 

 

Title: Chief Executive Officer

 

 

 

 

 

NATERA INTERNATIONAL, INC.

 

 

 

 

 

By:

/s/ Matthew Rabinowitz

 

 

Name: Matthew Rabinowitz

 

 

Title: Chief Executive Officer

 

 

 

 

 

ROS ACQUISITION OFFSHORE LP,

as the Lender, for itself and as agent

 

By ROS Acquisition Offshore GP Ltd.,

its General Partner

 

By OrbiMed Advisors LLC,

 

its investment manager

 

 

 

 

 

By:

/s/ Samuel D. Isaly

 

 

Name: Samuel D. Isaly

 

 

Title: Managing Member

 

Signature Page to Security Agreement

 


 

 

SCHEDULE I
to Security Agreement

 

Name of Grantor:

 

Interest:

Natera, Inc.

 

All common stock issued and outstanding of Natera International, Inc. owned by Natera, Inc.

 



 

SCHEDULE II
to Security Agreement

 

Item A.  Location of each Grantor .

 

Name of Grantor:

 

Location for purposes of UCC:

Natera, Inc.

 

Delaware

Natera International, Inc.

 

Delaware

 

Item B.  Filing locations last five years .

 

Delaware

 

Item C.  Trade names .

 

Name of Grantor:

 

Trade Names:

Natera, Inc.

 

Natera

Natera International, Inc.

 

Natera, Natera International

 

Item D.  Merger or other corporate reorganization .

 

None.

 

Item E.  Grantor’s federal taxpayer ID numbers .

 

Name of Grantor:

 

Taxpayer ID numbers:

Natera, Inc.

 

01-0894487

Natera International, Inc.

 

45-4907137

 

Item F.  Government Contracts .

 

None.

 

Item G.  Deposit Accounts, Securities Accounts and Commodities Accounts .

 

Name of Grantor:

Description of Deposit Accounts, Securities Accounts and Commodities Accounts:

 



 

Natera, Inc.

Comerica Bank (ABA 121137522)

c/o Angela Ong,

333 W. Santa Clara Street

San Jose, CA  95113

 

650-462-6036

 

Subject to Account Control Agreement

Operating: [*]

Money Market:  [*]

ZBA Insurance: [*]    (linked to a Lockbox [*])  (ZBA sweep to Operating [*])

International Ops: [*]

 

Not Subject to Account Control Agreement

Payroll:  [*]

Government Insurance: [*] (Linked to a Lockbox [*])

 

Not Subject to Account Control Agreement; Subject to separate perfected Lien interests

Credit Card Receivables: [*]   Value $150,000.00

Lease Letter of Credit (Nektar):  [*]  Value $745,254.60

 

Silicon Valley Bank (ABA 121140399)

c/o Account Services

3003 Tasman Drive

Santa Clara, CA 95054

 

888-572-7823

 

Subject to Account Control Agreement

None

 

Not Subject to Account Control Agreement; Subject to separate perfected Lien interests

Lease Letter of Credit (Redwood Junction):  [*]  Value $15,000.00

 

Natera International, Inc.

None.

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 



 

Item H.  Letter of Credit Rights .

 

None.

 

Item I.  Commercial Tort Claims .

 

None

 

Item J.  Pledged Notes .

 

Name of Grantor:

 

Description of Pledged Notes:

Natera, Inc

 

None.

Natera International, Inc.

 

None.

 


 

SCHEDULE III

to Security Agreement

 

Item A.  Patents

 

Title

 

Publication No.

 

Application No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Issue
Date

 

Expiration
Date

 

Assignee

System and Method for Improving Clinical Decisions by Aggregating, Validating and Analysing Genetic and Phenotypic Data

 

US2006/0052945

 

11/004,274

 

12/3/2004

 

US

 

Issued

 

8,024,128

 

9/20/2011

 

 

 

GSN / Natera

System and Method for Using Genetic, Phenotypic and Clinical Data to Make Predictions for Clinical or Lifestyle Decisions

 

US2007/0027636

 

11/496,982

 

7/31/2006

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data from Target Individuals Using Genetic Data from Genetically Related Individuals

 

US2007/0184467

 

11/603,406

 

11/22/2006

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data from Target Individuals Using Genetic Data from Genetically Related Individuals

 

 

 

13/793,133

 

3/11/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data from Target Individuals Using Genetic Data from Genetically Related Individuals

 

 

 

13/793,186

 

3/11/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

WO2007/062164

 

PCT/US06/045281

 

11/22/2006

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

EP1960929

 

06838311.6

 

11/22/2006

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 



 

Title

 

Publication No.

 

Application No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Issue
Date

 

Expiration
Date

 

Assignee

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

EP 2437191

 

11175867.8

 

11/22/2006

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

AU2006318425

 

2006318425

 

11/22/2006

 

AU

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

CA2632230

 

2632230

 

11/22/2006

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

CN101309703

 

200680049316.3

 

11/22/2006

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

HK1125195

 

9102141.5

 

3/5/2009

 

HK

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Using Data to Make Predictions

 

JP2009517050

 

2008-542450

 

11/22/2006

 

JP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Integrating and Validating Genotypic, Phenotypic and Medical Information into a Database According to a Standardized Ontology

 

US2007/0178501

 

11/634,550

 

12/6/2006

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

US2008/0243398

 

12/076,348

 

3/17/2008

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

WO2008/115497

 

PCT/US08/03547

 

3/17/2008

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

 


 

Title

 

Publication No.

 

Application No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Issue
Date

 

Expiration
Date

 

Assignee

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

EP2140386

 

08742125.1

 

3/17/2008

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

CN101790731

 

200880016123.7

 

3/17/2008

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Cell Genotyping

 

US2011/0033862

 

12/918,445

 

10/7/2010

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Cell Genotyping

 

WO2009/105531

 

PCT/US09/34506

 

2/19/2009

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

Methods for Embryo Characterization and Comparison

 

US2011/0092763

 

12/994,260

 

12/20/2010

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Embryo Characterization and Comparison

 

WO2009/146335

 

PCT/US09/45335

 

5/27/2009

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

US2011/0178719

 

13/057,350

 

3/29/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

 

 

13/846,111

 

3/18/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

WO2010/017214

 

PCT/US09/52730

 

8/4/2009

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

EP2321642

 

9805452.1

 

8/4/2009

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

AU2009279734

 

2009279734

 

8/4/2009

 

AU

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

CA2731991

 

2731991

 

8/4/2009

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

CN102171565

 

200980139431.1

 

8/4/2009

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

HK1159248

 

11113782.2

 

12/21/2011

 

HK

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 



 

Title

 

Publication No.

 

Application No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Issue
Date

 

Expiration
Date

 

Assignee

Methods for Non-invasive Prenatal Ploidy Calling

 

US2012/0185176

 

13/499,086

 

3/29/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

WO2011/041485

 

PCT/US2010/050824

 

9/30/2010

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

EP2473638

 

10821214.3

 

9/30/2010

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

CA2774252

 

2774252

 

9/30/2010

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

CN10257266

 

201080048121.3

 

9/30/2010

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

 

 

13100216.3

 

1/7/2013

 

HK

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

US2011/0288780

 

13/110,685

 

5/18/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

WO2011/146632

 

PCT/US2011/037018

 

5/18/2011

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

EP2572003

 

11784180.9

 

5/18/2011

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

AU2011255641

 

2011255641

 

5/18/2011

 

AU

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

CA2798758

 

2798758

 

5/18/2011

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

US2012/0270212

 

13/300,235

 

11/18/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

 

 

13/791,397

 

3/8/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

WO2012/108920

 

PCT/US11/61506

 

11/18/2011

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 


 

Title

 

Publication No.

 

Application No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Issue
Date

 

Expiration
Date

 

Assignee

Methods for Non-invasive Prenatal Paternity Testing

 

US2012/0122701

 

13/335,043

 

12/22/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Paternity Testing

 

 

 

13/846,160

 

3/18/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Paternity Testing

 

WO2012/088456

 

PCT/US11/66938

 

12/22/2011

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Preimplantation Genetic Diagnosis by Sequencing

 

 

 

PCT/US12/058578

 

10/3/2012

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Highly Multiplex PCR Methods and Compositions

 

 

 

13/683,604

 

11/21/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Highly Multiplex PCR Methods and Compositions

 

 

 

PCT/US12/66339

 

11/21/2012

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Highly Multiplex PCR Methods and Compositions

 

 

 

61/767,865

 

2/22/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Informatics Enhanced Analysis of Fetal Samples Subject to Maternal Contamination

 

 

 

13/780,022

 

2/28/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Informatics Enhanced Analysis of Fetal Samples Subject to Maternal Contamination

 

 

 

PCT/US2013/28378

 

2/28/2013

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Increasing Fetal Fraction in Maternal Blood

 

 

 

13/793,316

 

3/11/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Increasing Fetal Fraction in Maternal Blood

 

 

 

61/743,423

 

9/4/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Improved Methods and Reagents for Quantification of Amplification Products

 

 

 

61/675,020

 

7/24/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-Invasive Prenatal Testing Using Parental Mosaicism Data

 

 

 

61/684,243

 

8/17/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-Invasive Prenatal Testing Using Parental Mosaicism Data

 

 

 

61/790,108

 

3/15/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 



 

Title

 

Publication No.

 

Application No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Issue
Date

 

Expiration
Date

 

Assignee

Methods and Compositions for Reducing Genetic Library Contamination

 

 

 

61/683,331

 

8/15/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods and Compositions for Reducing Genetic Library Contamination

 

 

 

61/790,222

 

3/15/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 

Item B.  Patent Licenses

 

None.

 


 

SCHEDULE IV
to Security Agreement

 

Item A.  Trademarks

 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of

Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest
Information

PRENATUS

 

85/467718

 

 

 

Allowed

 

US

 

11/8/2011

 

 

 

42 Int. medical laboratory services; genetic testing for scientific research purposes in the field of human reproduction

44 Int. genetic testing for medical purposes and genetic counseling in the field of human reproduction

 

GSN / Natera

 

 

 



 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of

Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest
Information

NATERA

 

85/487673

 

4203883

 

Registered

 

US

 

12/5/2011

 

09/04/12

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for scientific purposes

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 


 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of

Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest
Information

NATERA

 

10930469

 

10930469

 

Registered

 

EP

 

6/1/2012

 

10/30/12

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical and scientific research and analysis in the field of genetic testing; medical laboratory services; genetic testing or scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing medical purposes; medical laboratory services

 

44 Int. genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling; genetic testing for medical purposes; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counselingcounseling

 

GSN / Natera

 

 

 



 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of

Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest
Information

NATERA

 

1580172

 

 

 

Filed

 

CA

 

6/1/2012

 

 

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing

 

44 Int. medical laboratory services; genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling

 

GSN / Natera

 

 

NATERA

 

11022636

 

 

 

Filed

 

CN

 

6/5/2012

 

 

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing

 

GSN / Natera

 

 

NATERA

 

11022635

 

 

 

Filed

 

CN

 

6/5/2012

 

 

 

44 Int. medical laboratory services; genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling

 

GSN / Natera

 

 

 


 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of

Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest
Information

NATERA

 

2012-44502

 

5521348

 

Registered

 

JP

 

6/4/2012

 

09/14/12

 

42 Int. medical and scientific research and analysis in the field of genetic testing, providing medical and scientific research information in the field of genetic testing, testing; inspection or research on therapeutic approaches and techniques related to medical treatment and providing information thereof, genetic testing for scientific research and analysis purposes, genetic testing for scientific research and analysis purposes in the field of human reproduction, hosting computer sites (web sites) featuring information in the field of genetic testing for medical purposes, research and development for others, providing information in the field of medical research, testing; inspection or research for medical care, computer software design, testing; inspection or research for medical care, computer software design; computer programming or maintenance of computer of computer software with respect to medical data, design of surgical instruments, analysis; research in the field of medical care and consultation thereof, testing or research on machines; apparatus and instruments and their parts for medical purposes

 

44 Int. genetic testing for medical purposes, counseling for medical purposes in the field of genetic, genetic testing for medical purpose and counseling as medical purposes related to inheritance in the field of human reproduction, providing information on gene therapy, medical services; providing medical information, counseling and advice on health care, counseling and advice on providing of medical information

 

GSN / Natera

 

 

 



 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of

Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest
Information

NATERA

 

1494690

 

 

 

Published

 

AU

 

6/5/2012

 

 

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing

 

44 Int. medical laboratory services; genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling, namely providing information about genetic testing and genetic counseling via a website

 

GSN / Natera

 

 

 



 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of

Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest
Information

NATERA

 

2012718511

 

 

 

Filed

 

RU (Russian Federation)

 

6/5/2012

 

 

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for medical purposes

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 


 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of

Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest
Information

NATERA

 

840152647

 

 

 

Filed

 

BR (Brazil)

 

6/5/2012

 

 

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for medical purposes

 

GSN / Natera

 

 

NATERA

 

840152671

 

 

 

Filed

 

BR

 

6/5/2012

 

 

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 



 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of

Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest
Information

NATERA

 

2343007

 

 

 

Filed

 

IN (India)

 

6/5/2012

 

 

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for medical purposes

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 



 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of

Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest
Information

PANORAMA

 

85/776044

 

 

 

Filed

 

US (foreign filing options are open)

 

11/9/2012

 

 

 

01 Int. kits and reagents for genetic testing for medical and scientific research purposes; kits and reagents for genetic testing for medical and scientific research purposes in the field of human reproduction; kits and reagents for prenatal testing for medical and scientific research purposes; nucleic acid based kits and reagents for testing for fetal chromosomal abnormalities for medical and scientific research purposes

42 Int. genetic testing for scientific research purposes; genetic testing for scientific research purposes in the field of human reproduction; prenatal testing for scientific research purposes; testing for fetal chromosomal abnormalities for research purposes; scientific, laboratory, clinical, medical, and technological research and analysis services in the fields of nucleic acid analysis, prenatal testing, and genetics; medical laboratory services; providing a website featuring information about genetic testing for scientific research purposes; providing a website featuring information about prenatal testing for scientific research purposes

44 Int. genetic testing for medical purposes; genetic testing for medical purposes in the field of human reproduction; prenatal testing for medical purposes; testing for fetal chromosomal abnormalities for medical purposes; genetic counseling; providing a website featuring information about genetic testing and genetic counseling for medical purposes; providing a website featuring information about prenatal testing and genetic counseling for medical purposes

 

GSN / Natera

 

 

 


 

Item B.  Trademark Licenses

 

None.

 



 

SCHEDULE V

to Security Agreement

 

Item A.  Copyrights/Mask Works

 

None.

 

Item B.  Copyright/Mask Work Licenses

 

None.

 



 

SCHEDULE VI

to Security Agreement

 

None.

 


 

EXHIBIT A

to Security Agreement

Execution Version

 

PATENT SECURITY AGREEMENT

 

This PATENT SECURITY AGREEMENT, dated as of April 18, 2013 (this “ Agreement ”), is made by NATERA, INC., a Delaware corporation (the “ Grantor ”), in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W   I   T   N   E   S   S   E   T   H :

 

WHEREAS, pursuant to a Credit Agreement, dated as of April 18, 2013 (as amended, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and between Natera, Inc., a Delaware corporation (the “ Borrower ”) and the Lender, the Lender has extended a Commitment to make the Loans to the Borrower;

 

WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of April 18, 2013 (as amended, supplemented or otherwise modified from time to time, the “ Security Agreement ”);

 

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (e) of Section 4.5 of the Security Agreement, the Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Patent Collateral (as defined below) to secure all of the Obligations; and

 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of the Lender, as follows:

 

SECTION 1. Definitions . Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

 

SECTION 2. Grant of Security Interest . The Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all of the Grantor’s right, title and interest in and to the following property, whether now or hereafter existing or acquired by the Grantor (the “ Patent Collateral ”):

 

(a)           all of its letters patent and applications for letters patent throughout the world, including each patent and patent application referred to in Item A of Schedule I attached hereto;

 

(b)           all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the items described in clause (a) ;

 



 

(c)           all patent licenses and other agreements providing the Grantor with the right to use any items of the type referred to in clauses (a) and (b) above, including each patent license referred to in Item B of Schedule I attached hereto; and

 

(d)           all Proceeds of, and rights associated with, the foregoing (including licenses, royalties income, payments, claims, damages and Proceeds of infringement suits) and the right to sue third parties for past, present or future infringements of any patent or patent application and for breach or enforcement of any patent license.

 

SECTION 3. Security Agreement . This Agreement has been executed and delivered by the Grantor for the purpose of registering the security interest of the Lender in the Patent Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Lender for its benefit under the Security Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms.

 

SECTION 4. Release of Liens . Upon (i) the Disposition of Patent Collateral in accordance with the Credit Agreement or (ii) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (A) such Patent Collateral (in the case of clause (i) ) or (B) all Patent Collateral (in the case of clause (ii) ). Upon any such Disposition or termination, the Lender will, at the Grantor’s sole expense, deliver to the Grantor, without any representations, warranties or recourse of any kind whatsoever, all Patent Collateral held by the Lender hereunder, and execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination.

 

SECTION 5. Acknowledgment . The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

 

SECTION 6. Loan Document . This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

 

SECTION 7. Effective . This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

[ Signature Page Follows ]

 

2



 

IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

 

 

NATERA, INC.

 

 

 

 

 

By:

/s/ Matthew Rabinowitz

 

 

Name:

Matthew Rabinowitz

 

 

Title:

Chief Executive Officer

 

[ Signature Page to Patent Security Agreement ]

 



 

SCHEDULE I

to Patent Security Agreement

 

Item A

 

See attached.

 

Item B

 

None.

 

[ Schedules to Patent Security Agreement ]

 


 

PATENTS

 

Title

 

Publication No.

 

Application No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Issue
Date

 

Expiration
Date

 

Assignee

System and Method for Improving Clinical

 

US2006/0052945

 

11/004,274

 

12/3/2004

 

US

 

Issued

 

8,024,128

 

9/20/2011

 

 

 

GSN / Natera

Decisions by Aggregating, Validating and

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Analysing Genetic and Phenotypic Data

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Using Genetic,

 

US2007/0027636

 

11/496,982

 

7/31/2006

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Phenotypic and Clinical Data to Make

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Predictions for Clinical or Lifestyle Decisions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

US2007/0184467

 

11/603,406

 

11/22/2006

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Genetic Data from Target Individuals Using

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Genetic Data from Genetically Related

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Individuals

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

 

 

13/793,133

 

3/11/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Genetic Data from Target Individuals Using

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Genetic Data from Genetically Related

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Individuals

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

 

 

13/793,186

 

3/11/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Genetic Data from Target Individuals Using

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Genetic Data from Genetically Related

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Individuals

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

WO2007/062164

 

PCT/US06/045281

 

11/22/2006

 

PCT

 

National

 

 

 

 

 

 

 

GSN / Natera

Genetic Data and Using Data to Make

 

 

 

 

 

 

 

 

 

Stage

 

 

 

 

 

 

 

 

Predictions

 

 

 

 

 

 

 

 

 

Entered

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

EP1960929

 

06838311.6

 

11/22/2006

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Genetic Data and Using Data to Make

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Predictions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

EP 2437191

 

11175867.8

 

11/22/2006

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Genetic Data and Using Data to Make

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Predictions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

AU2006318425

 

2006318425

 

11/22/2006

 

AU

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Genetic Data and Using Data to Make

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Predictions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

CA2632230

 

2632230

 

11/22/2006

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Genetic Data and Using Data to Make

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Predictions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

CN101309703

 

200680049316.3

 

11/22/2006

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Genetic Data and Using Data to Make

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Predictions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

HK1125195

 

9102141.5

 

3/5/2009

 

HK

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Genetic Data and Using Data to Make

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Predictions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Cleaning Noisy

 

JP2009517050

 

2008-542450

 

11/22/2006

 

JP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Genetic Data and Using Data to Make

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Predictions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

System and Method for Integrating and

 

US2007/0178501

 

11/634,550

 

12/6/2006

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Validating Genotypic, Phenotypic and Medical

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Information into a Database According to a

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Standardized Ontology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Title

 

Publication No.

 

Application No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Issue
Date

 

Expiration
Date

 

Assignee

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

US2008/0243398

 

12/076,348

 

3/17/2008

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

WO2008/115497

 

PCT/US08/03547

 

3/17/2008

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

EP2140386

 

08742125.1

 

3/17/2008

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

System and Method for Cleaning Noisy Genetic Data and Determining Chromosome Copy Number

 

CN101790731

 

200880016123.7

 

3/17/2008

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Cell Genotyping

 

US2011/0033862

 

12/918,445

 

10/7/2010

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Cell Genotyping

 

WO2009/105531

 

PCT/US09/34506

 

2/19/2009

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

Methods for Embryo Characterization and Comparison

 

US2011/0092763

 

12/994,260

 

12/20/2010

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Embryo Characterization and Comparison

 

WO2009/146335

 

PCT/US09/45335

 

5/27/2009

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

US2011/0178719

 

13/057,350

 

3/29/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

 

 

13/846,111

 

3/18/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

WO2010/017214

 

PCT/US09/52730

 

8/4/2009

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

EP2321642

 

9805452.1

 

8/4/2009

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

AU2009279734

 

2009279734

 

8/4/2009

 

AU

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

CA2731991

 

2731991

 

8/4/2009

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

CN102171565

 

200980139431.1

 

8/4/2009

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Allele Calling and Ploidy Calling

 

HK1159248

 

11113782.2

 

12/21/2011

 

HK

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

US2012/0185176

 

13/499,086

 

3/29/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

WO2011/041485

 

PCT/US2010/050824

 

9/30/2010

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

 


 

Title

 

Publication No.

 

Application No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Issue 
Date

 

Expiration 
Date

 

Assignee

Methods for Non-invasive Prenatal Ploidy Calling

 

EP2473638

 

10821214.3

 

9/30/2010

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

CA2774252

 

2774252

 

9/30/2010

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

CN10257266

 

201080048121.3

 

9/30/2010

 

CN

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

 

 

13100216.3

 

1/7/2013

 

HK

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

US2011/0288780

 

13/110,685

 

5/18/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

WO2011/146632

 

PCT/US2011/037018

 

5/18/2011

 

PCT

 

National Stage Entered

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

EP2572003

 

11784180.9

 

5/18/2011

 

EP

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

AU2011255641

 

2011255641

 

5/18/2011

 

AU

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

CA2798758

 

2798758

 

5/18/2011

 

CA

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

US2012/0270212

 

13/300,235

 

11/18/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

 

 

13/791,397

 

3/8/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Ploidy Calling

 

WO2012/108920

 

PCT/US11/61506

 

11/18/2011

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Paternity Testing

 

US2012/0122701

 

13/335,043

 

12/22/2011

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Paternity Testing

 

 

 

13/846,160

 

3/18/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-invasive Prenatal Paternity Testing

 

WO2012/088456

 

PCT/US11/66938

 

12/22/2011

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Preimplantation Genetic Diagnosis by Sequencing

 

 

 

PCT/US12/058578

 

10/3/2012

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Highly Multiplex PCR Methods and Compositions

 

 

 

13/683,604

 

11/21/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Highly Multiplex PCR Methods and Compositions

 

 

 

PCT/US12/66339

 

11/21/2012

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Highly Multiplex PCR Methods and Compositions

 

 

 

61/767,865

 

2/22/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Informatics Enhanced Analysis of Fetal Samples Subject to Maternal Contamination

 

 

 

13/780,022

 

2/28/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Informatics Enhanced Analysis of Fetal Samples Subject to Maternal Contamination

 

 

 

PCT/US2013/28378

 

2/28/2013

 

PCT

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Increasing Fetal Fraction in Maternal Blood

 

 

 

13/793,316

 

3/11/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 


 

Title

 

Publication No.

 

Application No.

 

Filing Date

 

Country

 

Status

 

Patent No

 

Issue
Date

 

Expiration
Date

 

Assignee

Methods for Increasing Fetal Fraction in Maternal Blood

 

 

 

61/743,423

 

9/4/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Improved Methods and Reagents for Quantification of Amplification Products

 

 

 

61/675,020

 

7/24/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-Invasive Prenatal Testing Using Parental Mosaicism Data

 

 

 

61/684,243

 

8/17/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods for Non-Invasive Prenatal Testing Using Parental Mosaicism Data

 

 

 

61/790,108

 

3/15/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods and Compositions for Reducing Genetic Library Contamination

 

 

 

61/683,331

 

8/15/2012

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

Methods and Compositions for Reducing Genetic Library Contamination

 

 

 

61/790,222

 

3/15/2013

 

US

 

Pending

 

 

 

 

 

 

 

GSN / Natera

 


 

EXHIBIT B

to Security Agreement

Execution Version

 

TRADEMARK SECURITY AGREEMENT

 

This TRADEMARK SECURITY AGREEMENT, dated as of April 18, 2013 (this “ Agreement ”), is made by NATERA, INC., a Delaware corporation (the “ Grantor ”), in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W   I   T   N   E   S   S   E   T   H :

 

WHEREAS, pursuant to a Credit Agreement, dated as of April 18, 2013 (as amended, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”), by and between Natera, Inc., a Delaware corporation (the “ Borrower ”) and the Lender, the Lender has extended a Commitment to make the Loans to the Borrower;

 

WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of  April 18, 2013 (as amended, supplemented, or otherwise modified from time to time, the “ Security Agreement ”);

 

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (e) of Section 4.5 of the Security Agreement, the Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Trademark Collateral (as defined below) to secure all of the Obligations; and

 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of each Lender, as follows:

 

SECTION 1.  Definitions . Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

 

SECTION 2.  Grant of Security Interest .  The Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all of Grantor’s right, title and interest in and to the following property, whether now or hereafter existing or acquired by the Grantor (the “ Trademark Collateral ”):

 

(a)   (i) all of its trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, certification marks, collective marks, logos and other source or business identifiers, and all goodwill of the business associated therewith, including those referred to in Item A of Schedule I hereto, whether currently in use or not, all registrations and recordings thereof and all applications in connection therewith, whether pending or filed, including registrations, recordings and applications in the United States Patent and Trademark Office or in any office or agency of the United States of America or any State thereof, and all

 



 

common-law rights relating to the foregoing, and (ii) the right to obtain all reissues, extensions or renewals of the foregoing (collectively referred to as the “ Trademarks ”);

 

(b)   all Trademark licenses for the grant by or to the Grantor of any right to use any Trademark, including each Trademark license referred to in Item B of Schedule I hereto;

 

(c)   all of the goodwill of the business connected with the use of, and symbolized by the items described in, clause (a), and to the extent applicable clause (b);

 

(d)   the right to sue third parties for past, present and future infringements of any Trademark Collateral described in clause (a) and, to the extent applicable, clause (b); and

 

(e)   all Proceeds of, and rights associated with, the foregoing, including any claim by the Grantor against third parties for past, present or future infringement or dilution of any Trademark, Trademark registration or Trademark license, or for any injury to the goodwill associated with the use of any such Trademark or for breach or enforcement of any Trademark license and all rights corresponding thereto throughout the world.

 

SECTION 3.  Security Agreement .  This Agreement has been executed and delivered by the Grantor for the purpose of registering the security interest of the Lender in the Trademark Collateral with the United States Patent and Trademark Office.  The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Lender for its benefit under the Security Agreement.  The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms.

 

SECTION 4.  Release of Liens .  Upon (i) the Disposition of Trademark Collateral in accordance with the Credit Agreement or (ii) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (A) such Trademark Collateral (in the case of clause (i) ) or (B) all Trademark Collateral (in the case of clause (ii) ).  Upon any such Disposition or termination, the Lender will, at the Grantor’s sole expense, deliver to the Grantor, without any representations, warranties or recourse of any kind whatsoever, all Trademark Collateral held by the Lender hereunder, and execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination.

 

SECTION 5.  Acknowledgment .  The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Trademark Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

 

SECTION 6.  Loan Document .  This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed,

 

2



 

administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

 

SECTION 7.  Effective .  This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received by the Lender.  Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

[ Signature Page Follows ]

 

3


 

Execution Version

 

IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

 

 

NATERA, INC.

 

 

 

 

 

By:

/s/ Matthew Rabinowitz

 

 

Name:

Matthew Rabinowitz

 

 

Title:

Chief Executive Officer

 

[ Signature Page to Trademark Security Agreement ]

 



 

SCHEDULE I

to Trademark Security Agreement

 

Item A

 

See attached.

 

Item B

 

None.

 

[ Schedules to Trademark Security Agreement ]

 


 

TRADEMARKS

 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of
Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest Information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PRENATUS

 

85/467718

 

 

 

Allowed

 

US

 

11/8/2011

 

 

 

42 Int. medical laboratory services; genetic testing for scientific research purposes in the field of human reproduction

 

44 Int. genetic testing for medical purposes and genetic counseling in the field of human reproduction

 

GSN / Natera

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NATERA

 

85/487673

 

4203883

 

Registered

 

US

 

12/5/2011

 

09/04/12

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for scientific purposes

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 


 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of
Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest Information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NATERA

 

10930469

 

10930469

 

Registered

 

EP

 

6/1/2012

 

10/30/12

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical and scientific research and analysis in the field of genetic testing; medical laboratory services; genetic testing or scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing medical purposes; medical laboratory services

 

44 Int. genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling; genetic testing for medical purposes; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NATERA

 

1580172

 

 

 

Filed

 

CA

 

6/1/2012

 

 

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing

 

44 Int. medical laboratory services; genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling

 

GSN / Natera

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NATERA

 

11022636

 

 

 

Filed

 

CN

 

6/5/2012

 

 

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing

 

GSN / Natera

 

 

 


 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of
Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest Information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NATERA

 

11022635

 

 

 

Filed

 

CN

 

6/5/2012

 

 

 

44 Int. medical laboratory services; genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling

 

GSN / Natera

 

 

 


 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of
Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest Information

NATERA

 

2012-44502

 

5521348

 

Registered

 

JP

 

6/4/2012

 

09/14/12

 

42 Int. medical and scientific research and analysis in the field of genetic testing, providing medical and scientific research information in the field of genetic testing, testing; inspection or research on therapeutic approaches and techniques related to medical treatment and providing information thereof, genetic testing for scientific research and analysis purposes, genetic testing for scientific research and analysis purposes in the field of human reproduction, hosting computer sites (web sites) featuring information in the field of genetic testing for medical purposes, research and development for others, providing information in the field of medical research, testing; inspection or research for medical care, computer software design, testing; inspection or research for medical care, computer software design; computer programming or maintenance of computer of computer software with respect to medical data, design of surgical instruments, analysis; research in the field of medical care and consultation thereof, testing or research on machines; apparatus and instruments and their parts for medical purposes

 

44 Int. genetic testing for medical purposes, counseling for medical purposes in the field of genetic, genetic testing for medical purpose and counseling as medical purposes related to inheritance in the field of human reproduction, providing information on gene therapy, medical services; providing medical information, counseling and advice on health care, counseling and advice on providing of medical information

 

GSN / Natera

 

 

 


 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of
Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest Information

NATERA

 

1494690

 

 

 

Published

 

AU

 

6/5/2012

 

 

 

42 Int. medical and scientific research in the field of genetic testing; providing medical and scientific research information in the field of genetic testing

 

44 Int. medical laboratory services; genetic testing; genetic counseling; genetic testing and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing and genetic counseling, namely providing information about genetic testing and genetic counseling via a website

 

GSN / Natera

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NATERA

 

2012718511

 

 

 

Filed

 

RU (Russian
Federation)

 

6/5/2012

 

 

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for medical purposes

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NATERA

 

840152647

 

 

 

Filed

 

BR (Brazil)

 

6/5/2012

 

 

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for medical purposes

 

GSN / Natera

 

 

 


 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of
Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest Information

NATERA

 

840152671

 

 

 

Filed

 

BR

 

6/5/2012

 

 

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NATERA

 

2343007

 

 

 

Filed

 

IN (India)

 

6/5/2012

 

 

 

42 Int. medical and scientific research and analysis in the field of genetic testing; providing medical and scientific research information in the field of genetic testing; medical laboratory services; genetic testing for scientific research and analysis purposes; genetic testing for scientific research and analysis purposes in the field of human reproduction; providing a website featuring information in the field of genetic testing for medical purposes

 

44 Int. genetic testing for medical purposes; genetic counseling; genetic testing for medical purposes and genetic counseling in the field of human reproduction; providing a website featuring information about genetic testing for medical purposes and genetic counseling

 

GSN / Natera

 

 

 


 

Trademark

 

Appl. #

 

Reg. #

 

Status

 

Country of Reg.

 

Appl. Dt

 

Reg. Dt

 

Goods and Services

 

Owner

 

Security Interest Information

PANORAMA

 

85/776044

 

 

 

Filed

 

US (foreign filing options are open)

 

11/9/2012

 

 

 

01 Int. kits and reagents for genetic testing for medical and scientific research purposes; kits and reagents for genetic testing for medical and scientific research purposes in the field of human reproduction; kits and reagents for prenatal testing for medical and scientific research purposes; nucleic acid based kits and reagents for testing for fetal chromosomal abnormalities for medical and scientific research purposes 

 

42 Int. genetic testing for scientific research purposes; genetic testing for scientific research purposes in the field of human reproduction; prenatal testing for scientific research purposes; testing for fetal chromosomal abnormalities for research purposes; scientific, laboratory, clinical, medical, and technological research and analysis services in the fields of nucleic acid analysis, prenatal testing, and genetics; medical laboratory services; providing a website featuring information about genetic testing for scientific research purposes; providing a website featuring information about prenatal testing for scientific research purposes 

 

44 Int. genetic testing for medical purposes; genetic testing for medical purposes in the field of human reproduction; prenatal testing for medical purposes; testing for fetal chromosomal abnormalities for medical purposes; genetic counseling; providing a website featuring information about genetic testing and genetic counseling for medical purposes; providing a website featuring information about prenatal testing and genetic counseling for medical purposes

 

GSN / Natera

 

 

 


 

EXHIBIT C

to Security Agreement

Execution Version

 

COPYRIGHT SECURITY AGREEMENT

 

Not Applicable.

 



 

ANNEX I

to Security Agreement

 

SUPPLEMENT TO

PLEDGE AND SECURITY AGREEMENT

 

This SUPPLEMENT, dated as of                 ,       (this “ Supplement ”), is to the Pledge and Security Agreement, dated as of [      ], 2013 (as amended, supplemented, amended and restated or otherwise modified from time to time, the “ Security Agreement ”), among the Grantors (such term, and other terms used in this Supplement, to have the meanings set forth in Article I of the Security Agreement) from time to time party thereto, in favor of ROS ACQUISITION OFFSHORE LP, a Cayman Islands Exempted Limited Partnership (together with its Affiliates, successors, transferees and assignees, the “ Lender ”).

 

W   I   T   N   E   S   S   E   T   H :

 

WHEREAS, pursuant to a Credit Agreement, dated as of [      ], 2013 (as amended, supplemented, or otherwise modified from time to time, the “ Credit Agreement ”), by and between Natera, Inc., a Delaware corporation (the “ Borrower ”) and the Lender, the Lender has extended a Commitment to make the Loans to the Borrower;

 

WHEREAS, pursuant to the provisions of Section 7.6 of the Security Agreement, each of the undersigned is becoming a Grantor under the Security Agreement; and

 

WHEREAS, each of the undersigned desires to become a “Grantor” under the Security Agreement in order to induce the Lender to continue to extend Loans under the Credit Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each of the undersigned agrees, for the benefit of the Lender, as follows.

 

SECTION 1.  Party to Security Agreement, etc .  In accordance with the terms of the Security Agreement, by its signature below, each of the undersigned hereby irrevocably agrees to become a Grantor under the Security Agreement with the same force and effect as if it were an original signatory thereto and each of the undersigned hereby (a) agrees to be bound by and comply with all of the terms and provisions of the Security Agreement applicable to it as a Grantor and (b) represents and warrants that the representations and warranties made by it as a Grantor thereunder are true and correct as of the date hereof, unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct as of such earlier date.  In furtherance of the foregoing, each reference to a “Grantor” and/or “Grantors” in the Security Agreement shall be deemed to include each of the undersigned.

 

SECTION 2.  Schedules .  Each of the undersigned Grantors hereby authorizes the Lender to add the information set forth on the Schedules to this Supplement to the correlative Schedules attached to the Security Agreement.

 



 

SECTION 3.  Representations .  Each of the undersigned Grantors hereby represents and warrants that this Supplement has been duly authorized, executed and delivered by it and that this Supplement and the Security Agreement constitute its legal, valid and binding obligation, enforceable against it in accordance with its terms.

 

SECTION 4.  Full Force of Security Agreement .  Except as expressly supplemented hereby, the Security Agreement shall remain in full force and effect in accordance with its terms.

 

SECTION 5.  Severability .  Wherever possible each provision of this Supplement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Supplement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Supplement or the Security Agreement.

 

SECTION 6.  Governing Law, Entire Agreement, etc .  THIS SUPPLEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SECURITY AGREEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).  This Supplement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto.

 

SECTION 7.  Effective .  This Supplement shall become effective when a counterpart hereof executed by the Grantor shall have been received by the Lender.  Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

[ Signature Page Follows ]

 

2



 

IN WITNESS WHEREOF, each of the parties hereto has caused this Supplement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

 

[NAME OF ADDITIONAL SUBSIDIARY]

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

 

 

 

 

[NAME OF ADDITIONAL SUBSIDIARY]

 

 

 

 

 

By:

 

 

 

Name: :

 

 

Title

 

Signature Page to Security Agreement Supplement

 



 

[COPY SCHEDULES FROM SECURITY AGREEMENT]

 




Exhibit 10.8.3

 

Execution Version

 

CONFIDENTIAL TREATMENT REQUESTED

ROYALTY AGREEMENT

 

This ROYALTY AGREEMENT, dated as of April 18, 2013 (as amended, supplemented or otherwise modified from time to time, this “ Royalty Agreement ”), is made by and between ROYALTY OPPORTUNITIES S.ÀR.L, a Luxembourg société à responsabilité limitée (together with its Affiliates, successors, transferees and assignees, “ ROS ”), and Natera, Inc., a Delaware corporation (“ Natera ”). ROS and Natera are sometimes referred to herein individually as a “ Party ” and collectively as the “ Parties ”.

 

W I T N E S S E T H :

 

WHEREAS, ROS Acquisition Offshore LP, a Cayman Islands Exempted Limited Partnership (“ Lender ”), and Natera have entered into that certain Credit Agreement, dated as of the date hereof (as subsequently amended or otherwise modified, the “ Credit Agreement ”); and

 

WHEREAS, the execution and delivery of this Royalty Agreement is a condition precedent to the making of the Initial Loan pursuant to the Credit Agreement.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in order to induce ROS to make the Loans pursuant to the Credit Agreement, the Parties hereto agree as follows.

 

ARTICLE I.
DEFINITIONS

 

SECTION 1.1                                              Certain Terms . The following terms (whether or not underscored) when used in this Royalty Agreement, including its preamble and recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof):

 

Applicable Amount ” has the meaning set forth in the definition of “ Purchase Price ”.

 

Applicable Period ” has the meaning set forth in the definition of “ Purchase Price ”.

 

Bankruptcy Event ” means any Event of Default of the type described in Section 9.1(h ) of the Credit Agreement.

 

Buy-Out Notice ” has the meaning set forth in Section 2.6 .

 

Buy-Out Option ” has the meaning set forth in Section 2.6 .

 

Confidential Information ” means any and all information or material (whether written or oral, or in electronic or other form) that, at any time before, on or after the Closing Date, has been or is provided or communicated to the Receiving Party by or on behalf of the Disclosing Party pursuant to this Royalty Agreement or in connection with the transactions contemplated hereby or any discussions or negotiations with respect thereto, and shall include the existence and terms of this Royalty Agreement.

 



 

Contract ” means any contract, license, indenture, instrument or agreement.

 

Credit Agreement ” has the meaning set forth in the recitals hereto.

 

Default Rate ” means the rate of interest applicable to Loans under Section 3.5 of the Credit Agreement.

 

Disclosing Party ” means the Party disclosing Confidential Information.

 

Judgment ” means any judgment, injunction, order or decree.

 

Law ” means any law, statute, rule, regulation or ordinance of any Governmental Authority that may be in effect from time to time.

 

Lender ” has the meaning set forth in the recitals hereto.

 

Natera ” has the meaning set forth in the preamble hereto.

 

Net Revenue ” means consolidated net sales, distribution income, service payments, license income, and other forms of consideration made to Natera and its Subsidiaries related to all products and services (including all Products) and shall be determined in accordance with GAAP. Net Revenue shall be determined in a manner consistent with the methodologies, practices and procedures used in developing Natera’s audited financial statements.

 

Party ” and “ Parties ” have the meanings set forth in the preamble hereto.

 

Payments ” means the Royalty Payments, the payment of the Purchase Price and any other payments to be made by Natera to ROS hereunder.

 

Pledge and Security Agreement ” means the Pledge and Security Agreement among Natera, Natera International Inc. and the Lender.

 

Purchase Price ” means, with respect to either (x) Natera’s election to exercise its Buy-Out Option at any time, or (y) ROS’s election to exercise its Put Option upon the occurrence of a Royalty Event of Default, an amount, payable by Natera to ROS in U.S. Dollars to an account designated in writing by ROS, equal to the difference between (i) the applicable amount set forth in the table below (the “ Applicable Amount ”) opposite the applicable period (the “ Applicable Period ”) set forth in the table below, during which such Buy-Out Option or Put Option as the case may be, was exercised (or deemed to be exercised), less (ii) the Recovered Amount. The Purchase Price shall not be less than zero.

 

2



 

Applicable Period

 

Applicable Amount if
the Delayed Draw Loan
Has Not Been Funded

 

Applicable Amount if 
the Delayed Draw Loan
Has Been Funded

 

On or before the 1st anniversary of the Closing Date

 

$

8,000,000

 

$

11,000,000

 

After the 1st anniversary of the Closing Date and on or before the 2nd anniversary of the Closing Date

 

$

8,875,000

 

$

12,000,000

 

After the 2nd anniversary of the Closing Date and on or before the 3rd anniversary of the Closing Date

 

$

9,750,000

 

$

13,000,000

 

After the 3rd anniversary of the Closing Date and on or before the 4th anniversary of the Closing Date

 

$

10,625,000

 

$

14,000,000

 

Any time after the 4th anniversary of the Closing Date

 

$

11,500,000

 

$

15,000,000

 

 

Put Notice ” has the meaning set forth in Section 5.2 .

 

Put Option ” has the meaning set forth in Section 5.2 .

 

Receiving Party ” means the Party receiving Confidential Information.

 

Recipients ” has the meaning set forth in Section 7.1 .

 

Recovered Amount ” means, as of the time the Purchase Price is paid pursuant to Section 2.6 hereof, the aggregate amount of all Royalty Payments previously paid to ROS by Natera or any Subsidiary pursuant to Section 2.1 as of the Fiscal Quarter last ended.

 

Related Agreement ” means any existing or future Contract entered into before or during the Royalty Term by Natera or any of its Subsidiaries (i) relating in any material respect, directly or indirectly, to any Product or (ii) that could reasonably be expected to affect in any material respect, directly or indirectly, the value of the Royalty Payments.

 

Related Party ” means any Party (other than Natera or any of its Subsidiaries) to any Related Agreement.

 

ROS ” has the meaning set forth in the preamble hereto.

 

Royalty Agreement ” has the meaning set forth in the preamble hereto.

 

Royalty Event of Default ” has the meaning set forth in Section 5.1 .

 

3



 

Royalty Payment ” has the meaning set forth in Section 2.1(b ).

 

Royalty Report ” has the meaning set forth in Section 2.1(c ).

 

Royalty Term ” means the period commencing on the Closing Date and ending on the earlier of (i) the tenth anniversary of the Closing Date and (ii) the date of payment of the Purchase Price pursuant to the exercise of the Put Option by ROS or the exercise of the Buy-Out Option by Natera, as the case may be.

 

Term ” has the meaning set forth in Section 6.1 .

 

Third Party ” means any Person, other than Natera or any of its Subsidiaries.

 

SECTION 1.2                                              Credit Agreement Definitions . Unless otherwise defined herein or the context otherwise requires, terms used in this Royalty Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement. In the event that the Credit Agreement terminates (in accordance with its terms or otherwise) prior to the expiration of the Term, terms used herein and defined in the Credit Agreement (as in effect immediately prior to such termination) shall continue to be used herein without regard to such earlier termination of the Credit Agreement (as if such agreement remained in full force and effect).

 

ARTICLE II.
ROYALTY PROVISIONS

 

SECTION 2.1                                              Royalty Payments .

 

(a)                                  Natera shall (or shall cause a Subsidiary to) pay to ROS, in respect of each Fiscal Year (or portion of a Fiscal Year, in the case of the first Fiscal Year and last Fiscal Year of the Royalty Term) during the Royalty Term and prior to the Fiscal Quarter in which the Delayed Draw Loan is funded, a royalty amount equal to the sum of (i) 1.00% of the aggregate Net Revenue during such Fiscal Year (or portion of a Fiscal Year, as the case may be) up to $50,000,000 of such Net Revenue, plus (ii) 1.50% of the aggregate Net Revenue during such Fiscal Year (or portion of a Fiscal Year, as the case may be) in excess of $50,000,000.

 

(b)                                  Natera shall (or shall cause a Subsidiary to) pay to ROS, in respect of each Fiscal Year (or portion of a Fiscal Year, in the case of the first Fiscal Year and last Fiscal Year of the Royalty Term) during the Royalty Term and during the Fiscal Quarter in which the Delayed Draw Loan has been funded and thereafter, a royalty amount equal to the sum of (i) 1.50% of the aggregate Net Revenue during such Fiscal Year (or portion of a Fiscal Year, as the case may be) up to $50,000,000 of such Net Revenue, plus (ii) 2.00% of the aggregate Net Revenue during such Fiscal Year (or portion of a Fiscal Year, as the case may be) in excess of $50,000,000.

 

(c)                                   Amounts payable pursuant to Section 2.1(a ) and Section 2.1(b ) shall be calculated quarterly as of the last day of each Fiscal Quarter during the Royalty Term, and shall be payable by Natera to ROS within [*] after the end of each such Fiscal Quarter (each such payment, a “ Royalty Payment ”). The first Royalty Payment shall be

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

4



 

determined based on Net Revenue for the entire first Fiscal Month following the month in which the Closing Date occurs through to the last Fiscal Month of the Fiscal Quarter in which the Closing Date occurs, and the last Royalty Payment (other than in the case of the Royalty Term ending on the date of payment of the Purchase Price pursuant to the exercise of the Put Option by ROS or the exercise of the Buy-Out Option by Natera) shall be determined based on the Net Revenue for the Fiscal Quarter up to the last day of the Fiscal Month in which the last day of the Royalty Term occurs. Royalty Payments shall first be determined in the currency of the country in which the corresponding Net Revenue occurred and then converted to its equivalent in U.S. Dollars. The rates of exchange for such payments shall be the average rate for U.S. Dollars, as quoted by JPMorgan Chase in New York City, at the close of business on the last day of the Fiscal Quarter in which such Net Revenue occurred.

 

(d)                                  Together with each Royalty Payment, Natera shall deliver a written report to ROS showing with respect to each Product (on a product-by-product and country-by-country basis) (i) Net Revenue for such Product in such country for the applicable Fiscal Quarter, including line items for any deductions to the gross invoiced amount made pursuant to the definition of Net Revenue, and (ii) the calculation (in reasonable detail) of the Royalty Payment owed (including any applicable exchange rates used) and paid for such Fiscal Quarter (each, a “ Royalty Report ”). Each delivery of a Royalty Report hereunder shall also be deemed to constitute a representation and warranty by Natera that such Royalty Report is true, correct and complete in all material respects (subject to normal year-end audit adjustments; provided that if such adjustments shall result in an increase in the calculation of Net Revenue, the calculations of Royalty Payments owed shall be adjusted to account for such increase and the Borrower shall immediately pay any Royalty Payment amounts owed); provided, that the sole remedy for any error, unless Royalty Payments are demonstrated in more than two Fiscal Quarters to be understated by more than [*] percent ([*]%) for each such Fiscal Quarter, shall be as provided in Section 2.4 .

 

SECTION 2.2                                              General Provisions as to Payments . All amounts payable to ROS under this Royalty Agreement (including the Payments) shall be (i) made [*] of any kind or nature whatsoever, (ii) made in U.S. Dollars and in immediately available funds and (iii) remitted by wire transfer to such bank account as shall have been designated by ROS in writing from time to time. Any Payments or other amounts due to ROS under this Royalty Agreement that are not made on or before the applicable due date shall, upon demand by ROS, bear interest, payable on demand (and compounded monthly), for each day from (and including) the applicable due date to (but excluding) the date of the payment thereof, at a rate per annum equal to the Default Rate.

 

SECTION 2.3                                              Taxes . The Parties hereby covenant and agree that, with respect to any Taxes payable on any Payments payable to ROS under this Royalty Agreement, Section 4.3 of the Credit Agreement shall apply and is hereby incorporated herein by reference as if set forth herein in its entirety; provided that references in such Section 4.3 to the “Borrower” shall be deemed to mean Natera, references to the “Lender” shall be deemed to mean ROS, and references to the Credit Agreement shall be deemed to mean this Royalty Agreement.

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

5



 

SECTION 2.4                                              Records and Audit .

 

(a)                                  Natera shall keep and maintain at its chief executive office in the United States complete and accurate records (on a product-by-product and country-by-country basis) of all sales, Net Revenue, and deductions to arrive at Net Revenue and Royalty Payments until the latest of (i) [*] years after the period to which such records relate, (ii) the expiration of the applicable tax statute of limitations, and (iii) such longer period as applicable Law requires.

 

(b)                                  Natera shall not later than [*] following its determination of Net Revenue and Royalty Payments for any Fiscal Quarter (or more frequently if Natera so elects) send written notice to ROS containing such Net Revenue and Royalty Payments determination. Natera shall provide to ROS reasonable access at reasonable times after [*] and during regular business hours of Natera to the personnel, properties, books and records of Natera solely for the purpose of a review by ROS of the calculation of Net Revenue and Royalty Payments; and ROS shall have the right, not more than [*] through the Term, at ROS’s expense (except as set forth below), at reasonable times after [*] and during regular hours of Natera, to investigate and audit such records, upon reasonable notice (and may, if it so chooses, retain an independent accountant to conduct such investigation and audit as and to the extent provided in Section 2.4(d )). Natera shall, and shall cause its Subsidiaries to, cooperate fully and completely with all reasonable requests with respect to such investigation and audit (and the Persons conducting such investigation and audit), and all results of any investigation and any audit under this Section 2.4 (and any associated underlying data and information) shall be made available to both Natera and ROS.

 

(c)                                   Within [*] after the delivery of any Royalty Report to ROS, ROS shall be entitled to request an audit of the Net Revenue or Royalty Payments determination with respect to previously delivered Royalty Reports (the “ Audit Request ”).

 

(d)                                  Within [*] after delivery to Natera of the Audit Request, if the Parties are not able to agree on the Net Revenue and Royalty Payments determination, then ROS shall be entitled to engage an independent auditor or valuation firm reasonably acceptable to Natera (the “ Independent Firm ”) to audit the Net Revenue and Royalty Payments calculations. Upon the engagement of the Independent Firm, both Natera and ROS will direct the Independent Firm to render a determination within [*] of its engagement, and Natera, ROS and their respective agents will cooperate with the Independent Firm during its engagement. The determination of the chosen Independent Firm shall be conclusive and shall become final and binding upon the parties hereto.

 

(e)                                   The fees and expenses of any investigation or audit under this Section 2.4 , including fees and expenses of the Independent Firm, shall be borne by ROS; provided, however, that if the Independent Firm determines that Natera’s initial Net Revenue as set forth in the Royalty Report has resulted in an underpayment of a Royalty Payment due to

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

6



 

ROS for any Fiscal Quarter by more than [*] percent ([*]%), then Natera shall pay the such reasonable fees and expenses of the Independent Firm conducting the audit.

 

(f)                                    If any investigation or audit under this Section 2.4 reveals an underpayment of a Royalty Payment, then Natera shall remit such underpayment to ROS not later than [*] after the completion of such investigation or audit. If any such investigation or audit reveals an overpayment, then ROS shall remit such overpayment to Natera not later than [*] after the completion of such investigation or audit.

 

SECTION 2.5                                              Related Agreements; Access to Records .

 

(a)                             Natera shall, and shall cause its Subsidiaries to, provide ROS, upon request, with true, correct and complete copies of each Related Agreement (including all amendments and supplements thereto).

 

(b)                             Natera shall, and shall cause its Subsidiaries to, provide ROS with access to records required to be maintained pursuant to Section 2.4 to verify and audit the Net Revenue attributable to Natera or such Subsidiaries in accordance with the audit and inspection process described in Section 2.4 . Natera will use commercially reasonable efforts to [*] and relevant to any audit or inspection process described in Section 2.4 .

 

SECTION 2.6                                              Buy-Out Option . At any time after the Closing Date, Natera shall have the right, exercisable in its sole discretion (the “ Buy-Out Option ”), to purchase from ROS all (but not less than all) of its rights to the remaining Royalty Payments that will become due pursuant to Section 2.1 . The amount payable by Natera to ROS in respect of the Buy-Out Option shall be the Purchase Price. If Natera elects to exercise its Buy-Out Option, it shall so notify ROS in writing (the “ Buy-Out Notice ”), which Buy-Out Notice shall set forth a calculation of the Purchase Price in reasonable detail. Delivery of a Buy-Out Notice (and exercise of the Buy-Out Option) shall be irrevocable. Unless ROS disputes in writing, within five (5) Business Days of its receipt of the Buy-Out Notice and with reasonable specificity the calculation of the Purchase Price prior to tender of the Purchase Price (in which case the Buy-Out Notice shall be of no force or effect), Natera shall, on the tenth Business Day following ROS’s receipt of such Buy-Out Notice, purchase from ROS all (but not less than all) of its rights to the remaining Royalty Payments that will become due pursuant to Section 2.1 . The payment of the Purchase Price shall be made by wire transfer of immediately available funds to an account designated by ROS, or, if not timely designated by ROS, to the ROS account set forth on its signature page to this Agreement.

 

SECTION 2.7                                              Release of Excess Collateral Security . At any time after the Termination Date, promptly upon request of Natera, so long as no Royalty Event of Default then exists, ROS agrees to release and reconvey to Natera, or to subordinate in favor of a third party lender designated by Natera, ROS’s Lien on Excess Collateral Security, and further agrees to execute and deliver, at Natera’s sole cost and expense, such financing statement amendments and releases, or subordination agreements if applicable, as reasonably requested by Natera in connection therewith. As used herein, “Excess Collateral Security” means any asset or

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

7



 

properties of Natera over which ROS then has a Lien as requested by Natera so long as, after giving effect to such collateral release or subordination the then applicable maximum Purchase Price is fully secured by a letter of credit in a form and issued by a bank, in each case reasonably acceptable to ROS.

 

SECTION 2.8                                              Lender Appointed as Agent . ROS hereby appoints Lender to act as ROS’s agent as set forth in Section 5.5 of the Pledge and Security Agreement.

 

ARTICLE III.
REPRESENTATIONS AND WARRANTIES

 

Natera hereby represents and warrants to ROS as of the Closing Date as follows:

 

SECTION 3.1                                              Credit Agreement Representations and Warranties . The representations and warranties of the Borrower contained in Article VI of the Credit Agreement are true and correct in all material respects, each such representation and warranty set forth in such Article and all other terms of the Credit Agreement to which reference is made therein, together with all related definitions and ancillary provisions, being hereby incorporated into this Royalty Agreement by this reference as though specifically set forth in this Article. Without limiting the foregoing, Section 6.17 Permits and Section 6.18 Regulatory Matters of the Credit Agreement are incorporated herein by this reference and Natera represents and warrants that the representations and warranties set forth therein are true and correct.

 

SECTION 3.2                                              Enforceability . Natera has the power and authority and the legal right to enter into this Royalty Agreement and perform its obligations hereunder and has taken all necessary action on its part required to authorize the execution and delivery of this Royalty Agreement and the performance of its obligations hereunder. This Royalty Agreement has been duly executed and delivered on behalf of Natera, constitutes a legal, valid and binding obligation of Natera and is enforceable against Natera in accordance with its terms (except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar Laws affecting creditors’ rights generally and by principles of equity).

 

SECTION 3.3                                              Related Agreements . None of Natera or any of the Subsidiaries has breached or defaulted under any provision of any Related Agreement in any material respect, and, to the knowledge of Natera no Related Party has breached or defaulted under any provision of any Related Agreement in any material respect. To the knowledge of Natera, except as otherwise disclosed in writing to ROS, no event has occurred that, upon notice or passage of time or both, could reasonably be expected to give rise to any breach or termination of or default under any Related Agreement by any party thereto.

 

ARTICLE IV.
COVENANTS

 

Natera covenants and agrees with ROS that throughout the Term Natera will, and will cause each of its Subsidiaries to, perform or cause to be performed the obligations set forth below.

 

8



 

SECTION 4.1                                              Transactions with Affiliates . None of Natera or any of its Subsidiaries will enter into or cause or permit to exist any arrangement, transaction or contract (including for the purchase, lease or exchange of property or the rendering of services) with any of its Affiliates, unless:

 

(a) such arrangement, transaction or contract is:

 

(x)(i) between or among Natera or any of its Subsidiaries, (ii) provides normal and reasonable compensation, benefits, reimbursement of expenses and indemnification to officers and directors, (iii) is a cash Investment in Natera, or (iv) is between or among Natera or any of its Subsidiaries on the one hand and a Permitted Joint Venture on the other hand and is not otherwise prohibited hereunder, and

 

(y)(i) is on fair and reasonable terms no less favorable to Natera or any Subsidiary than it could obtain in an arm’s-length transaction with a Person that is not one of its Affiliates and (ii) is of the kind which would be entered into by a prudent Person in its position with a Person that is not one of its Affiliates; or

 

(b) such arrangement, transaction or contract is not between or among Natera and any Parallel Entity and Natera has:

 

(x) provided ROS with not less than [*] prior written notice of such arrangement, transaction or contract and (y) certified in writing to ROS that such arrangement, transaction or contract (i) satisfies the requirements of clause (a)(y), and (ii) has been approved by Natera’s board of directors; or

 

(c) such arrangement, transaction or contract is approved by ROS.

 

SECTION 4.2                                              Maintenance of Existence; Licenses; Compliance with Laws and Related Agreements . Natera and each of the Subsidiaries shall (a) preserve and maintain its legal existence (except as otherwise permitted by Section 8.7 of the Credit Agreement), (b) preserve and maintain in all material respects all rights, privileges, Permits and franchises necessary or desirable in the normal conduct of its business, (c) comply in all material respects with all Laws and Judgments applicable to it, and (d) perform in all material respects its obligations under the Related Agreements to which Natera or any of the Subsidiaries is a party, except to the extent that the failure to do so could not reasonably be expected to affect in any material respect the value of the Royalty Payments.

 

SECTION 4.3                                              Maintenance of Patents . Natera and each of the Subsidiaries shall prosecute and maintain, at its own expense, each Patent included in the Intellectual Property, unless the failure to prosecute and maintain such Patent either (a) [*] or (b) [*].

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

9



 

SECTION 4.4                                              Enforcement of Intellectual Property

 

(a)                                  Natera shall promptly inform ROS of any suspected infringement by a Third Party of any Intellectual Property that Natera determines in its reasonable business judgment is reasonably likely to adversely affect in any material respect the value of the Royalty Payments. Natera shall promptly provide ROS with a copy of any written notice of any such suspected infringement of Intellectual Property delivered or received by Natera or any of its Subsidiaries as soon as practicable and in any event not less than [*] following such delivery or receipt.

 

(b)                                  Natera shall have the right (but not the obligation) to initiate, at its sole expense, an enforcement of the Intellectual Property against any Third Party. All sums received (including awards, damages and settlement payments) for compensatory damages only as a result of any enforcement of the Intellectual Property by Natera under this Section 4.4(b ), after deduction of all reasonable costs and expenses (including attorneys’ fees and expenses) incurred by Natera in connection with such enforcement, shall be included in the calculation of Net Revenue for the Fiscal Quarter in which any such amounts are indefeasibly received by Natera.

 

SECTION 4.5                                              Challenges to Intellectual Property .

 

(a)                                  Natera shall promptly inform ROS of any written notice of any challenge to the Intellectual Property that could reasonably be expected to adversely affect in any material respect the value of the Royalty Payments, and shall provide to ROS a copy of any such written notice of any such written notice received by Natera or any of its Subsidiaries as soon as practicable and in any event not less than five business days following such receipt.

 

(b)                                  Natera shall have the right (but not the obligation) to initiate, at its sole expense, a defense against such challenge to the Intellectual Property. If Natera elects to bring such a defense, Natera shall so notify ROS and use commercially reasonable efforts to defend the Intellectual Property against such challenge. Natera shall provide prompt written notice to ROS of the initiation of such defense. All sums received (including awards, damages and settlement payments), if any, as a result of any such defense by Natera under this Section 4.5(b ) shall for all purposes be excluded from the calculation of Net Revenue; provided, that the net amount received by Natera pursuant to any cross claim or counterclaim on account of compensatory damages only shall be included in the calculation of Net Revenue to the same extent as such amounts would be included pursuant to an enforcement of Intellectual Property under Section 4.4(b) .

 

(c)                                   In the event that Natera determines that it will not defend against such challenge to the Intellectual Property, Natera shall promptly inform ROS of that determination and ROS shall have the right (but not the obligation) to defend such challenge, on behalf of Natera but at ROS’s sole expense (an “ ROS Defense ”), subject to Section 4.5(d), and Natera agrees to be named as a party to any action, suit or other proceeding in connection therewith, if, in ROS’s view, it is necessary or desirable to do so. ROS shall (i) provide prompt written notice to Natera of the initiation of such defense and (ii) keep Natera promptly informed of the status of, and all material developments in, such defense. Natera shall also, at ROS’s sole expense, cooperate fully with ROS and

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

10



 

provide such assistance as ROS may reasonably request in connection with such ROS Defense. All sums received (including awards, damages and settlement payments), if any, as a result of any such ROS Defense of the Intellectual Property by ROS under this Section 4.5(c ) shall be allocated be allocated 95% to ROS and 5% to Natera and shall for all purposes be excluded from the calculation of Net Revenue.

 

(d)                                  In the event that ROS decides to pursue an ROS Defense, ROS agrees to indemnify Natera, each of its Subsidiaries and each of their respective officers, directors, employees and agents (collectively, the “ Indemnified Parties ”) for, and to defend, exonerate and hold Natera and each other Indemnified Party free and harmless, from and against, any and all actions, causes of action, suits, losses, costs, liabilities, obligations and damages, and expenses incurred in connection with or as a consequence of each and every ROS defense (including with respect to any counterclaims or cross claims and irrespective of whether any such Indemnified Party is a party to the action for which indemnification hereunder is sought), including reasonable attorneys’ and professionals’ fees and disbursements, whether incurred in connection with actions between the parties hereto or the parties hereto and Third Parties.

 

SECTION 4.6                                              [Intentionally omitted]

 

SECTION 4.7                                              Related Agreements . Promptly, and in any event within [*] following Natera becoming aware of a breach of any Related Agreement by a Related Party, in each case that could reasonably be expected to adversely affect in any material respect the value of the Royalty Payments, Natera shall provide notice of such breach to ROS. In addition, Natera shall provide to ROS a copy of any written notice of any such breach or alleged breach of any Related Agreement delivered or received by Natera or any of its Subsidiaries as soon as practicable and in any event not less than [*] following such delivery or receipt.

 

SECTION 4.8                                              No Impairments; Diligence . Natera agrees to meet such standards in developing and marketing the Products as are reasonable and customary in the industry and as required by this Royalty Agreement, until such time as Natera determines in its sole discretion that the Products is not “commercially marketable”. Nothing in this Royalty Agreement, however, will require Natera to develop, sell or market the Products should Natera determine, in its sole judgment, that a Product is not commercially marketable. In the event of a determination that the Products are not commercially marketable, Natera shall provide ROS with prompt written notice of such determination.

 

SECTION 4.9                                              Further Assurances; Information . Natera shall, shall cause each of its Subsidiaries to furnish, execute and deliver such additional documents, certificates, instruments, and statements, provide such additional data and information, and perform such additional acts, in each case, as may be reasonably requested by ROS in connection with, or in furtherance of, any of the provisions of this Royalty Agreement.

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

11


 

ARTICLE V.
EVENTS OF DEFAULT; REMEDIES

 

SECTION 5.1                                              Events of Default . The occurrence of any of the following events shall constitute a “ Royalty Event of Default ” under this Royalty Agreement:

 

(a)                                  Natera shall default in the payment (i) of any Royalty Payment when due hereunder, or (ii) any other payment when due hereunder, and in the case of clause (ii ) such default shall continue for a period of thirty days after such amount was due, or (iii) default in the payment when due (after any applicable period of grace) of any amount under the Credit Agreement;

 

(b)                                  Any representation or warranty of Natera contained or incorporated by reference herein, or in any Royalty Report, shall at any time prove to have been incorrect in any material respect when made;

 

(c)                                   An Event of Default (after any applicable period of grace) shall exist under Section 9.1(c) of the Credit Agreement;

 

(d)                                  Natera or any Subsidiary shall default in the due performance and observance of any other covenant, obligation or agreement contained in any Loan Document executed by it, and such default shall continue unremedied for a period of 30 days after the earlier to occur of (i) notice thereof given to Natera by ROS or (ii) the date on which Natera has knowledge of such default;

 

(e)                                   a default shall occur in the payment of any amount when due (subject to any applicable grace period), whether by acceleration or otherwise, of any principal or stated amount of or interest or fees on, any Indebtedness of Natera or any of the Subsidiaries having a principal or stated amount, individually or in the aggregate, in excess of $500,000, or a default shall occur in the performance or observance of any obligation or condition with respect to such Indebtedness if the effect of such default is to accelerate the maturity of any such Indebtedness or such default shall continue unremedied for any applicable period of time sufficient to permit the holder or holders of such Indebtedness, or any trustee or agent for such holders, to cause or declare such Indebtedness to become due and payable or to require such Indebtedness to be prepaid, redeemed, purchased or defease, or require an offer to purchase or defease such Indebtedness to be made, prior to its expressed maturity;

 

(f)                                    any judgment or order for the payment of money individually or in the aggregate in excess of $500,000 (exclusive of any amounts fully covered by insurance (less any applicable deductible) and as to which the insurer has acknowledged its responsibility to cover such judgment or order) shall be rendered against Natera or any of the Subsidiaries and such judgment shall not have been vacated or discharged or stayed or bonded pending appeal within 30 days after the entry thereof or enforcement proceedings shall have been commenced by any creditor upon such judgment or order;

 

(g)                                   any Loan Document shall (except in accordance with its terms) terminate or the terms thereof shall cease to be the legally valid, binding and enforceable obligation

 

12



 

of Natera or any Subsidiary thereto; Natera or any Subsidiary shall contest in any manner such validity, binding nature or enforceability; or, except as permitted under any Loan Document, any Lien securing any Obligation shall, in whole or in any material part, cease to be a perfected first priority Lien;

 

(h)                                  any Key Permit or any of Natera’s or any Subsidiary’s material rights or interests thereunder is terminated or amended in any manner materially adverse to Natera or Natera and its Subsidiaries taken as a whole;

 

(i)                                      any circumstance occurs that has had or would reasonably be expected to cause a Material Adverse Effect;

 

(j)                                     (i) the FDA, CMS, EMA or any other Governmental Authority (A)  issues a letter or other communication asserting that any Product lacks a required Regulatory Authorization or (B)  initiates enforcement action against, or issues a warning letter with respect to, Natera or any of the Subsidiaries, or any of their Products or the manufacturing facilities therefor, that causes Natera or such Subsidiary to discontinue marketing or withdraw any of its material Products, or causes a material delay in the manufacture or offering of any of its material Products, which discontinuance, withdrawal or delay could reasonably be expected to last for more than three months; (ii)  a recall; or (iii)  Natera or any of the Subsidiaries enters into a settlement agreement with the FDA, CMS, EMA or any other Governmental Authority, if any of the foregoing has had or would reasonably be expected to have or result in a Material Adverse Effect;

 

(k)                                  Any Change in Control shall occur; or

 

(l)                                      Natera or (except as permitted under the Credit Agreement) any of its Subsidiaries shall

 

(i)                                      become insolvent or generally fail to pay, or admit in writing its inability or unwillingness generally to pay, debts as they become due;

 

(ii)                                   apply for, consent to, or acquiesce in the appointment of a trustee, receiver, sequestrator or other custodian for any substantial part of the property of any thereof, or make a general assignment for the benefit of creditors;

 

(iii)                                in the absence of such application, consent or acquiescence in or permit or suffer to exist the appointment of a trustee, receiver, sequestrator or other custodian for a substantial part of the property of any thereof, and such trustee, receiver, sequestrator or other custodian shall not be discharged within 60 days; provided that, Natera hereby expressly authorizes ROS to appear in any court conducting any relevant proceeding during such 60 day period to preserve, protect and defend its rights under this Royalty Agreement;

 

(iv)                               permit or suffer to exist the commencement of any bankruptcy, reorganization, debt arrangement or other case or proceeding under any bankruptcy or insolvency law or any dissolution, winding up or liquidation proceeding, in respect thereof, and, if any such case or proceeding is not

 

13



 

commenced by Natera, such case or proceeding shall be consented to or acquiesced in by Natera, or shall result in the entry of an order for relief or shall remain for 60 days undismissed; provided that, Natera hereby expressly authorizes ROS to appear in any court conducting any such case or proceeding during such 60 day period to preserve, protect and defend its rights under this Royalty Agreement; or

 

(v)                                  take any action authorizing, or in furtherance of, any of the foregoing.

 

SECTION 5.2                                              Put Option . Upon the occurrence of, and during the continuation of, any Royalty Event of Default, in addition to any other rights and remedies available to ROS under this Royalty Agreement, any other Loan Document or otherwise, ROS shall have the right (at its option) to require Natera to purchase from ROS all of its rights to the remaining Royalty Payments that will become due pursuant to Section 2.1 (the “Put Option”) . The amount payable by Natera to ROS in respect of the Put Option shall be the Purchase Price. If ROS elects to exercise its Put Option, it shall so notify Natera in writing (the “ Put Notice ”), which Put Notice shall set forth a calculation of the Purchase Price in reasonable detail. Natera shall, on the fifth Business Day following its receipt of such Put Notice, pay the Purchase Price to ROS. The payment of the Purchase Price pursuant to this Section 5.2 shall be made by wire transfer of immediately available funds to an account designated by ROS.

 

SECTION 5.3                                              Other Rights and Remedies .

 

(a)                                    ROS shall have the right to enforce the provisions of this Royalty Agreement or any other Loan Document by legal proceedings for the specific performance of any covenant or agreement contained herein or for the enforcement of any other appropriate legal or equitable remedy, and ROS may recover its costs and expenses caused by any breach by Natera of the provisions of this Royalty Agreement or as a result of, or in connection with, the occurrence of any Royalty Event of Default, including court costs, attorneys’ fees and other costs and expenses incurred in the enforcement of the obligations of Natera, or any rights of ROS, under this Royalty Agreement .

 

(b)                                    ROS shall have the right to exercise all rights and remedies under this Royalty Agreement or any other Loan Document and all other rights and remedies which ROS may have under applicable Law or otherwise.

 

ARTICLE VI.
TERM

 

SECTION 6.1                                              Term . The term of this Royalty Agreement (the “ Term ”) shall commence on the Closing Date and shall expire on the first anniversary of the last day of the Royalty Term.

 

SECTION 6.2                                              Survival . The expiration of this Royalty Agreement shall be without prejudice to any rights or obligations of the Parties that may have accrued prior to such

 

14



 

expiration or termination, and the provisions of Article VII and Sections 6.2 , 8.4 , 8.5 , 8.8 , 8.9 , 8.11 and 8.12 shall survive the expiration of this Royalty Agreement.

 

ARTICLE VII.
CONFIDENTIALITY

 

SECTION 7.1                                              Confidential Information . Subject to the provisions of Section 7.2 , at all times prior to the fifth anniversary of the Royalty Term, the Receiving Party shall keep confidential and shall not publish or otherwise disclose any Confidential Information furnished to it by the Disclosing Party, except to those of the Receiving Party’s employees, advisors or consultants who have a need to know such information to assist such Party in the performance of such Party’s obligations or in the exercise of such Party’s rights hereunder and who are subject to obligations of confidentiality consistent with these provisions (collectively, “ Recipients ”). Notwithstanding anything to the contrary set forth herein, (a) ROS may disclose this Royalty Agreement and the terms and conditions hereof and any information related hereto, including the Royalty Reports (other than to any Competitor of Natera or any of its Subsidiaries) to (i) its Affiliates, (ii) potential and actual assignees of any of ROS’s rights hereunder (including the right to receive any Payments hereunder) and (iii) potential and actual investors in, or lenders to, ROS (including, in each of the foregoing cases, such Person’s employees, advisors or consultants); provided that in each case, each such Recipient shall be subject to reasonable obligations of confidentiality; and (b) upon receiving consent from ROS, which consent shall not be unreasonably withheld, delayed or conditioned, Natera may disclose this Royalty Agreement and the terms and conditions hereof and information related hereto, to potential or actual permitted acquirers or assignees, collaborators and other (sub)licensees, permitted subcontractors, investment bankers, investors, lenders (including, in each of the foregoing cases, such Person’s employees, advisors or consultants who have a need to receive and review such information); provided that in each case, each such Recipient shall be subject to reasonable obligations of confidentiality. In addition to the foregoing, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in order to comply with applicable laws (including any securities law or regulation or the rules of a securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance, provided that the Receiving Party (x) will only disclose those portions of the Confidential Information that are necessary or required to be so disclosed, (y) to the extent legally permissible, will notify the Disclosing Party of the Receiving Party’s intent to make any disclosure pursuant thereto, and (z) to the extent reasonably practicable, the Receiving Party shall provide such notice in advance of the disclosure so as to allow the Disclosing Party an opportunity to seek (at the Disclosing Party’s sole expense) a protective order or other appropriate remedy; provided, however, that no such notice will be required in respect of disclosures of Confidential Information to regulatory authorities having or claiming to have jurisdiction over the Receiving Party in connection with routine regulatory examinations. In the event that no such protective order or other remedy is obtained or that the Disclosing Party waives compliance with the provisions hereof, the Receiving Party and its Representatives may disclose such Confidential Information as may be required or requested pursuant to such laws or judicial process.

 

15



 

SECTION 7.2                                              Exceptions to Confidentiality . The Receiving Party’s obligations set forth in this Royalty Agreement shall not extend to any Confidential Information of the Disclosing Party:

 

(a)                                  that is or hereafter becomes part of the public domain (other than as a result of a disclosure by the Receiving Party or its Recipients in violation of this Royalty Agreement);

 

(b)                                  that is received from a Third Party without restriction on disclosure and without, to the knowledge of the Receiving Party, breach of any agreement between such Third Party and the Disclosing Party;

 

(c)                                   that the Receiving Party can demonstrate by competent evidence was already in its possession without any limitation on disclosure prior to its receipt from the Disclosing Party;

 

(d)                                  that is generally made available to Third Parties by the Disclosing Party without restriction on disclosure; or

 

(e)                                   that the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party.

 

SECTION 7.3                                              Remedies . Each Party agrees that the unauthorized disclosure of any information by the Receiving Party in violation of this Royalty Agreement will cause severe and irreparable damage to the Disclosing Party. In the event of any violation of this Article 7, the Receiving Party agrees that the Disclosing Party shall [*].

 

SECTION 7.4                                              Press Releases . No Party shall, and each Party shall instruct its Affiliates not to, issue a press release or other public announcement or otherwise make any public disclosure with respect to this Royalty Agreement or the subject matter hereof without the prior consent of the other Party hereto (which consent shall not be unnecessarily withheld or delayed), except as may be required by applicable Law (in which case the Party required to make the release or statement shall allow the other Party reasonable time to comment on such release or statement in advance of such issuance).

 

ARTICLE VIII.
MISCELLANEOUS PROVISIONS

 

SECTION 8.1                                              Loan Document . This Royalty Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with Article X thereof (including Section 10.4 thereof), which is incorporated herein by reference and deemed to apply to Natera, ROS and this Royalty Agreement, as applicable, throughout the Term (whether or not, and without regard to, any earlier termination of the Credit Agreement).

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

16



 

SECTION 8.2                                              Binding on Successors, Transferees and Assigns; Assignment . This Royalty Agreement shall remain in full force and effect until the Term has concluded and shall be binding upon the Parties hereto and their respective successors, transferees and assigns; provided that Natera may not assign or transfer any of its rights or obligations hereunder without the prior written consent of ROS; and provided further that ROS may not assign or transfer any of its rights or obligations hereunder to any Competitor without the prior written consent of Natera, except in the event that (i) a Royalty Event of Default has occurred and (ii) such Royalty Event of Default continues for thirty (30) days after ROS has notified Natera of its intent to make such an assignment or transfer to a Competitor .

 

SECTION 8.3                                              Amendments, etc . No amendment to or waiver of any provision of this Royalty Agreement, nor consent to any departure by Natera from its obligations under this Royalty Agreement, shall in any event be effective unless the same shall be in writing and signed by ROS, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

SECTION 8.4                                              Notices . All notices and other communications provided for hereunder shall be given or made as set forth in Section 10.2 of the Credit Agreement. Documents required to be delivered pursuant to Section 2.1(d), Section 2.4(b), Section 4.4.(a), Section 4.7 and Section 4.8 may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which (i) Natera posts such documents, or provides a link thereto on Natera’s website or the Internet at the following website address: [*] or (ii) such documents are posted on Natera’s behalf on an Internet or intranet website, if any, to which ROS has access (whether a commercial or third-party website), and in each case an email with a link to such posting has been provided to ROS’s email addresses set forth on Schedule 10.2 of the Credit Agreement.

 

SECTION 8.5                                              No Waiver; Remedies . No failure on the part of ROS to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by Law.

 

SECTION 8.6                                              Section Captions . Section captions used in this Royalty Agreement are for convenience of reference only and shall not affect the construction of this Royalty Agreement.

 

SECTION 8.7                                              Severability . Any provision of this Royalty Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Royalty Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

 

SECTION 8.8                                              Governing Law, Entire Agreement, etc . THIS ROYALTY AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS ROYALTY AGREEMENT SHALL BE GOVERNED BY, AND

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

17



 

CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Royalty Agreement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter hereof and supersedes any prior agreements, written or oral, with respect hereto.

 

SECTION 8.9                                              Forum Selection and Consent to Jurisdiction . ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS ROYALTY AGREEMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF ROS OR ANY GUARANTOR IN CONNECTION HEREWITH, SHALL BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE OPTION OF ROS, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. EACH OF NATERA AND ROS IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK AT THE ADDRESS FOR NOTICES SPECIFIED IN SECTION 10.2 OF THE CREDIT AGREEMENT. EACH OF NATERA AND ROS HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT THAT EITHER NATERA OR ROS HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, EACH OF NATERA AND ROS, ON ITS OWN BEHALF HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER THIS ROYALTY AGREEMENT.

 

SECTION 8.10                                       Counterparts . This Royalty Agreement may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. This Royalty Agreement shall become effective when counterparts hereof executed on behalf of Natera and ROS shall have been received by ROS. Delivery of an executed counterpart of a signature page to this Royalty Agreement by email (e.g. “pdf’ or “tiff’) or telecopy shall be effective as delivery of a manually executed counterpart of this Royalty Agreement.

 

SECTION 8.11                                       Waiver of Jury Trial . NATERA AND ROS HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY

 

18



 

IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS ROYALTY AGREEMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF NATERA OR ROS IN CONNECTION HEREWITH. EACH OF NATERA AND ROS ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR ROS AND NATERA, RESPECTIVELY TO ENTER INTO THIS ROYALTY AGREEMENT.

 

SECTION 8.12                                       Relationship of the Parties . The status of a Party under this Royalty Agreement shall be that of an independent contractor. Nothing contained in this Royalty Agreement shall be construed as creating a partnership, joint venture or agency relationship between Natera or any of its Affiliates, on the one hand, and ROS or any of its Affiliates, on the other hand. Except to the limited extent expressly provided in this Royalty Agreement, no Party hereto shall have the authority to bind, obligate or represent any other Party hereto.

 

[ Signature Page Follows ]

 

19



 

IN WITNESS WHEREOF, the Parties have executed this Royalty Agreement on the day and year first above written.

 

 

NATERA, INC.

 

 

 

 

 

By:

/s/ Matthew Rabinowitz

 

Name:

Matthew Rabinowitz

 

Title:

Chief Executive Officer

 

 

 

 

 

ROYALTY OPPORTUNITIES S.AR.L

 

By OrbiMed Advisors LLC,

 

its investment manager

 

 

 

 

 

By:

/s/ Samuel D. Isaly

 

Name:

Samuel D. Isaly

 

Title:

Managing Member

 

 

 

Account Information:

 

 

 

Number:

[*]

 

Bank:

[*]

 

Address:

[*]

 

 

 

 

[*]

 

 

Signature Page to Royalty Agreement

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 


 

Execution Version

 

FIRST AMENDMENT TO ROYALTY AGREEMENT

 

This FIRST AMENDMENT TO ROYALTY AGREEMENT (this “ Amendment ”) is made and entered into as of June 6, 2014 by and among NATERA, INC., a Delaware corporation (“ Natera ”), and ROYALTY OPPORTUNITIES S.À R.L, a Luxembourg société à responsabilité limitée (“ ROS ”).

 

WHEREAS, Natera and ROS are party to that certain Royalty Agreement, dated as of April 18, 2013 (the “ Royalty Agreement ”);

 

WHEREAS, pursuant to Section 8.3 of the Royalty Agreement, the Royalty Agreement may be amended by an instrument in writing signed by ROS; and

 

WHEREAS, Natera and ROS hereto desire to amend certain provisions of the Royalty Agreement as provided in this Amendment.

 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.             Definitions; Loan Document . Capitalized terms used herein without definition shall have the meanings assigned to such terms in the Royalty Agreement. This Amendment shall constitute a Loan Document for all purposes of the Royalty Agreement and the other Loan Documents.

 

2.             Amendment to Definition of Purchase Price . The definition of “Purchase Price” in Section 1.1 of the Royalty Agreement is hereby amended so that the definition reads in its entirety as follows:

 

Purchase Price ” means, with respect to either (x) Natera’s election to exercise its Buy-Out Option at any time, or (y) ROS’s election to exercise its Put Option upon the occurrence of a Royalty Event of Default, an amount, payable by Natera to ROS in U.S. Dollars to an account designated in writing by ROS, equal to the difference between (i) the applicable amount set forth in the table below (the “ Applicable Amount ”) opposite the applicable period (the “ Applicable Period ”) set forth in the table below, during which such Buy-Out Option or Put Option, as the case may be, was exercised (or deemed to be exercised), less (ii) the Recovered Amount. The Purchase Price shall not be less than zero.

 



 

 

 

 

 

Applicable

 

Applicable

 

 

 

 

 

Amount if the

 

Amount if the

 

 

 

Applicable

 

Delayed Draw Loan

 

Delayed Draw Loan

 

 

 

Amount if the Delayed

 

Has Been Funded in

 

Has Been Funded in

 

 

 

Draw Loan Has Not

 

an Amount Equal to

 

an Amount Equal to

 

Applicable Period

 

Been Funded

 

$10,000,000

 

$20,000,000

 

On or before the 1st anniversary of the Closing Date

 

$

8,000,000

 

$

10,000,000

 

$

11,000,000

 

After the 1st anniversary of the Closing Date and on or before the 2nd anniversary of the Closing Date

 

$

8,875,000

 

$

11,000,000

 

$

12,000,000

 

After the 2nd anniversary of the Closing Date and on or before the 3rd anniversary of the Closing Date

 

$

9,750,000

 

$

12,000,000

 

$

13,000,000

 

After the 3rd anniversary of the Closing Date and on or before the 4th anniversary of the Closing Date

 

$

10,625,000

 

$

13,000,000

 

$

14,000,000

 

Any time after the 4th anniversary of the Closing Date

 

$

11,500,000

 

$

14,000,000

 

$

15,000,000

 

 

3.             Amendment to Section 2.1(b ) . Section 2.1 of the Royalty Agreement is hereby amended by deleting clause (b) of such Section and replacing such clause with the following:

 

“(b) Natera shall (or shall cause a Subsidiary to) pay to ROS, in respect of each Fiscal Year (or portion of a Fiscal Year, in the case of the first Fiscal Year and last Fiscal Year of the Royalty Term) during the Royalty Term and during the Fiscal Quarter in which the Delayed Draw Loan has been funded and thereafter, a royalty amount equal to (i) if the Delayed Draw Loan has been funded in an amount equal to $10,000,000 the sum of (x) 1.00% of the aggregate Net Revenue during such Fiscal Year (or portion of a Fiscal Year, as the case may be) up to $50,000,000 of such Net Revenue, plus (y) 1.50% of the aggregate Net Revenue during such Fiscal Year (or portion of a Fiscal Year, as the case may be) in excess of $50,000,000 or (ii) if the Delayed Draw Loan has been funded in an amount equal to $20,000,000 the sum of (A) 1.50% of the aggregate Net Revenue during such Fiscal Year (or portion of a Fiscal Year, as the case may be) up to $50,000,000 of such Net Revenue, plus (B) 2.00% of the aggregate Net

 

2



 

Revenue during such Fiscal Year (or portion of a Fiscal Year, as the case may be) in excess of $50,000,000.”

 

4.           Conditions to Effectiveness of Amendment . This Amendment shall become effective upon receipt by ROS of (i) a Secretary’s Certificate, in a form reasonably acceptable to ROS, duly executed and delivered by the signatories thereto, and (ii) a counterpart signature to this Amendment duly executed and delivered by Natera.

 

5.           Expenses . [*]

 

6.           No Implied Amendment or Waiver . Except as expressly set forth in this Amendment, this Amendment shall not, by implication or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of ROS under the Royalty Agreement or the other Loan Documents, or alter, modify, amend or in any way affect any of the terms, obligations or covenants contained in the Royalty Agreement or the other Loan Documents, all of which shall continue in full force and effect. Nothing in this Amendment shall be construed to imply any willingness on the part of ROS to agree to or grant any similar or future amendment, consent or waiver of any of the terms and conditions of the Royalty Agreement or the other Loan Documents.

 

7.           Counterparts; Governing Law . This Amendment may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of such when so executed and delivered shall be an original, but all of such counterparts shall together constitute but one and the same agreement. Delivery of an executed counterpart of a signature page of this Amendment by fax transmission or other electronic mail transmission (e.g., “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Amendment. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).

 

[Remainder of Page Intentionally Left Blank]

 


[*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

 

3



 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized as of the day and year first above written.

 

 

 

NATERA, INC.

 

 

 

 

 

By:

/s/ Matthew Rabinowitz

 

Name:

Matthew Rabinowitz

 

Title:

Chief Executive Officer

 

 

 

 

 

ROYALTY OPPORTUNITIES S.À R.L,

 

 

 

By OrbiMed Advisors LLC,

 

its investment manager

 

 

 

 

 

By:

/s/ Samuel D. Isaly

 

Name:

Samuel D. Isaly

 

Title:

Managing Member

 

Signature Page to First Amendment to Royalty Agreement

 




Exhibit 10.13

 

CONFIDENTIAL TREATMENT REQUESTED

CONFIDENTIAL

CONFORMED COPY

 

 

SUPPLY AGREEMENT
(TG CONSUMABLES)

 

This Supply Agreement (the “ Agreement ”), as amended on September 18, 2014 (the “ First Amendment Date ”), is effective as of the date of last signature found below (the “ Effective Date ”) between Illumina, Inc., a Delaware corporation having a place of business at 5200 Illumina Way, San Diego, CA 92122 (“ Illumina ”) and Natera, Inc., having a place of business at 201 Industrial Road, Suite 410, San Carlos, CA 94070 (“ Customer ”).  Customer and Illumina may be referred to herein as “ Party ” or “ Parties .”

 

The Parties agree as follows:

 

1.               Definitions .  The following terms have these meanings.

 

Additional Clinical Use ” is defined on Exhibit A , Part 2 .

 

Affiliate(s) ” means with respect to a Party, any entity that, directly or indirectly, controls, is controlled by or is under common control with such Party for so long as such control exists.  For purposes of this definition, an entity has control of another entity if it has the direct or indirect ability or power to direct or cause the direction of management policies of such other entity or otherwise direct the affairs of such other entity, whether through ownership of the voting securities of such other entity, by contract or otherwise.

 

Application Specific IP ” means the Illumina Intellectual Property Rights that pertain to the Product, or use thereof, only with regard to specific field(s) or specific application(s).  Application Specific IP excludes all Core IP.  By way of non-limiting example, Illumina Intellectual Property Rights for NIPT, for specific diagnostic methods, for specific forensic methods, or for specific nucleic acid biomarkers, sequences, or combinations of biomarkers or sequences are examples of Application Specific IP.  For the avoidance of doubt, to the extent Illumina Intellectual Property Rights pertain solely to use of a Product to sequence genetic material, and do not pertain to subsequent use (for NIPT or otherwise) of the sequence data generated from such sequencing, those Illumina Intellectual Property Rights are within Core IP and are not within Application Specific IP.

 

Clinical Use ” is NIPT Use and/or Additional Clinical Use.

 

Consumable(s) ” means Illumina-Branded reagents and consumable items that are intended by Illumina for use with, and are to be consumed through the use of, Illumina Hardware.  Consumables are either TG Consumables (which Consumables are designated on Exhibit B with the pre-fix “TG” in their part number) or Non-TG Consumables (which are all other Consumables, including Temporary Consumables, as defined on Exhibit A and including the Temporary Consumables in the Final Shipment Purchase Order, as set forth in Section 7(e)).  All references in this Agreement to Consumables means both TG Consumables and Non-TG Consumables, unless specified otherwise in this Agreement.  Consumables purchasable under this Agreement as of the Effective Date are set forth on Exhibit B and, with respect to Temporary Consumables in the Final Shipment Purchase Order, set forth in Section 7(e).

 

Core IP ” means Illumina Intellectual Property Rights that pertain to or cover aspects or features of the Product, or use thereof, without regard to any specific application or field of use.  To avoid any doubt, and without limitation, Core IP specifically excludes any and all Illumina Intellectual Property Rights directed to NIPT, other than to the extent Illumina Intellectual Property Rights pertain solely to use of a Product to sequence genetic material and do not pertain to subsequent use for NIPT of the sequence data generated from such sequencing.

 

Customer Use ” means the fields of use specified on Exhibit A , Part 1 (NIPT Use), Part 2 (Additional Clinical Use) and Part 3 (Research Use), specifically excluding without limitation any use that (i) is not in accordance with the Product’s Specifications or Documentation, (ii) requires grants of rights or a license to any Application Specific IP (unless such rights or license are expressly granted in Exhibit A ), (iii) is a re-use of a previously used Consumable, (iv) is the disassembling, reverse-engineering, reverse-compiling, or reverse-assembling of the Product, (v) is the separation, extraction, or isolation of components of Consumables or other unauthorized analysis of the Consumables, (vi) seeks to gain access to or determine the methods of operation of the Product that are not discoverable through the use of the Product in accordance with this Agreement, (vii) is a use of a non-Illumina reagent/consumable with Illumina Hardware (unless the Specifications or Documentation state otherwise), or (viii) is the transfer to a third party of any Consumable or Software (including Embedded Software, or sub-licensing of any rights received hereunder, including rights to Software or third party software, wherein the exclusions in (i) through (viii) are the “ Exclusions ”.

 

1



 

Country ” or “ Countries ” means the following countries:  United States

 

Documentation ” means Illumina’s user manual, package insert and similar documentation for a Product that is provided to Customer or that is otherwise made publicly available (e.g., on Illumina’s website) and in effect on the date that the Product ships.  Documentation may be provided (including by reference to a website) with the Product at the time of shipment or provided electronically from Illumina.

 

Existing Instruments ” means Illumina Hardware that was purchased by Customer and supplied by Illumina prior to the Effective Date and that Customer intends to use with the Consumables purchased under this Agreement.

 

Existing Purchase Order ” means the purchase orders for Products dated March 20, 2013, and identified as PO#100531 (quote 2013-51136) and PO#100532 (quote 2013-51138), including any modifications (if any) that have been mutually agreed to between the Parties in writing.

 

Facility ” or “ Facilities ” means laboratories in the Country(ies) that are either owned by, rented by or leased by Customer.

 

Final Shipment Purchase Order ” is defined in Section 7(e).

 

Illumina-Branded ” means bearing Illumina branding or the branding of any Affiliate of Illumina.

 

Illumina Hardware ” means Illumina-Branded instruments, accessories or peripherals.  The Illumina Hardware purchaseable under this Agreement as of the Effective Date is set forth on Exhibit B .

 

Illumina Intellectual Property Rights ” means any and all Intellectual Property Rights owned or controlled by Illumina or Affiliates of Illumina as of the date of shipment of the Product from Illumina and thereafter during the Term.  Application Specific IP and Core IP are separate, non-overlapping, subsets within the Illumina Intellectual Property Rights.

 

Intellectual Property Right(s) ” means any and all rights in patents, copyrights, trade secrets, know-how, trademark, service mark and trade dress rights and other industrial or intellectual property rights under the laws of any jurisdiction, together with all applications therefor and registrations thereto.

 

NIPT ” means non-invasive pre-natal testing.

 

NIPT Use ” is defined on Exhibit A , Part 1 .

 

Product(s) ” means the Consumables, Illumina Hardware, or Software that are offered for sale under, purchased under, or supplied under this Agreement, wherein as of the Effective Date the Products are set forth on Exhibit B and, with respect to Temporary Consumables in the Final Shipment Purchase Order, set forth in Section 7(e), and include Software related thereto,

 

Research Use ” is defined on Exhibit A , Part 3 .

 

Software ” means Illumina-Branded software (e.g., Hardware operating software, data analysis software), regardless of whether it is embedded in or installed on Illumina Hardware or provided separately.  “ Embedded Software ” means all Software embedded in or installed on Illumina Hardware or provided by Illumina in connection with its provision of Illumina Hardware (and not ordered separately by Customer).

 

Specifications ” means Illumina’s written specifications for a Product in effect for that Product on the date that the Product ships, as set forth in the applicable Documentation.

 

2



 

2.               Applicability of Terms and Conditions .

 

a.               Scope .  (i) This Agreement exclusively governs the ordering, purchase, supply, and use of Products, and its terms shall override any conflicting, amending and/or additional terms contained in any purchase orders, invoices or similar documents regarding Products, which are hereby rejected and shall be null and void.  Failure of Illumina or Customer to object to any such conflicting, amending and/or additional terms shall not constitute a waiver by Illumina or Customer, nor constitute acceptance by Illumina or Customer of such terms.  The conditions and restrictions on use and other activities set forth in this Agreement are bargained for conditions of sale and, therefore, control the sale of Products and the rights in and to Products provided to Customer at purchase.  For the avoidance of doubt, Customer may, at Customer’s election, purchase Illumina products (other than the Products that are purchaseable under this Agreement) under Illumina’s standard terms and conditions of sale (outside of this Agreement) and use those products for the uses allowed under Illumina’s standard terms and conditions of sale.  (ii) However, unless an authorized officer of Illumina provides express, unambiguous written agreement otherwise, Customer may not use Illumina consumable reagents purchased outside of this Agreement for NIPT Use or Additional Clinical Use.

 

b.               Consumables .  The Consumables that may be purchased under this Agreement as of the Effective Date are set forth in Exhibit B and, with respect to Temporary Consumables in the Final Shipment Purchase Order, set forth in Section 7(e).  Upon the mutual agreement of the Parties, additional Consumables may be added to Exhibit B in accordance with Section 20(j) (Amendment).

 

c.                Instruments .  The Illumina Hardware that may be purchased under this Agreement as of the Effective Date is set forth in Exhibit B .  Upon the mutual agreement of the Parties, additional Illumina Hardware may be added to Exhibit B in accordance with Section 20(j) (Amendment).  For the avoidance of doubt, (i) notification of changes to Illumina Hardware and associated Embedded Software are not provided, and (ii) only Illumina Hardware listed in Exhibit B , as may be amended from time-to-time in writing by the Parties, may be purchased under this Agreement.

 

d.               Instrument Service Contract .  Customer will purchase and maintain during the Term a Gold Level Service Contract on all Illumina Hardware that are present in Facility(ies) during the Term.  The Gold Level Service Contract terms are set forth in Exhibit F and pricing is set forth in Exhibit E .

 

3.               Rights Accompanying Purchase of Product for Customer Use .

 

a.               Products .  Use rights accompanying purchase of Products under this Agreement, and certain additional obligations and requirements associated with the particular fields of Customer Use, are set forth on Exhibit A and this Section 3.  Customer is not granted any rights, express or implied, under this Agreement with respect to (A) distribution of any Product or acting as a distributor of any Product, (B) any direct-to consumer activity (other than in the field of paternity testing to the extent such is a permitted Customer Use), (C) manufacture, marketing, distribution, or sale of a kit, including a kit that incorporates any Products, and including an in vitro diagnostic device (IVD) .  Customer acknowledges and agrees that any use of a Product outside of the scope of rights expressly conferred on Customer under this Agreement is a prohibited and unauthorized use, and Illumina reserves the right to seek enforcement of its Intellectual Property Rights with respect to any such use, including as stated in Section 3(d).  Customer acknowledges and agrees that prohibited and unauthorized uses (i) will void the warranties for the Products and/or (ii) if covered by any Illumina Intellectual Property Rights (including Core IP), will require Customer to obtain additional rights and/or licenses from Illumina (including, by way of example, use rights in an additional field of use), and may require additional rights and licenses from third parties.

 

b.               Existing Instruments .  Subject to the terms and conditions of this Agreement, including without limitation, all restrictions and all Customer representations and warranties hereunder with respect to Products, Customer, during the Term, has the right to use Existing Instruments for NIPT Use and Additional Clinical Use solely with Consumables purchased under this Agreement.  For the avoidance of doubt, Customer has the right to use Existing Instruments for Research Use in accordance with the terms and conditions under which each such Existing Instrument was acquired, with Illumina-Branded consumables (including with the Consumables and including with the consumables purchased under the Existing Purchase Order), Customer agrees that Customer’s use of and disposition of the Existing Instruments is subject to the terms and conditions of this Agreement in addition to the original terms and conditions under which the Existing Instruments were purchased from Illumina (the “ Instrument Terms ”).  In the event of any conflict between the Instrument Terms and the terms and conditions of this Agreement with respect to the Existing Instruments, the terms and conditions of this Agreement shall supersede and govern Customer’s use of and disposition of the Existing Instruments.  Customer acknowledges and agrees that any use of the Existing Instruments outside of the Instrument Terms is a prohibited and unauthorized use, subject to Illumina’s rights under this Agreement, and Illumina reserves the right to seek enforcement of its Intellectual Property Rights (including Core IP) with respect to any such use, including as stated in Section 3(d).

 

3



 

c.                Software .  All Software is licensed, not sold, to Customer, is non-transferable (except as provided in Section 20(f) (Assignment)) non-sublicensable, and may be subject to additional terms set forth in the end user license agreement (“ EULA ”).  If Customer asks to review a EULA for any applicable Software prior to submitting a Purchase Order under which that Software will be supplied, then Illumina will promptly provide a copy of any applicable EULA to Customer for its review prior to purchase.  References in this Agreement to “purchase” or “sale” of Products or Products “purchased” or “sold” under the Agreement (and similar grammatical variations) is understood to mean, solely with respect to Software, that Software is licensed under this Agreement and not sold, Subject to the terms and conditions of the EULA and the terms and conditions of this Agreement, including without limitation, all restrictions and all Customer representations and warranties hereunder with respect to Products, Customer is expressly authorized to use Software provided by Illumina under this Agreement solely for Customer Use in connection with Customer’s use and operation of the Consumables and Illumina Hardware and in accordance with this Agreement, and is expressly authorized to store on a computer or server any such Software that is required to be installed on a computer or server for such Customer Use.

 

d.               All Rights Reserved .  The rights conveyed to Customer under Illumina Intellectual Property Rights are limited to those use rights granted in this Agreement (including, without limitation, Exhibit A); no sublicense or other right or license under any Illumina Intellectual Property Rights is or are granted, expressly, by implication, or by estoppel, to Customer under this Agreement.  Illumina, on behalf of itself and its Affiliates (including without limitation, Verinata Health, Inc. and BlueGnome Ltd.), retains and does not waive all rights not expressly conferred on Customer with purchase of Product, including without limitation the right to enforce Illumina Intellectual Property Rights, and bring suit against any person or entity, including Customer (and its Affiliates, successors, and assigns), with respect to any and all unauthorized uses of Product.  All uses of Products that infringe Application Specific IP are unauthorized uses and are subject to Illumina’s right to enforce Illumina Intellectual Property Rights.  Notwithstanding any term or provision to the contrary, Illumina does not make any representation, warranty, covenant, or guarantee that the Customer Use rights conferred on Customer upon purchase of Products includes all Illumina Intellectual Property Rights that Customer may require to avoid infringement of Illumina Intellectual Property Rights , and expressly disclaims any statement or implication otherwise.  Products and Existing Instruments may be covered by one or more U.S., or foreign patents.  As of the Effective Date, no rights under Application Specific IP have been granted to Customer and no rights under Application Specific IP will be granted, conferred upon, or conveyed to Customer under this Agreement.

 

4.               Additional Rights .  (a) Customer’s use of Products for Customer Use during the Term may require that it obtain from third parties or from Illumina (or its Affiliates) additional rights or licenses above and beyond rights under Core IP conferred upon purchase of Products hereunder, as set forth in Exhibit A and Section 3.  Any such Intellectual Property Rights of third parties or Illumina (including its Affiliates), other than the rights in Core IP, are referred to herein as “ Other IP .”  Other IP includes but is not limited to Application Specific IP and third party Intellectual Property Rights directed to specific nucleic acid sequences, or an association between a nucleic acid sequence and a disease or condition .  Illumina does not guarantee or warrant that use of Product for Customer Use will not infringe Other IP.  (b) Customer, not Illumina, is responsible for identifying and ensuring that it has rights to all Other IP that are required for Customer to use the Products for Customer Use without infringement or misuse of Other IP.  Customer is responsible for obtaining required rights to such Other IP from a third party under Application Specific IP) and, notwithstanding anything in this Agreement to the contrary, assumes all risk for not obtaining any required rights to such Other IP.  (c) Any future grant by Illumina to Customer of rights to Application Specific IP or other Illumina Intellectual Property Rights will be subject to the Parties’ negotiation of the terms and conditions under which such rights are to be granted, including consideration, and will be granted, if at all, under a separate written agreement.  (d) Notwithstanding the foregoing or anything to the contrary contained in this Agreement, Illumina may not (i) terminate this Agreement for Customer’s breach or (ii) suspend supply of Products under this Agreement, in each case (i) or (ii)  if the sole basis for such breach and termination, or the sole basis for such suspension, respectively, is Customer’s failure to have necessary rights to NIPT Application Specific IP, except that this Section 4(d) shall no longer be applicable at such time as a court or other tribunal of competent jurisdiction (regardless of Customer’s right of appeal) holds or finds that, or Illumina is granted a preliminary injunction on the basis that, Customer’s use of Products supplied under this Agreement infringed or infringes NIPT Application Specific IP.  “ NIPT Application Specific IP ” means Application Specific IP that pertains to the Products and use thereof for NIPT Use to perform NIPT .

 

5.               Limitations on Use .

 

a.               Limitations on Use .

 

i.                  Customer agrees:  (1) to use each Consumable only one time, (2) not to use non-Illumina reagents with Illumina Hardware, (3) to use the Products only for Customer Use, (4) when using Consumables for NIPT Use or Additional Clinical Use, to only use TG Consumables (or Temporary Consumables, if applicable), (5) to use the Non-TG Consumables only for Research Use (except to the extent a Non-TG Consumable is a Temporary Consumable and use for NIPT Use or Additional Clinical Use is permitted), and (6) to use Products only in Customer’s Facilities.  The limitations in (1) and (2) do not apply if the Specifications or Documentation for the applicable Consumable or Illumina Hardware expressly states otherwise.

 

ii.              Customer agrees it will not, and it will not authorize any third party to, engage in any of the following activities with respect to any Product:  (1) disassemble, reverse-engineer, reverse-compile, or reverse-assemble the Product,

 

4



 

(2) separate, extract, or isolate components of Product or subject Product or components thereof to any analysis not authorized in the Specifications or Documentation, (3) seek to gain access to or attempt to determine the methods of operation of the Product that are not discoverable through the use of the Product in accordance with this Agreement, (4) grant a sub-license to any rights received hereunder, including without limitation to grant a sublicense to any Software or to any third party software, or (5) transfer any Consumable or Software to a third party (including a Customer Affiliate).

 

iii.          Customer agrees it will not (1) use the Products for any use outside of Customer Use, (2) use the Products in any manner that infringes Application Specific IP, unless it has received prior express written permission from Illumina under a separate written agreement or amendment to this Agreement to use the Products in a manner addressed in (1) or (2).

 

b.               Illumina Proprietary Information .  Customer agrees that, with respect to adapter and primer sequences that are included in Products, that it shall only use same with the Products.  Customer acknowledges Illumina’s claim that the contents of and methods of operation of the Products are proprietary to Illumina and/or its Affiliates and contain or embody trade secrets of Illumina and/or its Affiliates.

 

c.                Unauthorized Uses .  Customer agrees that the limitations of use, including prohibited activities, described in Section 5(a) (Limitations on Use):  (A) are, without limitation, part of the bargained for conditions of sale of the Products, (B) the prohibited activities stated in Section 5(a) are not included within the Customer Use or otherwise within the rights expressly conferred on Customer pursuant to Exhibit A and Section 3 (Rights Accompanying Purchase of Product for Customer Use), and (C) each such prohibited activity stated in Section 5(a), including use of the Product to perform any of those prohibited activities, is an unauthorized use, may infringe patents within Illumina Intellectual Property Rights, and is part of the bargained for conditions of sale of the Products.

 

6.               [Reserved.]

 

7.               Pricing; Purchase Orders .

 

a.               Pricing .  The base prices for Products are found in Exhibit B and, with respect to Temporary Consumables in the Final Shipment Purchase Order, are found in Section 7(e).  Unless expressly stated otherwise in this Agreement, (i) all prices are in USD, (ii) all payments must be made in USD, (iii) each price in Exhibit B is the base price for the applicable Product during the Term, subject to discounts set forth therein (as applicable in accordance with exclusivity terms stated in Exhibit A, Part 1, Paragraph 3(a).) Note that if no price for Illumina Hardware is listed in Exhibit B , the price for Illumina Hardware will be agreed to between the Parties at the time of ordering.

 

b.               Test Fees .  The terms and conditions regarding NIPT Test Fees are set forth on Exhibit A .  Customer acknowledges that the NIPT Test Fees are payable under the Agreement for performance of NIPT Use using any Product as set forth on Exhibit A, in addition to the pricing for Products.

 

c.                Purchase Orders and Acceptance .  Customer shall order all Products using written purchase orders in a form reasonably acceptable to Illumina and that reference this Agreement (“ Purchase Order(s) ”).  Purchase Orders shall state, at a minimum, the Illumina part number, the Illumina provided quote number (or other reference provided by Illumina), the quantity ordered, price, requested delivery date (which shall be one or more dates during a [*] month period during the Term,) and address for delivery.  All Purchase Orders shall be sent to the attention of Illumina Customer Solutions or to any other person or department designated by Illumina in writing.  Acceptance of a Purchase Order occurs when Illumina provides Customer a Sales Order Confirmation (“ Order Confirmation ”).  Purchase Orders submitted in accordance with this Agreement will not be unreasonably rejected by Illumina.  It shall be deemed an unreasonable rejection of a Purchase Order if Illumina rejects a Purchase Order that is submitted in accordance with this Agreement and Illumina has the ability to supply the Products ordered under such Purchase Order.  Illumina shall be obligated to fill all accepted Purchase Orders.

 

d.               Additional Terms for TG Consumables .  Additional terms and conditions pertaining to purchase and supply of TG Consumables for Clinical Use are set forth in Section 10 herein below.

 

e.                Existing Purchase Order; New Quotes; New Purchase Order .

 

(i)              The Existing Purchase Order is void and of no effect and, subject to the proviso that follows, each Party hereby releases the other Party from any and all claims and causes of action relating to or arising out of the Existing Purchase Order, including without limitation (1) whether the Existing Purchase Order was validly accepted by

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

5



 

Illumina or (2) whether Customer had the right to use the products supplied under that Existing Purchase Order for NIPT, provided that the foregoing does not limit or restrict Illumina’s right to enforce the following terms, including payment terms, in the Existing Purchase Order set forth in the following paragraphs of the Terms and Conditions of Sale-Research Use Products that are part of the quotes that govern the Existing Purchase Order:  Paragraph 3 (Unauthorized Uses of Products); the last sentence of Paragraph 4 (Regulatory); Paragraph 9 (Payment Terms) and Paragraph 11 (Taxes); or the right of both Parties to enforce Paragraph 7 (Product Warranty) and Paragraph 8 (Indemnification).  For the avoidance of doubt, this subpart (i) is not applicable to any activity other than claims and causes of action relating to or arising out of the Existing Purchase Order.

 

(ii)           Attached as Exhibit E, is a quote for TG Consumables, Non-TG Consumables, and [*] HiSeq 2500 Sequencing Systems, at the discounts off the base price listed on Exhibit B (the “ Quote ”).  The Parties agree that the terms and conditions of sale attached to the Quote (“ Quote Ts&Cs ”) are not applicable to the Quote, the Quote Ts&Cs are deemed to be cancelled from this Agreement, and that this Agreement, and not the Quote Ts&Cs, exclusively governs the ordering, purchase, supply, and use of Products on the Quote.  The initial Purchase Order, issued in accordance with the Quote, and the Quote, are attached in Exhibit E.

 

(iii)        Attached as Exhibit H is a Purchase Order (the “ Final Shipment Purchase Order ”) submitted under this Agreement for certain Consumables that were included on, but not yet supplied under, the Existing Purchase Order.  With respect to the Final Shipment Purchase Order and the Consumables to be supplied thereunder, the Parties agree (A) those Consumables are deemed to be Temporary Consumables and Product under this Agreement, (B) the pricing and requested delivery schedule for those Consumables is as set forth in Exhibit H, (C) the terms and conditions of this Agreement, and not the terms and conditions that governed the Existing Purchase Order, exclusively govern the ordering, purchase, supply, and use of the Consumables on the Final Shipment Purchase Order.  For the avoidance of doubt, Customer has the right under this Agreement to use the Temporary Consumables supplied under the Final Shipment Purchase Order for Customer Use.  The Parties acknowledge that the following Products ordered on the Final Shipment Purchase Order were supplied by Illumina to Customer on or before the Effective Date:  [*].

 

8.               Invoices; Payment; Taxes .

 

a.               Invoices and Payment .  Illumina shall issue invoices upon shipment of Products.  Invoices shall be sent to Customer’s accounts payable department, or any other address designated by Customer in writing.  All payments by Customer on such invoices are due within [*] after the date of the invoice.  Without limiting any remedies available to Illumina, any amounts (other than amounts disputed in good faith) not paid when due under this Agreement will accrue interest at the rate of [*] per month, or the maximum amount allowed by applicable law, if lower.  In the event that any payment (other than amounts disputed in good faith) is not made within [*] after receiving notice of the delinquency, Illumina shall have the right, with respect to any Products that have not been paid for, to suspend performance, including shipment, until all payments are made current and, further, Illumina shall have the right to take any action allowed in law and in equity to address such breach, in addition to any and all rights under this Agreement.  Customer shall have no right or license to use any Product that it has not paid for and any such use is an unauthorized use.  Customer shall pay for all costs (including reasonable fees of attorneys’ and collection agencies) incurred by Illumina in connection with the collection of late payments.  Each Purchase Order is a separate, independent transaction under this Agreement, and neither Party has any right of set-off against other Purchase Orders or other transactions with the other Party.  Customer agrees to pay for Products supplied hereunder in accordance with the terms and conditions of this Agreement.

 

b.               Taxes .  All prices and other amounts payable to Illumina hereunder are exclusive of and are payable without deduction for taxes, GST, VAT, customs duties, tariffs or charges now or hereafter claimed or imposed by any governmental authority upon the sale of the Product, all of which will be added to the purchase price or subsequently invoiced to the Customer.  With respect to New Zealand Customers only, Customer and Illumina agree that subsection 8(4) Goods and Services Tax Act 1985 does not apply

 

c.                Additional Terms for TG Consumables .  Additional terms and conditions pertaining to purchase and supply of TG Consumables for Clinical Use are set forth in Section 10 herein below.

 

9.               Shipping Terms; Title and Risk of Loss .  Unless otherwise agreed upon in writing, all shipments are made DAP (Incoterms 2010) at Customer’s address on the Purchase Order and Customer is responsible for freight and insurance which will be added to the invoice and paid by Customer, except that all shipments to member countries of the E.U. are made DDP (Incoterms 2010) at Customer’s address on the Purchase Order.  In all cases title (except for Software and third party software) and risk of loss transfers to Customer when Product is made available at such address.

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

6



 

10.        Additional Terms for TG Consumables:  Forecast; Initial Shipment Date; Purchase orders; Deliveries; Shelf Life .  This Section 10 is applicable only to TG Consumables.

 

a.               Forecast .  Please refer to the example in Exhibit C when reading this Section.  Customer shall, no later than the 1 st  day of each calendar month (the 1st day of each such calendar month being a “ Forecast Due Date ”), provide a written non-binding (in part) forecast detailing the quantity of TG Consumables, on a TG Consumable-by-TG Consumable basis, that Customer requires during the 4th through 9th calendar months following that Forecast Due Date (each a “ Forecast ”); provided, however, that Customer shall not be obligated to submit Forecasts for any post-termination month if Customer has given written notice of termination under Section 17(c)(v) (Termination by Customer for Convenience).  For clarity, each Forecast starts with the calendar month that begins on the Forecast Due Date.  The general form of the Forecast along with an example of how forecasting works and when Purchase Orders (defined below) are to be provided is found in Exhibit C .  The first Forecast is attached to this Agreement as Exhibit D .  All Forecasts shall be deemed Customer’s Confidential Information.

 

i.                  One Forecast per Calendar Month Only .  Customer may only provide one Forecast per calendar month.  If Customer provides more than one Forecast in any given calendar month, then Illumina has the right to reject all but the first of the Forecasts submitted by Customer.

 

ii.              Initial Shipment Date .  Illumina agrees that it can and, subject to the terms and conditions of this Agreement, will supply the TG Consumables ordered by Customer on the initial Purchase Order attached as Exhibit E , which is submitted against the Quote set forth in Exhibit E , in accordance with the ordered quantities and shipping schedule set forth therein.  The initial Purchase Order attached as Exhibit E and the Final Shipment Purchase Order attached as Exhibit H will be deemed an accepted Purchase Order under this Agreement.

 

b.               Binding Commitments; Flexibility .  The 4th calendar month of each Forecast provided under this Agreement is a binding commitment by Customer to take receipt of and pay for that quantity and type of TG Consumables found in such 4 calendar month (the “ Binding Consumable Month ”); provided that, the quantity of each TG Consumable (on a TG Consumable-by-TG Consumable basis) to be delivered in such 4th calendar month may vary from the quantity of each TG Consumable (on a TG Consumable-by-TG Consumable basis) that were forecasted to be required in the same calendar month as found in prior Forecast (which was the 5th calendar month of that prior Forecast) only by up to +/-25%, provided that Illumina agrees to supply any such additional amounts as soon as commercially practicable, in light of the circumstances, including orders placed by all Illumina customers.  If inventory constraints make it difficult, impractical or impossible for Illumina to fill a Purchase Order for a Binding Consumable Month (including the +/- variance permitted) with the quantity of TG Consumables set forth therein, then Illumina may, at its sole discretion, supply Customer with a combination of TG Consumables and the corresponding Non-TG Consumables in quantities required to fill that Purchase Order, wherein (i) any such Non-TG Consumables will be Temporary Consumables under this Agreement, with all attendant rights and obligations, and (ii) pricing for any such Temporary Consumables will be at the Non-TG Consumables pricing under this Agreement (subject to any applicable discount).

 

c.                New TG Consumables .  With respect to any TG Consumables added to this Agreement after the Effective Date upon the mutual agreement of the Parties, Illumina shall use commercially reasonable efforts to provide Customer with such TG Consumables that are newly added to this Agreement in accordance with Customer’s orders, however, Illumina makes no commitment with respect to volumes of any such Consumables that it can provide in the first three (3) calendar months after such Consumables are added to the Agreement.

 

d.               TG Consumable Purchase Orders .  The first Purchase Order for TG Consumables (initial Quote and initial Purchase Order are in Exhibit E ), along with the first Forecast (first Forecast is Exhibit D ) are provided herein on the Effective Date.  Subsequent Purchase Orders for TG Consumables must be provided on the Forecast Due Date and must be for a quantity of and type of TG-Consumables as found in the Binding Consumable Month.  For the avoidance of doubt, if Customer has not provided a Purchase Order by the Forecast Due Date such failure may result in a delay in delivery of Products to Customer, wherein the length of delay will be dependent upon Illumina’s commitment to supply other customers with the same Products.  Each Purchase Order for TG Consumables must include a ship schedule, [*], that details the quantity of and type of TG Consumables (on a TG Consumable-by-TG Consumable basis) that Customer requires in each calendar month that is covered by the Purchase Order (“ Ship Schedule ”).  Subject to Section 10(b) (Binding Commitments; Flexibility), including +/-25% flexibility therein, Illumina makes no delivery commitments with respect to Purchase Orders that contain TG Consumables or quantities of TG Consumables that exceed that which was forecasted by Customer for the Binding Consumable Month.  Such additional quantities of TG Consumables must be ordered by using Additional Purchase Orders (set forth below).

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

7



 

e.                Additional Purchase Orders for TG Consumables .  Illumina will, in its reasonable discretion, accept additional Purchase Orders for additional quantities of TG Consumables that were not within a given Forecast (“ Additional Purchase Orders ”) and, if any such Additional Purchase Order is accepted by Illumina, then shall deliver such TG Consumables [*].  Ship dates, any increased pricing to accommodate unforecasted needs, and quantities of TG Consumables on any Additional Purchase Orders will be [*], Illumina may supply Customer with Non-TG Consumables to fill additional quantities of the corresponding TG Consumables ordered by Customer to meet its unforecasted needs (above and beyond the +25% variance permitted pursuant to Section 10(b)), wherein (i) such Non-TG Consumables will be Temporary Consumables under this Agreement, with all attendant rights and obligations, and (ii) pricing for such Temporary Consumables will be at the corresponding TG Consumables pricing under this Agreement (subject to any applicable discount).

 

f.                 Payment Instead of Taking TG Consumable .  Illumina reserves the right to invoice Customer for [*] of any TG Consumables that Customer has a binding commitment to purchase under this Agreement (whether under a Forecast or a Purchase Order), but for which Customer has not provided a Purchase Order after written notice by Illumina, or for which Customer purports to cancel the order or delivery without the written authorization of Illumina.  If there is no applicable Purchase Order, the purchase price used will be the purchase price applicable to the TG Consumable that was most recently shipped to Customer.

 

g.               Shelf-life for TG Consumables .  The TG Consumables delivered hereunder shall have no less than [*] months shelf life at the time of shipment.  Shelf-life will be pre-printed on the TG Consumable packaging.

 

h.               Single Lot Shipments / Kit Lot Testing for TG Consumables .

 

i.                  Single Lot Shipments .  Illumina shall use commercially reasonable efforts to ensure each shipment of a given TG Consumable includes only such TG Consumable manufactured from the same lot.

 

ii.              Kit Lot Testing .  Illumina shall test each component reagent that comprises a given TG Consumable together with the other component reagents of that TG Consumable to ensure their functionality, unless sufficient data are available to demonstrate that a given component reagent, or component reagents, if quality tested independently, does not affect performance of the TG Consumable.

 

i.                  Discontinued/Changed TG Consumables .  TG Consumables will not be manufactured in their current configurations indefinitely as a result of product life cycle or other business considerations.  Accordingly, a given TG Consumable may be phased out of production and no longer available and/or there may be a new, reconfigured, or repackaged version of a TG Consumable that embodies a material change to form, fit or function of such TG Consumable (such discontinued or materially changed Consumable is referred to as a “ Discontinued Consumable ”), Any product or combination of products that is intended by Illumina to replace such Discontinued Consumable shall be referred to as a “ Substitute Consumable .”  In some instances a Substitute Consumable may differ from the Discontinued Consumable through changes in one or more components that comprised the Discontinued Consumable (“ Changed Components ”).  In other instances the Substitute Consumable may represent a complete change from the Discontinued Consumable (“ Complete Change ”).  In the case of a Discontinued Consumable that will have Changed Components, Illumina will use commercially reasonable efforts to make the Changed Components and instructions on how to modify the Discontinued Consumable in order to use the Changed Components available as soon as practical, but no later than [*] months prior to the date that the Discontinued Consumable will no longer be available for purchase.  Illumina will provide a reasonable quantity of Changed Components free of charge to facilitate Customer’s validation efforts in support of the change.  In the case of a Discontinued Consumable that will have a Complete Change, Illumina will use commercially reasonable efforts to make the Substitute Consumable available for purchase by Customer as soon as practical, but no later than [*] months prior to the date that the Discontinued Consumable will no longer be available for purchase.  Illumina will provide a reasonable quantity of Substitute Consumable free of charge to facilitate Customer’s validation efforts in support of the change.  Once a Discontinued Consumable is no longer available for purchase (either in the instance of a Complete Change or Changed Component), the Substitute Consumable will automatically be added to this Agreement as a Consumable and the Discontinued Consumable will be removed.  The price for a Substitute Consumable will be Illumina’s published list price for the Substitute Consumable, and will be subject to the same discounts as provided for the Discontinued Consumable.  Use of Substitute Consumables shall be subject to the terms and conditions of this Agreement applicable to TG Consumables.

 

j.                  For clarity, the Parties acknowledge that (a) the first Forecast (Exhibit D) provides Customer’s forecast for TG Consumables beginning September 1, 2013 through May 31, 2013, (b) the initial Purchase Order (Exhibit E) satisfies

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

8


 

Customer’s obligation to provide a Purchase Order for the Binding Consumables Month (i.e., December, 2013) in the first Forecast, provided that Customer may resubmit the Initial Purchase Order on or before September 1, 2013, for the sole purpose of adjusting the quantity of each type of Consumable for December, 2013 by a quantity that is within [*] from the quantity of that type of Consumable forecasted for December, 2013 in the initial Purchase Order of Exhibit E, provided that the quantities, types and ship dates of Consumables for September, October and November, 2013 remain unchanged from the Initial Purchase Order of Exhibit E, (c) the next Forecast due under this Agreement is due October 1, 2013 and will span October 1, 2013 through June 30, 2014, (d) the next Purchase Order due under this Agreement is due October 1, 2013 and will including the quantity and type of TG Consumables found in the Binding Consumables Month (i.e., January, 2014) of that October 1, 2013 Forecast, and (e) the Final Shipment Purchase Order submitted under this Agreement is outside of the Forecast.

 

11.        Regulatory; Quality Audits .

 

a.               Product Label .  Customer acknowledges that, unless expressly stated otherwise in writing by Illumina, no Product has been subjected to regulatory review or approved or cleared by the United States Food and Drug Administration or any other regulatory entity whether foreign or domestic, or otherwise reviewed, cleared or approved under any statute, law, rule or regulation for any purpose, whether research, commercial, diagnostic or otherwise.  The Products are labeled For Research Use Only, however, such label is distinct from the business terms that govern the use of the Products for Customer Use as expressly set forth herein.  Illumina does not make any representation, warranty or covenant that pertains in any way to the regulatory status of the Products and Customer’s intended use for Customer Use.

 

b.               Regulatory Approvals .  Customer, and not Illumina, is responsible for obtaining any and all regulatory approvals, licenses, and/or certifications necessary for Customer to use the Products as intended by Customer, including without limitation, for Customer Use (“ Regulatory Approvals ”).  Customer will ensure it has any and all Regulatory Approvals that are necessary for Customer’s intended use of the Products.  Accordingly, Customer agrees to (i) diligently investigate and identify which Regulatory Approvals apply to Customer’s use of the Products, (ii) obtain and maintain all Regulatory Approvals throughout the time that Customer so uses the Products, and (iii) use the Products in compliance with all applicable laws and regulations.  To the extent permitted by applicable law, Customer agrees to promptly disclose to Illumina any communication that it receives from any government body, agency, or other regulatory or accrediting body to the extent solely pertaining to the Products including Customer’s use of the Products.

 

c.                Quality Audits .  If Illumina is supplying TG Consumables to Customer under this Agreement, Illumina agrees to allow Customer to audit Illumina’s operations that pertain to such TG Consumables, upon [*] prior written notice, during normal business hours, no more often than [*] and at Customer’s sole expense, to the extent necessary to satisfy its obligations under applicable law.  The locations, times, dates, scope, and goals for such audits will be mutually agreed upon in writing between the Parties.  Customer shall sign Illumina’s confidentiality agreement, if requested by Illumina, prior to conducting such audit.

 

12.        Limitation of Liability .

 

TO THE EXTENT PERMITTED BY LAW, AND SUBJECT TO SECTION 3(d) (All Rights Reserved) AND THIS SECTION 12, IN NO EVENT SHALL EITHER PARTY OR ITS AFFILIATES BE LIABLE TO THE OTHER PARTY OR ANY THIRD PARTY FOR COSTS OF PROCUREMENT OF SUBSTITUTE PRODUCTS OR SERVICES, LOST PROFITS, DATA OR BUSINESS, OR FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY, CONSEQUENTIAL, OR PUNITIVE DAMAGES OF ANY KIND ARISING UNDER THIS AGREEMENT, HOWEVER ARISING OR CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE).

 

SUBJECT TO THIS SECTION 12, EACH PARTY’S TOTAL AND CUMULATIVE LIABILITY ARISING UNDER THIS AGREEMENT, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE, SHALL IN NO EVENT EXCEED THE AMOUNT PAID OR PAYABLE TO ILLUMINA BY CUSTOMER UNDER THIS AGREEMENT DURING THE 12 MONTHS PRECEDING THE DATE THE CLAIM OR CAUSE OF ACTION AROSE .

 

THE LIMITATION OF LIABILITY IN THIS SECTION 12 SHALL APPLY EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.

 

NOTWITHSTANDING ANYTHING IN THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, THE PARAGRAPHS IN THIS SECTION 12, TO THE CONTRARY, THIS AGREEMENT DOES NOT LIMIT (A) EITHER PARTY’S LIABILITY FOR GROSS NEGLIGENCE, INTENTIONAL MISCONDUCT, FAILURE TO COMPLY WITH APPLICABLE LAW OR WILLFUL BREACH OF THIS AGREEMENT, (B) ILLUMINA’S OBLIGATIONS UNDER SECTION 15(a) (Indemnification), (C) CUSTOMER’S OBLIGATIONS UNDER SECTION 15(c) (Indemnification), (D) EITHER PARTY’S LIABILITY FOR ANY BREACH OF SECTION 14 (Confidential Information) , (E) EITHER PARTY’S LIABILITY TO THE OTHER PARTY OR ITS AFFILIATES FOR ANY INFRINGEMENT BY THAT PARTY OR ITS AFFILIATES OF THE OTHER PARTY’S OR ITS AFFILIATES’ INTELLECTUAL PROPERTY RIGHTS, INCLUDING WITHOUT LIMITATION, INFRINGEMENT OF APPLICATION SPECIFIC IP BY CUSTOMER OR ITS AFFILIATES, OR ANY RECOVERY ASSOCIATED WITH ENFORCEMENT ACTION(s) DIRECTED TO SUCH INTELLECTUAL PROPERTY RIGHTS, OR (F) CUSTOMER’S LIABILITY FOR CLAIMS BY THIRD PARTIES THAT ARE BASED ON CUSTOMER’S ACTS OR OMISSIONS IN PERFORMANCE OF ANY TEST OR SERVICE USING THE PRODUCTS, INCLUDING WITHOUT LIMITATION LIABILITY DUE TO HARM FROM MISDIAGNOSIS, MISSED DIAGNOSES, AND ACTIONS OR INACTIONS TAKEN AS A RESULT OF INFORMATION PROVIDED DIRECTLY OR INDIRECTLY BY CUSTOMER TO PATIENTS .

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

9



 

13.        Product Warranty Disclaimer .  TO THE EXTENT PERMITTED BY LAW AND EXCEPT FOR THE EXPRESS LIMITED PRODUCT WARRANTIES SET FORTH IN SECTION 16 OF THIS AGREEMENT, ILLUMINA MAKES NO (AND EXPRESSLY DISCLAIMS ALL) WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE PRODUCTS SUPPLIED UNDER THIS AGREEMENT, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR ARISING FROM COURSE OF PERFORMANCE, DEALING, USAGE OR TRADE.  WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, ILLUMINA MAKES NO CLAIM, REPRESENTATION, OR WARRANTY OF ANY KIND AS TO THE UTILITY OF THE PRODUCTS FOR CUSTOMER’S INTENDED USES.

 

14.        Confidentiality .

 

a.               Confidential Information .  The Parties acknowledge that a Party (the “ Recipient Party ”) may have access to confidential or proprietary information (“ Confidential Information ”) of the other Party (the “ Disclosing Party ”) under or in connection with this Agreement.  In order to be protected as Confidential Information, information must be disclosed with a confidential or other similar, proprietary legend and in the case of orally or visually disclosed Confidential Information that pertains to a Disclosing Party’s Intellectual Property Rights (including trade secrets),the Disclosing Party shall notify the Recipient Party of its confidential nature at the time of disclosure and provide a written summary that is marked with a confidential or other similar proprietary legend to the Recipient Party within 30 days (email acceptable).  Notwithstanding anything to the contrary contained in this Agreement, the Parties acknowledge and agree that the content of all conversations and correspondence (including emails) relating to the negotiation of this Agreement shall be deemed the Confidential Information of the providing Party.  Confidential Information may include, but shall not be limited to, inventions, designs, formulas, algorithms, trade secrets, know-how, customer lists, cost and pricing information, business and marketing plans, and other business, regulatory, manufacturing and financial information.  This Agreement, including its terms and conditions is Confidential Information of both Parties.  During the Term of this Agreement or for a period [*] after the date of each disclosure, whichever is longer, the Recipient Party shall hold the Disclosing Party’s Confidential Information in confidence using at least the degree of care that is used by the Recipient Party with respect to its own Confidential Information of similar nature or importance, but no less than reasonable care.  The Recipient Party shall disclose the Confidential Information of the Disclosing Party solely on a need to know basis to its employees, contractors, officers, directors, representatives, and Affiliates under written nondisclosure and restricted use terms consistent with this Agreement or under professional ethics rules to which certain professionals (including attorneys) are bound.  The Recipient Party shall not use the Disclosing Party’s Confidential Information for any purpose other than exercising its rights and fulfilling its obligations under this Agreement.  The Confidential Information shall at all times remains the property of the Disclosing Party.  The Recipient Party shall, upon written request of the Disclosing Party, return to the Disclosing Party or destroy the Confidential Information of the Disclosing Party.  Notwithstanding the foregoing, the Recipient Party may maintain one copy of the Disclosing Party’s Confidential Information to be retained by the Recipient Party’s Legal Department for archival purposes only.

 

b.               Exceptions .  Notwithstanding any provision contained in this Agreement to the contrary, neither Party shall be required to maintain in confidence or be restricted in its use of any of the following:  (i) information that, at the time of disclosure to the Recipient Party, is in the public domain through no breach of this Agreement or another obligation of confidentiality owed to the Disclosing Party or its Affiliates by the Receiving Party; (ii) information that, after disclosure hereunder, becomes part of the public domain by publication or otherwise, except by breach of this Agreement or breach of another obligation of confidentiality owed to the Disclosing Party or its Affiliate by the Receiving Party; (iii) information that was in the Recipient Party’s or its Affiliate’s possession at the time of disclosure hereunder by the Disclosing Party unless subject to an obligation of confidentiality or restricted use owed to the Disclosing Party or its Affiliate; (iv) information that is independently developed by or for the Recipient Party or its Affiliates without use of or reliance on any Confidential Information of the Disclosing Party; or (v) information that the Recipient Party receives from a third party where Recipient Party reasonably believes such third party was under no obligation of confidentiality to the Disclosing Party or its Affiliate with respect to such information.

 

c.                Disclosures Required by Law .  The Recipient Party may disclose Confidential Information of the Disclosing Party as required by court order, operation of law, or government regulation (including the Sunshine Act), including in connection with submissions to regulatory authorities; provided that, the Recipient Party promptly notifies the Disclosing Party of the specifics of such requirement prior to the actual disclosure, or promptly thereafter if prior disclosure is impractical under the circumstances, uses diligent efforts to limit the scope of such disclosure or obtain confidential treatment of the Confidential Information if available, and allows the Disclosing Party to participate in the process undertaken to protect the confidentiality of the Disclosing Party’s Confidential Information including, without

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

10



 

limitation, cooperating with the Disclosing Party in order to comply with the requirements of such order, law, or regulation in a manner that discloses the least amount necessary, if any, of the Confidential Information of the Disclosing Party.

 

d.               Injunctive Relief .  Each Party acknowledges that any use or disclosure of the other party’s Confidential Information other than in accordance with this Agreement may cause irreparable damage to the other Party.  Therefore, in the event of any such use or disclosure or threatened use or threatened disclosure of the Confidential Information of either Party hereto, the non-breaching Party shall be entitled, in addition to all other rights and remedies available at law or in equity, to seek injunctive relief against the breach or threatened breach of any obligations under this Section.

 

e.                Disclosure of Agreement .  Except as expressly provided otherwise in this Agreement, neither Party may disclose this Agreement, the terms of this Agreement, including any financial terms thereof, and the subject matter of this Agreement to any third party without the prior written consent of the other Party, which consent shall not be unreasonably withheld.  In the event either Party desires to provide a copy of this Agreement, or otherwise disclose its terms, on a confidential basis in connection with any financing transaction or due diligence inquiry, then it may do so on a confidential basis under written terms and conditions no less stringent than set forth herein.  In addition, each Party may disclose this Agreement and the terms hereof in connection with any legal action related hereto, including any enforcement hereof.

 

f.                 Service Representatives .  A “ Service Representative ” is an individual who is authorized by Illumina and approved by Customer to be on-site at Customer’s Facility (as defined in Agreement) to provide technical support and/or technical services with respect to Illumina equipment located at that Facility.

 

i.                  In the event a Service Representative receives, views, hears or is otherwise exposed to confidential or proprietary information of Customer when the Service Representative is on-site at Customer Facility to provide technical support and/or technical service, and such information is not tangibly identified and marked as Confidential Information in accordance with Section 14(a) of the Agreement, including if disclosed orally or visually, Illumina and the Service Representative shall nevertheless be obligated to treat the confidential or proprietary information as if it were Confidential Information under the Agreement.

 

ii.              Prior to commencing work on-site at Customer’s Facility (except to the extent Customer has permitted that Service Representative to commence work on-site prior to executing that Acknowledgement and Agreement), each Service Representative shall execute the Acknowledgement and Agreement Regarding Confidential Information that is set forth hereto as Attachment A, and shall provide a copy of the executed document to Customer.  As more completely stated in Attachment A, the Acknowledgement and Agreement documents that the Service Representative has read, understands, and agrees to be bound by these terms and conditions regarding confidential or proprietary information, including Confidential Information, that may be disclosed (in writing, orally, visually) to the Service Representative or that the Service Representative may be exposed to while on-site at Customer’s Facility providing technical support and/or technical services, unless instructed otherwise by an authorized Illumina attorney (or outside counsel retained by Illumina) for the purpose of Illumina enforcing its rights under the Agreement.  Notwithstanding anything to the contrary, nothing in this Agreement or the Acknowledgement and Agreement Regarding Confidential Information prevents or restricts a Service Representative from (1) disclosing to Illumina information that relates to Products or Illumina Intellectual Property Rights or (2) disclosing confidential or proprietary information to an authorized Illumina attorney (or outside counsel retained by Illumina) for the purpose of Illumina enforcing its rights under the Agreement, if the Service Representative is instructed by an authorized Illumina attorney (or outside counsel retained by Illumina) to disclose the confidential or proprietary information.

 

iii.          Notwithstanding the foregoing, Customer agrees that it shall take commercially reasonable steps to prevent the disclosure (in writing, orally, visually) to Service Representatives, and prevent their access to, confidential or proprietary information except to the extent such disclosure or access is required for that Service Representative to perform technical support and/or technical services.  Without limitation, commercially reasonably steps include Customer instructing its employees, contractors and agents who will come in contact with Service Representatives of the terms and conditions of this Article 14.

 

11



 

15.        Indemnity; Insurance .

 

a.               Indemnification by Illumina for Infringement .  Subject to the Exclusions to Illumina Indemnification Obligation (Section 15(b) below), Indemnification by Customer (Section 15(c) below) and Conditions of Indemnification Obligation (Section 15(d) below), Illumina shall (i) defend, indemnify and hold harmless Customer and its Affiliates, and their respective officers, directors, representatives and employees (each a “ Customer Indemnitee ”), against any claim or action brought by a third party (including an Affiliate of Illumina, but excluding an Affiliate of Customer) that alleges or asserts infringement, violation or misappropriation by Customer in the Country of any Intellectual Property Right of a third party (including an Affiliate of Illumina, but excluding an Affiliate of Customer) by the use of the Product(s) by Customer for Customer Use as expressly authorized pursuant to this Agreement, wherein such Intellectual Property Right of a third party pertain to or cover aspects or features of the Product(s), or use thereof, without regard to any specific application(s) or field(s) of use (each, an “ Illumina Infringement Claim ”), and (ii) pay all settlements entered into, and all final judgments and costs (including reasonable attorneys’ fees) awarded against such Customer Indemnitee in connection with such Illumina Infringement Claim consistent with Section 15(d).  For the avoidance of doubt, if any such Intellectual Property Right of a third party pertains to or covers aspects or features of the Product(s), or use thereof, that is with regard to any specific application(s) or field(s) of use then such Intellectual Property Right cannot form the basis of an Illumina Infringement Claim, and may form the basis of an Indemnification Exclusion in Section 15(b).  If the Products or any part thereof, become, or in Illumina’s opinion may become, the subject of an Illumina Infringement Claim against Illumina (including its Affiliates) or Customer, Illumina shall have the right, at its option, to (I) procure for Customer the right to continue using such Products in accordance with this Agreement, (II) modify or replace such Products with substantially equivalent non-infringing substitutes, or (III) require the return of such Products that are or may become the subject of an Illumina Infringement Claim and terminate the rights, license, and any other permissions given hereunder with respect thereto, and no longer be obligated to supply such Products hereunder, and refund to Customer the depreciated value (as shown in Customer’s official records) of the returned Product at the time of such required return; provided that, no refund will be given for used-up or expired Consumables.  This Section (including Sections referenced herein) states the entire liability of Illumina for any infringement of third party Intellectual Property Rights or indemnification obligations to Customer.

 

b.               Exclusions to Illumina Indemnification Obligation .  Illumina shall have no obligation under Section 15(a), including to defend, indemnify or hold harmless Customer or other Customer Indemnitees, or pay any settlements, final judgments or costs (including reasonable attorneys’ fees) with respect to any Illumina Infringement Claim, to the extent such Illumina Infringement Claim arises or results from:  (1) the use of the Products in any manner or for any purpose outside the scope of the rights, license(s), or permissions expressly granted by Illumina to Customer with respect to the Products, as set forth in Exhibit A and Section 3, (ii) the use of the Products in any manner or for any purpose not in accordance with the Specifications or Documentation, (iii) the use of the Products in combination with any other products, materials, or services not supplied by Illumina (except as expressly provided in the applicable Documentation), (iv) the use of the Products to perform any assay or other process not supplied by Illumina, including without limitation to perform assays or tests for NIPT Use or for Additional Clinical Use by any method not supplied by Illumina, (v) Illumina’s compliance with specifications or instructions for such Products furnished to Illumina by Customer or by a third party on behalf of Customer (e.g., custom goods), (vi) the use of the Products in any manner or for any purpose that requires rights to any Intellectual Property Right that pertains to or covers aspects or features of the Product(s) or use thereof that is with regard to any specific application(s) or field(s) of use (“ Third Party Other IP ”) or that is the basis for a third party alleging or asserting infringement of its Intellectual Property Rights in or to Third Party Other IP, or (vii) Customer’s breach of the Agreement, including without limitation failure to obtain and maintain required Regulatory Approvals wherein any use specified in (i), (ii), (iii), (iv) or (vi) is a use performed by Customer or other Customer Indemnitee, its Affiliate, or a party to whom Customer or its Affiliate transfers Product (regardless of whether such use or transfer is permitted under this Agreement) (each of (i) — (vii), is an “ Indemnification Exclusion ”).  Notwithstanding anything to the contrary in this Agreement, Illumina shall have no obligation under this Agreement to defend, indemnify or hold harmless Customer or any other Customer Indemnitee (or any of their successors or assigns) with respect to any claim or action (A) brought by Sequenom, Inc. relating to U.S. Patent No. 6,258,540 and its foreign equivalents or any other intellectual property right asserted against Customer by Sequenom, Inc. that pertains to NIPT Use or Other Clinical Use, or, without limiting the scope of any Indemnification Exclusion in (i)-(vii) above, (B) brought by a third party (including Sequenom) relating to Third Party Other IP that pertains to any use within any Customer Use, wherein each of (A) and (B) is an Indemnification Exclusion.  Illumina has not provided or supplied Customer with any instruction, method, assay or process to perform any test or assay within NIPT Use or Additional Clinical Use, and has no obligation under this Agreement to do so.

 

c.                Indemnification by Customer .  Subject to the Indemnification by Illumina for Infringement (Section 15(a) above, including Indemnification Exclusions in Section 15(b) above) and Conditions of Indemnification Obligation (Section

 

12



 

15(d) below), Customer shall (i) defend, indemnify and hold harmless Illumina and its Affiliates and their respective officers, directors, representatives and employees (“ Illumina Indemnitee(s) ”), against any and all claims or actions brought by a third party (including an Affiliate of Customer, but excluding an Affiliate of Illumina), including all liabilities, damages, fines, penalties, causes of action and losses of any and every kind including personal injury and death (each a “ Claim ”), to the extent resulting from or arising out of (A) Customer’s marketing and use of Products, including without limitation actions (or inactions) taken by individuals who receive results from Customer’s use of Products for NIPT Use or for Additional Clinical Use, or (B) any act or omission of the Customer Indemnitees that is or that gives rise to an Indemnification Exclusion, and (ii) pay all settlements entered into, and all final judgments and costs (including reasonable attorneys’ fees) awarded against such Illumina Indemnitee in connection with any such claim consistent with Section 15(d).  For the avoidance of doubt, the term Claim includes, without limitation, claims by third parties that are based on Customer’s acts or omissions in performance of any test or service using the Products, including without limitation liability due to harm from misdiagnosis, missed diagnoses, and actions or inactions taken as a result of information provided by Customer to patients.  Customer shall have no obligation under this Section 15(c), including to defend, indemnify or hold harmless Illumina or any Illumina Indemnitee, or pay any settlements, final judgments or costs (including reasonable attorneys’ fees) with respect to any claim that is the subject of, and only to the extent of, Illumina’s obligations under Section 15(a).

 

d.               Conditions of Indemnification .  The Parties’ indemnification obligations under this Section 15 are subject to the Party seeking indemnification (i) notifying the other, indemnifying Party promptly in writing of any claim subject to such obligations, provided that any delay or failure in notification shall not relieve the indemnifying Party of its obligations except to the extent it is prejudiced thereby, (ii) giving the indemnifying Party exclusive control and authority over the defense of such claim, (iii) not admitting infringement of any Intellectual Property Right without prior written consent of the indemnifying Party, (iv) not entering into any settlement or compromise of any such action without the indemnifying Party’s prior written consent, which consent shall not be unreasonably withheld, conditioned, or delayed, and (v) providing all reasonable assistance, including access to information and materials, to the indemnifying Party that the indemnifying Party requests and ensuring that its officers, directors, representatives and employees and other indemnitees likewise provide assistance (provided that indemnifying Party reimburses the indemnified Party(ies) for its/their reasonable out-of-pocket expenses incurred in providing such assistance).  An indemnifying Party will not enter into or otherwise consent to an adverse judgment or order, or make any admission as to liability or fault that would adversely affect the indemnified Party, or settle any matter that would otherwise lead to indemnification hereunder.

 

e.                Third Party Goods .  Notwithstanding anything in this Agreement to the contrary, Illumina shall have no indemnification obligations with respect to any goods or software originating from a third party (other than an Affiliate of Illumina) and supplied to Customer under this Agreement in substantially the same form as received by Illumina from the third party supplier.  Third party goods are those that are labeled or branded with a third party’s name Customer’s sole right to indemnification with respect to such third party goods or software shall be pursuant to the original manufacturer’s or licensor’s indemnity, if any, to Customer, to the extent provided by the original manufacturer or licensor.

 

f.                 Insurance .  Each Party shall obtain and maintain insurance coverage as follows:  (i) professional liability insurance and/or errors and omissions liability insurance and products and completed operations insurance in the amount of not less than [*] per occurrence and in the aggregate and (ii) commercial general liability insurance in the amount of not less than [*] per occurrence and in the aggregate, in the case of each of (i) and (ii) to, at minimum, protect the Illumina Indemnitees under the indemnification provided hereunder, but only to the extent coverage is provided for in such insurance.  Each Party agrees that it shall not cancel or not renew its policy(ies) without providing a minimum of 30 days prior written notice to the other Party of any cancellation or non-renewal of such coverage that is not replaced by equivalent coverage.  Each Party shall maintain such insurance at all times during the Term of this Agreement and as respects any claims made coverage for a period of [*] years following expiration or termination of this agreement.

 

16.        Warranty for Products .  All warranties are personal to Customer and may not be transferred or assigned to a third party, including an Affiliate of Customer.  All warranties are Facility location specific and do not transfer if the Product is moved to another Facility of Customer, unless Illumina conducts such move.  These warranties only apply to Products purchased under this Agreement.

 

a.               Warranty for TG Consumables and Non-TG Consumables .  Illumina warrants that TG Consumables, other than custom TG Consumables, will conform to their Specifications until the later of (i) [*] months from the date of shipment from Illumina, and (ii) any expiration date or the end of the shelf-life pre-printed on such TG Consumable by Illumina, but in no event later than [*] months from the date of shipment.  Illumina warrants that Non-TG

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

13



 

Consumables, other than custom Non-TG Consumables, will conform to their Specifications until the later of (i) [*] months from the date of shipment from Illumina, and (ii) any expiration date or the end of the shelf-life pre-printed on such Non-TG Consumable by Illumina, but in no event later than [*] months from the date of shipment.  With respect to custom Consumables (i.e., Consumables, whether they are TG Consumables or Non-TG Consumables) made to specifications or designs made by Customer or provided to Illumina by, or on behalf of, Customer, Illumina only warrants that the custom Consumables will be made and tested in accordance with Illumina’s standard manufacturing and quality control processes.  Illumina makes no warranty that custom Consumables will work as intended by Customer or for Customer’s intended uses.

 

b.               Warranty for Hardware .  Illumina warrants that Illumina Hardware purchased under this Agreement, other than Upgraded Components, will conform to its Specifications for a period of [*] months after its shipment date from Illumina unless the Illumina Hardware includes Illumina-provided installation in which case the warranty period begins on the date of installation or 30 days after the date the Illumina Hardware was delivered, whichever occurs first (“ Base Hardware Warranty ”).  “ Upgraded Components ” means Illumina-provided components, modifications, or enhancements that are provided under this Agreement and serve to modify or enhance Illumina Hardware that was acquired by Customer prior to the date Illumina provides these components, modifications or enhancements.  Illumina warrants that Upgraded Components will conform to their Specifications for a period of [*] from the date the Upgraded Components are installed.  Upgraded Components do not extend the warranty for the corresponding Illumina Hardware unless the upgrade was conducted by Illumina at Illumina’s facilities in which case the upgraded Illumina Hardware shipped to Customer comes with a Base Hardware Warranty commencing on the date the upgraded Illumina Hardware is shipped back to Customer.

 

c.                Exclusions from Warranty Coverage .  The foregoing warranties in Section 16(a) and (b) shall not apply to the extent a non-conformance is due to (i) abuse, misuse, neglect, negligence, accident, improper storage, or use contrary to the Documentation (misuse includes use of a Consumable more than one time), (ii) improper handling, installation, maintenance, or repair (other than by Illumina personnel), (iii) unauthorized alteration, (iv) acts of God, including without limitation, fire, flood, tornado, earthquake, hurricane, lightning, threat of or actual acts of terrorism or war, or (v) use with a third party’s good not provided by Illumina or an Illumina Affiliate (unless applicable Documentation or Specifications expressly state such third party’s good is for use with it).

 

d.               Sole Remedy .  In the event Product does not conform to warranty in this Section 16 (referred to in (i) and (ii) below as non-conforming), Illumina will repair or replace the Product, the choice being in its discretion.  The following states Customer’s sole remedy and Illumina’s sole obligations under the foregoing warranties.

 

i.                  Consumables .  Illumina will repair or replace non-conforming Consumables in its discretion.  Repaired or replaced Consumables come with a warranty for the longer of (a) [*] after delivery of the repaired or replaced consumable or (b) the original warranty period for the Consumable.  With respect to replaced TG Consumables, Illumina will use commercially reasonable efforts to provide replacement TG Consumables in Customer’s next scheduled shipment where single lot per shipment can be maintained.

 

ii.              Hardware .  Illumina will repair or replace non-conforming Illumina Hardware in its discretion.  Illumina Hardware may be repaired or replaced with functionally equivalent, reconditioned, or new Illumina Hardware or components (if only a component of Illumina Hardware is non-conforming).  If the Illumina Hardware is replaced in its entirety, the warranty period for the replacement is [*] from the date of shipment or the remaining period on the original Illumina Hardware warranty, whichever is longer.  If only a component is being repaired or replaced, the warranty period for such component is [*] from the date of shipment or the remaining period on the original Illumina Hardware warranty, whichever is longer.

 

e.                Procedure .  In order to be eligible for repair or replacement under warranty in Section 16 Customer must (i) promptly (within the applicable warranty period) contact Illumina’s customer support department to report the non-conformance, (ii) cooperate with Illumina in the diagnosis of the non-conformance, and (iii) return the Product (or, in the case of Consumables, the unused portion thereof), transportation charges prepaid, to Illumina following Illumina’s instructions or, if agreed by Illumina, grant Illumina’s authorized repair personnel access to this Product in order to confirm the non-conformance and make repairs.

 

f.                 Third Party Goods .  Illumina has no warranty obligations with respect to any goods or software originating from a third party (other than an Affiliate of Illumina) and supplied to Customer under this Agreement in substantially the same form as received by Illumina from the third party supplier.  Third party goods or software are those that are labeled or branded with a third party’s name The warranty for third party goods or software, if any, is provided by the original manufacturer.  Illumina will cooperate with Customer in filing any warranty claims with such third-parties.

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

14



 

17.        Term; Cancellation; Termination .

 

a.               Term .  This Agreement shall commence on the Effective Date and terminate on the date that is three (3) years after the First Amendment Date unless otherwise terminated early as provided hereunder or extended longer by the mutual written agreement of the Parties.  For clarity, Customer has the right after the Term to use for Customer Use the particular Consumables Products that were purchased by Customer during the Term under this Agreement, with Illumina Hardware and Existing Instruments.  For the avoidance of doubt, Customer will have the foregoing right to use Consumables Products for Customer Use after the Term only with respect to the actual units of Consumables Product supplied under this Agreement during the Term and payment of any applicable NIPT Test Fee corresponding to use of such Consumable Product.  After the term, Customer has the right to use Illumina Hardware and Existing Instruments for Research Use with Illumina-branded consumables whether purchased outside of or under this Agreement.  The period from the Effective Date to the date the Agreement is terminated is the “ Term .”  Customer’s issuance of or Illumina’s fulfillment of any Purchase Order after the end of the Term shall not be deemed agreement of Illumina to extend this Agreement beyond the Term.  Illumina has no obligation to accept or fulfill any Purchase Order submitted by Customer after the Term.

 

b.               Cancellation of Orders .  All Purchase Orders submitted under and in accordance with this Agreement and accepted by Illumina are non-cancelable by Customer or Illumina and may not be modified without the prior written consent of both parties, subject to Section 17(d.)

 

c.                Termination .  Without limiting any other rights to terminate expressly provided in this Agreement or under law, this Agreement may be terminated early as follows:

 

i.                  Breach of Provision .  If either Party materially breaches any of its obligations under this Agreement and fails to cure such breach within 30 days after receiving written notice of the breach from the non-breaching Party, then the non-breaching Party shall have the right to terminate this Agreement by providing written notice to the other Party at any time during the one month period that begins on the day after the last day of the cure period .  Notwithstanding the foregoing, if a Party has provided notice to the other Party of a material breach that is not capable of cure, then the non-breaching Party shall have the right to terminate this Agreement by providing written notice to the breaching party at any time during the one month period that begins five (5) business days after the written notice of breach .  A non-breaching Party shall be entitled, in addition to all other rights and remedies available at law or in equity, to seek injunctive relief against the breach or threatened breach of this Agreement Notwithstanding the foregoing or anything to the contrary contained in this Agreement, Illumines right to terminate this Agreement for Customer’s breach is subject to Section 4(d) (Additional Rights).

 

ii.              Bankruptcy .  Either Party may terminate this Agreement, with immediate effect upon written notice, if the other Party becomes the subject of a voluntary or involuntary petition in bankruptcy or any proceeding relating to insolvency, receivership, liquidation or composition for the benefit of creditors that is not dismissed within 60 days.  In the event of any bankruptcy or insolvency proceeding commenced by or against Customer other than a proceeding in which a the trustee in bankruptcy is continuing to perform all of Customer’s obligations under this Agreement, Illumina shall be entitled to cancel any Purchase Order then outstanding and not accept any further Purchase Order until bankruptcy or insolvency proceeding is resolved, unless Customer provides pre-payment for any unpaid Purchase Order or provides pre-payment for any new Purchase Order at the time the Purchase Order is delivered.

 

iii.          Change in Control of Customer .  (A) Customer shall promptly notify Illumina in writing if it undergoes any Change in Control and shall provide Illumina with the name of any parties to the transaction.  Illumina shall have a 30 day period, that begins on the date of Change in Control and ends on the date that is the later of 30 days after the Change in Control or 30 days after receipt of notice of the Change in Control, to terminate the Agreement by written notice, unless prior to the Change in Control, Customer notified Illumina of the planned Change in Control (including the name of the party(ies) to the transaction) and Illumina agreed in writing to not exercise its right of termination set forth in this subpart (iii).  Illumina agrees that it will not unreasonably withhold or delay its agreement to waive exercise of its right of termination.  Customer agrees that it shall not be unreasonable for Illumina to withhold or delay such agreement based on the bona fide business considerations of Illumina, which include without limitation business considerations pertaining to litigation or enforcement of Illumina Intellectual Property Rights, or whether the other party to the Change in Control transaction is a competitor of Illumina or its Affiliates, including without limitation a Direct Competitor.  Termination pursuant to this subpart (iii) shall

 

15



 

become effective (I) if none of the other parties to the Change in Control transaction is a Direct Competitor, on the date that is six (6) months after the effective date of the Change of Control, or (II) if one of the parties to the Change in Control transaction is a Direct Competitor, on the date that is thirty (30) days after written notice of termination by Illumina.  Illumina agrees that it will not exercise its right to terminate the Agreement under this Section 17(c)(iii) if the other party to the Change in Control transaction is a clinical laboratory that is not a Direct Competitor.

 

(B) “ Change in Control ” means (a) any person or entity becomes the beneficial owner, directly or indirectly, of Customer’s securities representing 50% or more of the combined voting power of Customer’s then outstanding securities entitled to vote in the election of directors; (b) Customer is party to a merger or consolidation which results in the voting securities of Customer outstanding immediately prior thereto failing to continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving or another entity) at least fifty (50%) percent of the combined voting power of the voting securities entitled to vote in the election of directors of Customer or such surviving or other entity outstanding immediately after such merger or consolidation; (c) a majority of the board of directors (or similar governing body) of Customer shall consist of individuals other than members of the board of directors (or similar governing body) of Customer on the Effective Date; (d) the sale or disposition of all or substantially all of Customer’s assets (or consummation of any transaction having similar effect to a non-Affiliate of Customer); or (e) the dissolution or liquidation of Customer; provided, however, that Change of Control shall not include any transaction or series of transactions entered into primarily for corporate restructuring or equity financing purposes (including, without limitation, any venture capital or private equity investment or any public offering of securities) in which no other entity to the transaction or series of transactions is (1) a Direct Competitor or (2) is an Affiliate of Customer at the time of such transaction(s) or becomes an Affiliate of Customer by nature of such transaction(s).  As of the Effective Date, a Direct Competitor is not, and to the knowledge of Customer, is not preparing to become, a significant investor in Customer.

 

(C) “ Direct Competitor ” means an entity (or its Affiliates) that develops, manufactures, or sells high throughput sequencing systems that could practically be used for NIPT .  By way of non-limiting example, as of the Effective Date, Life Technology, Inc., Qiagen and BGI (or entities that acquire the business assets directed to the high through put sequencing systems currently marketed by such entities, including evolutions thereof) are Direct Competitors.

 

iv.           Termination by Customer for Supply Failure .  Customer shall have the right to terminate this Agreement (and all outstanding Purchase Orders, to the extent Illumina has not yet supplied thereunder) upon at least ten (10) business days prior written notice in the event of a Supply Failure that that extends for greater than two (2) months.  A “ Supply Failure ” is the failure of Illumina to supply Product ordered on a Purchase Order submitted by Customer in accordance with this Agreement, wherein the failure to supply is a direct result of a Force Majeure Event (defined in Section 20(i)).

 

v.               Termination by Customer for Convenience .  Customer may terminate this Agreement for convenience by providing Illumina with four (4) months prior written notice and, at the same time, submitting a Purchase Order for Consumables in fulfillment of the binding portion of Forecast (for which a Purchase Order has not at that time been submitted) applicable to the quarter in which termination notice is provided and in any portion of a Forecast that is binding for the next subsequent quarter.

 

d.               Right to Cease Delivery .  In addition to any other remedies available to Illumina under this Agreement, in equity, or at law, but in all cases subject to Section 4(d) (Additional Rights), Illumina reserves the right to cease shipping Product to Customer immediately if Customer (1) uses any Product outside the scope of the rights expressly conferred to Customer on Exhibit A and Section 3 (Rights Accompanying Purchase of Product for Customer Use) of this Agreement, (2) fails to pay invoices in full when due, (3) breaches any provision of Section 5 (Limitations on Use), or (4) breaches any Customer representation or warranty made hereunder.

 

18.        Survival of Obligations .  All provisions of this Agreement that by their nature should survive termination or expiration of the Agreement shall survive termination or expiration, including without limitation, Sections 1 (Definitions), 2.a.ii (Scope), 3.a, 3.c and 3.d (Rights Accompanying Purchase of Product for Customer Use), 5 (Limitations on Use), 7(e)(i) (Existing Purchase Order), 8 (Invoices, Payments, Taxes), 11.a (Product Label, 11.b (Regulatory Approval), 12 (Limitation on Liability), 13 (Product Warranty Disclaimer), 14 (Confidentiality), 15 (Indemnification, Insurance), 16 (Warranty for Product), 17.a (Term), 17.b (Cancellation of Orders), 18 (Survival of Obligations), 19 (Governing Law), and 20 (Miscellaneous), Exhibit A (to the extent applicable to use of Products already purchased under Agreement), and all payment obligations incurred hereunder, representations and warranties, and disclaimers of representation and warranties.  Termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement, nor prejudice either Party’s right to obtain performance of any obligation.

 

16


 

19.        Governing Law .  This Agreement and performance by the Parties hereunder shall be construed in accordance with the laws of the State of California, U.S.A., without regard to provisions on the conflicts of laws.

 

20.        Miscellaneous .

 

a.               General Representations and Warranties .  Customer represents and warrants and covenants that (i) it owns, rents or leases the Facilities; (ii) it has the right and authority to enter into this Agreement; (iii) it has all rights and licenses necessary to purchase and use the Products for Customer Use; (iv) as of the Effective Date, and after due and sufficient inquiry undertaken by individual(s) qualified to make the inquiry, Customer believes that it does not require a license to any Illumina Application Specific IP in order to use the Products for Customer Use and (v) the person(s) signing this Agreement on its behalf has the right and authority to bind Customer to the terms and conditions of this Agreement.  Illumina represents and warrants and covenants that (x) it has the right and authority to enter into this Agreement; (y) it has all rights and licenses necessary to enter into and perform it obligations under this Agreement, and to grant the rights and licenses granted hereunder; and (z) the person(s) signing this Agreement on its behalf has the right and authority to bind Illumina to the terms and conditions of this Agreement.

 

b.               Illumina Affiliates .  Customer agrees that Illumina may delegate its performance under this Agreement to one or more of its Affiliates, provided that Illumina remains ultimately responsible for performance of the obligations under this Agreement.  Illumina invoices and other documentation may come from an Illumina Affiliate and Customer shall honor those just as if they came directly from Illumina.

 

c.                Legal Compliance .  Nothing in this Agreement is intended, or should be interpreted, to prevent either Party from complying with all applicable laws, regulations, or governmental orders.

 

d.               Documentation .  Customer agrees that it shall use the Documentation in accordance with the restrictions set forth therein (e.g., restrictions against altering, modifying or copying, or removing the Documentation from Customer’s Facility(ies)), and further agrees that it will use Products in accordance with the Product Documentation.  Notwithstanding the foregoing or anything set forth in the Documentation, Customer may make a reasonable number of copies of the Documentation for use only by Customer at its Facilities to support its authorized use of the Products.  Permitted copies of the Documentation shall include Illumina’s copyright and other proprietary notices.

 

e.                Severability; No Waiver .  If any provision of this Agreement is held invalid or unenforceable, such provision shall be enforced to the maximum extent permissible so as to effect the intent of the Parties, and the remainder of this Agreement will continue in full force and effect.  The failure of either Party to exercise any right granted herein or to require any performance of any term of this Agreement or the waiver by either Party of any breach of this Agreement shall not prevent a subsequent exercise or enforcement of, or be deemed a waiver of any subsequent breach of, the same or any other term of this Agreement.

 

f.                 Assignment .  Neither Party may assign or transfer this Agreement or any rights or obligations under this Agreement, whether voluntary, by operation of law or otherwise (including by way of reverse triangular merger or other merger), without the prior written consent of the other Party; provided, however, that no consent shall be required for any assignment in connection with any merger, acquisition or the sale of all or substantially all of the stock or assets of the assigning party to a party that agrees in writing to be bound by the terms and conditions of this Agreement.  Illumina may assign all or part of the right to payments hereunder.  Any assignment or transfer of this Agreement made in contravention of the terms hereof shall be null and void.  Subject to the foregoing, this Agreement shall be binding on and inure to the benefit of the parties’ respective successors and permitted assigns.

 

g.               Export .  Customer agrees that the Products, or any related technology provided under this Agreement may be subject to restrictions and controls imposed by the United States Export Administration Act and the regulations thereunder (or the regulations and laws of another country).  Without limiting the other restrictions set forth herein, Customer agrees not to export or re-export the Products, or any related technology into any country in violation of such controls or any other laws, rules or regulations of any country, state or jurisdiction.

 

h.               Notices .  All notices required or permitted under this Agreement shall be in writing and shall be deemed received when (i) delivered personally; (ii) 5 days after having been sent by registered or certified mail, return receipt requested, postage prepaid (or 10 days for international mail); or (iii) 1 day after deposit with a commercial express courier specifying next day delivery or, for international courier packages, 2 days after deposit with a commercial express courier specifying 2-day delivery, with written verification of receipt.  All notices shall be sent to the following or any other address designated by a party using the procedures set forth in this Sub-Section:

 

17



 

If to Illumina:

 

Illumina, Inc.

5200 Illumina Way

San Diego, CA 92122

Attn: Sr. VP. Corporate Development

 

With a copy to:

 

Illumina, Inc.

5200 Illumina Way

San Diego, CA 92122

Attn: General Counsel

 

If to Customer

 

Natera, Inc.

201 Industrial Rd.

San Carlos, CA 94070

Attn: CEO

 

With a copy to:

 

Natera, Inc.

201 Industrial Rd.

San Carlos, CA 94070

Attn: General Counsel

 

i.                  Force Majeure .  Except for payment of amounts due, neither Party shall be responsible for any failure to perform or delay in the performance of this Agreement attributable in whole or in part to any cause beyond its reasonable control, including but not limited to acts of God, fire, flood, tornado, earthquake, hurricane, lightning, government actions, actual or threatened acts of war, terrorism, civil disturbance or insurrection, sabotage, labor shortages or disputes, failure or delay in delivery by Illumina’s suppliers or subcontractors, transportation difficulties, shortage of energy, raw materials or equipment, or the other Party’s fault or negligence, each of which is an “ Event of Force Majeure .”  In the event of any such delay the delivery date for performance shall be deferred for a period equal to the time lost by reason of the delay, subject to Customer’s right to terminate the Agreement set forth in Section 17(c)(iv) (Supply Failure),

 

j.                  Entire Agreement; Amendment; Waiver .  This Agreement, including all Exhibits, represents the entire agreement between the Parties regarding the subject matter hereof and supersedes all prior discussions, communications, agreements, and understandings of any kind and nature between the Parties.  No amendment to this Agreement will be effective unless in writing and signed by both Parties.  No waiver of any right, condition, or breach of this Agreement will be effective unless in writing and signed by the Party who has the right to waive the right, condition or breach and delivered to the other Party.  Customer agrees that, from and after the Effective Date, (i) actual knowledge by Illumina, Illumina’s Affiliates, or their respective directors, officers, employees, or agents that Customer is using Product supplied under this Agreement in any manner or for any purpose outside the scope of the rights expressly granted to Customer as set forth in Exhibit A and Section 3 (Rights Accompanying Purchase of Product for Customer Use) does not (A) waive or otherwise limit any rights that Illumina, or Illumina’s Affiliates, may have as a result of such use of the Product, including without limitation, any rights or remedies available under the terms and conditions of this Agreement, and any rights or remedies available at law or in equity, (B) grant Customer a license to any intellectual property owned or controlled by Illumina or Illumina’s Affiliates whether by implication, estoppel, or otherwise with respect to such use of the Product, and (ii) any trade usage, and any course of performance or course of dealing between Illumina and Customer, will not be used to interpret the terms and conditions of this Agreement, including without limitation, the scope of the rights for Product supplied under this Agreement conferred under Exhibit A and Section 3 (Rights Accompanying Purchase) .

 

k.               Relationship of the Parties; No Third Party Beneficiaries .  The Parties are independent contractors under this Agreement and nothing contained in this Agreement shall be construed as creating a partnership, joint venture or agency relationship between the Parties or, as granting either Party the authority to bind or contract any obligation in the name of the other Party, or to make any statements, representations, warranties or commitments on behalf of the other Party.

 

l.                  Publicity; Use of Names or Trademarks .  Each Party shall obtain the prior written consent of the other Party (which may be granted or denied in such party’s sole discretion) on all press releases or other public announcements relating to this Agreement, including its existence or its terms, except to the extent the press release or public announcement includes public information.  The Parties agree to work together diligently and in good faith to issue, no later than fourteen (14) days after the Effective Date, a press release substantially in the form attached as Exhibit G announcing that they entered into an agreement for Illumina to supply Customer with consumables and equipment for Customer to use to perform NIPT and other tests within Customer Use and will make good faith efforts to arrive at mutually acceptable text for such press release.  Notwithstanding any of the foregoing, if required by law, including without limitation by the U.S. Securities and Exchange Commission or any stock exchange or Nasdaq, then a Party may issue a press release or other public announcement regarding this Agreement, provided that the other Party has received

 

18



 

prior written notice of such intended press release or public announcement and an opportunity to seek confidential treatment and/or a protective order if practicable under the circumstances, and the Party subject to the requirement cooperates with the other Party to limit the disclosure and includes in such press release or public announcement only such information relating to this Agreement as is required by such law.  Neither Party shall use the name or trademarks of the other Party without the express prior written consent of the other Party, except as permitted under this Agreement.

 

m.           Headings; Interpretation; Miscellaneous .  Sections, titles and headings in this Agreement are for convenience only and are not intended to affect the meaning or interpretation hereof.  This Agreement has been negotiated in the English language.  Any translation is for convenience only.  Only the English language version shall control.  Whenever required by the context, the singular term shall include the plural, the plural term shall include the singular, and the gender of any pronoun shall include all genders.  As used in this Agreement except as the context may otherwise require, “include”, “includes”, “including”, and “such as” are deemed to be followed by “without limitation”, whether or not they are in fact followed by such words or words of like import, and “will” and “shall” are used synonymously.  Except as expressly stated, any reference to “days” shall be to calendar days, and “business day” shall mean all days other than Saturdays, Sundays or a national or local holiday recognized in the United States, and any reference to “calendar month” shall be to one of the 12 months of the year and not a 30 day period, and any reference to “calendar quarter” shall mean the first 3 calendar months of any year, the 4-6th calendar months of any year, the 7-9 th  calendar months of any year, and the last 3 calendar months of any year.  Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall on a Saturday, Sunday, or national holiday, the Party having such privilege or duty shall have until 5:00 pm Pacific Time on the immediately following business day to exercise such privilege or to discharge such duty.  It is further agreed that no usage of trade or other regular practice between the Parties hereto shall be used to interpret or alter the terms of this Agreement.  Ambiguities, if any, in this Agreement shall not be construed against any particular Party, irrespective of which Party may be deemed to have authored the ambiguous provision.  Illumina is constantly innovating and developing new products or new versions of products.  If specific products are listed in this Agreement, Illumina is not guaranteeing that the specific products will be manufactured or available throughout the Term.

 

n.               Counterparts .  This Agreement may be executed in one or more counterparts, and each of which shall be deemed to be an original, and all of which shall constitute one and the same instrument.

 

o.               Customer Agreements .  Customer is not an authorized dealer, representative, reseller, or distributor of any of Illumina’s, or its Affiliates’, products or services.  Customer agrees, represents and warrants that it (i) is not purchasing any Product on behalf of a third party, (ii) is not purchasing any Product in order to resell or distribute the Product to a third party, (iii) is not purchasing any Product in order to export the Product from the country in which Illumina shipped the Product pursuant to the ship-to address designated by Customer at the time of ordering, and (iv) will not export the Product out of the country of the ship-to address designated by Customer at the time of ordering.

 

IN WITNESS WHEREOF , the Parties hereto acknowledge and agree to the terms and conditions of this Agreement and have caused this Agreement to be executed by their respective duly authorized representatives.

 

Customer:

Illumina:

 

 

 

 

By:

/s/ Matthew Rabinowitz

 

By:

/s/ Nicholas Naclerio

 

 

 

 

Name:

Matthew Rabinowitz

Name:

Nicholas Naclerio

 

 

 

 

Title:

CEO

Title:

SVP Corporate & Venture Development

 

 

 

 

Date:

August 16, 2013

Date:

August 15, 2013

 

19



 

ATTACHMENT A

 

ILLUMINA SERVICE REPRESENTATIVES
ACKNOWLEDGEMENT AND AGREEMENT OF CONFIDENTIALITY TERMS AND CONDITIONS
PERTAINING TO ON-SITE SUPPORT AND SERVICE AT NATERA, INC. (“Natera”)

 

1.                                       Illumina has authorized and Natera has permitted you to be on-site at Natera’s laboratory facility to provide technical support for and/or technical services with respect to Illumina equipment located at that facility.

 

2.                                       Article 14, attached, are the terms and conditions regarding confidential or proprietary information that may be disclosed between Illumina and Natera.  These terms, particularly subsection (f), are applicable to you (as a “Service Representative”) with respect to information that is disclosed to you when you are on-site at Natera as a representative of Illumina.  If at any time you have any questions about these terms, then please discuss with your supervisor.

 

3.                                       While on-site at Natera, you may receive information disclosures directly, such as information that Natera tells you in a conversation, through a document, or through servicing an instrument, and information also may be disclosed to you indirectly, such as if you see something while walking through the Natera facility or overhear a conversation while you are on-site at Natera.  You should not accept disclosure of confidential or proprietary information unless you require that information to perform the authorized technical support or technical services.  If you are told, given or are otherwise exposed to information that you do not require in order to perform the authorized technical support or technical services, then take appropriate action to immediately stop the disclosure.  Appropriate action may be asking that you not be told certain information, returning documents that you do not require, or walking away from an area where disclosures are occurring.  If you have any concerns regarding appropriate action, then please discuss with your contact at Natera and your supervisor.

 

4.                                       Despite the foregoing, if you receive confidential or proprietary information of Natera that you do not require, then you may tell your supervisor that there has been a disclosure, the general nature of the disclosure (without revealing the confidential or proprietary information disclosed), and the circumstances under which the disclosure occurred and discuss ways to prevent similar disclosures in the future.  However, do not disclose the actual confidential or proprietary information of Natera to your supervisor or any other person at Illumina, unless an authorized Illumina attorney (or outside counsel retained by Illumina) instructs you to disclose the actual confidential or proprietary information for the purpose of Illumina enforcing its rights under the Agreement.  Notwithstanding anything to the contrary, nothing in the Agreement or this Acknowledgement and Agreement Regarding Confidential Information prevents or restricts you from (1) disclosing to Illumina information that relates to the Products supplied under this Agreement or Illumina Intellectual Property Rights or (2) disclosing confidential or proprietary information to an authorized Illumina attorney (or outside counsel retained by Illumina) for the purpose of Illumina enforcing its rights under the Agreement, if the Service Representative is instructed by an authorized Illumina attorney (or outside counsel retained by Illumina) to disclose the confidential or proprietary information.

 

5.                                       You are not authorized to disclose to Natera any Illumina confidential or proprietary information.  If you believe that such disclosure is necessary in order to provide technical support and technical services for Natera, or if you have any question as to whether information is confidential or proprietary to Illumina, then please inform your supervisor.

 

6.                                       By signature below, you are acknowledging that you read and understand, and agree to abide by , the terms and conditions regarding confidential and proprietary information of Natera that may be disclosed to you while you are on-site at Natera performing technical support for and/or technical services to the Illumina equipment located at the Natera facility.

 

7.                                       By signature below, you acknowledge and agree that you are not authorized to disclose to Natera any confidential or proprietary information of Illumina, nor are you authorized to disclose to Illumina any confidential or proprietary information of Natera, except as expressly permitted herein .

 

Read, Understood, and Agreed to:

 

 

 

 

Signature

 

Date

 

Name:

 

 

 

 

 

Title:

 

 

 



 

Confidentiality Terms in Natera-Illumina Supply Agreement (August 16, 2013, as amended)

 

14.                                Confidentiality

 

a.         Confidential Information .  The Parties acknowledge that a Party (the “ Recipient Party ”) may have access to confidential or proprietary information (“ Confidential Information ”) of the other Party (the “ Disclosing Party ”) under or in connection with this Agreement.  In order to be protected as Confidential Information, information must be disclosed with a confidential or other similar proprietary legend and in the case of orally or visually disclosed Confidential Information that pertains to a Disclosing Party’s Intellectual Property Rights (including trade secrets),the Disclosing Party shall notify the Recipient Party of its confidential nature at the time of disclosure and provide a written summary that is marked with a confidential or other similar proprietary legend to the Recipient Party within 30 days (email acceptable).  Notwithstanding anything to the contrary contained in this Agreement, the Parties acknowledge and agree that the content of all conversations and correspondence (including emails) relating to the negotiation of this Agreement shall be deemed the Confidential Information of the providing Party.  Confidential Information may include, but shall not be limited to, inventions, designs, formulas, algorithms, trade secrets, know-how, customer lists, cost and pricing information, business and marketing plans, and other business, regulatory, manufacturing and financial information.  This Agreement, including its terms and conditions is Confidential Information of both Parties.  During the Term of this Agreement or for a period of [*] after the date of each disclosure, whichever is longer, the Recipient Party shall hold the Disclosing Party’s Confidential Information in confidence using at least the degree of care that is used by the Recipient Party with respect to its own Confidential Information of similar nature or importance, but no less than reasonable care.  The Recipient Party shall disclose the Confidential Information of the Disclosing Party solely on a need to know basis to its employees, contractors, officers, directors, representatives, and Affiliates under written nondisclosure and restricted use terms consistent with this Agreement or under professional ethics rules to which certain professionals (including attorneys) are bound.  The Recipient Party shall not use the Disclosing Party’s Confidential Information for any purpose other than exercising its rights and fulfilling its obligations under this Agreement.  The Confidential Information shall at all times remains the property of the Disclosing Party.  The Recipient Party shall, upon written request of the Disclosing Party, return to the Disclosing Party or destroy the Confidential Information of the Disclosing Party.  Notwithstanding the foregoing, the Recipient Party may maintain one copy of the Disclosing Party’s Confidential Information to be retained by the Recipient Party’s Legal Department for archival purposes only.

 

b.         Exceptions .  Notwithstanding any provision contained in this Agreement to the contrary, neither Party shall be required to maintain in confidence or be restricted in its use of any of the following: (i) information that, at the time of disclosure to the Recipient Party, is in the public domain through no breach of this Agreement or another obligation of confidentiality owed to the Disclosing Party or its Affiliates by the Receiving Party; (ii) information that, after disclosure hereunder, becomes part of the public domain by publication or otherwise, except by breach of this Agreement or breach of another obligation of confidentiality owed to the Disclosing Party or its Affiliate by the Receiving Party; (iii) information that was in the Recipient Party’s or its Affiliate’s possession at the time of disclosure hereunder by the Disclosing Party unless subject to an obligation of confidentiality or restricted use owed to the Disclosing Party or its Affiliate; (iv) information that is independently developed by or for the Recipient Party or its Affiliates without use of or reliance on any Confidential Information of the Disclosing Party; or (v) information that the Recipient Party receives from a third party where Recipient Party reasonably believes such third party was under no obligation of confidentiality to the Disclosing Party or its Affiliate with respect to such information.

 

c.          Disclosures Required by Law .  The Recipient Party may disclose Confidential Information of the Disclosing Party as required by court order, operation of law, or government regulation (including the Sunshine Act), including in connection with submissions to regulatory authorities; provided that, the Recipient Party promptly notifies the Disclosing Party of the specifics of such requirement prior to the actual disclosure, or promptly thereafter if prior disclosure is impractical under the circumstances, uses diligent efforts to limit the scope of such disclosure or obtain confidential treatment of the Confidential Information if available, and allows the Disclosing Party to participate in the process undertaken to protect the confidentiality of the Disclosing Party’s Confidential Information including, without limitation, cooperating with the Disclosing Party in order to comply with the requirements of such order, law, or regulation in a manner that discloses the least amount necessary, if any, of the Confidential Information of the Disclosing Party.

 

d.               Injunctive Relief .  Each Party acknowledges that any use or disclosure of the other party’s Confidential Information other than in accordance with this Agreement may cause irreparable damage to the other Party.  Therefore, in the event of any such use or disclosure or threatened use or threatened disclosure of the Confidential Information of either Party hereto, the non-breaching Party shall be entitled, in addition to all other rights and remedies available at law or in equity, to seek injunctive relief against the breach or threatened breach of any obligations under this Section.

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 



 

e.          Disclosure of Agreement .  Except as expressly provided otherwise in this Agreement, neither Party may disclose this Agreement, the terms of this Agreement, including any financial terms thereof, and the subject matter of this Agreement to any third party without the prior written consent of the other Party, which consent shall not be unreasonably withheld.  In the event either Party desires to provide a copy of this Agreement, or otherwise disclose its terms, on a confidential basis in connection with any financing transaction or due diligence inquiry, then it may do so on a confidential basis under written terms and conditions no less stringent than set forth herein.  In addition, each Party may disclose this Agreement and the terms hereof in connection with any legal action related hereto, including any enforcement hereof.

 

f.           Service Representatives .  A “ Service Representative ” is an individual who is authorized by Illumina and approved by Customer to be on-site at Customer’s Facility (as defined in Agreement) to provide technical support and/or technical services with respect to Illumina equipment located at that Facility.

 

(i) In the event a Service Representative receives, views, hears or is otherwise exposed to confidential or proprietary information of Customer when the Service Representative is on-site at Customer Facility to provide technical support and/or technical service, and such information is not tangibly identified and marked as Confidential Information in accordance with Section 14(a) of the Agreement, including if disclosed orally or visually, Illumina and the Service Representative shall nevertheless be obligated to treat the confidential or proprietary information as if it were Confidential Information under the Agreement.

 

(ii) Prior to commencing work on-site at Customer’s Facility (except to the extent Customer has permitted that Service Representative to commence work on-site prior to executing that Acknowledgement and Agreement), each Service Representative shall execute the Acknowledgement and Agreement Regarding Confidential Information that is set forth hereto as Attachment A, and shall provide a copy of the executed document to Customer.  As more completely stated in Attachment A, the Acknowledgement and Agreement documents that the Service Representative has read, understands, and agrees to be bound by these terms and conditions regarding confidential or proprietary information, including Confidential Information, that may be disclosed (in writing, orally, visually) to the Service Representative or that the Service Representative may be exposed to while on-site at Customer’s Facility providing technical support and/or technical services, unless instructed otherwise by an authorized Illumina attorney (or outside counsel retained by Illumina) for the purpose of Illumina enforcing its rights under the Agreement.  Notwithstanding anything to the contrary, nothing in this Agreement or the Acknowledgement and Agreement Regarding Confidential Information prevents or restricts a Service Representative from (1) disclosing to Illumina information that relates to Products or Illumina Intellectual Property Rights or (2) disclosing confidential or proprietary information to an authorized Illumina attorney (or outside counsel retained by Illumina) for the purpose of Illumina enforcing its rights under the Agreement, if the Service Representative is instructed by an authorized Illumina attorney (or outside counsel retained by Illumina) to disclose the confidential or proprietary information.

 

(iii) Notwithstanding the foregoing, Customer agrees that it shall take commercially reasonable steps to prevent the disclosure (in writing, orally, visually) to Service Representatives, and prevent their access to, confidential or proprietary information except to the extent such disclosure or access is required for that Service Representative to perform technical support and/or technical services.  Without limitation, commercially reasonably steps include Customer instructing its employees, contractors and agents who will come in contact with Service Representatives of the terms and conditions of this Article 14.

 


 

Exhibit A - Customer Use Rights and Related Obligations

 

Part 1— NIPT USE

 

1.                                       NIPT Use ” means the detection or determination of (1) Fetal Chromosomal Abnormalities and/or (2) fetal gender, in each case of (1) and (2), by sequencing nucleic acids present in the cell-free fraction of maternal blood or maternal blood components and analyzing the data generated from such sequencing, subject to the Exclusions from Customer Use (defined in Section 1 of the main body of this Agreement, Customer Use).

 

Fetal Chromosomal Abnormalities ” means (1) numerical anomalies including (a) abnormal numbers of autosomes (including but not limited to trisomy 21, trisomy 13, and trisomy 18) and (b) abnormal numbers of sex (X and/or Y) chromosomes (including but not limited to Turner Syndrome and Klinefelter’s syndrome) and (2) structural anomalies having a length greater than [*] kilobases, including but not limited to chromosomal deletions, insertions, duplications, translocations, and inversions (including but not limited to chromosome 5q deletion syndrome .

 

LDT ” means a laboratory developed test performed in a CLIA Laboratory.

 

CLIA Laboratory ” means a laboratory in the United States meeting all applicable requirements of the Clinical Laboratory Improvement Amendments.

 

2.                                       NIPT Use Rights — Subject to the terms and conditions and requirements of this Agreement, Customer’s purchase of TG Consumables and Temporary Consumables under this Agreement confers upon Customer the non-exclusive, non—transferable (except as set forth in Section 20(f) of the Agreement), personal, non-sublicensable right solely under Core IP (and no Application Specific IP) to use those Consumables with Illumina Hardware and Software for NIPT Use , such Consumables and Illumina Hardware and Software to be used in the Country, including without limitation the requirements that (i) when Customer uses Consumables for NIPT Use, Customer only uses TG Consumables and Temporary Consumables, and (ii) Customer uses such Consumables, Illumina Hardware and Software for NIPT Use only with each other and only in Customer’s Facilities.  The Parties agree that the preceding sentence is designed to and does alter the effect of the exhaustion of patent rights that would otherwise result if the sale was made without restriction and that Illumina reserves all rights to enforce its patent rights against unauthorized use .

 

3.                                       Exclusivity; TG Consumables and Temporary Consumables.

 

a.                                       Exclusivity .  In exchange for the discounts on Consumables and Illumina Hardware offered Customer under this Agreement, Customer will use only Illumina TG Consumables and Temporary Consumables and Illumina Hardware for all NIPT Uses performed by Customer during the Term.  If Customer, at its discretion, chooses to not use such Products exclusively for all such NIPT Uses (which choice, for clarity, shall not be deemed a breach of this Agreement), then (i) Customer will not be entitled to the discounts for Products (for any Customer Use) set forth on Exhibit B and (ii) if at any time during the period beginning on the First Amendment Date and ending on the date of the [*] anniversary of the First Amendment Date Customer does not use only Illumina TG Consumables and Temporary Consumables and Illumina Hardware exclusively for all tests for NIPT Use performed by Customer during such period , then Customer shall refund to Illumina an amount equal to [*]% of the Base Price of all Consumables for which Customer received a [*] % discount , wherein such refund is payable on the first date that it is not exclusively using Illumina TG Consumables and Temporary Consumables and Illumina Hardware for all NIPT Uses and is due within [*] business days after Customer’s notice as provided in the next sentence.  Customer will notify Illumina in writing within [*] days of the first date that it is not exclusively using Illumina TG Consumables and Temporary Consumables and Illumina Hardware for all NIPT Uses and, after such written notice, Customer will not be entitled to the discounts for Products that may be purchased under this Agreement for any Customer Use .  In addition, if Customer gives such notice of non-exclusivity during the [*] period that begins on the Effective Date , then Customer will promptly refund to Illumina the discount it received on any Illumina Hardware purchased during such period .  If Customer has not notified Illumina that it is using Illumina Products non-exclusively for NIPT Uses , then Illumina may request from time to time that an authorized officer of Customer provide Illumina with written certification that Customer is, and has been since the Effective Date or the last such certification, exclusively using Illumina TG Consumables and Temporary Consumables and Illumina Hardware for all NIPT Uses , and Customer will provide such certification.  Illumina will waive the requirement for exclusivity in Paragraph 3(a), and will supply in accordance with the discounts offered on Exhibit B, in the event of, and only during the period of, a Supply Failure that pertains to Product for NIPT Use .  Notwithstanding the foregoing, development by Customer of assays or tests for NIPT Uses (but provided that Customer is not marketing or commercializing such assays or tests) on non-Illumina sequencing platforms will not, without more, result in loss of the discounts on Exhibit B.

 

b.                                       TG Consumables for Clinical Use .  During the Term, when Customer uses Consumables for NIPT Use or Additional Clinical Use, Customer will use only TG Consumables and Temporary Consumables for NIPT Use and Additional Clinical Use, and will not use Non-TG Consumables (other than Temporary Consumables) for NIPT Use or for Additional Clinical Use.

 

c.                                        Temporary Consumables .  This provision only applies to Non-TG Consumables purchased under this Agreement that Illumina has given Customer the right to, and Customer intends to, use for Clinical Use, and for which a TG version of such Consumable is not available (including, without limitation, in the event of a Supply Failure) for supply to Customer from Illumina as of the Effective Date (“ Temporary Consumable(s) ”).  In the event Illumina makes commercially available during the Term a TG version of a Temporary Consumable (“ TG Version ”) with pricing that is substantially similar to the percentage difference in pricing between TG Consumables and Non-TG Consumables offered under this Agreement prior to such date, Customer must, within [*] months after the commercial availability of the TG Version, cease using the Temporary Consumable for Clinical Use.  No later than at expiration of the [*] month period, and only with respect to Consumables purchased for Clinical Use, Illumina will supply Customer with only the TG Version of the applicable Consumable under the terms of this Agreement.  The Temporary Consumables shall, solely for the purposes of the Clinical Use rights granted to Customer in this Exhibit A and under Section 3, be considered to be TG Consumables until the expiration of the [*] month period described in the preceding sentence.  For the avoidance of doubt, after expiration of the [*] month period, Customer may use Non-TG Consumables (including former Temporary Consumables) only (i) for Research Use or (ii) if TG Consumables are not available for supply under this Agreement and Illumina provides written consent for use of the Non-TG Consumables for Clinical Use (for clarity, this subpart (ii) is applicable to Temporary Consumables referred to in Sections 10(b) and 10(e) in the main body of the Agreement).  Except as expressly set forth otherwise in writing by Illumina, notification of changes is not provided for Non-TG Consumables.

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 



 

4.                                       IVD Product.   During the Term, Illumina may make one or more FDA-cleared or FDA-approved IVD products for particular clinical applications within Clinical Use (“ IVD Product ”) available for purchase by Customer under this Agreement.  If, prior to such time as Illumina makes a particular IVD Product available for purchase under this Agreement, Customer had been using Consumables or a set of Consumables to perform its own LDT for that particular clinical application (“ Current Consumables ”), then Customer will consider in good faith whether to transition to that Illumina IVD Product within [*] after it is available for purchase by Customer under this Agreement.  For the avoidance of doubt, it is the intent of both Customer and Illumina that the availability of supply under this Agreement of the Current Consumables for use with such Customer LDT shall continue following Illumina’s making available for purchase such IVD Product.  “ Clinical Application LDT ” means Customer’s own LDT for a particular clinical application (including NIPT) within Clinical Use that Customer was performing with Current Consumables prior to the time Illumina makes an IVD Product available for purchase under this Agreement for that clinical application.  Notwithstanding the foregoing, if, in Customer’s reasonable determination, any such IVD Product does not have substantially equivalent or enhanced clinical, medical or scientific value, utility or performance as a corresponding Clinical Application LDT, and Customer decides that, because of such differences between the IVD Product and the Clinical Application LDT, it will not transition to that IVD Product, then Illumina shall not use that Customer decision as a basis to discontinue sale of the applicable Current Consumables to Customer for use in that Clinical Application LDT.  Notwithstanding the foregoing, if, due to the availability of the IVD Product, Illumina is required (in the reasonable judgment of outside legal counsel for Illumina, who is a specialist in the regulation in the United States of diagnostic products (“ Regulatory Counsel ”)), following disclosure of any non-privileged (as determined in good faith by Illumina) factual bases for this conclusion to outside regulatory legal counsel for Natera, who is also such a specialist (“ Natera Counsel ”), or pursuant to a written communication received by Illumina from a competent regulatory agency in the United States (“ Regulatory Communication ”), which Regulatory Communication has been shared with Natera Counsel) under applicable law, rule or regulation to discontinue supplying such Current Consumables to Customer for use with the Clinical Application LDT, then Illumina may discontinue sale and/or supply of the Current Consumables for use with the Clinical Application LDT.  If Illumina so discontinues supply of such Current Consumables, then Customer shall have a period of at least [*] to wind-down and discontinue ordering the Current Consumables for use with the Clinical Application LOT under this Agreement (unless, in the reasonable judgment of Regulatory Counsel, following disclosure of any non-privileged (as determined in good faith by Illumina) factual bases for this conclusion to Natera Counsel, or pursuant to a Regulatory Communication, which Regulatory Communication has been shared with Natera Counsel, a shorter time period for discontinuing supply or ordering is required by law, rule or regulation, in which case, within that shorter time period).  Illumina’s agreement (subject to the conditions stated herein) to not discontinue sale of applicable Current Consumables for use with the Clinical Application LDT is not a waiver of, and is subject to, any and all other rights under this Agreement of Illumina to discontinue sale and/or supply of Product.  If, in the reasonable judgment of Regulatory Counsel or pursuant to a Regulatory Communication, a shorter time period than the [*] stated above for discontinuing supply or ordering Current Consumables is required by law, rule or regulation, then Customer shall have the right to terminate this Agreement effective on or before the expiration of such shorter time period.  Upon Customer’s request, the Parties will work together in good faith to coordinate Customer’s transition to an IVD Product.  Any information shared by Illumina or its Regulatory Counsel with Natera’s Counsel shall not be shared with Customer except to the extent that it is public information, provided that Natera’s counsel shall be permitted to convey to Natera whether it does or does not agree with Illumina’s conclusion of a required discontinuation of Product sale and/or supply.

 

5.                                       Purchase Commitments.

 

a.                                       Quarterly Purchase Minimums .  In each calendar quarter during the Term, Customer will take delivery of TG Consumables and Temporary Consumables (as identified in Exhibit B) that it purchased under the Agreement and that, in the aggregate, total at least [*] after any discounts.  Customer will submit Forecasts that, at minimum, reflect the quarterly purchase minimums.  The quarterly purchase minimums will be waived on a pro-rata basis, corresponding to the length of Supply Failure, by Illumina in any quarter in which there is a Supply Failure.

 

b.                                       Initial Purchase Order; Final Shipment Purchase Order .  Concurrent with execution of the Agreement, Customer has submitted a binding initial Purchase Order to purchase the Illumina Hardware and Consumables set forth on the Quote, wherein the Quote and initial Purchase Order are in Exhibit E, and a Final Shipment Purchase Order in Exhibit H.

 

6.                                       NIPT Test Fee.

 

a.                                       In consideration for the negotiated discounts on Consumables provided in Exhibit B and the use of the Illumina Core IP in the field of NIPT Use, Customer agrees to pay Illumina a fee for each test (on a per patient basis) for NIPT Use performed on or after September 1, 2013 using any Product purchased under this Agreement, a product purchased under the Existing Purchase Order, or Existing Instrument where the result is reported (by Customer or another party) to a patient, doctor, other

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 



 

authorized person or referring laboratory (“ NIPT Test Fee ”).  For clarity, any test for NIPT Use run on a re-drawn sample during the same pregnancy to fill in missing information shall not be deemed a separate test for purposes of calculating the NIPT Test Fee.  For the avoidance of doubt, no right or license is being granted to utilize Application Specific IP in return for the NIPT Test Fee .  The NIPT Test Fee will apply in accordance with the time period stated above, whenever Customer uses Consumables (purchased during the Term) or product purchased under the Existing Purchase Order, or Illumina Hardware or Existing Instruments to perform any portion of a NIPT or test for NIPT Use, irrespective of whether a third party performs a portion of the NIPT or test on Customer’s behalf and irrespective of whether the Customer has invoiced or received payment for the NIPT.  For the avoidance of doubt, and without limitation, Customer will owe a NWT Test Fee if Customer uses the aforementioned Products and products to sequence, in whole or in part for an NIPT or test for NIPT Use, nucleic acids present in the cell-free fraction of maternal blood or maternal blood components, and then another party analyzes the data generated from such sequencing.  The NIPT Test Fee will be $[*] multiplied by the number of tests for NIPT Use performed (in whole or in part) by Customer in that quarter, except that the NIPT Test Fee for any such test that detects or determines structural anomalies having a length between [*] kilobases and [*] kilobases will be $[*] multiplied by the number of tests that meet that length criteria.  As of the Effective Date, the market for tests for NIPT Use that detect or determine structural anomalies having a length [*] kilobases is relatively undeveloped and, therefore, difficult to value .  Upon Customer’s request to negotiate with Illumina to expand the definition of NIPT Use to include tests that detect or determine structural anomalies having a length [*] kilobases, each Party agrees that it will negotiate with the other reasonably and in good faith to arrive at mutually acceptable terms and conditions, including pricing terms under which the definition of NIPT Use will be appropriately expanded.

 

b.                                       Customer will calculate the NIPT Test Fee owed to Illumina on a [*] basis, and provide payment of NIPT Test Fees to Illumina no later than [*] after the end of each [*].  Each such quarterly payment shall be accompanied by a written report that states for each [*] of the [*] the number of tests for NIPT Use performed in the Facilities, along with all other information that is needed to calculate the total amount of the NIPT Test Fee payment, including as applicable the type and number of tests for which a $[*] NIPT Test Fee is due.

 

c.                                        Customer will maintain true and accurate financial books and records relating to NIPTs for which an NIPT Test Fee is due under the Agreement for [*] years, wherein such books and records shall, at minimum, include sufficient information to confirm the information required to be included in quarterly NIPT Test Fee reports, confirm the amount of NIPT Test Fee payable to Illumina under the Agreement, and confirm compliance with the exclusivity provisions in this Exhibit A to the extent Customer is purchasing Products at the discounts provided.  Illumina may appoint an independent auditor (who shall be a certified public accountant reasonably acceptable to Customer) to audit such books and records, for the sole purpose of verifying NIPT Test Fees, information required to be included in quarterly NIPT Test Fee reports, and compliance with exclusivity (if Customer chooses exclusivity to benefit from the discounts provided), [*] during the Term and one time during the [*] period immediately following the Term, during business hours and upon at least [*] prior written notice to Customer.  All books and records examined by the auditor shall be kept strictly confidential by the auditor, and the auditor may provide only the results of its findings to Illumina, which in the event of a discrepancy in compliance will be supported by a copy of applicable records, with a copy to Customer.  Customer may require that the auditor sign Customer’s form nondisclosure agreement prior to granting access to any books and records.  If the auditor determines Customer has underpaid any amount due and payable to Illumina, then, provided that Customer does not dispute such determination in good faith, Customer will pay Illumina the difference between the amount due and payable and the amount actually paid, within [*] of invoice.  If Customer disputes the determination, then it will within the [*] period provide Illumina written notice of the basis for its dispute and the Parties will in good faith undertake resolution of the dispute.  In addition to all other remedies available to Illumina under this Agreement and at law and in equity, Customer shall be responsible for paying for, or reimbursing Illumina for, the costs of any audit (or, in the event Customer disputes the determination reached for a portion of the audit, then for the costs of any undisputed portion of any audit) that results in a final determination of an underpayment of NIPT Test Fees of [*] or more during any [*] period that was included in the audit or that results in a final determination that Customer’s purchase of Product was not in compliance with the exclusivity purchased Product using discounts when it was not in compliance with the exclusivity provisions required for discounts.

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 



 

Exhibit A (continued) - Customer Use Rights and Related Obligations

 

Part 2 — Additional Clinical Use

 

1.                                       Additional Clinical Use ” means use for the following testing on human samples: (1) non-invasive prenatal paternity testing, (2) genetic mutation screening of parental samples that do not include any fetal material, (3) pre-implantation genetic testing of embryos and (4) products of conception testing, and excludes all NIPT Uses .  Additional Clinical Use is a Clinical Use.  If reasonable minds could differ with respect to whether a particular use is within NIPT Use or is within Additional Clinical Use, then that use will be considered to be within NIPT Use under this Agreement.

 

2.                                       Additional Clinical Use Rights - Subject to the terms and conditions and requirements of this Agreement, Customer’s purchase of TG Consumables and Temporary Consumables under this Agreement confers upon Customer the non-exclusive, non-transferable (except as provided in Section 20(f) of the Agreement), personal, non-sublicensable right solely under Core IP (and no Application Specific IP) to use such Consumables with Illumina Hardware and Software for Additional Clinical Use in the Country, including without limitation the requirements that (i) when Customer uses Consumables for Additional Clinical Use, Customer only uses TG Consumables and Temporary Consumables, and (ii) Customer uses such Consumables, Illumina Hardware and Software for Additional Clinical Use only with each other and only in Customer’s Facilities.  The Parties agree that the preceding sentence is designed to and does alter the effect of the exhaustion of patent rights that would otherwise result if the sale was made without restriction and that Illumina reserves all rights to enforce its patent rights against unauthorized use .

 

3.                                       For the avoidance of doubt, (a) Paragraph 3 (Exclusivity; TG Consumables and Temporary Consumables) and Paragraph 5 (Purchase Commitments) on Exhibit A, Part 1, are applicable to Products for Additional Clinical Use and (b) use of Products for Additional Clinical Use does not require payment of a per test fee under this Agreement.

 



 

Exhibit A (continued) — Customer Use Rights and Related Obligations

 

Part 3 — Research Use

 

1.               Research Use ” means use for (i) internal research, and (ii) to perform research services provided to third-parties, subject to the Exclusions from Customer Use.  Research Use includes performance of clinical trials in cases where the data generated from use of the Products is not used for a treatment decision .

 

2.               Research Use Rights - Subject to the terms and conditions and restrictions of this Agreement, Customer’s purchase of Products under this Agreement confers upon Customer the non-exclusive, non-transferable (except as provided in Section 20(f) of the Agreement), personal, non-sublicensable right solely under Core IP (and no Application Specific IP) to use Products for Research Use in the Country, including without limitation the requirements that Customer use Consumables, Illumina Hardware and Software for Research Use only with each other and such Consumables and Illumina Hardware and Software to be used only in Customer’s Facilities.  The Parties agree that the preceding sentence is designed to and does alter the effect of the exhaustion of patent rights that would otherwise result if the sale was made without restriction and that Illumina reserves all rights to enforce its patent rights against unauthorized use.

 



 

Exhibit B — Illumina Hardware and Consumables

 

Illumina Hardware (Equipment)

 

Only the Illumina Hardware listed on this Exhibit B is subject to purchase under this Agreement.

 

Part Number

 

Description

 

Base Price

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

HiSeq 2500 [*] HiSeq 2500 Sequencing System. [*]

 

[*]

[*]

 

[*]

 

[*]

 

Illumina Hardware Purchase Price — Subject to exclusivity terms stated in Exhibit A, Part 1, Paragraph 3(a), the purchase prices for Illumina Hardware listed in the Table above are subject to a [*] discount.  Accordingly, if the [*] discount is applicable, then the purchase price for a unit of Illumina Hardware listed above is calculated by multiplying the base price by [*].

 

Prior to the First Amendment Date, Customer submitted a purchase order for a [*] Sequencing System.  The Parties agree that the [*] Sequencing System purchased prior to the First Amendment Date will be deemed to be “Existing Instrument” under the Agreement on and after the First Amendment Date.

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 



 

Exhibit B (continued) — Illumina Hardware and Consumables

 

Consumables

 

Only the Consumables listed on this Exhibit B are subject to purchase under this Agreement.

 

TG Consumables

 

Part Number

 

Description

 

Base Price

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

Non-TG Consumables

 

Part Number

 

Description

 

Base Price

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

Consumable Volume Discount: Based on Consumable Spend

 

 

 

TG Consumables

 

Non-TG Consumables

Consumable Spend

 

Discount off of Base Price

 

Discount off of Base Price

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

[*]

 

[*]

 

[*]

 

Consumables Purchase Price

 

(A)  Beginning on the Effective Date and ending on the First Amendment Date , the purchase price for Consumables ordered on Purchase Orders submitted in accordance with this Agreement during this period is equal to the base price for Consumables listed in this Exhibit and, in all cases (including (1), (2), (3) and (4) herein) subject to exclusivity terms stated in

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 



 

Exhibit A, Part 1, Paragraph 3(a), less the discount in the table above corresponding to the applicable Consumable Spend, provided that:

 

(1) for Consumable Spend that is $[*] and above during such period, the maximum discount for TG Consumables is [*],

 

(2) subject to part (3) herein, but otherwise notwithstanding anything in this Agreement to the contrary, during such period Customer is entitled to purchase Consumables in accordance with this Agreement at the base price in this Exhibit, less (i) for TG Consumables, the discount that is the greater of [*] or the TG Consumables discount in the table above corresponding to Customer’s actual Consumable Spend and (ii) for non-TG Consumables, the discount that is the greater of [*] or the Non-TG Consumables discount in the table above corresponding to Customer’s actual Consumable Spend, and

 

(3) for Purchase Order numbers 103340 and 103341, dated August 1, 2014, and Purchase Order numbers 103557 and 103558, dated September 1, 2014, and attached hereto as Schedule 2, Illumina has agreed to a [*] discount off of the base price, but only for the Products and quantities set forth on those two Purchase Orders as of August 1, 2014, and two Purchase Orders as of September 1, 2014; and

 

(4) for Purchase Order number 103342, dated August 1, 2014, and Purchase Order number 103559, dated September 1, 2014, and also attached hereto as Schedule 2, Illumina has agreed to a [*] discount off of the base price, but only for the Products and quantities set forth on those that Purchase Order as of August 1, 2014, and that Purchase Order as of September 1, 2014.

 

(B)  Beginning on the day after the First Amendment Date and ending on September 30, 2014 (end of Q3’14) , the purchase price for Consumables ordered on Purchase Orders submitted in accordance with this Agreement during this period is equal to the base price for Consumables listed in this Exhibit and, in all cases (including in all cases (i) and (ii) herein) subject to exclusivity terms stated in Exhibit A, Part 1, Paragraph 3(a), less the discount in the table above corresponding to the applicable Consumable Spend, provided that, notwithstanding anything in this Agreement to the contrary, during such period Customer is entitled to purchase Consumables in accordance with this Agreement at the base price in this Exhibit, less (i) for TG Consumables, the discount that is the greater of [*] or the TG Consumables discount in the table above corresponding to Customer’s actual Consumable Spend and (ii) for non-TG Consumables, the discount that is the greater of [*] or the Non-TG Consumables discount in the table above corresponding to Customer’s actual Consumable Spend.

 

(C)  Beginning on October 1, 2014 (start of Q4’14) and ending on expiration or termination of this Agreement , the purchase price for Consumables ordered on Purchase Orders submitted in accordance with this Agreement during this period is equal to the base price for Consumables listed in this Exhibit and, in all cases subject to exclusivity terms stated in Exhibit A, Part 1, Paragraph 3(a), less the discount in the table above corresponding to the applicable Consumable Spend.

 

Consumable Spend ” for Purchase Orders submitted prior to the First Amendment Date equals (1) the total amount (minus freight, taxes, and any product credits or offsets) Illumina has invoiced Customer for shipments of all Illumina products (which includes services) to Customer during the 12 calendar months that ended prior to the date a Purchase Order is due under the Agreement, which includes Products purchased under this Agreement and Illumina products (which includes services) purchased from Illumina outside of this Agreement, including Illumina’s array products, plus (2) the total amount of NIPT Test Fees received by Illumina from Customer during the 12 calendar months that ended prior to the date a Purchase Order is due under the Agreement.

 

Consumable Spend ” for Purchase Orders submitted after the First Amendment Date and thereafter until expiration or termination of the Agreement, is determined quarterly at the first day of each calendar quarter (i.e., January 1, April 1, July 1, October 1), and equals (1) the total amount (minus freight, taxes, and any product credits or offsets) Illumina has invoiced Customer for shipments of all Illumina products (which includes services) delivered to Customer during the 12 calendar month period that immediately precedes such first day of a calendar quarter under this Agreement, which includes Products purchased under this Agreement and Illumina products (which includes services) purchased from Illumina outside of this Agreement, including Illumina’s array products, plus (2) the total amount of NIPT Test Fees received by Illumina from Customer during the same 12 calendar month period.

 

Notwithstanding the foregoing, the only consumable products that can be purchased at the discounts listed in his Exhibit are the Consumables purchasable under this Agreement.

 

By way of example, the purchase price for Consumables purchased on Purchase Orders submitted in accordance with this Agreement during the first calendar quarter of 2015 (the period January 1, 2015 through March 31, 2015) is equal to the base price for Consumables listed in this Exhibit and, subject to exclusivity terms stated in Exhibit A, Part 1, Paragraph 3(a), less the discount in the table above corresponding to the Consumable Spend amount calculated by adding (1) the total amount (minus freight, taxes, and any product credits or offsets) Illumina invoiced Customer for shipments of all Illumina products delivered to Customer during the period January 1, 2014 through December 31, 2014 and (2) the total amount of NIPT Test Fees received by Illumina from Customer during the same period of January 1, 2014 through December 31, 2014.

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 



 

Attached as Schedule 1 hereto is a certification that Customer is, and has been since the Effective Date up to the later of the date of Customer’s signature on the certification or the First Amendment Date, exclusively using Illumina TG Consumables and Temporary Consumables and Illumina Hardware for all NIPT Uses other than as permitted by the last sentence of Exhibit A, Part 1, Section 3(a).

 


 

Schedule 1

 

Certification Regarding Exclusivity

 

The undersigned certifies that he/she is an officer of Natera and is authorized to, and hereby does, certify that from the Effective Date of the Agreement to the First Amendment Date, Natera has exclusively used Illumina TG Consumables and Temporary Consumables and Illumina Hardware for all NIPT Uses performed by Natera since the Effective Date other than as permitted by the last sentence of Exhibit A, Part 1, Section 3(a).

 

 

/s/ Matthew Rabinowitz

 

Name: Matthew Rabinowitz

 

 

 

Title:

CEO

 

 

 

 

Date:

09/17/2014

 

 



 

Schedule 2

 

Purchase Orders 103340, 103341, and 103342 dated August 1, 2014 and Purchase Orders 103557, 103558, and 103559 dated September 1, 2014 follow.

 


^g

*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 25 nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 103340 ORDER DATE: 8/1/14 PAYMENT TERMS: Net 30 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY B.O. QTY DELIVERY DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] NOTES: Lisa It’s [*]% discount rate Thank you SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 26 nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 103341 ORDER DATE: 8/1/14 PAYMENT TERMS: Net 30 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY B.O. QTY DELIVERY DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] NOTES: Lisa we have [*]% rate discount now thank you SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 27 nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 103342 ORDER DATE: 8/1/14 PAYMENT TERMS: Net 30 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY B.O. QTY DELIVERY DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] 11/19/2014 [*] [*] [*] [*] [*] [*] [*] 11/19/2014 [*] [*] NOTES: OLE Link present. SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090 Hi Seq 2500. Hi Seq 2500. Hi Seq 2500. Hi Seq 2500. Hi Seq 2500. [*]

 

 

27

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 28 nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 103557 ORDER DATE: 9/2/14 PAYMENT TERMS: Net 30 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY B.O. QTY DELIVERY DATE UNIT PRICE EXT PRICE 1 [*] [*] [*] [*] 12/04/2014 [*] [*] 2 [*] [*] [*] [*] 12/11/2014 [*] [*] 3 [*] [*] [*] [*] 12/18/2014 [*] [*] 4 [*] [*] [*] [*] 12/30/2014 [*] [*] NOTES: Lisa, We are now @ [*]% discount rate on TG parts thank you SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 29 nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 103558 ORDER DATE: 9/2/14 PAYMENT TERMS: Net 30 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY B.O. QTY DELIVERY DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] 12/04/2014 [*] [*] [*] [*] [*] [*] [*] 12/11/2014 [*] [*] [*] [*] [*] [*] [*] 12/18/2014 [*] [*] [*] [*] [*] [*] [*] 12/30/2014 [*] [*] NOTES: Lisa, We are now @ [*]% on TG parts thank you SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 30 nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 103559 ORDER DATE: 9/2/14 PAYMENT TERMS: Net 30 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY B.O. QTY DELIVERY DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] 12/16/2014 [*] [*] [*] [*] [*] [*] [*] 12/16/2014 [*] [*] NOTES: OLE Link present. SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090 Hi Seq 2500. Hi Seq 2500. Hi Seq 2500. Hi Seq 2500. Hi Seq 2500. [*]

 

 

30

 


31 Exhibit C Form of Forecast Example Only First Forecast Month # of the Forecast 1 2 3 4 5 6 7 8 9 Provided on Calendar Month of the Year January February March April May June July August September Effective Date Forecasted quantities of a given TG Convertible 100 100 100 100 100 100 2nd Forecast Month # of the Forecast 1 2 3 4 5 6 7 8 9 Due Feb 1st Calendar Month of the Year February March April May June July August September October Max allowed variance from same calendar month in prior Forecast +/-25 - - - - - Possible range of quantities allowed. 75-125 ** ** ** ** ** 3rd Forecast Month # of the Forecast 1 2 3 4 5 6 7 8 9 Due Mar 1st Calendar Month of the Year March April May June July August September October November Max allowed variance from same calendar month in prior Forecast +/-25 - - - - - Possible range of quantities allowed. * * * ** ** ** 4th Forecast Month # of the Forecast 1 2 3 4 5 6 7 8 9 Due April 1st Calendar Month of the Year April May June July August September October November December Max allowed variance from same calendar month in prior Forecast +/-25 - - - - - Possible range of quantities allowed. * * * ** ** ** DETAILS This example assumes the Agreement was executed during the month of December of the prior year. Fourth calendar month of each Forecast is binding, but can vary +/-25 from what was previously forecasted for that month. PO for this Binding Consumable Month is due on each Forecast Due Date * Number depends on what was forecasted in that calendar month in the previous forecast. ** Months 5-9 of each Forecast can be determined by Customer as appropriate. 4th month of each Forecast is the Binding Consumables Month. It may vary +/-25 from what was previously forecasted for the calendar month. PO for each Binding Consumables is due on each Forecast Due Date. In this example, PO is due February 1st Forecast Due Date is 1st day of each calendar month.

 

 

 

Exhibit D

 

First Forecast

 

 

 

 

 

1

 

2

 

3

 

4

 

5

 

6

 

7

 

8

 

9

 

Part Number

 

Description

 

Sep’13

 

Oct’13

 

Nov’13

 

Dec’13

 

Jan’14

 

Feb’14

 

Mar’14

 

Apr’14

 

May’14

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 


 

Exhibit E
Quote and Initial Purchase Order

 



 

Exhibit E - Quote

 

 

QUOTATION FOR SUPPLY OF GENETIC ANALYSIS PRODUCTS

 

Prepared by:
Illumina, Inc.
5200 Illumina Way
San Diego, CA 92122, USA
Hereinafter referred to as “Illumina”

 

Prepared for:
Natera
Hereinafter referred to as “Natera” or “Customer”

 

 

Quotation Number:

 

20130806SK101

 

 

 

 

 

Quotation Date:

 

August 6, 2013

 

 

 

 

 

Expiration Date:

 

September 30, 2014

 

 

 

 

 

Prepared By:

 

Shervin Kamkar

 

 

 

 

 

Phone Number:

 

415-405-6074

 

 

 

 

 

Email:

 

skamkar@illumina.com

 

FOR SMOOTH PROCESSING OF YOUR ORDER, ILLUMINA ASKS THAT YOU PLEASE REFERENCE THE ABOVE QUOTATION NUMBER ON ANY PURCHASE ORDER SUBMITTED AGAINST THIS QUOTATION.

 

Quote Template Standing Quote AMR 04JUNE13

Pub No. 062410

 

Proposal # 20130806SK1D1

 

 

 



 

I. CUSTOMER INFORMATION

 

Company or Institution Name:

 

Natera

Address:

 

To be determined on Purchase Order

Contact Name:

 

To be determined on Purchase Order

 

II. PRODUCT & PRICING INFORMATION

 

Customer receives the discounts specified in table herein (excludes promotionally priced consumables, software, hardware or new instrument purchases). For the discount to apply, Customer must agree to the following:

 

·                   This Master Quote, which can be used for multiple purchases, will only be valid until 5:00 pm on September 30, 2014.

·                   All Customer Purchase Orders received by Illumina that include this discounted pricing must be in USD and reference this quotation.

·                   All discounts will be applied to Illumina’s then current list price. Illumina reserves the right to offer lower or higher discounts for future products.

·                   The pricing and terms of this offer are kept confidential except as needed to execute the purchase.

·                   Discount applies only to the products specified in table herein.

·                   Customer shall remain responsible for all shipping and freight charges for the products ordered hereto. Goods shall be delivered FOB DESTINATION PRE-PAID BY ILLUMINA AND CHARGED BACK TO CUSTOMER. Customer understands that estimated shipping and freight charges listed on this quotation may differ from actual charges. Customer agrees to pay for all actual shipping/freight expenses upon invoice.

 

Catalog #

 

Product Description

 

Unit Price
(USD)

 

Customer Price

 

SAMPLE PREPARATION KITS

 

[*]

 

[*] HiSeq 2500. [*]

 

[*]

 

[*]

 

[*]

 

[*] HiSeq 2500. [*]

 

[*]

 

[*]

 

[*]

 

[*] HiSeq 2500. [*]

 

[*]

 

[*]

 

[*]

 

[*] HiSeq 2500.

 

[*]

 

[*]

 

[*]

 

HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System. [*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 



 

III.                               CONDITIONS OF SALE

 

By this quotation Illumina, offers to Customer the Illumina products and/or services as described above. By submitting an order, Customer accepts the terms of this quotation, including the attached terms and conditions of sale.

 

Illumina does not supply plastics such as microplates or pipette tips for use in the listed assays and these are not included in the consumables pricing provided; however, as a result of the highly multiplexed nature of all assays, plastics alone contribute minimally to the final cost.

 

IV.                                SHIP HOLD

 

In cases where this Quotation does not include a pre-defined ship schedule, the following ship hold terms shall apply:

 

·                   ·All orders must have a defined ship schedule. The initial ship date must be no later than three (3) months from the date the purchase order is received by Illumina (as provided in the Order Confirmation) and the entire order must be shipped complete within twelve (12) months from Illumina’s receipt of the purchase order.

·                   Any exceptions to these ship hold terms must be agreed to in writing by Illumina and the Customer must pre-pay at least fifty percent (50%) of the purchase order amount of the affected shipments.

·                   Customers may request two (2) shipment delays for any single purchase order. The total months of delayed shipment for shipments associated with a single purchase order shall not exceed six (6) months.

·                   if Customer has requested a delayed shipment, Illumina reserves the right to change the lead time necessary to initiate Customer’s first shipment (which may be longer than the lead time quoted at the time of the order placement).

·                   If Customer cannot take shipment in accordance with these terms, Illumina reserves the right to cancel the order in its entirety without any liability to the Customer

 

V.                                     HOW TO ORDER

 

 

For all other orders

 

 

For all consumable and Eco System orders

Please submit your institutional Purchase Order and a

 

complete copy of this quotation to the attention of:

Please submit your order online through Myllmn

 

(http://icom.illumina.com).

Illumina Customer Service

 

 

 

customerservice@illumina.com

 

Fax: +1.858.202.4766

 

Customer Service

 

Having trouble submitting orders online or questions with an order? Please contact us.

Phone: +1.858.202.4566

Toll Free: +1.800.809.ILMN (4566)

 

Order Confirmation

 

You will receive an e-mail confirmation containing your order number within 1 business day. Another email will be sent to notify you when your order has been shipped.

 

VI.                                EXPIRATION OF OFFER

 

The offer contained in this document is revocable at the sole discretion of Illumina if not executed by Customer and a purchase order received by Illumina before 5:00 pm Pacific Time on the expiration date shown on page 1 of this quotation.

 


 

Terms and Conditions of Sale—Research Use Products

 

1.             Definitions . “ Consumable(s) ” means Seller branded reagents and consumable items that are intended by Seller for use with, and are to be consumed through the use of, Hardware. “ Documentation ” means Seller’s user manual, package insert, and similar documentation, for the Product in effect on the date that the Product ships. Documentation may contain additional terms and conditions and any such terms and conditions are hereby incorporated herein by reference. Documentation may be provided (including by reference to a website) with the Product at time of shipment or provided electronically from Seller. “ Hardware ” means Seller branded instruments, accessories, or peripherals. “ Product(s) ” means the item(s) acquired hereunder. Products may be Hardware, Consumables, or Software. Software may be embedded in or installed on Hardware or provided separately. All Software is licensed and not sold. “ Purchaser ” means the person or entity acquiring the Product hereunder. “ Seller ” means the entity selling the Product hereunder. The Selling entity is identified on the quotation, order acknowledgment or similar communication, or Seller website if the order is being placed electronically at Seller’s website. “ Software ” means Seller branded software (e.g., Hardware operating software, data analysis software). All Software is licensed and not sold and may be subject to additional terms found in the Software’s end user license agreement. “ Specifications ” means Seller’s written specifications for the Product in effect on the date that the Product ships from Seller.

 

2.             Rights to Products upon Purchase . Subject to these terms and conditions, Purchaser is granted only a non-exclusive, non-transferable, personal, non-sublicensable right under Seller’s Core IP, in existence on the date that the Product ships from Seller, solely to use the Product in Purchaser’s facility for Purchaser’s internal research purposes (which includes research services provided to third parties) and solely in accordance with the Product’s Documentation, but specifically excluding any use that (a) would require rights or a license from Seller to Application Specific IP, (b) is a re-use of a previously used Consumable, (c) is the disassembling, reverse-engineering, reverse-compiling, or reverse-assembling of the Product, (d) is the separation, extraction, or isolation of components of the Product or other unauthorized analysis of the Product, (e) gains access to or determines the methods of operation of the Product, (f) Is the use of non-Seller reagent/consumables with Seller’s Hardware (does not apply if the Specifications or Documentation state otherwise), or (g) is the transfer to a third-party of, or sub-licensing of, Software or any third-party software. All Software, whether provided separately, installed on, or embedded in a Product, is licensed to Purchaser and not sold. “ Application Specific IP ” means Seller owned or controlled intellectual property rights that pertain to the Product (and use thereof) only with regard to specific field(s) or specific application(s). Application Specific IP excludes all Seller owned or controlled intellectual property that cover aspects or features of the Product (or use thereof) that are common to the Product in all possible applications and all possible fields of use (the “Core IP”). Application Specific IP and Core IP are separate, non-overlapping, subsets of all Seller owned or controlled intellectual property. By way of non-limiting examples, Seller intellectual property rights for specific diagnostic methods, for specific forensic methods, or for specific nucleic acid biomarkers, sequences, or combinations of biomarkers or sequences are examples of Application Specific IP. Except as expressly stated In this Section, no right or license under any of Seller’s intellectual property rights is or are granted expressly, by implication, or by estoppel.

 

Purchaser is solely responsible for determining whether Purchaser has all Intellectual property rights that are necessary for Purchaser’s intended uses of the Product, Including without limitation, any rights from third parties or rights to Application Specific IP. Seller makes no guarantee or warranty that purchaser’s specific intended uses will not infringe the intellectual property rights of a third party or Application Specific IP.

 

3.             Unauthorized Uses of Products . Purchaser agrees: (a) to use each Consumable only one time, and (b) to use only Seller’s consumables/reagents with Seller Hardware. The limitations in (a)-(b) do not apply if the Documentation or Specifications for the Product state otherwise. Purchaser agrees not to, nor authorize any third party to, engage in any of the following activities: (i) disassemble, reverse-engineer, reverse-compile, or reverse-assemble the Product, (ii) separate, extract, or isolate components of the Product or subject the Product or components thereof to any analysis not expressly authorized in the Product’s Documentation, (iii) gain access to or attempt to determine the methods of operation of the Product, or (iv) transfer to a third-party, or grant a sublicense, to any Software or any third-party software. Purchaser further agrees that the contents of and methods of operation of the Product are proprietary to Seller and the Product contains or embodies trade secrets of Seller. The conditions and restrictions found in these terms and conditions are bargained for conditions of sale and therefore control the sale of and use of the Products by Purchaser.

 

4.             Regulatory . The Product has not been approved, cleared, or licensed by the United States Food and Drug Administration or any other regulatory entity whether foreign or domestic for any specific intended use, whether research, commercial, diagnostic, or otherwise. The Product is labeled For Research Use Only. Purchaser must ensure it has any regulatory approvals that are necessary for Purchaser’s intended uses of the Product.

 

5. Limited Liability. TO THE EXTENT PERMITTED BY LAW, IN NO EVENT SHALL SELLER OR ITS SUPPLIERS BE LIABLE TO PURCHASER OR ANY THIRD PARTY FOR COSTS OF PROCUREMENT OF SUBSTITUTE PRODUCTS OR SERVICES, LOST PROFITS, DATA OR BUSINESS, OR FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY, CONSEQUENTIAL, OR PUNITIVE DAMAGES OF ANY KIND ARISING OUT OF OR IN CONNECTION WITH, WITHOUT LIMITATION, THE SALE OF THE PRODUCT, ITS USE, SELLER’S PERFORMANCE HEREUNDER OR ANY OF THESE TERMS AND CONDITIONS, HOWEVER ARISING OR CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE). SELLER’S TOTAL AND CUMULATIVE LIABILITY TO PURCHASER OR ANY THIRD PARTY ARISING OUT OF OR IN CONNECTION WITH THESE TERMS AND CONDITIONS, INCLUDING WITHOUT LIMITATION, THE PRODUCT (INCLUDING USE THEREOF) AND SELLER’S PERFORMANCE HEREUNDER, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE, SHALL IN NO EVENT EXCEED THE AMOUNT PAID TO SELLER FOR THE PRODUCT.

 

6.             Limitations on Warranties. TO THE EXTENT PERMITTED BY LAW AND SUBJECT TO THE EXPRESS PRODUCT WARRANTY MADE IN THESE TERMS AND CONDITIONS SELLER MAKES NO (AND EXPRESSLY DISCLAIMS ALL) WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE PRODUCT, INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR ARISING FROM COURSE OF PERFORMANCE, DEALING, USAGE OR TRADE. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, SELLER MAKES NO CLAIM, REPRESENTATION, OR WARRANTY OF ANY KIND AS TO THE UTILITY OF THE PRODUCT FOR PURCHASER’S INTENDED USES.

 

7.             Product Warranty . All warranties are personal to the Purchaser and may not be transferred or assigned to a third-party, including an affiliate of Purchaser. All warranties are facility specific and do not transfer If the Product is moved to another facility of Purchaser, unless Seller conducts such move.

 

        a.     Warranty for Consumables. Seller warrants that Consumables, other than custom Consumables, will conform to their Specifications until the later of (i) 3 months from the date of shipment from Seller, and (ii) any expiration date or the end of the shelf-life pre-printed on such Consumable by Seller, but in no event later than 12 months from the date of shipment. With respect to custom Consumables (i.e., Consumables made to specifications or designs made by Purchaser or provided to Seller by, or on behalf of, Purchaser), Seller only warrants that the custom Consumables will be made and tested in accordance with Seller’s standard manufacturing and quality control processes. Seller makes no warranty that custom Consumables will work as intended by Purchaser or for Purchaser’s intended uses.

 



 

b.     Warranty for Hardware. Seller warrants that Hardware, other than Upgraded Components, will conform to its Specifications for a period of 12 months after its shipment date from Seiler unless the Hardware includes Seller provided installation In which case the warranty period begins on the date of installation or 30 days after the date it was delivered, whichever occurs first (“ Base Hardware Warranty ”). “ Upgraded Components ” means Seller provided components, modifications, or enhancements to Hardware that was previously acquired by Purchaser. Seller warrants that Upgraded Components will conform to their Specifications for a period of 90 days from the date the Upgraded Components are installed. Upgraded Components do not extend the warranty for the Hardware unless the upgrade was conducted by Seller at Seller’s facilities in which case the upgraded Hardware shipped to Purchaser comes with a Base Hardware Warranty.

 

c.     Exclusions from Warranty Coverage . The foregoing warranties do not apply to the extent a non-conformance is due to (i) abuse, misuse, neglect, negligence, accident, improper storage, or use contrary to the Documentation or Specifications, (ii) improper handling, installation, maintenance, or repair (other than if performed by Seller’s personnel), (iii) unauthorized alterations, (iv) Force Majeure events, or (v) use with a third party’s good not provided by Seller (unless the Product’s Documentation or Specifications expressly state such third party’s good is for use with the Product).

 

d.     Procedure for Warranty Coverage . In order to be eligible for repair or replacement under this warranty Purchaser must (i) promptly contact Seller’s support department to report the non-conformance, (ii) cooperate with Seller in confirming or diagnosing the non-conformance, and (iii) return the Product, transportation charges prepaid to Seller following Seller’s instructions or, if agreed by Seller and Purchaser, grant Seller’s authorized repair personnel access to the Product in order to confirm the non-conformance and make repairs.

 

e.     Sole Remedy under Warranty . Seller will, at its option, repair or replace nonconforming Product that it confirms is covered by this warranty. Repaired or replaced Consumables come with a 30-day warranty. Hardware may be repaired or replaced with functionally equivalent, reconditioned, or new Hardware or components (if only a component of Hardware is non-conforming). If the Hardware is replaced In its entirety, the warranty period for the replacement is 90 days from the date of shipment or the remaining period on the original Hardware warranty, whichever is shorter. If only a component is being repaired or replaced, the warranty period for such component is 90 days from the date of shipment or the remaining period on the original Hardware warranty, whichever ends later. The preceding states Purchaser’s sole remedy and Seller’s sole obligations under the warranty provided hereunder.

 

f.     Third-Party Goods and Warranty . Seller has no warranty obligations with respect to any goods originating from a third party and supplied to Purchaser hereunder. Third-party goods are those that are labeled or branded with a third-party’s name. The warranty for third-party goods, if any, is provided by the original manufacturer. Upon written request Seller will attempt to pass through any such warranty to Purchaser.

 

8. Indemnification.

 

a.     Infringement Indemnification by Seller . Subject to these terms and conditions, including without limitation, the Exclusions to Seller’s Indemnification Obligations (Section 7.f(d) below), the Conditions to Indemnification Obligations (Section 7.f(d) below), Seller shall (i) defend, indemnify and hold harmless Purchaser against any third-party claim or action alleging that the Product when used for research use purposes, in accordance with these terms and conditions, and in accordance with the Product’s Documentation and Specifications infringes the valid and enforceable Intellectual property rights of a third party, and (ii) pay all settlements entered into, and all final judgments and costs {including reasonable attorneys’ fees) awarded against Purchaser in connection with such infringement claim. If the Product or any part thereof, becomes, or in Seller’s opinion may become, the subject of an infringement claim, Seller shall have the right, at its option, to (A) procure for Purchaser the right to continue using the Product, (B) modify or replace the Product with a substantially equivalent non-infringing substitute, or (C) require the return of the Product and terminate the rights, license, and any other permissions provided to Purchaser with respect the Product and refund to Purchaser the depreciated value (as shown in Purchaser’s official records) of the returned Product at the time of such return; provided that, no refund will be given for used-up or expired Consumables. This Section states the entire liability of Seller for any infringement of third party intellectual property rights.

 

b.     Exclusions to Seller Indemnification Obligations . Seller has no obligation to defend, indemnify or hold harmless Purchaser for any Seller Infringement Claim to the extent such infringement arises from: (i) the use of the Product in any manner or for any purpose outside the scope of research use purposes, (ii) the use of the Product in any manner not in accordance with its Specifications, its Documentation, the rights expressly granted to Purchaser hereunder, or any breach by Purchaser of these terms and conditions, (iii) the use of the Product in combination with any other products, materials, or services not supplied by Seller, (iv) the use of the Product to perform any assay or other process not supplied by Seller, or (v) Seller’s compliance with specifications or instructions for such Product furnished by, or on behalf of, Purchaser (each of (i) — (v), is referred to as an “ Excluded Claim ”),

 

c.     Indemnification by Purchaser . Purchaser shall defend, indemnify and hold harmless Seller, its affiliates, their non-affiliate collaborators and development partners that contributed to the development of the Product, and their respective officers, directors, representatives and employees against any claims, liabilities, damages, fines, penalties, causes of action, and losses of any and every kind, including without limitation, personal injury or death claims, and infringement of a third party’s intellectual property rights, resulting from, relating to, or arising out of (i) Purchaser’s breach of any of these terms and conditions, (ii) Purchaser’s use of the Product outside of the scope of research use purposes, (iii) any use of the Products not in accordance with the Product’s Specifications or Documentation, or (iv) any Excluded Claim.

 

d.     Conditions to Indemnification Obligations . The parties’ indemnification obligations are conditioned upon the party seeking indemnification (i) promptly notifying the other party in writing of such claim or action, (ii) giving the other party exclusive control and authority over the defense and settlement of such claim or action, (iii) not admitting infringement of any intellectual property right without prior written consent of the other party, (iv) not entering into any settlement or compromise of any such claim or action without the other party’s prior written consent, and (v) providing reasonable assistance to the other party in the defense of the claim or action; provided that, the party reimburses the indemnified party for its reasonable out-of-pocket expenses incurred in providing such assistance.

 

e.     Third-Party Goods and Indemnification . Seller has no indemnification obligations with respect to any goods originating from a third party and supplied to Purchaser. Third-party goods are those that are labeled or branded with a third-party’s name. Purchaser’s indemnification rights, if any, with respect to third party goods shall be pursuant to the original manufacturer’s or licensor’s indemnity. Upon written request Seller will attempt to pass through such indemnity, if any, to Purchaser.

 

9.             Payment Terms . Seller will invoice upon shipment. All payments are due within 30 days of the date of the invoice except that payments in Japan are due within 60 days of the date of the invoice. All amounts due shall be paid in the currency found on the invoice. If any payment is not made by the due date Seller may exercise all rights and remedies available by law, including without limitation, suspending performance. Purchaser shall pay for all costs (including reasonable attorneys’ fees) incurred by Seller in connection with the collection of late payments. Each purchase order is a separate, independent transaction, and Purchaser has no right of set-off against other purchase orders or other transactions with Seller. Seller will determine payment terms on a per-order basis and may modify credit terms in its discretion. Any amounts not paid when due will accrue interest at the rate of 1.5% per month, or the maximum amount allowed by law, if lower.

 

10.          Shipping Terms; Title and Risk of Loss . Unless otherwise set forth in writing by Seller or otherwise agreed between the parties, all shipments are made DAP (Incoterms 2010) at the address designated by Purchaser at the time of ordering, except that all shipments to member countries of the E.U. are made DAP (Incoterms 2010) at the address designated by Purchaser at the time of ordering. In all cases, title (except for Software and third-party software) and risk of loss transfers to Purchaser when Product is made available at such address.

 



 

11,          Taxes . Purchaser agrees that any applicable sales, use, excise, VAT (value added tax), GST (goods and services tax), withholding and other taxes will be calculated based on both the tax rates in effect on the date of shipment and the ship to address for the Product. Any amounts for tax listed on a quotation, if any, are for reference purposes only and are not binding on Seller. All prices and other amounts payable to Seller hereunder are exclusive of and are payable without deduction for any taxes, customs duties, tariffs or charges no or hereafter claimed or imposed by any governmental authority upon the sale of Product, all of which will be paid by Purchaser. In the event Seller is required by law or regulation to pay any such tax, duty or charge, such amount will be added to the purchase price or subsequently invoiced to the Purchaser. For Purchasers in New Zealand, Seller and Purchaser agree that subsection 8(4) Goods and Services Tax Act 1985, as may be amended, does not apply to the Products.

 

12.          General .

 

a.     Applicability of Terms and Conditions . These terms and conditions, including any terms in the Documentation, exclusively govern the ordering, purchase, supply, and use of Product, and override any conflicting, amending and/or additional terms contained in any purchase orders, invoices, or similar documents all of which are hereby rejected and are null and void. Seller’s failure to object to any such terms shall not constitute a waiver by Seller, nor constitute acceptance by Seller of such terms and conditions.

 

b.     Governing Law . These terms and conditions, their interpretation, and the performance of the parties shall be governed by the laws of (i) the State of California, U.S.A., if Purchaser is located in North or South America; (ii) England and Wales, If Purchaser is located in Europe, the Middle East, or Africa; and (iii) the Republic of Singapore, if Purchaser is located in Asia, Australia, the South Pacific region or anywhere not covered by (i) or (ii) of this Section.

 

c.     Facility Requirements and Installation of Hardware . Purchaser  acknowledges that it is responsible for ensuring at Purchaser’s sole cost that its facility meets the site requirements for the Hardware. If the purchase of Hardware includes installation it will be completed within 30 days of delivery of all components of the Hardware and the facility meeting such requirements.

 

d.     Service Contracts . If a Seller extended service contract for Hardware Is being provided hereunder then Seller’s standard terms and conditions for such Service Contract shall exclusively govern such Service Contract.

 

e.     Future Products . Any future products and/or services are subject to new part numbers, pricing, and specifications and the acquisition of Product hereunder is not in reliance on the availability of any such future products or services.

 

f.     Seller Affiliates . Any actions or rights that may be performed or exercised by Seller hereunder may be performed or exercised by Seller itself or by any of its affiliates. By way of non-limiting example, Seller’s affiliates may carry out shipment, servicing, invoicing and receipt of payment.

 

g.     Force Majeure . Seller Is not responsible for any failure to perform or delay attributable in whole or in part to any cause beyond its reasonable control, including but not limited to acts of God, fire, flood, tornado, earthquake, hurricane, lightning, government actions, actual or threatened acts of war, terrorism, civil disturbance or insurrection, sabotage, labor shortages or disputes, failure or delay in delivery by Seller’s suppliers or subcontractors, transportation difficulties, shortage of energy, raw materials or equipment, or Purchaser’s fault or negligence. In the event of any such delay the delivery date shall be deferred for a period equal to the time lost by reason of the delay.

 

h.     Notices . Any notice required or permitted hereunder shall be in writing arid shall be deemed received when (i) delivered personally; (ii) 5 days after having been sent by registered or certified mail, return receipt requested, postage prepaid (or 10 days for international mail); or (iii) 1 day after deposit with a commercial express courier that provides written verification of receipt.

 

i.      Assignment . Purchaser may not assign or transfer these terms and conditions or any rights or obligations hereunder, whether voluntary, by operation of law or otherwise, without the prior written consent of Seller; provided that, no consent shall be required for any assignment in connection with any merger, acquisition or the sale of all or substantially all of the stock or assets of Purchaser to a party that (i) agrees in writing to be bound by these terms and conditions, and (ii) is not a competitor of Seller or any of Seller’s business units or Seller’s affiliates. Seller may assign all or part of the right to payments hereunder. Any assignment or transfer made in contravention of the terms hereof shall be null and void. Subject to the foregoing, these terms and conditions shall be binding on and inure to the benefit of the parties’ respective successors and permitted assigns.

 

j.      Seller Information . Seller may maintain and use a database of orders and account information pertaining to Purchaser for purposes of order processing, maintaining records, assisting with future orders of Purchaser, and compliance with applicable laws and regulations. Purchaser may not disclose any financial terms of this transaction to any third party without the prior written consent of the Seller, except as (and only to the extent) required by securities or other applicable law.

 

k.     Export Compliance . The Products, any related technology, or information provided to Purchaser may be subject to restrictions and controls imposed by the United States Export Administration Act and the regulations thereunder (or the export regulations and laws of another country). Purchaser agrees not to export or re-export the Products, any related technology, or information provided to Purchaser into any country, or in any manner, in violation of such controls or any other laws, rules or regulations of any country, state or jurisdiction.

 

l.      Miscellaneous . All references to days mean calendar days unless specifically stated otherwise. Seller may cease performance hereunder immediately without liability to Purchaser if Purchaser becomes the subject of a voluntary or involuntary petition in bankruptcy or any proceeding relating to insolvency, receivership, liquidation or composition for the benefit of creditors. These terms and conditions, including any terms and conditions in the Documentation, represent the entire agreement between the parties regarding the subject matter hereof and supersede all prior discussions, communications, agreements, and understandings of any kind between the parties. No amendment to these terms or waiver of any right, condition, or breach will be effective unless made in a writing signed by both parties. if any provision hereunder is held invalid or unenforceable, such provision shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the remaining terms will continue in full force and effect. The failure of either party to exercise any right granted herein or to require any performance of any term or the waiver by either party of any breach hereunder shall not prevent a subsequent exercise or enforcement of, or be deemed a waiver of any subsequent breach of, the same or any other term hereunder. Nothing herein shall constitute or create a joint venture, partnership, or any other similar arrangement between the parties.

 


 

*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 100150 ORDER DATE: 8/15/13 PAYMENT TERMS: Net 30 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY PRM DATE REQ DATE UNIT PRICE EXT PRICE [*] [*] [*] HiSeq 2500 Sequencing

System [*] [*] [*] HiSeq 2500 Sequencing

System [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] NOTES: Quote #: 20130806SK101 SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 100155 ORDER DATE: 8/15/13 PAYMENT TERMS: Net 15 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY PRM DATE REQ DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] NOTES: Quotation Number: 20130806SK101 SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 100156 ORDER DATE: 8/15/13 PAYMENT TERMS: Net 15 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY PRM DATE REQ DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] NOTES: Quotation Number: 20130806SK101 SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090

 


*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 101157 ORDER DATE: 8/15/13 PAYMENT TERMS: Net 15 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY PRM DATE REQ DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] NOTES: Quotation Number: 20130806SK101 SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090

 


 

 

*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 101158 ORDER DATE: 8/15/13 PAYMENT TERMS: Net 15 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY PRM DATE REQ DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System[*] HiSeq 2500 Sequencing System[*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] NOTES: Quotation Number: 20130806SK101 SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090

 


 

 

*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 101159 ORDER DATE: 8/15/13 PAYMENT TERMS: Net 15 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY PRM DATE REQ DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] HiSeq 2500 Sequencing System [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] NOTES: Quotation Number: 20130806SK101 SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090

 

 

 

Exhibit F

 

Gold Level Service Contract and Pricing

 



 

Data Sheet:  Sequencing + Array

 

Illumina Service Contracts

 

A comprehensive one year base warranty at our Standard service level is included with every new Illumina instrument purchase, along with installation and basic applications training.  Illumina also offers several options to extend or upgrade your level of service contract coverage.  For more information, please contact your Illumina Account Manager or Illumina Inside Sales at 1.800.809.4566 (toll free), 1.858.202.4566 (outside North America), or servicecontract@illumina.com.

 

Illumina Service Contract Comparison

 

 

 

Parts Only

 

Standard

 

Silver

 

Gold

 

Platinum

 

Dedicated Onsite

Term (Years)

 

1

 

1

 

1

 

1

 

 

 

2

Replacement Parts

 

Yes

 

Yes

 

Yes

 

Yes

 

Yes

 

Parts Only Contract Required(1)

Labor (2)

 

No

 

Yes

 

Yes

 

Yes

 

Yes

 

Yes

5 x 24 Email Support

 

Yes

 

Yes

 

Yes

 

Yes

 

Yes

 

Yes

5 x 18 Phone Support (3)

 

Yes

 

Yes

 

Yes

 

Yes

 

Yes

 

Yes

Average Onsite Response Time

(Business Days)

 

5
(from Service
PO Receipt)

 

5

 

3

 

2

 

1

 

Immediate

Preventative Maintenance

 

No

 

No

 

1

 

2

 

2

 

2(4)

Software/Hardware Updates

 

No

 

Yes

 

Yes

 

Yes

 

Yes

 

Yes

Applications Support (5)

 

No

 

Yes

 

Yes

 

Yes

 

Yes

 

Yes

Advanced Applications Training

 

No

 

Discounts Available

 

Discounts Available

 

Discounts Available

 

Discounts Available

 

Yes (Onsite)(6),(7)

 


(1) Must purchase Parts Only service contract for all instruments covered by Dedicated Onsite support agreement

(2) Standard onsite support hours:

AMR

Monday to Friday (excluding national holidays) 8:00 am to 5:00 pm

 

APAC

Monday to Friday (excluding national holidays) 9:00 am to 5:30 pm

 

EMEA

Monday to Friday (excluding national holidays) 9:00 am to 5:30 pm

Outside standard onsite hours, overtime rates may apply

(3) Monday 8:00 am Singapore Time Zone — Friday 5:00 pm US Pacific Time Zone

(4) PM parts purchased separately

(5) Includes on-site troubleshooting and repair

(6) Excludes reagents

(7) Discounts available for courses taken at Illumina training facilities

 



 

Illumina Service Contract Descriptions

 

Level

 

Description

Parts Only

 

Includes full coverage for replacement parts. On-site Service labor not included. Includes comprehensive 5 x 24 e-mail support and 5 x 18(1) telephone support (instrument, applications, and bioinformatics).

Standard

 

Includes full coverage for all service parts and labor. Includes comprehensive 5 x 24 e-mail support and 5 x 18(1) telephone support (instrument, applications, and bioinformatics), five business day average on-site response time, critical and non-critical hardware and software updates, applications support, access to online training modules, and discounts on optional advanced training programs. This is the same coverage level that is provided for the first year with new instrument purchases.

Silver

 

Includes full coverage on all service parts and labor. Includes comprehensive 5 x 24 e-mail support and 5 x 18(1) telephone support (instrument, applications, and bioinformatics), three business day average on-site response time, critical and non-critical updates, applications support, access to online training modules, and discounts on optional advanced training programs. Includes one Preventative Maintenance visit per year.

Gold

 

Includes full coverage on all service parts and labor. Includes comprehensive 5 x 24 e-mail support and 5 x 18(1) telephone support (instrument, applications, and bioinformatics), two business day average on-site response time, critical and non-critical updates, applications support, access to online training modules, and discounts on optional advanced training programs. Includes two Preventative Maintenance visits per year. Limited availability.

Platinum

 

Includes full coverage on all service parts and labor. Includes comprehensive 5 x 24 e-mail support and 5 x 18(1) telephone support (instrument, applications, and bioinformatics), one business day average on-site response time, critical and non-critical updates, applications support, access to online training modules, and discounts on optional advanced training programs. Includes two Preventative Maintenance visits per year. Limited availability.

Dedicated On-Site SST Normal Hours + Local FAS Support

 

Dedicated On-Site Support Technician, normal business hours (Monday-Friday), excludes holidays. On-site support to maintain and repair instruments. Requires all covered instruments to be on a Parts Only service contract. Also includes per site local FAS support equivalent to our Standard level service contract. An initial two-year minimum commitment is required. Limited availability.

Dedicated On-Site SST Normal Hours

 

Dedicated On-Site Support Technician, normal business hours (Monday-Friday), excludes holidays. On-site support to maintain and repair instruments. Requires all covered instruments to be on a Parts Only service contract. Also requires either (1) Dedicated On-Site FAS service contract or (1) Dedicated On-Site SST + Local FAS Support service contract per site. An initial two-year minimum commitment is required. Limited availability.

Dedicated On-Site SST After Hours

 

Dedicated On-Site Support Technician. May be placed on a regular schedule outside of normal business hours for up to 40 hours per week. On-site support to maintain and repair instruments. Requires all covered instruments to be on a Parts Only service contract. Also requires either (1) Dedicated On-Site FAS service contract or (1) Dedicated On-Site SST + Local FAS Support service contract per site. An initial two-year minimum commitment is required. Limited availability.

Dedicated On-Site FAS Normal Hours

 

Dedicated On-Site Field Applications Scientist, normal business hours (Monday-Friday), excludes holidays. Includes on-site applications support and customer training. Requires all covered instruments to be on a Parts Only and On-Site SST service contract. An initial two-year minimum commitment is required. Limited availability.

Dedicated On-Site FAS After Hours

 

Dedicated On-Site Field Applications Scientist. May be placed on a regular schedule outside of normal business hours for up to 40 hours per week. Includes on-site applications support and customer training. Requires all covered instruments to be on a Parts Only and On-Site SST service contract. An initial two-year minimum commitment is required. Limited availability.

 


(1) Monday 8:00 am Singapore Time Zone - Friday 5:00 pm US Pacific Time Zone

 

Illumina · 1.800.809.4566 toll-free (U.S.) · +1.858.202.4566 tel · techsupport@illumina.com · www.illumina.com FOR

RESEARCH USE ONLY

© 2012 Illumina., Inc. All rights reserved.

Illumina, IlluminaDx. BaseSpace. BeadArray, Bead)(press. cBot, CSPro. DASL, Des:gnStudio. Eco, GAllx, Genetic Energy. Genome Analyzer. GenomeStudio, GoldenGate. HiScan. HiSeq, Infinium, iSeIect. MiSeq. Nextera, NuPCR. SeqMonitor, Solexa, TruSeq. VeraCode, the pumpkin orange color, and the Genetic Energy streaming bases design are trademarks or registered trademarks of Illumina, Inc. All other brands and names contained herein are the property of their respective owners.

Pub. No. 970-2012-016 Current as of 30 October 2012

 


 

ILLUMINA TERMS AND CONDITIONS – SERVICE CONTRACTS AND BILLABLE SERVICES

 

1.               Definitions . “ Agreement ” means the terms of the applicable Service Contract and (i) Quotation, including these terms and conditions and attached appendices which form a part thereof; (ii) all electronic information and terms of Illumina referenced during an Electronic Order, including these terms and conditions and attached appendices which form a part thereof in the case of an Electronic Order; or (iii) all terms referenced in an Order Confirmation, including these terms and conditions and attached appendices which form a part thereof in the case of an order placed without a Quotation. “ Billable Services ” means those services provided by or on Illumina’s behalf and not covered by a Service Contract. “ Covered Hardware ” means those portions of the Hardware that are covered by a Service Contract purchased by Customer hereunder. “ Current Specifications ” means Illumina’s written specifications for the Covered Hardware that apply to such Hardware as provided in the Service Contract that is purchased hereunder, but only if the purchased Service Contract provides that the Covered Hardware will conform to current specifications rather than the Original Specifications. “ Customer ” means the customer as identified on the Quotation. “ Documentation ” means user manuals, protocols or other documentation provided by Illumina at the time of acquisition of the Covered Hardware related to the use and maintenance of the Covered Hardware or any components thereof, “ Electronic Order ” means an order placed by Customer utilizing Illumina’s electronic commerce system (e.g., iCom). “ EULA ” means the software end user license agreement for Software. “ Hardware ” means the Instruments, accessories or peripherals, and other hardware. “ Hardware Quotation ” means the written quotation provided by Illumina corresponding to the Hardware when originally acquired. “ Intellectual Property Rights ” means all patent rights, copyrights, trade secrets, know-how, trademark, service mark and trade dress rights and other Intellectual property rights, current or future, under the laws of any jurisdiction, together with all applications therefor and registrations thereto. “ Instrument ” means the equipment as specified in the Original Specifications (e.g., HiSeq2000, Genome Analyzer Ilx, IScan, HiScan, HiScanSQ, and BeadXpress). “ Original Specifications ” means the written specifications provided by Illumina for the Hardware that applied to such Hardware at the time of its acquisition from Illumina (the Original Specifications may be referenced in the Hardware Quotation). “ Original Terms ” means those terms and conditions that governed the acquisition and use of the Covered Hardware, components thereof, and Software from Illumina. “ Quotation ” means a written quotation provided by Illumina to Customer for the Service Contract and Billable Services, as applicable. “ Service Contract ” means the service, maintenance, and support as set forth in the Quotation and which includes these terms and conditions. “ Specifications ” means the Current Specifications or the Original Specifications, as applicable; provided that, Specifications shall in all cases refer to the Original Specifications unless otherwise set forth in the Service Contract. “ Order Confirmation ” means a sales order confirmation document provided by Illumina. “ Site ” means the smallest definable room that contains the Covered Hardware. “ Software ” means the software provided by Illumina with the Covered Hardware whether provided under this Agreement, or as updates or options under future agreements, or as incorporated or embedded in Hardware or components thereof or otherwise provided whether or not there is a separate charge thereof, including any software that is provided from a third party. In all cases, Software is licensed and not sold. “ Term ” means the term of the commitment set forth in the Service Contract.

 

2.               General . This Agreement shall exclusively govern and shall override any conflicting, amending and/or additional terms contained in any purchase orders, invoices or similar documents, which are hereby rejected and shall be null and void. Illumina’s failure to object to any such conflicting, amending and/or additional terms shall not constitute a waiver by Illumina, nor constitute acceptance by Illumina of such terms and conditions.

 

3.               Term for Service Contracts . Illumina agrees that during the Term, Customer’s Covered Hardware shall be serviced with all necessary skill and expertise using Illumina’s designated service personnel and Illumina shall be responsible for the safe and suitable packaging of any parts for delivery to the Site in conjunction with this Agreement. Illumina represents and warrants that it shall use all commercially reasonable efforts to service and support the Covered Hardware in accordance with the applicable Service Contract so as to maintain the Covered Hardware in a manner of operation that conforms with the Specifications.

 

4.               Recertification Requirement . In the event of termination or non-renewal of the Service Contract, if Customer requires services or support for the Covered Hardware, Customer shall allow Illumina reasonable access to the Covered Hardware as well as other Illumina equipment and shall provide any relevant data to Illumina to determine what, if anything, is required to re-qualify the Covered Hardware for continuation or renewal of coverage hereunder. Before providing any services or effecting any repairs, Illumina will provide Customer with a detailed quotation, including an estimate of parts and labor required and other associated costs, to bring the Covered Hardware up to warrantable level. Once Illumina has provided Customer with written documentation to certify that the Covered Hardware is eligible for continuation or renewal hereunder, Customer may, within one (1) month of such recertification, enter into a new term for a Service Contract,

 

5.               Services by OEM Vendors . Illumina reserves the right to retain or contract outside vendors of its choosing to provide service and support hereunder. In any instance where the terms and conditions of such vendor’s service, support, and warranty agreement conflicts with the terms and conditions of this Agreement, the terms and conditions of this Agreement shall govern; provided, however that any exclusions on coverage contained in an OEM vendor’s terms and conditions shall remain in full force and effect.

 

6.               Response Time and On-site Support . Illumina will use commercially reasonable efforts to respond to Customer’s requests for service within the time period specified in the Service Contract All requests for service must be made through Illumina’s customer support organization (“Customer Solutions”). Please refer to www.illumina.com for Customer Solutions contact information. Illumina reserves the right to provide service and support by any method in its sole discretion, including but not limited to, remote instruction via telephone, Internet or email, mailing to Customer replacement parts or test equipment, exchanging Customer’s component equipment with loaner equipment while repairs are being made, and deploying service or applications personnel for on-site services. Other than installation and preventative maintenance visits, Illumina shall determine in its sole discretion whether and when any personnel or replacement parts or equipment are to be sent to Customer’s site. Illumina shall respond to Customer’s request for support in accordance with the average response time specified in the Service Contract. Illumina will provide a minimum number of on-site support visits as specified in the Service Contract if the Customer has identified a specific need that can be fulfilled by the visit and if the Customer has made reasonable accommodation for scheduling the visit. If no need is identified and the timing of any visit cannot be scheduled at a mutually-agreeable date and time, Illumina may provide fewer visits than prescribed in the Service Contract.

 

7.               Software Support . During the Term, Illumina shall use commercially reasonable efforts to provide all Software updates and qualified Software upgrades in accordance with the terms of the Service Contract as such materials become commercially available for distribution. Customer’s use of all Software, updates, and upgrades of Software shall be subject to this Agreement, the Original Terms, and the applicable EULA.

 

8.               Hardware Support . During the Term, Illumina shall use commercially reasonable efforts to install mandatory Hardware updates in accordance with the terms of the Service Contract as such materials become available for distribution. Whether a Hardware update is mandatory shall be determined by Illumina in its sole discretion. Illumina shall reschedule Hardware updates to coincide with preventive maintenance visits. If Customer requests that such Hardware updates occur at a time or date other than during preventive maintenance visits, Illumina may, at its sole discretion, charge Customer for any costs and expenses incurred in connection with such Hardware update visit. All updated Hardware and components thereof and Customer’s use of the same shall be subject to this Agreement and the Original Terms.

 

9.               Hardware Repairs . Illumina shall use commercially reasonable efforts to repair Covered Hardware reported by Customer and deemed inoperable by Customer Solutions. Illumina’s sole obligation hereunder is to provide parts and labor according to the terms of the Service Contract and is limited to only repair or replacement of Illumina-supplied parts, including any third-party parts originally provided by Illumina All repaired or replaced items and Customer’s use of the Covered Hardware including the repaired or replaced components shall be subject to this Agreement and the Original Terms. For clarity, repaired or replaced items will be warranted to conform to the Specifications for ninety (90) days from the date of installation or repair of such repaired or replaced item.

 

10.        Documentation Updates . Illumina shall use commercially reasonable efforts to provide updates to Documentation according to the terms of the Service Contract as they become available for distribution. Whether a Documentation update is mandatory shall be determined by Illumina in its sole discretion. All updates to Documentation and Customer’s use of the Documentation shall be subject to this Agreement and the Original Terms.

 

11.        Replacement Parts . All replacement parts and components provided by Illumina will be nevi or refurbished, in Illumina’s sole discretion, and shall be furnished on an exchange basis. All Hardware or components thereof or other parts removed for replacement shall become the property of Illumina. All replaced parts and components and Customer’s use of the Covered Hardware including the replaced parts and components shall be subject to this Agreement and the Original Terms. For clarity, repaired or replaced items will be warranted to conform to the Specifications for ninety (90) days from the date of installation or repair of such repaired or replaced item.

 

12.        Loaner Hardware . Illumina may choose to provide, in its sole discretion, loaner hardware or components to Customer to substitute for the Covered Hardware or a component thereof, while service is being provided. Illumina will be responsible for all costs associated with the shipment of such loaner hardware or components to Customer’s Site, exclusive of any taxes or duties, which are the sole responsibility of Customer. Loaner hardware or components shall be certified by Illumina’s Customer Solutions using the same criteria as used for new hardware or components. Loaner hardware or components shall remain the sole property of Illumina, and must be returned within thirty (30) days of Illumina’s request. Customer’s use of loaner hardware or components shall be subject to Illumina’s current terms and conditions that apply to such loaner hardware or component.

 

13.        Preventative Maintenance Visits . Illumina will provide a preventative maintenance on-site visit according to the terms of the Service Contract, which may result in two to three days of system down time to Customer. Illumina shall cooperate with Customer to schedule such preventative maintenance visits at a time that is mutually convenient for both parties. All such preventative maintenance services will be provided by Illumina designated service personnel. All travel, labor and parts/materials expenses associated with prescribed preventative maintenance visits, visits to service, repair or replace covered items, and applications support visits as provided for in the Service Contract are included in the price set forth for

 



 

such Service Contract. Preventative maintenance services include testing and adjusting the Covered Hardware to the Specifications, If any preventative maintenance visit within the Term is precluded due to Customer’s inability to provide a sufficient time period for such services and down time, Illumina shall not be obligated to provide a substitute preventative maintenance visit. Illumina shall not be liable for any economic, consequential, incidental, special or other damages or losses of any kind resulting from the down time during such preventative maintenance visits.

 

14.        Customer Responsibilities .

 

Proper Use :  The performance of Covered Hardware when operated in corrosive environments, or in conditions, or in a manner, outside of the Specifications including Illumina’s site requirements found in the Documentation or not in accordance with its Documentation may have their performance adversely affected, and are therefore not guaranteed hereunder. The Customer agrees to use the Covered Hardware in a safe and reasonable manner pursuant to the Documentation and the Original Terms.

 

Access :  The Customer will provide Illumina with access to the Covered Hardware along with adequate working space and facilities within a reasonable distance of the Covered Hardware. Access will also be provided to all information and facilities that are reasonably necessary for Illumina to service the Covered Hardware.

 

Data Back-up and Security :  The Customer is responsible for maintaining a procedure to reconstruct any lost or altered files, data, or programs, as well as for the security of all confidential, proprietary, and classified Information.

 

Networking :  The Customer is responsible for maintaining all computer networking as it relates to the integration of any components of the Covered Hardware outside of such system and within the Customer’s network.

 

Representative :  A representative of Customer will be present on-site at at times service is being performed by Illumina’s designated service personnel.

 

Toxic/BioHazardous Substances :  The Customer will notify Illumina in writing if any Covered Hardware is used for analysis of toxic, hazardous or dangerous substances. Such Covered Hardware must be decontaminated by Customer in accordance with Illumina’s decontamination procedures and Customer shall fax a completed and executed Decontamination Certificate to Customer Solutions before any service may be performed on the Covered Hardware.

 

Environment :  The Customer agrees to provide Illumina’s designated service personnel with a safe environment for their work.

 

Disposal of Waste Products :  The Customer is responsible for the proper disposal of waste products that result from maintenance and service work on the Covered Hardware.

 

Facilities :  The Customer is responsible for ensuring that the Site will adhere to Illumina’s site requirements found in the Documentation or Specifications. Any material deviation from Illumina’s site requirements affecting the proper functioning of the Covered Hardware shall relieve Illumina of its obligations under this Agreement, including without limitation, under the Service Contract.

 

15.        Exclusions and Restrictions . The terms of this Agreement cover maintenance and repair for conditions that result from normal use and operation as described in the Documentation for the Covered Hardware. Illumina will not be obligated to perform maintenance or repair on any Covered Hardware which, in its reasonable judgment:

 

a.               Has been subjected to abuse, misuse, neglect, negligence, accident, improper testing, improper installation other than installation performed by Illumina authorized personnel, improper storage, improper handling, or use contrary to any instructions issued by Illumina or has been used in any manner inconsistent with its Documentation;

 

b.               Has been repaired, altered, disassembled, reassembled, or damaged as a result of modifications made to the Covered Hardware that were not authorized in writing by Illumina;

 

c.                Has been damaged by environmental conditions at the Site;

 

d.               Has not been installed, operated, repaired and maintained in accordance with its Documentation or has been damaged due to operators failing to perform standard operating procedures or routine maintenance as prescribed in the applicable Documentation;

 

e.                Has been moved from the Site by persons not expressly authorized in writing by Illumina;

 

f.                 Has been used with any third party software, hardware, or item including, without limitation, reagent which has not been previously approved in writing by Illumina;

 

g.                Has been exposed to Bio-safety Level 3 or 4 agents (as defined by The Occupational Safety and Health Administration);

 

h.               Has been exposed to radioactivity, and has not been decontaminated to below exempt levels; or

 

i.                   Has been damaged due to an act of Force Majeure as defined herein.

 

Customer agrees that Customer shall not, nor will Customer allow any third party to, engage In any of the following activities without the prior express written permission of an officer of Illumina: (i) disassemble, reverse-engineer, reverse-compile, or reverse-assemble the Covered Hardware and Software, or (ii) otherwise gain access to or determine the methods of operation of the Covered Hardware and Software. In addition to any other remedies available to Illumina, a breach of this provision shall immediately terminate the rights, license(s), or permissions given under this Agreement and the Original Terms and void all warranties.

 

16.        Term, Termination, and Survivability . Customer may renew its Service Contract up to one month prior to the expiration of the original warranty or Service Contract then in effect. After such time, Customer’s Covered Hardware may be subject to a recertification requirement as set forth in Section 4 herein. If either party breaches a material provision of this Agreement and fails to cure such breach within thirty (30) days after receiving written notification of such breach, the non-breaching party shall have the right to terminate this Agreement. Either party may terminate the Service Contract effective immediately upon written notice, if the other party becomes the subject of a voluntary or involuntary petition in bankruptcy or any proceeding relating to insolvency, receivership, liquidation or composition for the benefit of creditors that is not dismissed within sixty (60) days. This Agreement shall automatically terminate if the Service Contract terminates or expires.

 

17.        Billable Services Not Covered By Service Contract . If applicable and at a mutually agreed upon time, Illumina will provide Billable Services to Customer as set forth on the Quotation. For the avoidance of doubt, Billable Services are not covered by a Service Contract. When performing Billable Services, Illumina will use reasonable care commensurate with industry standards. Unless expressly set forth in the Quotation, Illumina does not guarantee or warrant the outcome of the Billable Services.

 

18.        Financial Terms . Illumina will determine payment terms on a per-order basis and such terms are subject to a credit review by Illumina. Any amounts not paid when due will accrue interest at the rate of one and one half percent (1.5%) per month, or the maximum amount allowed by law, if lower. In the event that any payment is not made within the time period specified in this Agreement, Illumina shall have the right to revoke the rights conferred and/or licenses given hereunder, and suspend performance, until all payments are made current. Customer shall pay for all costs (including reasonable attorneys’ fees) incurred by Illumina in connection with the collection of late payments. The amount of credit may be changed or credit withdrawn by Illumina at any time. Each accepted purchase order is a separate, independent transaction, and Customer has no right of set-off against other purchase orders or other transactions with Illumina. All payments, except for orders with Customers in Japan, shall be made in full by the Customer within thirty (30) days from the date of the invoice. All payments for orders with Customers in Japan shall be made in full within sixty (60) days from the date of the invoice. Invoices will be issued by Illumina for the term of the Service Contract at the commencement of the Term. Unless otherwise set forth in the Quotation or Service Contract, all prices are exclusive of shipping and insurance charges, all of which are the Customer’s responsibility and will be invoiced to the Customer separately. Unless otherwise set forth in the Quotation or Service Contract, all prices and other amounts payable to Illumina under this Agreement are exclusive of and are payable without deduction for all sales, use, excise, value added, GST (goods and services tax), withholding and other taxes, customs duties, tariffs or charges now or hereafter claimed or imposed by any governmental authority upon the provision of items and services hereunder, all of which will be paid by Customer. In the event Illumina is required, by applicable law or regulation, to pay any such tax, duty or charge, such amount will be added to the purchase price or subsequently invoiced to Customer.

 

19.        Privacy . Illumina shall not sell, trade or otherwise share with any other customer of Illumina any account information of Customer, Customer acknowledges and agrees that Illumina may maintain and use a database of orders and account information pertaining to Customer purposes of order processing, maintaining records and assisting with future orders of Customer. Neither party may disclose any financial terms of this Agreement to any third party without the consent of the other party, except as is required by securities or other applicable laws.

 

20.        Limited Warranties . EXCEPT FOR THE EXPRESS LIMITED WARRANTIES SET FORTH IN THIS AGREEMENT, ILLUMINA MAKES NO WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE SERVICES PROVIDED HEREUNDER, REPAIRED OR REPLACED COVERED HARDWARE OR COMPONENTS THEREOF, SOFTWARE, OR ANY LOANER HARDWARE OR COMPONENTS PROVIDED IN CONNECTION WITH THIS AGREEMENT, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR ARISING FROM COURSE OF PERFORMANCE, DEALING, USAGE, OR TRADE.

 

21.        Limitation of Liability . TO THE EXTENT PERMITTED BY LAW, IN NO EVENT SHALL ILLUMINA OR ITS SUPPLIERS BE LIABLE TO CUSTOMER OR ANY THIRD PARTY FOR COSTS OF PROCUREMENT OF SUBSTITUTE PRODUCTS OR SERVICES, LOST PROFITS, DATA OR BUSINESS, OR FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY, CONSEQUENTIAL, OR PUNITIVE DAMAGES OF ANY KIND ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE). ILLUMINA’S TOTAL AND CUMULATIVE LIABILITY ARISING UNDER OR IN CONNECTION WITH THIS AGREEMENT, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE, SHALL IN NO EVENT EXCEED THE AMOUNT RECEIVED BY ILLUMINA FROM CUSTOMER UNDER THIS AGREEMENT. THE LIMITATIONS SET FORTH IN THIS SECTION SHALL APPLY EVEN IF ILLUMINA OR ITS SUPPLIERS HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.

 

22.        Miscellaneous .

 

a.               If any provision of this Agreement is held invalid or unenforceable, such provision shall be enforced to the maximum extent permissible so as to effect the intent of the parties, and the remainder of this Agreement will continue in full force and effect. The failure of either party to exercise any right granted herein or to

 



 

require any performance of any term of this Agreement or the waiver by either party of any breach of this Agreement shall not prevent a subsequent exercise or enforcement of, or be deemed waiver of any subsequent breach of, the same or any other term of this Agreement. Nothing in this Agreement shall constitute or create a joint venture, partnership, or any other similar arrangement between the parties. No party is authorized to act as an agent for the other party hereunder except as expressly stated in this Agreement.

 

b.               All notices required or permitted under this Agreement shall be in writing and shall be deemed received when (a) delivered personally; (b) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid (or ten (10) days for international mail); or (c) one (1) day after deposit with a commercial express courier specifying next day delivery or, for international courier packages, two (2) days after deposit with a commercial express courier specifying 2-day delivery, with whiten verification of receipt

 

c.                Any Service Contract provided by Illumina extends only to the Customer unless otherwise agreed upon in writing by Illumina. Each Service Contract is non-assignable and is non-transferable; provided, however that no consent shall be required for any assignment in connection with any merger, acquisition or the sale of all or substantially all of the stock or assets of Customer to a party that (i) agrees In writing to be bound by the terms and conditions of this Agreement, and (ii) is not, in Illumina’s reasonable Judgment, a competitor of Illumina. Illumina may assign or transfer this Agreement to any (i) successor by way of merger, acquisition or sale of all or substantially all of its stock or assets relating to this Agreement, (ii) of its affiliated entities. Illumina or any successor may assign all or part of the right to payments under this Agreement Any assignment or transfer of this Agreement made in contravention of the terms hereof shall be null and void. Subject to the foregoing, this Agreement shall be binding on and inure to the benefit of the parties’ respective successors and permitted assigns.

 

d.               For orders by Customers located in the United States of America, this Agreement and performance by the parties hereunder shall be construed in accordance with the laws of the State of California, U.S.A., without regard to provisions on the conflicts of laws. For orders by Customers located outside of the United States of America, this Agreement and performance by the parties hereunder shall be construed in accordance with the laws of the country where the Illumina entity named on the Quotation or Order Confirmation, as applicable, is located.

 

e.                Illumina shall not be responsible for any failure to perform or delay attributable in whole or in part to any cause beyond its reasonable control, including but not limited to acts of God, fire, flood, tornado, earthquake, hurricane, lightning, government actions, actual or threatened acts of war, terrorism, civil disturbance or insurrection, sabotage, labor shortages or disputes, failure or delay in delivery by Illumina’s suppliers or subcontractors, transportation difficulties, shortage of energy, raw materials or equipment, or Customer’s fault or negligence. In the event of any such delay the delivery date shall be deferred for a period equal to the time lost by reason of the delay.

 

f.                 This Agreement is not intended to and shall not be interpreted in a manner so as to grant or expand Customer’s rights with respect to the Covered Hardware provided pursuant to the Hardware Quotation and Original Terms,

 

g.                This Agreement represents the entire agreement between the parties regarding the subject matter hereof and supersedes all prior discussions, communications, agreements, and understandings of any kind and nature between the parties. No amendment to this Agreement or waiver of any right, condition, or breach will be effective unless in writing and signed by both parties.

 


 

Exhibit G
Form of Press Release
Illumina to Supply Natera With Sequencing Instruments and Consumables for Non-Invasive Prenatal Testing (NIPT)
Natera Will Continue to Use Illumina’s HiSeq® 2500 for NIPT

 

SAN DIEGO—(BUSINESS WIRE)—August XX, 2013—Illumina, Inc. (NASDAQ:ILMN) and Natera, Inc. today announced that they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq® 2500 sequencing system and associated consumables for performing the non-invasive prenatal test (NIPT) Panorama™. Invasive methods to obtain fetal DNA samples from amniotic fluid (amniocentesis) and placental tissue (chorionic villus sampling) have been used for decades to identify some fetal chromosomal abnormalities in utero. Over the last few years, researchers refined a non-invasive method that analyzes cell-fee fetal DNA from maternal plasma. Combined with next-generation sequencing (NGS), this method is the foundation of several commercial prenatal screening tests to detect chromosomal abnormalities in the fetal genome, such as trisomies.

 

“We are pleased to be selected again as Natera’s next-generation sequencing system provider for the Panorama test,” said Nick Naclerio, Senior Vice President Corporate and Venture Development for Illumina. “Our goal is to enable the rapid growth of NIPT and the broader reproductive health market with technology, products, and ultimately cleared InVitro Diagnostic Systems.”

 

Added Matthew Rabinowitz, Ph.D., Chief Executive Officer of Natera, “We are pleased to continue working with Illumina as our primary provider of next-generation sequencing technology. This deal enables a major expansion of Natera’s laboratory capacity to support the fast-growing demand for our Panorama™ test.”

 

About Illumina

 

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

 

About Natera

 

Natera is a leading genetic testing company that has developed a proprietary bioinformatics-based technology (NATUS) to deliver accurate and comprehensive high-throughput testing for reproductive indications from tiny quantities of DNA. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening tests to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks. Natera’s PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NTH and is being conducted by the leaders in maternal-fetal medicine in the United States. For more information, visit www.natera.com.

 

Forward-Looking Statements

 

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

 

Illumina, Inc.

Natera, Inc.

 

 

Investors:

Ian Stone

Rebecca Chambers

619-308-6541

858-255-5243

ian.stone@russopartnersllc.com

rchambers@illumina.com

or

or Media :

Solomon Moshkevich

Jennifer Temple

650-249-9090

858-882-6822

smoshkevich@natera.com

pr@illumina.com

 

 



 

Exhibit H
Final Shipment Purchase Order

 


 

*CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. nateraTM PURCHASE ORDER Natera, Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 Ph: 650-249-9090 Fax: 650-362-9357 PURCHASE ORDER #: 101183 ORDER DATE: 8/13/13 PAYMENT TERMS: Net 15 BUYER ID: wremo VENDOR: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122 Fax: 858-202-4766 SHIP TO: Natera, Inc. 201 Industrial Road Suite 410 San Carlos, CA 94070 Account # 23955 * CHANGED SINCE LAST REVISION LINE# VENDOR ITEM # NATERA ITEM # QTY PRM DATE REQ DATE UNIT PRICE EXT PRICE [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] NOTES: SUBTOTAL [*] FREIGHT [*] TOTAL [*] Natera, Inc. 201 Industrial Road, Suite 410, San Carlos, CA 94070 Ph 650-249-9090 HiSeq 2500. HiSeq 2500. HiSeq 2500. HiSeq 2500. HiSeq 2500. HiSeq 2500. HiSeq 2500. HiSeq 2500.